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Abstract 
The main aim of this project was to enhance our knowledge on angiogenesis by 
developing systems that enable us to study and promote angiogenesis in tissue 
engineering and regenerative medicine applications. 
Over the last 30 years, there have been significant advances in the production of tissue-
engineered (TE) materials suitable for use in the clinic. However, one of the key 
challenges is to ensure rapid neovascularisation into these constructs in order for them 
to survive post-transplantation. While relatively thin simple TE constructs can survive on 
well-vascularised wound beds, thicker constructs (>200 µm) usually fail to engraft due 
to lack of oxygen and nutrients in vivo. Both prevascularisation and scaffold 
functionalisation strategies with the use of angiogenic factors are viewed as promising 
approaches to accelerate vascular ingrowth into TE constructs to circumvent slow 
vascularisation after implantation. 
Angiogenesis is a tightly regulated process and the majority of the current strategies for 
promoting rapid neovascularisation focus either on the addition of proangiogenic factors 
to TE constructs or adding laboratory expanded proangiogenic cells such as endothelial 
cells, endothelial progenitors or stem cells to tissue engineering scaffold systems prior to 
implantation.  
For functionalisation of the TE constructs with the proangiogenic factors, vascular 
endothelial growth factor (VEGF) is recognised to be the most well-studied angiogenic 
factor due to occupying a key role in the angiogenic cascade. VEGF has been proven to 
have important roles in different steps of the angiogenic process in vivo: vasodilation and 
permeability, destabilisation of vessels and degradation of extracellular matrix (ECM), 
proliferation and migration of endothelial cells, and lumen formation and vessel 
stabilisation. However, VEGF acts as part of a well-regulated process, and its actions are 
highly dose-dependent, and a range of studies show that VEGF addition can lead to 
excessively leaky, permeable and haemorrhagic vessels such as those that are found in 
tumorigenesis. Therefore, seeking alternatives to VEGF is inevitable.  
Accordingly, I have investigated the angiogenic potential of 2-deoxy-D-Ribose (2dDR) 
using well-established in vitro and in vivo models. For the in vitro assessments, the 
vi 
 
proliferation, migration and tube formation of human aortic endothelial cells (HAECs) in 
response to different concentrations of 2dDR were assessed. The angiogenic activity of 
2dDR was further assessed in vivo using two well-established angiogenesis systems; ex-
ovo chick chorioallantoic membrane (CAM) assay and diabetic rat wound healing model. 
In vitro and in vivo angiogenesis models are important tools to explore the newly 
discovered pro-angiogenic or and anti-angiogenic agents. Although in vivo assays are the 
most representative and reliable models for the evaluation of angiogenesis, they are also 
expensive, technically difficult, time-consuming, and ethically questionable. On the other 
hand, in vitro angiogenesis assays are inexpensive, quick, technically simple, and 
reproducible, but they are usually based on evaluating only one aspect of angiogenesis 
(for example, only proliferation, migration or differentiation), and they may produce false 
results due to the unspecific reaction of cells. Moreover, most of the in vitro angiogenesis 
assays are limited to static, 2D cell culture systems where culturing cells on stiff and flat 
substrates is a simplified method and does not represent the dynamic and highly complex 
tissue systems. 2D culture of cells distorts cell-cell and cell-matrix interactions which 
affects cell proliferation, migration and differentiation, where 3D in vitro models better 
represent the in vivo in a cost-effective way and with no ethical concerns. To date, none 
of the studies demonstrated any in vitro models that allow researchers to evaluate 
angiogenesis assessing both proliferation and migration of ECs in a 3D environment. 
Thus, in this project, three different systems made of synthetic and natural polymers 
were developed to be used as in vitro platforms to study and promote angiogenesis.  
First angiogenesis model was a poly-(3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV) 
synthetic vascular scaffold developed by combining electrospinning and 3D printing. 
Nanofibrous PHBV channels were capable of supporting human dermal microvascular 
endothelial cells (HDMEC) to adhere and create an endothelium monolayer within the 
channels. The use of the developed system as an in vitro platform to study angiogenesis 
was evaluated using Matrigel. The outgrowth of HDMECs was further analysed using a 
reconstructed human skin model which was also developed in the scope of this project. 
The second model was developed via decellularisation of baby spinach leaves. The 
natural vascular structure of the leaves was then repopulated with HDMECs in the 
presence of helper human dermal fibroblasts, and their potential to promote 
angiogenesis was investigated using ex-ovo CAM assay. The decellularised spinach leaves 
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were further assessed for their potential use as an in vitro angiogenesis model where 
outgrowth of HDMECs was analysed in response to VEGF and 2dDR. 
The third synthetic model was developed via a combination of electrospinning and 
emulsion templating techniques. The developed 3D dynamic model was made of 
electrospun PHBV tube and polycaprolactone (PCL) polymerised high internal phase 
emulsion (PolyHIPE). The model was capable of supporting HAECs to form an 
endothelium-like monolayer within the tubular channel, and the outgrowth of HAECs was 
investigated in response to 2dDR and VEGF under static and dynamic conditions.  
Then, as an alternative to the use of pro-angiogenic agents, I assessed the effectiveness of 
prevascularisation (use of pro-angiogenic cells) technique for promoting angiogenesis in 
ex-ovo CAM assay. I fabricated basic electrospun PHBV scaffolds and cellularised them 
with a combination of endothelial cells and fibroblasts to evaluate the potential of these 
cells to induce angiogenesis in vivo. 
Finally, in collaboration with my colleague, Betül Aldemir, we investigated an alternative 
use of the bilayer scaffolds manufactured by combining electrospinning and emulsion 
templating techniques, which was found very rapid and effective route to produce TE 
scaffolds that have the potential to be used in various tissue engineering and regenerative 
medicine applications. To explore the use of these scaffolds as a bilayer barrier 
membrane for guided tissue regeneration (GTR) applications, we explored the cell-
occlusiveness of electrospun layer and the bone promoting properties of the PolyHIPE 
layer. 
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CHAPTER I 
Literature Review 
 Vascular System 
 Structure and function  
Beyond the diffusion limit where it is not possible to meet the essential metabolic 
demands of the cells, a vascular system is responsible for supplying oxygen and nutrients 
to the tissues and organs via a complex network of interconnected blood vessels. There 
are three main types of blood vessels; arteries, veins, and capillaries (Figure 1) [1]. All 
types of blood vessels have a thin layer of endothelial cell (EC) monolayer (endothelium 
or tunica intima). The capillaries are partially covered by pericytes which promote 
stabilisation of the vessel and provides a little elasticity. On the other hand, larger arteries 
and veins have multilayers of smooth muscle cells (SMCs) which stabilise the large 
vessels and enable contraction. SMCs form a middle layer (tunica media) which is thicker 
in arteries and highly elastic in order to provide mechanical resistance to pulsatile 
pressure caused by the blood being pumped from the heart. The outer layer, tunica 
adventitia, is rich in collagen fibres to provide a mechanical competence for stretching 
and recoiling [2].  
 
Figure 1. Three main types of blood vessels in the body; artery, vein and capillary, and their 
structures 
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 Formation 
Blood vessels are crucial for providing oxygen and nutrients to the tissues and organs and 
start to develop early in embryonic development. Blood vessel formation in vivo is mostly 
based on three strategies: vasculogenesis, angiogenesis, and arteriogenesis (Figure 2) 
[3]. 
 
Figure 2. Vessel formation strategies in vivo: vasculogenesis, angiogenesis, and arteriogenesis 
 Vasculogenesis 
Blood vessel formation is critical for organogenesis and for embryonic and fetal 
development. Development of very early capillaries occurs by vasculogenesis. Firstly, 
mesodermal stem cells differentiate to form hemangioblasts which will then differentiate 
into angioblasts. Clusters of angioblasts form blood islands that are composed of 
endothelial progenitor cells (EPCs) and hematopoietic stem cells (HSCs). Finally, the 
blood islands merge, and HSCs differentiate into blood, and EPCs develop into mature 
ECs, which will then create first primary capillaries [4–7]. 
 Angiogenesis 
The first capillaries developed by vasculogenesis grow into a primitive network and 
remodel new blood vessels via angiogenesis which takes place via two mechanisms; 
sprouting and intussusception [8] (Figure 3).  
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Figure 3. Process of sprouting and intussusceptive angiogenesis from a primary capillary network 
formed by vasculogenesis 
Sprouting angiogenesis refers to the process of branching out of new capillaries from an 
existing vessel via reorganisation of extracellular matrix (ECM) and EC migration, 
proliferation and stabilisation. The steps of sprouting angiogenesis are outlined below 
[9,10]: 
• Vasodilation: increased permeability of the existing vessels, detachment of 
the pericytes from the capillaries, and degradation of the basement membrane 
• Migration: migration of the endothelial cells towards the extracellular area 
and the formation of the endothelial sprouts 
• Proliferation: proliferation of the endothelial cells from the tip cells 
• Tube formation: inhibition of the proliferation and migration of the 
endothelial cells and remodelling into capillary tubes 
• Stabilisation: Recruitment of periendothelial cells such as pericytes for 
capillary and smooth muscle cells for large vessels 
Intussusceptive (non-sprouting) angiogenesis is an alternative route to sprouting 
angiogenesis and can be defined as the formation of two new capillaries from a single 
capillary by the processes given below [8,11]:  
• Intraluminal pillar formation: creation of a zone of contact between two 
opposite walls of capillaries. 
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• Central perforation formation: reorganisation of the inter-endothelial cell 
junctions and the formation of a central perforation 
• Pericyte and myofibroblast invasion: formation of an interstitial pillar 
core, invasion of pericytes and myofibroblasts, and consequently deposition 
of ECM. 
• Enlargement and stabilisation: Increase in the size of the formed pillars to 
the size of a normal capillary, split up into new capillaries, and the 
mechanical stabilisation of the capillary with the formation of ECM.  
Angiogenesis is a critical aspect for production of a vascularised tissue during embryonic 
development, wound healing, cell growth and functions of female reproductive organs 
such as ovaries and the repair mechanisms in the menstrual cycle [12,13], and it is a 
highly organised process depending on various factors. These key factors can be 
identified as molecular mechanisms which are angiogenic regulators used for promoting 
angiogenesis and biomechanical mechanisms such as role of ECM which does not only 
support the cells physically, but also regulates cellular functions and other biomechanical 
forces created by blood flow such as shear stress which has a positive effect on the 
formation of more sprouts rather than low or no shear stress, or extracellular 
environment [14–16]. 
Hypoxia is a key stimulus for growth of blood vessels. It establishes a connection between 
metabolic oxygen demand and vascular oxygen supply. Normally, cells uptake oxygen by 
diffusion, but hypoxia triggers the formation of new blood vessels when tissue growth 
exceeds the diffusion limits for oxygen diffusion [17,18]. At the cellular level, exposure of 
hypoxia for a long time leads to triggering of molecular pathways to deal with stress due 
to oxygen deficiency. One of the cellular responses is the formation of new blood vessels 
to relieve the increased metabolic demands due to hypoxia. Oxygen deficiency stimulates 
the development and remodelling of the existing vascular structure via upregulating the 
expression of genes which have important roles in steps of angiogenesis such as vascular 
endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), 
transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF) and 
fibroblast growth factor (FGF) to increase blood flow in an attempt to supply oxygen to 
hypoxic tissues [13,17].  
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 Arteriogenesis 
After formation and stabilisation of blood vessels, some vessels are surrounded by 
muscular layers which provide mechanical strength, elasticity and the capability of 
vasomotor control and contractile properties to the vessel. This process of increase in the 
diameter of arterial vessels is referred to arteriogenesis [19]. 
 The Need for Vascularisation in Tissue Engineering Applications 
Diffusion of oxygen and nutrients from their higher concentrations to lower 
concentrations is a frequently used mechanism in vivo. However, when the distance is 
beyond 0.2 mm, it is slow and sometimes impossible to provide the metabolic needs of 
cells and tissues. At this point, the circulatory system plays a key role to transport the 
required molecules to tissues and organs. The vascular system consists of three main 
types of blood vessels: arteries, veins and capillaries, which play a key role in the 
transportation of blood and nutrients to tissues and organs as well as the removal of 
metabolic waste products from them. These types of blood vessels are composed of 
several layers of cells (Figure 4) which dictate their properties and function. All vessels 
are composed of an inner single EC layer (tunica intima) which is wrapped around by 
contractile mural cells in order to alter the vessel diameter according to blood flow. This 
middle layer of smooth muscle cells (or tunica media) stabilises the vascular tube, and its 
thickness varies in different types of vessels [20,21].  
 
Figure 4. The greatest distance between capillaries and tissues is approximately 0.2mm (diffusion 
and transport phenomena in tissues). The figure shows the capillary structures in tissues to provide 
required oxygen and nutrients to and remove CO2 and waste products from cells 
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Tissue and organ failure or losses are major problems that are seen in human health, and 
tissue engineering offers an opportunity to develop functional substitutes for damaged 
tissues. Most of the conventional tissue engineering approaches have mainly focused on 
attachment and proliferation of cells, and their formation of ECM [22]. Over 20 different 
tissue types such as nerve, cornea, liver, cartilage, heart, bone and skin have been 
attempted to be engineered, and the most successful ones of these tissue-engineered (TE) 
constructs are, however, thin (<2mm) or involved cells with low oxygen requirements 
(avascular). The lack of blood vessels in current TE constructs is one of the most 
important challenges in the survival of engineered tissue substitutes [23,24]. Although 
significant progress has been made, the main problem with tissue engineering constructs 
still remains the same and is based on the slow formation of new blood vessels, known as 
angiogenesis, after implantation. In the body, blood vessels are subdivided into capillary 
structures in tissues to provide the required oxygen and nutrients to cells, and the 
greatest distance between capillaries and tissues is approximately 0.2mm, which is also 
referred to as the diffusion limit for oxygen [7,25].  
When a TE substitute is implanted, nutrients and oxygen must be provided to cells to 
survive in vivo, and formation of vascular structures in TE substitute can take weeks 
which is a long period for cells to survive without oxygen (hypoxia) and essential 
nutrients, and this leads to the failure of the constructs [26]. 
I screened PubMed and Web of Science databases to see how the number of studies on 
angiogenesis has been increased over the years. All screening results showed that studies 
on angiogenesis have significantly increased over the last two decades. This data is 
summarised in Table 1. 
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Table 1. Screening of PubMed and Web of Science databases to see how the number of studies on 
angiogenesis has been increased over the years. The graph on the right shows the distribution of 
angiogenesis-related studies published on PubMed from 1950 to date 
Dates 
Number of 
publications studying 
angiogenesis on: 
 
PubMed 
Web of 
Science 
1950 to 1960 1 1 
1960 to 1970 5 5 
1970 to 1980 169 92 
1980 to 1990 1038 619 
1990 to 2000 8657 13080 
2000 to 2010 43327 59312 
2010 to date 65229 85219 
  
 Key Factors in Angiogenesis 
 Molecular factors 
Several biochemical factors have been reported as critical for stimulating angiogenesis. 
These factors are mostly the interaction of cytokines with their receptors and the 
adhesion of ECM molecules with the integrins [27,28]. 
 Cytokines and their receptors 
Hypoxia is the reduction in the physiological oxygen level that reaches cells. This is due 
to the alteration between the requirement and supply of oxygen which is caused by 
several reasons such as acute and chronic vascular and pulmonary diseases. Hypoxia-
inducible factors 1 (HIF-1) is a heterodimeric transcription factor which plays a key role 
in the cellular responses to hypoxia. HIF-1 is the main regulator of a range of genes which 
are upregulated in response to oxygen deprivation. The activity of HIF-1α, a subunit of 
HIF-1 family, is regulated by the prolyl hydroxylase domain (PHD) enzymes. Under 
physiological oxygen conditions (sufficient oxygen), PHD enzymes hydroxylate HIF-α 
which initiates binding to the von Hippel–Lindau E3 ubiquitin ligase complex, and thus 
HIF-α undergoes proteasomal degradation. Under hypoxic conditions, the hydroxylation 
is suppressed, and as a result, HIF-1α accumulates in the cell and leads to angiogenesis-
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related gene activation for the regulation of angiogenic factors such as vascular 
endothelial growth factor (VEGF), angiopoietin-1 and 2 (Ang-1 and Ang-2), platelet-
derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and transforming 
growth factor-β (TGF-β) [29–31]. These pro-angiogenic factors act via their receptors on 
the EC surface and promote angiogenesis through EC proliferation, migration, and 
survival [32]. 
 Vascular Endothelial Growth Factor (VEGF) 
VEGF is a well-established stimulator of angiogenesis. The VEGF family is composed of 7 
members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFE, and VEGF-F. VEGF A (which will be 
referred as VEGF in the rest of the text) particularly has been reported as an important 
factor which regulates several angiogenic processes. Although there are several isoforms 
of VEGF such as VEGF145, VEGF165, VEGF189, and VEGF206, VEGF165 has been demonstrated 
to have optimal bioavailability, biological activity and consequently widely-used in 
studies focusing on promoting angiogenesis [33–35]. VEGF has important roles in the 
various steps of the angiogenic process: vasodilation and permeability, destabilisation of 
vessels and degradation of ECM, proliferation and migration of endothelial cells, and 
lumen formation and vessel stabilisation [13,36–38].  
VEGF receptor 2 (VEGFR-2) is generally recognised as the main receptor responsible for 
regulating the VEGF-dependant angiogenic processes, and it is widely expressed by ECs. 
Binding of VEGF to VEGFR-2 leads the activation of the multiple intracellular cascades, 
which triggers angiogenesis [39,40]. The mechanism of action of VEGFR2-dependant 
angiogenesis is summarised below. 
VEGF receptor 1 (VEGFR-1) is expressed on the surface of hematopoietic cells and ECs 
and has an affinity to VEGF-A. Although VEGFR-1 function is not as clear as VEGFR-2, it 
has been shown to regulate angiogenesis both in positive and negative manner [41]. Its 
most important function is the negative regulation of VEGFR-2 by acting as a trap for 
VEGF-A. Thus, it is recognised as a suppressor of pro-angiogenic signals [42,43]. 
VEGF receptor 3 (VEGFR-3) is expressed in lymphatic ECs and binds VEGF-C and VEGF-D 
but not VEGF-A. VEGFR-3 has shown to be involved in the regulation of 
lymphangiogenesis and lymphatic endothelium maintenance. Furthermore, it also takes 
a regulatory role in the formation of the blood vessels during embryogenesis [44,45]. 
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Proliferation:  
VEGF acts as a mitogen for ECs, and it stimulates proliferation via activation of VEGFR-2 
which triggers RAS/ Rapidly Accelerated Fibrosarcoma (RAF) /extracellular signal-
regulated kinase (ERK)/ Mitogen-activated protein kinase (MAPK) pathway stimulates 
proliferation of ECs [46,47]. One thing to note is that VEGFR-2 stimulates the ERK via 
pY1175-dependent phosphorylation of phospholipase C-γ (PLCγ) and subsequent 
activation of Protein kinase C (PKCs) whereas most of the receptor-type tyrosine kinases 
(RTK) mainly uses growth factor receptor-bound protein (GRB2)/RAS pathway for this. 
Alternatively, activation of PKC results in activation of protein kinase D (PKD), which 
promotes the proliferation of ECs [48]. 
Migration: 
Various signal transducers bind to the phosphorylated tyrosines Y951, Y1175, and Y1214 
and promote VEGF-dependant migration of endothelial cells. Y951 binds T Cell–Specific 
Adapter (TSAd) which creates a complex with Rous sarcoma oncogene cellular homolog 
(SRC) in a VEGF-dependent manner [49]. Y1175 binds SH2 Domain Containing Adaptor 
Protein B (SHB) which binds focal adhesion kinase (FAK) and regulates cell adhesion 
dynamics and migration [50]. Y1214 allows the formation of the non-catalytic region of 
tyrosine kinase adaptor protein (NCK)/FYN complex which promotes phosphorylation of 
p21-activated kinase-2 (PAK-2) that activates the Cdc42 and p38 mitogen-activated 
protein kinases (p38MAPK) to induce migration [51].  
Survival:  
VEGFR-2 dependent activation of Phosphoinositide 3 kinase (PI3K)-AKT8 virus oncogene 
cellular homolog (AKT) signalling with the activation of y951 promotes survival of EC via 
the production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) which mediates 
phosphorylation of protein kinase B (PKB)/AKT [52]. AKT phosphorylates B cell 
leukaemia 2 protein (BCL-2) associated death promoter (BAD) and caspase 9 and inhibits 
apoptotic activity of ECs [53].  
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Permeability:  
VEGFR-2 activation regulates the permeability of ECs via endothelial nitric oxide 
synthase (eNOS)-mediated generation of nitric oxide (NO) [54] which can be activated by 
either PLCγ or AKT/PKB pathway. 
VEGFR-2 signalling and trafficking pathways mediated by VEGF are given in Figure 5. 
 
Figure 5. Molecular mechanism of VEGFR2 dependant angiogenesis 
 Platelet-Derived Growth Factor (PDGF) 
PDGF is another stimulator of angiogenesis through its receptors, and it is produced in 
several cell types, including platelets, macrophages, fibroblasts, and ECs [55]. PDGF 
signalling stimulates angiogenesis particularly by mediating vessel maturation which 
causes stabilisation and integrity of the newly formed blood vessels [56]. 
 Angiopoietins (Ang-1 and Ang-2) 
Angiopoietins are paracrine factors, and they are ligands for tyrosine kinase receptor 
(Tie-2). Ang-2 plays a role in the destabilisation of vessels and degradation of ECM, 
proliferation and migration of endothelial cells where Ang-1 takes part in vessel 
stabilisation [17,18]. 
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 Transforming growth factor-beta (TGF-β) 
TGF-β is a member of TGF superfamily and has known effects on tissue morphogenesis 
including apoptosis, cell proliferation, cell adhesion, differentiation, inflammation, cell 
migration and angiogenesis. Unlike VEGF which protects cells from apoptosis, TGF- β 
induces EC apoptosis. Although, TGF- β has a positive effect on angiogenesis in-vivo, in-
vitro it inhibits EC growth and proliferation [57]. Thus, the effect of TGF- β on 
angiogenesis is found to be dependent on its concentration. At low concentrations, it has 
a positive effect on angiogenesis, whereas the effect is negative at high concentrations. In 
other words, while low concentrations of TGF- β play a role in proliferation and migration 
of endothelial cells during sprouting, high doses of TGF- β induce vessel stabilisation [58]. 
 Fibroblast Growth Factor (FGF) 
FGF-1 and FGF-2 are growth factors that have positive effects on angiogenesis and are 
mitogenic to cell types such as ECs and fibroblasts. Particularly, FGF-2 (also known as 
bFGF) increases the expression of VEGF, which plays a key role in angiogenesis. 
Moreover, FGF-2 has a role in the sprouting stage of angiogenesis by stimulating the 
breakdown of ECM in ECs. This breakdown then allows the migration of ECs to form tubes 
like capillaries [59,60]. 
 Estradiol (E2) 
As an alternative to VEGF, E2 has been shown to promote endothelial cell migration and 
proliferation in vitro [61,62] and to stimulate new blood vessel formation both in vitro 
and in vivo [63]. E2 has an important role in neovascularisation during the menstrual 
cycle [64,65]. It is used clinically in the treatment of osteoporosis and heart disease [66]. 
Moreover, blocking the E2 receptor with adjuvants such as tamoxifen for estrogen 
receptor-positive tumours, in which high estrogen helps the cancer cells grow and 
spread, is an effective method to reduce tumour vasculature. This therapy has been in 
clinics for many years, especially for the treatment of breast cancer [67,68]. Recently, our 
group confirmed that poly-L-lactic-acid (PLLA) scaffolds loaded with E2 were highly 
angiogenic using the CAM assay [69]. 
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 Thymidine Phosphorylase (TP) & 2-deoxy-D-Ribose (2dDR) 
Phosphorylases catalyse the addition of a phosphate group from an inorganic phosphate 
to an acceptor. In the body, Thymidine phosphorylase (TP) plays an important role to 
recover nucleosides after DNA degradation. Although the reaction is reversible, TP’s 
function is primarily catabolic [70,71]. TP has an amino acid sequence identical to 
platelet-derived endothelial cell growth factor (PD-ECGF) [72,73] and is an enzyme that 
catalyses phosphorylation of thymidine to thymine [74,75] and 
2-deoxyribose-1-phosphate (2dDR1P). 2dDR1P will then be dephosphorylated within 
the cytoplasm to 2-deoxy-D-Ribose (2dDR), which is the form that can pass the cell 
membrane. It has previously been shown that addition of thymidine to platelets gave rise 
to thymine and 2dDR but not 2dDR1P in the extracellular medium [70], which clearly 
shows that the phosphate is removed within the cytoplasm. Dephosphorylation allows 
the mobility of 2dDR from the cell membrane.  
The angiogenic activity of TP is known to be dependent upon its enzymatic activity [76–
78] although its molecular mechanism is still unclear. There are two possible reasons for 
ECs to be attracted (as an indicator of angiogenesis) to an area where there is an enzyme 
activity; (i) the substrate (thymidine) for the enzymatic reaction or (ii) the products are 
chemoattractant. Since thymidine has not been found as an chemoattractant for ECs, the 
latter reason, which is the catalytic release of 2-deoxy-D-ribose (2dDR), has been 
considered to be the reason for TP’s angiogenic activity [71,79] 
2dDR is one of the degradation products of thymidine, and it has previously been 
reported to have a chemotactic and angiogenic activity in vitro and in vivo [80,81]. 
However, no other similar molecules, including thymidine, thymine, 2-deoxy-L-ribose 
(2dLR), 2-deoxy-D-ribose-1-phosphate (2dDR1P) have been reported to be angiogenic 
when compared to 2dDR [71,81]. To date, several groups explored 2dDR’s angiogenic 
potential using in vitro and in vivo assays. 2dDR has been shown to enhance proliferation 
and migration [82], induce tubulogenesis [83,84], inhibit hypoxia-induced apoptosis [85], 
and increase VEGF and IL-8 production [86] in vitro. Recently, our group demonstrated 
that 2dDR is not only angiogenic but also stimulates wound healing released from a 
hydrogel in a rat skin wound model [87].  
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In addition to this very limited literature on 2dDR, during my PhD research, we have 
demonstrated an effective dose range that can be used to stimulate proliferation, 
migration and tube formation of ECs in vitro [88] and to stimulate angiogenesis and 
wound healing in vivo using the ex-ovo CAM assay [89] and diabetic rat wound healing 
model [90], which will be explained in detail in further chapters of this thesis.  
The enzymatic reaction of the degradation of thymidine to thymine catalysed by TP is 
given in Figure 6. 
 
Figure 6. The enzymatic reaction of the degradation of thymidine to thymine catalysed by TP. 
Dephosphorylation of 2dDR1P allows the mobility of 2dDR from the cell membrane. 
There are only limited groups working to explore its potential in the field of angiogenesis 
inducers as explained above. Thus, to date, the literature on the angiogenic activity of 
2dDR is not very comprehensive.  PubMed was screened for the articles in which 2dDR, 
TP and VEGF were studied for their angiogenic activity. Only 29 studies (including 3 
TP 
Dephosphorylation 
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publications from our group) were found studying the potential angiogenic effect of 2dDR 
to date whereas there were 447 and 34556 studies on the angiogenic activity of TP and 
VEGF, respectively. As can be seen from PubMed screening of these three pro-angiogenic 
agents, the literature on 2dDR still needs to be investigated. Screening of PubMed and 
Web of Science databases (from 1970 to date) to find the number of publications on 
several angiogenic factors is given in Table 2. 
Table 2. Screening of PubMed and Web of Science databases to find the number of publications on 
established pro-angiogenic factors 
Pro-angiogenic agent 
Number of publications on: 
PubMed Web of Science 
VEGF 34556 37995 
PDGF 2730 2801 
TGF-β 2584 3143 
FGF 6595 11297 
E2 718 824 
TP 447 679 
2dDR 29 23 
 
Distribution of the angiogenesis-related publications about 2dDR and TP (combined) on 
the PubMed database over the years (from 1970 to date) is given in Figure 7. 
 
Figure 7. Distribution of the angiogenesis-related publications about 2dDR and TP (combined) on 
PubMed database by years (from 1970 to date) 
To clarify the literature on how TP and 2dDR can potentially be an alternative agent as 
an alternative to VEGF, the milestones of the exploration of them to date are given in 
Figure 8.  
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Figure 8. Timeline showing the key studies on TP and 2dDR for the exploration of the angiogenic 
activity of 2dDR  
 ECM integrins and matrix-degrading enzymes 
ECM is the non-cellular component and responsible for providing physical support to 
cells and tissues. However, beside its mechanical support function, it is also involved in 
many biochemical processes which regulate cellular functions which take part in 
angiogenesis [91].  
The mechanism of action of ECM components is mostly regulated by the cell-surface 
receptors, integrins. The major integrins found on ECs include but are not limited to α1β1, 
α2β2, α3β1, α5β1, α6β4, α6β1, and αvβ3. Among all these integrins αvβ3 has been studied 
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widely for its importance in the angiogenic processes. In addition to its 
arginylglycylaspartic acid (RGD) peptide sequence binding properties, the interaction 
between αvβ3 integrin and VEGF-R2 has been investigated [92,93]. The affinities of the 
integrins to the ECM molecules and the cellular mechanisms that are involved are given 
in Table 3. 
Table 3. The affinities of the integrins to the ECM molecules and the cellular mechanisms which they 
involve 
Integrin Affinity to Cellular mechanism 
α1β1 Collagen 
Regulates the responsiveness of VEGFR-2 to VEGF 
and promotes angiogenesis via VEGF pathway [94] 
α2β1 Collagen 
Regulates the responsiveness of VEGFR-2 to VEGF, 
and promotes tube formation [94,95] 
α3β1 Laminin 
Regulates EC adhesion and promotes migration 
[96] 
α6β4 Laminin 
Regulates EC adhesion and promotes migration 
[97,98] 
α6β1 Laminin Regulates EC adhesion [98,99] 
α5β1 
RGD sequence: 
Fibronectin 
Regulates / promotes migration [100] 
αvβ3 
RGD sequence: 
Vitronectin, 
Fibronectin 
Regulates VEGFR-2 activation: migration, survival, 
and matrix degradation [93,101] 
 
Several ECM molecules have been reported for their angiogenic or anti-angiogenic 
activities. Collagen [102], laminin [103], fibronectin [104], and vitronectin [105] have 
previously been reported to participate in promoting angiogenesis as summarised in 
Table 3. Similarly, hyaluronan has been shown to have antiangiogenic effects when it is 
present in a high molecular weight form under a native environment. However, when it 
breaks down into smaller segments and has a lower molecular weight, it has been 
reported to have angiogenic activity [106].  
During the angiogenic process in ECM, matrix metalloproteases (MMPs), extracellular 
endopeptidases which selectively degrades ECM proteins, also plays a critical role in the 
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degradation of ECM for the release of angiogenic factors that are stored in ECM. However, 
the enzymatic activity of MMPs is highly regulated by the protease inhibitors in order to 
prevent over degradation of the ECM which also guides the ECs proliferation and 
migration and thus, excessive release of angiogenic factors from it. Several types of cells 
can produce MMPs such as ECs, stromal cells, inflammatory cells, and tumour cells 
[107,108]. Some of the MMPs produced by ECs and that play a role in angiogenesis are 
MMP-1 (Collagenase 1), MMP-2 (Gelatinase A), MMP-9 (Gelatinase B), and MMP-14. 
 Mechanical factors 
Every single cell in their native environment in body is exposed the several mechanical 
forces either self-generated, or ECM related [109]. Thus cells continuously receive the 
mechanical forces and transduce them into biochemical signals which results in 
alteration of several ECM genes and thus, protein expression levels in order to maintain 
their structure and shape in their native environment [110]. Apart from the ECM forces 
they are exposed, cells also generate mechanical forces which will act on ECM. These 
cellular forces are called as cell traction forces (CTFs). For this reason, adherent cells are 
under tension created by cell-ECM contacts, and they use these CTFs for remodelling their 
adhesion and migration profiles, which can be linked with angiogenesis when it comes to 
ECs and communicating with adjacent cells [110,111].  
Blood vessels are also continuously exposed to external forces either due to the flow of 
blood or the extracellular environment. ECs are highly mechanosensitive, and they are 
reported to have phenotypic and functional changes based on various flow patterns 
[112]. Shear stress is the main force acting on ECs, and it has previously been reported to 
reduce the apoptosis while increasing the VEGF expression [113] and regulates EC 
proliferation and migration, which are essential for sprouting [114]. 
The key steps and the biochemical/mechanical regulators of angiogenesis is given in 
Figure 9.  
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Figure 9. The key steps and the chemical and mechanical factors that regulate angiogenesis 
The functions of the biochemical and mechanical factors in the steps of angiogenesis are 
summarised in Table 4. 
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Table 4. Summary of biochemical and mechanical factors that regulate the key steps in angiogenesis 
Angiogenic Step Factor Function 
Angiogenic Trigger 
Hypoxia 
Activation of angiogenesis-related genes due to 
reduction in oxygen [32]. 
Shear Stress 
Shear stress caused by laminar flow has been 
reported to reduce the apoptosis while increasing the 
VEGF expression [113] and demonstrated to regulate 
EC migration [114]. 
Vessel 
Destabilisation 
VEGF Increases the vessel permeability [47,115]. 
Ang-2 
Mediates EC monolayer destabilisation and loosen EC-
pericyte interaction [17,18]. 
MMPs 
Breaks down ECM to maintain a space for ECs to 
migrate and proliferate [107,108]. 
Vessel sprouting 
VEGF Stimulates EC proliferation and migration 
Ang-2 Maintains the loosen space for ECs to migrate [17,18]. 
FGF Stimulates to generation of MMPs [59,60]. 
MMPs 
Degrades ECM not only to maintain a space for ECs to 
migrate and proliferate but also to regulate the 
release of angiogenic factors that is naturally stored 
extracellularly [107,108]. 
TGF-β 
Induces endothelial proliferation and migration. 
Regulates MMPs at lower concentrations [58]. 
Integrins 
Regulates matrix degradation VEGFR-2 activation and 
subsequently proliferation, migration, and survival of 
ECs [92,93,101]. 
CTFs Helps ECs to migrate [110,111]. 
Vessel Stabilisation 
TGF-β 
Inhibits EC proliferation and induces 
basement membrane reformation [58]. 
PDGF 
Promotes vessel stabilisation and maintains vascular 
integrity [56]. 
Ang-1 
Induces pericytes recruitment and vascular 
maturation [116] 
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 Current Strategies to Overcome Slow Neovascularisation in TE constructs 
 Use of proangiogenic cells (prevascularisation) 
Prevascularisation approach aims to generate a preformed microvascular structure 
within the scaffold prior to implantation. This primitive microvascular network can then 
anastomose simultaneously with the surrounding host microvasculature rapidly upon 
implantation and supply nutrients to the construct in a reduced time [26,117]. 
 In vitro prevascularisation systems 
 Seeding vessel-forming (pro-angiogenic) cells  
Cell seeding is one of the most widely used in vitro prevascularisation technique where 
cells which have vessel-forming capabilities are seeded on TE or natural (decellularised) 
scaffolds.  
In the early studies, endothelial cells have been used as pro-angiogenic cell sources [118]. 
Scientists reported successful inosculation of the formed microvasculature with the host 
tissues within the first ten days of implantation when ECs are seeded on various 
biomaterials including calcium phosphate cement [119], polymer scaffolds [120,121], 
collagen [122]. Although they have great potential to be used in prevascularisation 
studies, use of ECs also bears some disadvantages such as difficulties for harvesting ECs 
in large quantities, slow proliferation during cultivation, and showing different 
angiogenic properties in terms of permeability, immune tolerance and angiogenic 
potential when harvested from different sources [123,124]. Thus, fast proliferating 
endothelial progenitor cells (EPCs), which can be harvested from bone marrow or 
peripheral blood, were suggested as alternatives to overcome these drawbacks 
[125,126]. Apart from EPCs, scientists also reported successful prevascularisation of 
tissue engineering constructs with the use of mesenchymal stem cells (MSCs) [127,128], 
which can be harvested from bone marrow or adipose tissue. 
Tissue engineering constructs used for in vitro prevascularisation approaches can be 
derived from either synthetic or natural sources, and selection of material is critical as it 
affects the degradation time in vivo and integrity of the TE construct in terms of structure 
and function [129]. A large number of scaffold materials can be used in this approach. 
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Synthetic polymers are widely used as scaffold materials because of their controllable 
properties to mimic the natural environment. Polycaprolactone (PCL) [130–132], Poly-L-
lactic acid (PLLA) [133,134], poly(glycolic acid) (PGA) [135], poly(lactic-co-glycolic acid) 
(PLGA) [136], polyurethane (PU) [137,138], poly(glycerol sebacate) (PGS) [139], and 
their composites are widely used synthetic biodegradable polymers for prevascularised 
TE constructs. On the other hand, natural polymers are abundant and contain 
components that are naturally presented in biological extracellular matrices, which 
makes these polymers more compatible for implantation and supporting cell function. 
The most common natural-origin polymers used in tissue engineering applications are 
Polyhydroxyalkanoates (PHAs) such as Poly (3-hydroxybutyrate) (PHB) [140], Poly (3‐
hydroxyoctanoate) [141], Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) 
[142,143], and other natural polymers including collagen [144–146], elastin [147], silk 
fibroin [148,149], gelatin [59,150], cellulose acetate [151], polyethylene glycol (PEG) 
[152,153], dextran [154], and hyaluronic acid (HA) [145]. 
Developing a synthetic vascular architecture is a good approach to promote enough cell 
attachment as well as storing and releasing angiogenic factors. The channels can be 
created by combining several methods such as 3D printing and leaching [155], 3D 
printing and electrospinning [143,156], direct bioprinting of cell-laden hydrogels 
[157,158] with biomimetic ECM structure [159], photolithography [160] can act as an 
angiogenic factor releasing bioreactor for appropriate cell types which can be cultured 
inside the channels to form tubule-like structures prior to implantation. 
On the other hand, development of decellularised natural constructs for their use in in 
vitro prevascularisation studies is a well-established and promising way of scaffold 
fabrication. In this technique, biological tissues or organs with natural vasculature can be 
obtained by decellularising, and then they can be repopulated with appropriate cells 
before implantation to create prevascularised TE constructs. These kinds of structures 
provide a natural environment for cells to attach and form new microvascular structures 
[161]. Some examples for in vitro use of natural structures are acellular cadaveric hearts 
which were recellularised with cardiac cells and rat aortic ECs [162], decellularised 
porcine jejunum was seeded with porcine ECs [163], acellular porcine heart was then 
reseeded with human umbilical vein endothelial cells (HUVEC) [164], and recently our 
group developed a decellularised rat intestine repopulated with Human Dermal 
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Fibroblasts (HDFs) and Human Dermal Microvascular Endothelial Cells (HDMECs) [165]. 
Recently, Gershlak et al., demonstrated that decellularised spinach leaves could be 
recellularised with human ECs used as prevascularised constructs [166,167].  
 Generating spheroids from proangiogenic cells 
Spheroids are 3D cell clusters generated by several methods such as the hanging drop, 
the non-adhesive surface, the micromolding, spinner flask, and rotary system techniques 
[168], and they are used in various biomedical applications including but not limited to 
angiogenesis, drug discovery, toxicity analysis, and cancer studies [169–172]. Over the 
last years, spheroids were also reported for their use in prevascularisation studies. ECs 
are combined with various cell types to successfully create prevascularised tissue 
constructs such as prevascularised bone when ECs combined with osteoblasts [173], 
prevascularised adipose tissue when ECs are combined with adipose-derived stromal 
cells [174]. Beside the use of ECs, spheroids formed with the use of MSCs were also 
reported as in vitro prevascularised constructs [175]. 
 Cell sheet technology 
Cell sheet technology is a scaffold-free method where a temperature-sensitive smart 
surface (poly-(N-isopropylacrylamide) (PIPAAm)) is used for generating prevascularised 
cell sheets [176,177]. Several examples of prevascularised tissues have been reported 
including but not limited to prevascularised fibroblast cell sheets [178], bone cell sheets 
[179] cardiac cell sheet with ECs [180,181], and without any other cell types (ECs in 
isolation) [182] or with periendothelial cells [183]. 
 In vivo prevascularisation systems 
In vivo prevascularisation is another approach to overcome slow neovascularisation 
problem. In this approach, natural vasculature of the host (like a natural bioreactor) is 
used to prevascularised the developed construct. The most basic approach is to implant 
a scaffold into a well-vascularised part of the host, such as subcutaneous skin [184]. 
Similarly, prelamination or flap technique, which is defined as the implantation of 
scaffolds into a muscle flap for prevascularisation to occur [185]. The importance of the 
flap technique is that this method has been reported as the first successful example of in 
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vivo prevascularisation techniques which were clinically used in an adult male patient 
[186]. The Arteriovenous (AV) loop technique is another method for fabricating 
prevascularised constructs. It was originally developed in the late 1970s when an 
arteriovenous fistula was constructed, and its shape is a loop leading to new capillary 
formation into that loop [187]. The method of prevascularisation via an AV loop 
technique is that when the AV loop is placed in a protected space (i.e. a chamber) filled 
with appropriate ECM contents (soft or hard matrices), a prevascularised construct in a 
defined shaped can be generated [188]. Several matrix materials either enriched with 
growth factors or not have been reported for their use in an AV loop prevascularisation 
technique; soft matrices such as Matrigel [189], fibrin [190], and natural dermis [191] 
and hard matrices such as PLGA [192] and bovine cancellous bone have been used 
[193,194]. 
 Use of pro-angiogenic agents (functionalisation of the scaffolds) 
Growth factors are key elements in regulating angiogenesis, and therefore incorporation 
of these growth factors into TE constructs to ensure rapid neovascularisation upon 
implantation is a widely studied approach. In the developed scaffolds, growth factors can 
be directly used either on their own: VEGF [195], PDGF [196] or in combination with 
other factors such as PDFG and VEGF together [197] to promote vascularisation. Details 
of the well-established proangiogenic factors were given in Section 1.3.1.1.  
In addition to direct use of well-established growth factors, indirect activation of these 
growth factors have been established with the delivery of other biomolecules such as 
heparin [198], hypoxia-inducible factor 1 (HIF-1) [199], bone morphogenetic protein 
(BMP) [200], and sonic hedgehog homolog (SHH) [201]. 
Functionalised scaffolds with growth factors can be fabricated using either synthetic or 
natural polymers, and carry single or multiple growth factors in order to deliver these 
growth factors in a controlled manner [202]. The selection of materials is especially 
important according to the intended usage area as the growth factor release profile will 
be influenced by varying degradation rates and the degradation profile of the material, 
which depends on the chemistry and geometry of the material [26]. One approach to 
control these factors is material selection. However, a novel approach has been suggested 
to overcome this problem in an on-demand manner, which is a specific chemical linkage 
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of the growth factors to a gel matrix which will be degraded by the MMPs that is naturally 
secreted by the endothelial cells of the host. This degradation will enable cells to release 
growth factors in response to a need in a local area [203]. 
 Established Angiogenesis Assays 
 In vitro angiogenesis assays 
 EC proliferation assays 
The proliferation of ECs plays a key role in sprouting angiogenesis. Thus, proliferation 
assays are commonly used to study angiogenesis in vitro. They are quick, reproducible, 
inexpensive and easy to perform. Proliferation assays can be performed using various 
tools [204,205].  
Determining the net cell number is the simplest method where a defined number of ECs 
are seeded and treated with proangiogenic or antiangiogenic drugs, and after a certain 
period of time, the increase in the number of ECs is measured by counting cells using a 
haemocytometer or automated devices [206,207]. 
Another widely used method is tracking the metabolic activities of ECs via metabolic 
activity assays such as the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT), which is based on enzymatic conversion of yellow coloured tetrazolium 
salt to purple⁄blue coloured water-insoluble formazan crystals by living cells. This 
enzymatic reaction occurs by the activity of nicotinamide adenine dinucleotide 
phosphate (NADPH)-dependent cellular oxidoreductase mainly at mitochondria. The 
water-insoluble formazan crystals then can be dissolved in dimethyl sulfoxide (DMSO), 
and the solubilised formazan product is quantified using a plate reader. A reference curve 
can be used to correlate the formed formazan crystals by ECs with the cell number 
[208,209]. As an alternative to MTT, AlamarBlue® assay (also known as resazurin 
reduction assay) is a well-established method for the quantification of metabolic activity 
of cells. The principle of this assay is based on irreversible NADPH-dependant reduction 
of weakly fluorescent resazurin to purple coloured and highly fluorescent resorufin 
mainly in the mitochondria of the living cells. The biggest advantage of the AlamarBlue 
assay is that it is a non-destructive method which means the same samples can be used 
for the measurement of metabolic activities at different time points [210]. 
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DNA synthesis is another method for the assessment of ECs proliferation, which is based 
on the determination of bromodeoxyuridine (BrdU), a molecule competing for thymidine 
for incorporation into DNA during replication, by immunocytochemistry or by ELISA to 
determine the total number of cells [211,212]. 
Quantitative methods for the determination of DNA content in different time points is an 
alternative method to investigate the proliferation of ECs. PicoGreen assay is a well-
known method to quantify DNA content which can be used to assess ECs proliferation. 
The principle of this assay is based on the affinity of PicoGreen fluorescent probe to 
double-stranded (ds) DNA which creates a highly fluorescent complex. The major 
interactions of PicoGreen binding to dsDNA are intercalation (the insertion of the dye 
between the planar bases of dsDNA) and electrostatic attractions [213].  
 EC migration assays 
During angiogenesis, ECs migrate into the perivascular area by degrading the basement 
matrix in response to stimulation. Therefore, assessment of the migratory response of 
ECs is recognised as an important marker of angiogenesis. A modified version of a Boyden 
chamber assay, originally developed for studying leukocyte chemotaxis in the 1960s 
[214], is a frequently used method for the assessment of EC migration in vitro. It is a type 
of transfilter assay which consists of two chambers and is based on the migration of ECs 
from the upper chamber (upper side of the filter) to the lower chamber (lower side of the 
filter) in response to a chemoattractant [215]. The migrated cells can be stained with 
various dyes (such as crystal violet) and quantified by either manual counting of cells by 
eye, which is difficult and time consuming, or image processing. The Boyden chamber 
assay is easy to perform, fast, inexpensive, accurate and reproducible [205]. 
Scratch assays, or in vitro wound healing assays, are also widely used assays for the 
determination of the migratory response of ECs to an external stimulus. Briefly, a 
scraping tool is used to remove a known area of confluent EC monolayer, which creates a 
margin for ECs to migrate into and close the scratch [216]. The migration rate and the 
closure of the scratched area can be calculated by capturing the closure at different time 
points using several microscopy techniques. The results can be quantified by processing 
the images using image processing software such as ImageJ. The biggest advantage of this 
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method is the continuous monitoring of cell migration (at different time points) which 
can be used to estimate the rate of migratory response [217]. 
As an alternative method, cell motility can be measured directly by phagokinetic tracking 
methods. The earliest version of this type of assay was based on using colloidal gold-
plated coverslips which were replaced by the preparation of 96-well plates by depositing 
of 1 µm polystyrene beads onto the bottom of the wells. In both versions of the cell 
motility assays, ECs generate tracks either on colloidal gold-plated coverslips or 
polystyrene beads, which can be used to determine the directional properties and total 
distance of migration [205,218]. Although this method is an accurate way of measuring 
the motility of ECs, the analysis of the results is time consuming, and it requires complex 
software to track cell paths. 
 EC differentiation (tube formation) assays 
The EC differentiation assays are based on evaluating the formation of tube-like 
structures that are regarded as mimicking the differentiation stage of angiogenesis in 
response to proangiogenic or antiangiogenic compounds. The simplest differentiation 
assays are those where ECs are plated onto/into gel layer (such as Matrigel, collagen or 
fibrin gel), which act as a basement matrix to promote attachment, migration and tube 
formation of ECs. The selection of the gel matrix is particularly important for the quality 
of the assessment. Using collagen I and III can result in enhanced proliferation of ECs but 
not tube formation while collagen IV and V show an exact opposite reaction [219,220]. 
Matrigel® is the trade name of a gelatinous protein mixture derived from a hamster 
fibrosarcoma, which is rich in collagen IV, laminin, proteoglycans and growth factors. This 
biologically active protein mixture has been shown to be a good candidate for mimicking 
native basement membrane of ECs in vitro and promotes ECs to form tube-like capillary 
structures [221]. More recently, a company has introduced a growth factor reduced 
version of Matrigel, which helps to reduce the unspecific reaction of ECs with the 
cytokines and growth factors naturally presented in the matrix to form tube-like 
structures [205]. 
An alternative tube formation assay is that ECs are co-cultured with a stromal type of cells 
(fibroblasts, SMCs or pericytes) either in the presence or absence of an ECM. The assay is 
based on the assessment of tube formation within the ECM secreted by stromal cells. 
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In addition to 2D assays, 3D tube formation assays have previously been developed 
where ECs are seeded between two layers of gels (such as collagen, fibrin or Matrigel). 
This method enables the evaluation of the tube formation in two different planes. It has 
been reported that ECs form tube-like structures in horizontal plane in 7 days, whereas 
after day 15, the existing tubules branch upwards and create a 3D network [222]. The 
major drawback of 3D tube formation assays is that the difficulty of analysing the results 
as the imaging should ideally be performed in more than one plane. 
 Ex vivo angiogenesis assays 
 Rat aortic ring assay 
The aortic ring assay has been developed following the observation of spontaneous 
branching from aortas when cultured in vitro [223] in order to mimic in vivo angiogenesis 
in vitro [204,205]. The aortic ring assay is a commonly used method for studying 
angiogenic activity in response to a drug. Briefly, the explanted aorta (usually from rats) 
is cleaned to remove the surrounding fibrous and adipose tissue before cutting into 
smaller segments (usually 1 mm thick). Aorta segments are then embedded in matrix gels 
such as collagen, fibrin, or Matrigel [224,225] and the outgrowth of vessels in response 
to a stimulus or deterrent can be analysed via imaging the rings at different time points. 
The aortic ring assay is an effective way of evaluating angiogenic or antiangiogenic 
response. However, the drawbacks of this assay are the ethical concerns, special skill 
requirement and difficulties of quantification [226]. 
 Chick aortic arch assay 
A modified version of the rat aortic ring assay is where the chick aortic arch is used to 
study angiogenesis ex vivo [227]. The ECs of chick aortic arch shows the characteristics 
of microvascular cells. The chick aortic arch assay is rapid and inexpensive and raises less 
ethical concerns (when compared with rat aortic arch assay). The major disadvantage of 
this assay is that the aortic rings are explanted from immature embryos, whereas the ECs 
are very proliferative. Thus, it does not fully represent angiogenic sprouting in vivo [205]. 
 
 
28 
 
 In vivo angiogenesis assays 
 Chick chorioallantoic membrane (CAM) assay 
The CAM of the chick embryo is an extraembryonic membrane that functions as an organ 
for gas exchange between the embryo and the environment. It is home to a lot of blood 
vessels with a dense capillary network, and because it stays on top of the developing 
embryo, it is easily accessible for experimental interventions. The chick is relatively 
immunotolerant, and the CAM assay has traditionally been used to test the pro and anti-
angiogenic response to drugs [228], to study many aspects of tumour angiogenesis 
[229,230], to study mammalian tissue explants [231] since the 1970s when it has been 
introduced to the world of angiogenesis by Folkman et al. [232]. With recent advances in 
biomaterials science and engineering, another area where the CAM assay can prove 
useful is in biomaterials testing.  
The CAM assay can be a valuable assay to test biomaterials extensively in vivo before they 
are further investigated in relevant animal models [233]. In the context of biomaterials 
testing, the CAM can be effectively used as a short term host for grafted materials, organs 
and tissue samples where the angiogenic response and their safety and biocompatibility 
can be studied [234]. It is also promising that the CAM assay has recently been 
demonstrated to produce data that is comparable to mouse assays in testing 
biodistribution and in vivo stability of radiopharmaceuticals [235].  
For the purpose of biomaterials testing in-ovo [236] and ex-ovo [69,237] culture methods 
have been used. The ex-ovo (embryo is cultured outside of the eggshell) modification of 
the classical in ovo CAM assay (embryo is cultured inside of the eggshell) offers several 
unique advantages for biomaterials testing. The ability to grow ex-ovo cultures with 
comparable survival rates was first reported in 1974 [232]. Although it was reported by 
several authors that the ex-ovo modification is associated with worse survival rates [238], 
our experience does not confirm this finding. We consistently have survival rates above 
80% [69,239,240]. The main advantage of the ex-ovo culture method is better 
visualisation of the growing embryo and access to a larger area of the CAM to study 
angiogenesis. Additionally, the vascularisation process can be observed at all times 
during the experiment. Further details of the CAM assay and a step-by-step 
demonstration of the protocol can be found in our published video protocol paper [241]. 
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Comparison of in-ovo and ex-ovo CAM assay procedures in terms of survival rate, ease of 
assay procedure, cost, CAM accessibility, and monitoring of angiogenesis is given in 
Table 5. 
Table 5. Comparison of in-ovo and ex-ovo CAM assay procedures in terms of survival rate, ease of 
assay procedure, cost, CAM accessibility, and monitoring of angiogenesis. (+ = very low, ++ = low, 
+++ = medium, ++++ = high) 
Parameters In-ovo Ex-ovo 
Survival rate ++++ +++ 
Technical challenge ++ ++++ 
Cost effectivity ++ ++ 
Accessibility of the CAM ++ ++++ 
Monitoring of angiogenesis + ++++ 
Quality of imaging of angiogenesis ++ ++++ 
 Corneal angiogenesis assay 
The cornea is an avascular and translucent tissue, which makes it attractive for 
angiogenesis studies due to the fact that any blood vessel observed on corneal stroma 
will be newly formed and readily detectable [242,243]. The corneal angiogenesis assay is 
based on stimulation of ECs from the edge of the cornea to migrate and form new sprouts 
into space where the corneal epithelium and stromal cells located in response to an 
angiogenic signal. The corneal assay can be performed in various animal models such as 
the rabbit, rat, and mouse [244–246]. The major drawbacks of this assay are being 
expensive and showing different angiogenic responses in response to different types of 
injuries [247]. 
 Zebrafish assay 
Zebrafish (Danio rerio), a translucent freshwater fish, is able to produce hundreds of 
embryos per week, and in recent years, it caught scientist’s attention to be used in 
angiogenesis studies. Zebrafish angiogenesis assay provides some advantages such as 
being inexpensive, develop rapidly, share many genetic materials with mammals, and the 
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optical transparency of the embryos [248]. To visualise the newly forming blood vessels, 
various techniques can be used including such as alkaline phosphatase staining and 
confocal microangiography [249–251] 
 The dorsal skinfold chamber assay 
The principle of the dorsal skinfold chamber assay is based on the implantation of a 
translucent chamber which enables in vivo imaging of the blood vessel development in 
mammals. The visualisation of the vasculature can be performed via several microscopy 
techniques such as light transillumination microscopy (where the thickness of the tissue 
is less than 300 µm), epi-illumination microscopy or intravital microscopy [252]. The 
earliest example of the transparent chamber models is the rabbit ear chamber that was 
then adapted to be used in mice models in 1940s [253].  
Several animal models have been used for chamber implantation to dorsal skinfold. These 
include mice, rat and hamster [254–256]. In this assay, a transparent chamber is 
implanted into dorsal skinfold of the animal, which enables the visualisation and 
quantification of angiogenesis in vivo. The parameters which can be evaluated include 
blood vessel density and blood flow velocity [248]. The major advantage of this model is 
that the evaluation of vessel growth in 3D is that it is possible to do when the animal is 
conscious over four weeks (no need to use multiple animals for different time points). 
Animals are placed in a restraining chamber for the duration (often several hours) of the 
assay. However, the assay is technically challenging and requires special skills to perform. 
Furthermore, the quantification is time consuming, and it requires complex image 
analysis systems [205].  
 Animal matrix implantation assays 
Various materials have been implanted into animals to monitor angiogenesis and/or 
wound healing. These materials include stainless steel meshes [257], polymer sponge 
matrices [258], and Matrigel plugs [259]. Such assays are performed by implanting a type 
of matrix scaffold (frequently Matrigel plug or a polymeric scaffold) subcutaneously into 
rat, mouse, or rabbit. The implant usually contains a test substance such as pro-
angiogenic or anti-angiogenic agents, growth factors, cells, tumour fragments etc..) and 
angiogenesis in response to the test substance is assessed at the end of the assay which 
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is typically 7-10 days after implantation. The Matrigel plug or polymer matrix can then 
be explanted, fixed, sectioned and histologically evaluated for the angiogenesis. Although 
being relatively easy to set up and less time consuming make this assay versatile and 
powerful, the main drawbacks of this assay are non-specific host response to the implant, 
varying results depending on the material properties used (implant size, structure, pore 
size, porosity, interconnectivity etc..) [204,260]. In addition, Matrigel is an expensive and 
tumour-derived extract which contains intrinsic growth factors and cytokines, which 
may cause false-positive results and sectioning of Matrigel can be difficult and time 
consuming [205]. 
A summary of established angiogenesis assays is given in Table 6. 
Table 6. A summary of established in vitro, ex vivo, and in vivo angiogenesis assays 
  Advantages Disadvantages 
In
 v
it
ro
 a
ss
a
ys
 
Proliferation 
assays 
• Cost-effective 
• Highly reproducible 
• Short duration 
• Sensitive 
• Easy to set up 
• Quantitative results 
• No ethical concern 
 
• Only one aspect of angiogenesis can 
be assessed 
• Static conditions 
• 2D environment 
• Low representation of in vivo 
angiogenesis 
Migration assays 
• Reproducible 
• Relatively short 
duration 
• Sensitive 
• Can estimate 
migration rate and cell 
motility 
• No ethical concern 
 
• Only one phase of angiogenesis can 
be assessed 
• Static conditions 
• 2D environment 
• Low representation of in vivo 
angiogenesis 
• Quantification may lead to false 
results 
• Results may vary depending on 
experimental conditions 
 
Differentiation 
assays 
• Very short duration 
• Sensitive 
• Easy to analyse 
• No ethical concern 
 
• Only one phase of angiogenesis can 
be assessed 
• Difficult to perform 
• Static conditions 
• 2D environment 
• Low representation of in vivo 
angiogenesis 
• Results may vary depending on 
experimental conditions 
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x 
v
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o
 a
ss
a
y
s 
Rat aortic ring 
assay 
• Better mimicking of in 
vivo conditions 
• Rapid assay procedure 
• Relatively inexpensive 
• Less ethical concern 
• Technically challenging 
• Difficult to quantify 
• Static conditions 
• Results may vary depending on 
experimental conditions 
Chick aortic arch 
assay 
• More representative of 
in vivo conditions 
• Rapid assay procedure 
• Relatively inexpensive 
• Less ethical concern 
 
• Technically challenging 
• Difficult to quantify 
• Static conditions 
• Results may vary depending on 
experimental conditions 
In
 v
iv
o
 a
ss
a
ys
 
CAM assay 
• More representative of 
in vivo conditions 
• Rapid procedure 
• Reproducible 
• Relatively inexpensive 
• Less ethical concern 
• Allows to test multiple 
test substances in one 
experiment 
 
• Technically challenging 
• Very difficult to quantify 
• Hard to distinguish between existing 
and newly formed blood vessels 
• Non-specific reaction due to 
experiment conditions such as 
infection or physical irritation of the 
membrane 
Corneal assay 
• Reliable 
• Easy to quantify 
 
• Expensive assay 
• Technically challenging 
• Results may vary depending on 
experimental procedure such as 
different wound types 
• Use of an avascular tissue for 
studying angiogenesis is disputable 
• Ethical concern 
Zebrafish assay 
• Easy to monitor 
angiogenesis 
• More representative of 
in vivo conditions 
• Less ethical concern 
• Inexpensive 
• Rapid procedure 
• Easy to quantify 
• Use of fish ECs to study human 
angiogenesis can be disputable 
• Requires to establish a zebrafish 
facility 
 
Dorsal skinfold 
chamber assay 
• More representative of 
in vivo conditions 
• Reliable results 
• High ethical concern 
• Technically challenging 
• Invasive procedure 
• Expensive 
• Quantification is time consuming 
• Requires complex image analysis 
systems 
33 
 
Matrix 
implantation 
assay 
• More representative of 
in vivo conditions 
• Not technically 
difficult 
• Easy to set up 
• Can be used to study 
more than one aspect 
such as angiogenesis, 
wound healing, cell 
proliferation, invasion 
etc. 
• Time consuming analysis of the 
explants 
• Expensive 
• Ethical concern 
• Non-specific host tissue response to 
implant 
• Variable results depending on the 
material properties used (implant 
size, structure, pore size, porosity, 
interconnectivity etc..) 
 The Structure of Human Skin 
Skin is the outmost layer of human body and serves as a physical barrier between the 
body and the external environment. Its function as a barrier is not limited to the 
prevention against microorganism invasion [261], but also includes prevention from 
dehydration, mechanical, chemical, and thermal damage, and exposure to ultraviolet (UV) 
[262,263]. Beside its main barrier function, skin also has a role in sensation and 
regulation of thermal, chemical, metabolic and immune system functions [264]. Almost 
15% of the human body consists of skin which is the largest organ of the body. Its 
thickness ranges from 40 µm (eyelids) to 1 mm (palm of the hand) [265]. 
There are three main layers of skin clearly distinguishable: (i) epidermis, (ii) dermis, and 
(iii) subcutaneous layer [266]. However, basement membrane and skin vasculature also 
have importance to understand the structural organisation of skin. The schematic 
illustration showing the layers of skin is given in Figure 9. 
 Epidermis 
The epidermis is the outermost layer of skin and consists of mostly keratinocytes 
(approximately 95%) and other cells including melanocytes (pigment-producing cells), 
Langerhans cells (cells which form a very early immune defence of skin by presenting 
antigens), and Merkel cells (cells which acts as transducers of light touch sensation) 
[265]. The epidermis has distinct layers from the upper layer to the lower layer to down; 
(i) the stratum corneum consists of cornified keratinocytes and acts as the primary 
barrier against bacteria entry and water loss, (ii) the stratum granulosum has been 
named due to the granules (keratohyaline) it contains, which help the aggregation of the 
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keratin filaments, (iii) the stratum spinosum consists of four to ten layers of polyhedral 
(spinous) cells, and (iv) the stratum basale which is the lowest layer and plays a key role 
as the junction between the epidermis and the dermis [267–269]. 
 Basement membrane 
The basement membrane separates the epidermis from the dermis, acts as a mechanical 
support and mediates chemical signal passage between these two layers [270,271]. The 
basement membrane dominantly consists of collagens IV and VII, integrins 
(predominantly α6β4 that binds to laminin), laminin and elastic fibres which link the 
epidermis to the dermis [272,273]. 
 Dermis 
The dermis is localised between the epidermis and the subcutaneous tissues and consists 
of collagen (responsible for the strength), elastin (responsible for elasticity), 
glycosaminoglycans (GAGs), dermal fibroblasts (the main type of cells that present in the 
dermis), macrophages, dendrocytes (dendritic cells which appear to have a role in 
immune function with their cytochemical characteristics), mast cells (migrant connective 
tissue cells which mainly take part in allergic reactions and also in wound healing and 
angiogenesis), blood vessels, and nerves [265]. 
The dermis has two distinct layers: (i) the papillary dermis which contains thin, loosely 
arranged elastin and collagen fibres and (ii) the reticular dermis which is mostly 
composed of disorganised connective tissue (mostly collagen running horizontally to 
provide mechanical support) [274]. GAGs in dermis supports collagen and elastin fibres 
and are responsible for holding water (up to a thousand times higher volume than their 
volume), for aiding the passage of nutrients and other molecules [275].  
 Subcutaneous layer 
The subcutaneous layer (also known as the hypodermis) lies below the dermis, and it 
mainly consists of adipose tissue and connective tissue. It also contains hair roots, blood 
vessels and nerve endings traversing fat and connective tissues. The subcutaneous layer 
serves as an insulator to aid regulating body temperature, and it also acts as a cushion 
that provides mechanical support to protect muscles, bones, organs etc. [265]. 
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 Vasculature in skin 
Blood vessels are present in the dermis have functions in providing oxygen and nutrients 
to the dermis, removal of waste products and maintaining body temperature by the 
dilation or contraction of vessels to regulate surface heat loss [264]. Vascular networks 
in skin consist of two plexuses: (i) superficial plexus and (ii) deep plexus, which lies in 
the upper and lower parts of reticular dermis, respectively [276]. 
 
Figure 10. Schematic illustration of the structure of human skin (figure modified from 
lumenlearning.com with permission). Skin is composed of three histologically distinguishable layers: 
(i) epidermis, (ii) dermis, and (iii) hypodermis 
 Natural Wound Healing in Cutaneous Wounds 
A wound can be defined as an injury that results in disruption or damage to the 
anatomical structure and function of the native tissue. Wounding can be either as simple 
as the loss of the epithelial integrity or deeper and more complex, reaching to 
subcutaneous tissue, including muscles, nerves and blood vessels. Wounds are classified 
in three main categories: (i) acute wounds which repair themselves anatomically and 
functionally following the natural order of the wound healing process, (ii) complicated 
wounds that are mostly a combination of a tissue defect with infection which is a constant 
threat for wound healing process, and (iii) chronic wounds which do not heal in an 
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orderly way following the stages of wound healing in a timely manner. Wound healing is 
a complex series of events involving haemostasis, inflammation, granular tissue 
formation, proliferation, neovascularisation and remodelling in which many growth 
factors plays a pivotal role (Figure 10).  
 
Figure 11. Schematic illustration showing the wound healing phases: (i) bleeding, (ii) haemostasis, 
(iii) inflammation, (iv) granular tissue formation, (v) re-epithelialisation, (vi) neovascularisation, 
and (vii) remodelling 
 Haemostasis 
Haemostasis is defined as the response of body to prevent and stop bleeding by the 
platelet adhesion and aggregation. Following tissue injury, platelets form a fibrin clot 
which limits haemorrhage in the wound site [277]. The clot seals the injury and prevents 
the spread of infection in the area and further bleeding. Although haemostasis is the first 
stage of wound healing and mainly plays a role in blood clotting, it also provides a matrix 
for the recruitment of the cells to the injury site [278]. In addition, clotting plays a key 
role in the activation of the inflammation process [279]. 
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 Inflammation 
The inflammation phase is a result of the host immune response to the wound. Several 
types of cells, including neutrophils, macrophages, mast cells, T cells and B cells, take part 
in the inflammatory response to wound healing [280,281]. The inflammatory response 
begins with the invasion of the site of wound with neutrophils which not only clears out 
the dead cells, bacteria and other pathogens and debris but also provides a chemotactic 
stimulus for other inflammatory cells and facilitates their migration by stimulating the 
release of several ECM molecules [282]. Monocytes (which will become macrophages 
when migrated to the wound site from the bloodstream) then migrate to the area of 
inflammation to induce the secretion of cytokines and growth factors which 
consecutively initiate granular tissue formation. Macrophages have been shown to have 
a significant role in the transition of the inflammatory response to the wound healing 
phase. The latest phase of the inflammatory response is the entering of lymphocytes (T 
cells and B cells) to the wound area in response to interleukin-1 (IL-1) which plays a 
pivotal role in collagen remodelling and ECM formation [283,284]. 
 Granular tissue formation and proliferation 
Following the wound creation, haemostasis and inflammatory response phases, the 
tissue repair phase takes place. About 4-days after injury, granulation tissue which 
mainly consists of macrophages, fibroblasts, early connective tissue, and blood vessels 
form [285,286]. The fibrin clot formed during the haemostasis stage provides an ECM to 
promote granular tissue formation. Macrophages from the inflammatory phase 
continuously secrete cytokines to promote fibrous tissue formation and angiogenesis in 
the site of the wound. Particularly TGFβ and PDGF attract fibroblasts, which are the main 
type of cells that are present in the proliferative phase [287]. Fibroblasts produce 
fibronectin to replace the fibrin clot and then collagen to gradually replace fibronectin 
with an ultimate aim of producing a mature ECM, and they begin differentiating into 
myofibroblasts [288]. In addition, wound contraction begins in the proliferative phase. 
 Re-epithelialisation 
Following the granular tissue formation and proliferative phase of fibroblasts, 
keratinocytes are needed to proliferate and reconstitute the cutaneous barrier [289]. Re-
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epithelialisation takes place via cell-cell, cell-basement membrane contact and molecular 
signalling. Briefly, keratinocytes sense the absence of neighbour cells and begin changing 
morphologically. Epithelial growth factor (EGF), keratinocyte growth factor (KGF) and 
TGFβ induces the proliferation and migration of keratinocytes while MMPs generated by 
damaged keratinocytes facilitate the migration by degrading basal membrane [290]. 
Once a full closure of the wound is achieved, cell-cell contact of keratinocytes inhibits 
further proliferation [291,292], and keratinocytes become strongly adhered to the newly 
formed basement membrane and reconstitute an epithelium [290].  
 Neovascularisation 
The neovascularisation of the healing area wound is crucial and involves complex 
angiogenic phases. After wounding of a tissue, clotting and granulation, capillaries begin 
invading to the healing site. During the haemostatic and proliferative phase of wound 
healing, a large number of pro-angiogenic factors including VEGF, TGF-β, PDGF and FGF 
are released to promote angiogenesis [293–295]. Since the ECs are responsive to these 
pro-angiogenic factors as well as ECM molecules, capillaries from the surrounding tissues 
start to invade the formed clot and within a couple of days a microvascular network forms 
within the area of healing [296]. The details of the angiogenic processes and the signalling 
pathways were explained in the previous sections. 
 Remodelling 
The remodelling phase is the final stage of wound healing which may take up to 1 – 2 
years and involves the maturation of the ECM which has been synthesised temporarily 
during the earlier phases of wound healing [297,298]. The remodelling phase is highly 
controlled to maintain a balance between degradation and synthesis, where MMPs plays 
a key role. Collagen fibrils increase in diameter, whereas fibronectin and hyaluronic acid 
are degraded gradually, and collagen bundles become more oriented from their initial 
disorganised structures [299,300]. The connective tissue begins shrinking and brings 
wound margins together. By the time the wound heals, the density of macrophages and 
fibroblasts reduces [301], and at the end, a fully matured scar is obtained with organised 
blood vessel network [302,303]. 
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 Strategies to Fabricate Vascular Networks for Angiogenesis Studies 
 Natural scaffold systems 
Development of natural constructs with an intrinsic 3D architecture of a tissue or organ 
by decellularisation is an important approach in angiogenesis studies. This technique is 
mainly based on decellularisation of a tissue or organ to obtain 3D microvascular 
networks. These networks can be recellularised with cells to study or promote 
angiogenesis. The major advantage of this method is the retaining of the intrinsic ECM 
components that improve the attachment and proliferation of ECs.  
Use of decellularised biological constructs has become an emerging strategy for 
producing physiologically relevant scaffolds for use in both pre-clinical and clinical 
applications [304,305]. The methodology for decellularisation of tissues and organs is 
well-established, and several studies have reported on the use of this approach for 
generating patches for tissue regeneration, as in vitro models or drug screening 
platforms. For example, Sarig et al. successfully decellularised a porcine heart and 
constructed an acellular matrix to be repopulated with progenitor cells and used as an ex 
vivo drug screening platform, as an in vitro model for studying human cardiac tissue and 
transplantable patches. [164] Similarly, our group generated a decellularised rat 
intestine and repopulated it with human microvascular endothelial and stromal cells 
successfully as an in vitro model to study several aspects of neovascularisation [306]. 
Melo et al. established an in vitro multicellular bronchial model using decellularised 
porcine luminal trachea membrane [307]. Uygun et al. developed a decellularised liver 
matrix and recellularised it with adult hepatocytes as a transplantable liver graft [308]. 
Mertsching et al. developed an acellular porcine small bowel segment and conducted a 
pilot trial for evaluating the tissue capabilities in terms of vessel patency and tissue 
viability by clinical transplantation of their bioartificial vascularised scaffold repopulated 
with patient’s peripheral blood cells [309]. Recently, Zhang et al. developed vascularised 
soft tissue flaps as an alternative to autografting. They generated an acellular 
skin/adipose tissue and repopulated it with human adipose-derived stem cells and 
HUVECs [310].  
Thus, the use of acellular mammalian scaffolds has great potential in tissue engineering 
applications, but they are expensive and difficult to obtain. It also requires experience to 
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harvest tissues or organs from man or animals and prepare these to completely remove 
cells and cell epitopes to avoid them, causing immune reaction following implantation 
[311]. On the other hand, decellularised plant tissues and organs are promising possible 
alternatives to explore as tissue engineering scaffolds. They are readily available, cost-
effective and safe to use.  
The in vivo biocompatibility of plant-derived cellulose has previously been proven by 
Modulevsky et al. by implanting a decellularised McIntosh Red apple section into mice 
subcutaneously [312]. Similarly, the results of the subcutaneous implantation of bacterial 
cellulose (BC) in rats showed full biocompatibility [313]. The use of cellulose in tissue 
engineering applications has also been reported as a TE scaffold for cartilage tissue 
engineering [314] and temporary skin substitutes [315]. Interestingly, Gershlak et al. 
reported that cheap and abundant acellular plant leaves could be used as tissue 
engineering scaffolds. The study illustrated that embryonic stem cell-derived 
cardiomyocytes (hPS-CMs) and HUVECs could be grown on decellularised spinach and 
parsley leaves [166]. The feasibility of using different types of decellularised plant leaves 
has been further confirmed by a number of studies as tissue engineering scaffolds for 
different applications. Parsley stems and baby spinach leaves gained attention in 
vascularisation studies due to the suitability of their intrinsic vascular structure to be 
recellularised with human ECs [166,167,316]. All the studies above concluded that 
cellulose is inexpensive, biocompatible and therefore a good candidate for use in tissue 
engineering applications. 
 Synthetic scaffold systems 
Tissue engineering scaffolds are expected to have several properties such as being 
biocompatible and supporting cell attachment and proliferation, allowing the exchange 
of gas and media with their porous structure, storing and releasing several agents 
according to the intended use of the scaffold, being inexpensive, and easy to fabricate. 
Synthetic scaffolds are important candidates to be used as tissue engineering scaffold 
systems, and this has led researchers to fabricate synthetic vascular networks for 
angiogenesis studies.  
Use of microfluidic systems is a technique where several methods such as microneedle 
casting, stamping, sacrificial channel dissolving are used to fabricate 3D microchannels 
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as networks embedded in PDMS chambers [317]. Yeon et al. manufactured 3D networks 
using soft lithography and rapid prototyping to study migration and lumen formation in 
vitro [318]. Li et al. demonstrated an alternative technique to create synthetic vascular 
scaffolds by combining 3D printing, casting and porogen leaching and successfully 
endothelialised the vascular channels [319]. Similarly, Miller et al. combined 3D printing 
and porogen leaching to generate carbohydrate glass 3D networks which they 
repopulated with ECs and perfused with blood [320]. Kim et al. reported the use of rapid 
prototyping and electrospinning for the fabrication of PCL 3D networks [321]. Similarly, 
our group has previously combined these two techniques to manufacture PHBV 
perfusable vascular channels and cellularised these networks with HDMECs [322,323]. 
Van Duinen et al. used a microchannel platform based on a 384-well plate system to study 
sprouting and anastomosis in vitro [324]. Kim et al. fabricated the microchannels using 
soft lithography and PDMS replica moulding to be used to study migration and lumen 
formation in vitro [325]. 
 Project Aims and Objectives 
The main aims of my PhD project are to: 
• Explore the angiogenic potential of 2dDR, a small sugar molecule, as a potent 
alternative to the well-established pro-angiogenic agent, VEGF, using established 
in vitro and in vivo angiogenesis assays. 
• Develop in vitro systems which have the potential to be used to study aspects of 
neovascularisation and to promote angiogenesis, and to be used in regenerative 
medicine applications. 
To achieve these aims, the experimental objectives of this project are to: 
(Chapter II) Investigate the angiogenic potential and the effective dose range of 2dDR 
using well-established in vitro assays; proliferation, migration and tube formation assays 
and in vivo assays, ex-ovo CAM assay and a diabetic rat wound healing model.  
(Chapter III) Develop a synthetic vascular scaffold by combining two well-known 
scaffold fabrication techniques, electrospinning and 3D printing, to study angiogenesis at 
cellular and tissue levels.  
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(Chapter IV) Develop a natural vascular scaffold by decellularising plant tissue to retain 
the intrinsic 3D vascular architecture to study and promote angiogenesis.  
(Chapter V) Develop a novel in vitro 3D dynamic system as an angiogenesis model to 
better represent the physiological environment by combining emulsion templating and 
electrospinning.  
(Chapter VI) Investigate the practicability of prevascularisation approach to induce 
angiogenesis by pre-seeding simple electrospun scaffolds with a combination of 
endothelial cells and fibroblasts. 
(Chapter VII) Develop a bilayer PCL barrier membrane for guided bone/tissue 
regeneration (GBR/GTR) applications by combining electrospinning and emulsion 
templating scaffold fabrication techniques.  
 Statement of Originality 
I confirm that the work submitted is my own, apart from the works which have been 
produced from our collaborative studies. Jointly authored publications have also been 
included in the chapters with permission from the authors. My and my co-authors' 
contributions in each chapter have been explicitly indicated below. 
Chapter I: The literature review presented in this chapter was written solely by me. 
Chapter II: A part of this chapter includes a collaborative work with Dr Muhammad Yar 
from the Interdisciplinary Research Centre in Biomedical Materials (IRCBM), COMSATS 
University Islamabad, Lahore, Pakistan. The preparation of the alginate dressings, 
stability, sterilisation, 2dDR release tests, and implantation of the dressings were 
conducted in Pakistan. Permission has been granted from the authors of the published 
work and from the journal to use these data in my thesis. The rest of the work presented 
in this chapter are my own. 
Chapter III: The work presented in this chapter is entirely my own. 
Chapter IV: The work presented in this chapter is entirely my own. 
Chapter V: This chapter includes a collaborative work with my colleague Betül Aldemir 
Dikici from Kroto Research Institute at the University of Sheffield. I was responsible for 
the experimental design, analysis, acquisition, and interpretation of data, statistical 
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analysis of the experiments related with the electrospun layer and endothelial cell-
related work, while Betül was responsible from the experiments related with the 
emulsion templated layer. Permission has been granted from the authors and from the 
journal to use these data in my thesis. 
Chapter VI: The work presented in this chapter is entirely my own. 
Chapter VII: The data presented in this chapter is a 6-month collaborative project with 
Massachusetts Institute of Technology (MIT), and the experiments were conducted 
jointly with my colleague Betül Aldemir Dikici from the University of Sheffield. I was 
responsible for the experimental design, analysis, acquisition, and interpretation of data, 
statistical analysis of the experiments related with the electrospun layer and fibroblast 
related experiments, while Betül was responsible from the experiments related with the 
emulsion templated layer. Permission has been granted from the authors and from the 
journal to use these data in my thesis. 
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CHAPTER II 
Exploration of 2-deoxy-D-ribose (2dDR) as an 
alternative to exogenous VEGF to promote 
angiogenesis in tissue-engineered constructs 
 Aims and Objectives 
The aim of this chapter is to investigate the angiogenic potential of 2dDR using well-
established in vitro and in vivo angiogenesis assays. In order to satisfy this aim; the 
objectives of this chapter are to: 
• Evaluate the angiogenic dose range of 2dDR by investigating its stimulatory effect 
on endothelial cell proliferation, migration and tube formation. 
• Investigate the angiogenic potential of 2dDR either applied as solutions or 
released from tissue engineering constructs and explore if it is possible to define 
certain concentrations of either 2dDR or E2 which are as effective as VEGF in 
stimulating angiogenesis in the chick chorioallantoic membrane (CAM) bioassay. 
• Investigate the stimulatory effect of 2dDR on angiogenesis and wound healing 
using a diabetic rat model. 
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 Introduction 
Over the last 30 years, there have been significant advances in the production of tissue-
engineered materials suitable for use in the clinic. However, one of the key challenges is 
to ensure rapid neovascularisation into these constructs in order for them to survive 
post-transplantation [37]. While relatively thin simple tissue-engineered constructs can 
survive on well-vascularised wound beds, thicker constructs (>200 µm) usually fail to 
engraft due to lack of oxygen and nutrients in vivo [22,24]. Both prevascularisation and 
scaffold functionalisation strategies with the use of angiogenic factors are viewed as 
promising approaches to accelerate vascular ingrowth into tissue engineering (TE) 
constructs to circumvent slow vascularisation after implantation [37,326].  
Although there are some well-known growth factors such as transforming growth factor-
beta (TGF-β), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) 
which have the potential to promote neovascularisation [327], vascular endothelial 
growth factor (VEGF) is recognised to be the most well-studied angiogenic factor due to 
occupying a key role in the angiogenic cascade. The role of VEGF and other pro-angiogenic 
factors in the angiogenic cascade is described in Section 1.3.1.  
VEGF acts as part of a well-regulated process, and its actions are highly dose-dependent. 
It is largely bound to glycosaminoglycans in vivo and released in response to need. Its 
angiogenic potential has been assessed in many in vitro studies such as cell migration 
assays using Matrigel [328], collagen gels [329] and transwell migration assays [330]. It 
has also been evaluated in the CAM assay [144,331–333] as well as in vivo studies. 
However, a range of studies shows that VEGF addition can lead to excessively leaky [334], 
permeable [335] and haemorrhagic [336] vessels such as those that are found in 
tumorigenesis [337]. Controlled and slow release of VEGF may help to regulate the 
delivery rate of VEGF and circumvent these problems by creating mature, more durable 
and stable vessels [338,339]. One promising approach is to use the glycosaminoglycan 
heparin, which is found on the cell surface and in ECM [340], to bind VEGF. Heparin found 
in ECM plays a role in the storage and prolonging the release of heparin-binding growth 
factors such as FGF and VEGF. It also regulates their stability and biological activity as 
well as long-term stimulation of endothelial cells [341–343]. Our group has previously 
explored the approach of using heparin bound to biomaterials to deliver VEGF using a 
layer-by-layer method for coating scaffolds with heparin and then binding VEGF [344], 
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and we have also reported on chitosan-based hydrogels for binding heparin [345,346]. 
However, binding VEGF with heparin requires multistep actions to introduce VEGF with 
the TE scaffolds.  
As an alternative to VEGF, 17β-Estradiol (E2) has been shown to promote endothelial cell 
migration and proliferation in vitro [61,62] and to stimulate new blood vessel formation 
both in vitro and in vivo [63]. E2 has an important role in neovascularisation during the 
menstrual cycle [64,65]. It is used clinically in the treatment of osteoporosis and heart 
disease [66]. Moreover, blocking the E2 receptor with adjuvants such as tamoxifen for 
estrogen receptor-positive tumours, in which high estrogen helps the cancer cells grow 
and spread, is an effective method to reduce tumour vasculature. This therapy has been 
in clinics for many years, especially for the treatment of breast cancer [67,68]. Recently, 
our group confirmed that poly-L-lactic-acid (PLLA) scaffolds loaded with E2 were highly 
angiogenic using the CAM assay [69]. In contrast to VEGF, E2 has proven to be safe to be 
used clinically. To date, the angiogenic response to different doses of E2 has been studied 
not only by our group but also by several other groups [347–349].  
In contrast to VEGF and E2, there is very limited literature on the angiogenic activity of 
2dDR as explained in Section 1.3.1.1.7, and none of these studies defined an effective 
concentration range but only used a single dose of 2dDR to promote angiogenesis. The 
dosage-dependence to 2dDR remained to be established. 
Accordingly, our aim in this chapter was to establish useful proangiogenic concentration 
ranges of 2dDR in vitro and in vivo and to compare its angiogenic activities with VEGF to 
progress our understanding of the potential value of 2dDR to the world of proangiogenic 
biomaterials and to the problem of improving rapid neovascularisation in TE constructs.  
In order to satisfy this aim, our objectives were to: 
• explore the angiogenic dose range of 2dDR in vitro using well-established 
angiogenesis assays 
• investigate the angiogenic potential of 2dDR either applied as a solution or 
released from PHBV fibres for stimulating neovascularisation in the CAM assay in 
which one can demonstrate significant increases in blood vessel formation within 
seven days, which is a time period very relevant to driving angiogenesis non-
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healing chronic wounds in vivo and to stimulating the formation of new blood 
vessels after engraftment of TE constructs. 
• demonstrate the stimulatory effect of 2dDR in inducing angiogenesis and wound 
healing in diabetic rats. 
 Materials 
Chemical / Reagent 
Catalogue 
Number 
Supplier 
Mouse/rabbit specific horseradish peroxidase 
(HRP)/ 3,3′-Diaminobenzidine (DAB) Detection 
IHC Kit 
ab64264 
Abcam 
Rabbit anti-CD34  ab81289 
Mouse anti-CD163 MCA342 AbD Serotec 
Alginate dressings (10 cm x 10 cm) 10007431 Activeheal 
Alexa Fluor® 594 anti-human CD31 Antibody 303126 Biolegend 
Matrigel® (Growth Factor Reduced) 356231 
Corning 
Transwell EC migration assay inserts 10167000 
Hypermer B246 - Croda 
Chloroform 10784143 
Fisher 
Scientific 
Dichloromethane (DCM) 10127611 
DPX mounting medium D/5319/05 
Industrial methylated spirit (IMS) M/4450/17 
Methanol 10626652 
Toluene 10102740 
Triton X-100 BP151 
Xylene X/0100/17 
Poly3-hydroxybutyrate-co-3-hydroxyvalerate 
(PHBV) (PHV content 12 mol %) 
BV326301 GoodFellow 
Optimum cutting temperature tissue freezing 
medium (OCT-TFM) 
14020108926 
Leica 
Biosystems 
Fertilised chicken eggs - MedEggs 
Hydrochloric acid fuming 37% 100317 Merck 
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RCOM King SURO humidified egg incubator MX-SURO P&T Poultry 
EC GM 2 Supplement Pack (for HAECs) C-39211 
PromoCell 
EC GM MV Supplement Pack (For HDMECs) C-39220 
Endothelial Cell Growth Medium 2 (EC GM) (for 
HAECs) 
C-22211 
Endothelial Cell Growth Medium MV (EC GM) (for 
HDMECs) 
C-22220 
Human Aortic Endothelial Cells (HAECs) C-12271 
Human Dermal Microvascular Endothelial Cells 
(HDMECs) 
C-12210 
Mouse anti-CD80 sc-376012 SantaCruz 
17β-Estradiol (E2) E8875 
Sigma Aldrich 
2-deoxy-D-glucose (2dDG) D8375 
2-deoxy-D-ribose (2dDR) 121649 
2-deoxy-L-ribose (2dLR) 75617 
37% formaldehyde (FA) solution F8775 
4',6-diamidino-2-phenylindole (DAPI) solution  D8417 
AlamarBlue Cell Metabolic Activity Assay R7017 
Amphotericin B A2942 
Bovine serum albumin (BSA) A7030 
Collagenase A COLLA-RO 
Crystal violet C6158 
D-Glucose (DG) G8270 
Dimethyl sulphoxide (DMSO) 472301 
Dulbecco’s Modified Eagle’s Medium (DMEM) D6546 
Eosin Y solution HT110232 
Ethanol 51976 
Ferric chloride hexahydrate 236489 
Fetal calf serum (FCS) F9565 
Formalin solution (10%) HT501128 
Glutaraldehyde (25%) G5882 
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Goat serum G9023 
Hematoxylin solution HHS16 
Ketamine hydrochloride BP736 
Luria Bertani (LB) broth  L24040 
Methacrylic anhydride (MAA) 276685 
Orcinol monohydrate 447420 
Paraformaldehyde (PFA) 158127 
Penicillin / Streptomycin P0781 
Pentaerythritol (98%) P4755 
Photoinitiator (PI) (2,4,6-Trimethylbenzoyl 
Phosphine Oxide/2-Hydroxy-2-
Methylpropiophenone blend) 
405663 
Polycaprolactone (PCL) (Mn: 80.000 g/mol) 440744 
Polydimethylsiloxane (PDMS) (SYLGARD®184) 761036 
Streptozotocin (STZ) S0130 
Tin (II) 2-ethylhexanoate S3252 
Triethylamine (TEA) 471283 
Trypan blue T6146 
Trypsin EDTA T3924 
Tween®20 P1379 
Vascular endothelial growth factor (VEGF) V7259 
ε-caprolactone 704067 
Alexa Fluor 594 Phalloidin A12381 
ThermoFisher 
Scientific 
Rhodamine labelled lens culinaris agglutinin (LCA) RL-1042 
Vector 
Laboratories 
 
 Methods 
 General cell culture protocol for Human Aortic Endothelial Cell (HAEC)  
HAECs were used between P2 and P6. Cells were taken out from liquid nitrogen (LN2) 
and immediately thawed at 37°C. Once cell suspensions was completely thawed, it was 
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transferred into a container with 10 mL of EC GM (PromoCell Endothelial Cell Growth 
Medium 2 basal medium supplemented with 2% FCS, 5 ng/mL EGF, 10 ng/mL bFGF, 20 
ng/mL insulin-like growth factor, 0.5 ng/mL VEGF, 1 µg/mL ascorbic acid, 22.5 µg/mL 
heparin, 0.2 µg/mL hydrocortisone). HAECs were centrifuged at 1000 rpm for 5 minutes, 
and the cell pellet was resuspended in EC GM. The cell suspension was split into the 
desired number of T75 flasks (VWR International, Pennsylvania, USA) and the final 
volume was then adjusted to 12-15 mL with EC GM. T75 flasks were then incubated at 
37°C (Sanyo, Osaka, Japan). The culture media was replaced every 2-3 days until they 
reached ~80-90% confluency. Once the culture was confluent (around 80-90%) cell 
culture medium was removed from the flask, and flasks were washed with PBS. Following 
that, 5 mL of trypsin/EDTA solution was added to each flask, and flasks were incubated 
at 37°C for 5 minutes. When cells were detached from the surface, trypsin was neutralised 
with culture medium containing 10% FCS (approximately 15  mL) and the cell suspension 
was centrifuged at 1000 rpm for 5 minutes. The supernatant was removed, and the cell 
pellet was broken up by tapping the bottom of the universal container gently. Cells were 
then resuspended in EC GM to be used in the experiments.  
 Assessment of the angiogenic activity of 2dDR on promoting ECs proliferation 
with AlamarBlue® metabolic activity assay, fluorescent staining and the 
assessment of CD31 expression 
 Preparation of the potential angiogenic agent solutions 
10 mM 2dDR solution was prepared as the stock solution. To prepare the 10 mM 2dDR 
stock solution, 0.067 g of 2dDR powder was dissolved in 50 mL of 2% FCS containing low 
serum EC GM and filter sterilised. Lower concentrations of 2dDR were prepared by serial 
dilutions of the stock solution EC GM down to 1 mM, 100 µM, 10 µM, and 1 µM 
concentrations.  
10 mM 2-deoxy-L-ribose (2dLR) solution was prepared as the stock solution. To prepare 
the 10 mM 2dDR stock solution, 0.067 g of 2dLR powder was dissolved in 50 mL of 2% 
FCS containing low serum EC GM and filter sterilised. Lower concentrations of 2dLR were 
prepared by serial dilutions of the stock solution EC GM down to 1 mM and 100 µM 
concentrations. 
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10 mM 2-deoxy-D-glucose (2dDG) solution was prepared as the stock solution. To 
prepare the 10 mM 2dDG stock solution, 0.082 g of 2dDG powder was dissolved in 50 mL 
of 2% FCS containing low serum EC GM and filter sterilised. Lower concentrations of 
2dDG were prepared by serial dilutions of the stock solution EC GM down to 1 mM and 
100 µM concentrations. 
10 mM D-glucose (DG) solution was prepared as the stock solution. To prepare the 10 
mM DG stock solution, 0.090 g of DG powder was dissolved in 50 mL of 2% FCS containing 
low serum EC GM and filter sterilised. Lower concentrations of DG were prepared by 
serial dilutions of the stock solution EC GM down to 1 mM and 100 µM concentrations. 
VEGF solution was used at 80 ng/mL concentration, and the working solution was 
prepared by the dilution of sterile VEGF stock solution (100 ng/µL) in 2% FCS containing 
low serum EC GM. 
 AlamarBlue® metabolic activity assay 
AlamarBlue® Cell Viability Assay was performed to evaluate the effect of different 
concentrations of 2dDR (10 mM, 1 mM, 100 µM, 10 µM, and 1 µM) on HAECs growth in 
vitro in comparison with 80 ng/mL VEGF (as positive control). The principle of this assay 
is the reduction of non-fluorescent resazurin to highly fluorescent resorufin upon 
entering cells. The viable cells convert resazurin to resorufin continuously.  
Once the cells reached confluence, HAECs were trypsinised and seeded into 48-well 
plates with a seeding density of 1x104 HAECs/cm-1. HAECs were cultured with EC GM, 
either containing different concentrations of 2dDR or VEGF. AlamarBlue Cell Viability 
Assay was performed at days 1, 4 and 7. Briefly, 0.1 mM AlamarBlue working solution 
was prepared by 10x dilution of the 1 mM AlamarBlue stock solution with EC GM. Growth 
medium was removed, and the cells were washed with PBS. 1 mL of AlamarBlue working 
solution was added to each well and incubated at 37°C for 4 hours. After an incubation 
period, 200µL of the solution was transferred into a 96-well plate, and the fluorescence 
readings were done at an excitation wavelength of 540 nm and an emission wavelength 
of 635 nm. 
Following determining the effective concentration range of 2dDR, AlamarBlue Cell 
Viability Assay was also used to compare the effect of 2dDR with other small sugar 
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molecules including 2dLR, 2dDG and DG on HAEC’s metabolic activities. The metabolic 
activity assay was conducted following the protocol described above. 
 Fluorescent staining 
In order to visualize the cells after 7 days, fluorescent staining was performed by labelling 
F-actin and cell nuclei of HAECs. Cells were washed with PBS before (once) and after 
(three times) fixing them in 4% PFA for 15 minutes. 0.1% (v/v) Triton 100x (in PBS) was 
added on samples, and the samples were incubated for 20-30 minutes at room 
temperature (RT). After three times washing with PBS, Alexa Fluor 594 Phalloidin (1:40 
diluted in PBS from stock solution) solution was added to cells in order to stain F-actin 
filaments of cells and incubated for 30 minutes at room temperature in the dark. Cells 
were then washed three times with PBS. In order to stain cell nuclei, DAPI solution 
(1:1000 diluted in PBS), which strongly binds the adenine-thymine rich regions of DNA, 
was added and incubated for 10-15 minutes RT in the dark. Cells were washed 3 times 
with PBS and then examined with a fluorescent microscope (Nikon Eclipse Ti, Tokyo, 
Japan). The steps of the fluorescent staining protocol are summarised in Table 7. 
Table 7. The steps of the fluorescent staining protocol 
 Step Reagent Time (minutes) 
1 Washing PBS 3 
2 Permeabilisation Triton-X 100 20 
3 F-actin staining Phalloidin solution 30 
4 Washing PBS 3 
5 Cell nuclei staining DAPI solution 10-15 
6 Washing PBS 3 
 CD31 expression 
CD31 immunofluorescent staining was performed to evaluate the expression of CD31 of 
HAECs treated with different concentrations of 2dDR and VEGF. At day 7, cells were fixed 
with 4% PFA and washed with PBS. To avoid non-specific binding, cells were incubated 
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with 5% goat serum. Alexa Fluor® 594 anti-human CD31 Antibody staining solution was 
prepared by the dilution of 1:50 in 5% goat serum. Cells were incubated with the antibody 
staining solution overnight at 4°C. HAECs were finally counterstained with DAPI (1:1000 
diluted in PBS) for 15 minutes after washing three times with PBS. CD31 expression is 
visualised under a fluorescent microscope after washing the cells with PBS. The steps of 
the immunofluorescent staining using Alexa Fluor® 594 conjugated antibody are 
summarised in Table 8. 
Table 8. The steps of the immunofluorescent staining using Alexa Fluor® 594 conjugated antibody 
 Step Reagent Duration Temperature 
1 Washing PBS 1 minute RT 
2 Blocking unspecific binding 5% goat serum 60 minutes RT 
3 Primary antibody labelling 
Alexa Fluor® 594 
primary antibody 
solution 
Overnight 4°C 
4 Washing PBS 3 times RT 
5 Counterstaining with DAPI DAPI solution 15 minutes RT 
6 Washing PBS 3 times RT 
 
 Assessment of the angiogenic activity of 2dDR on stimulating ECs migration using 
a modified Boyden chamber assay 
The Boyden chamber assay was developed for analysing the leukocyte chemotaxis in the 
1960s [214]. There are two compartments containing two media, and these 
compartments are separated with a microporous membrane. Cells are seeded into the 
top compartment (a cell culture insert) and allowed to migrate through the pores, to the 
other side of the membrane where the chemoattractant is placed in the container below 
(well plate) (Figure 12). The migration was assessed by investigating the migration of 
ECs is assessed by quantifying the cells migrated to the bottom surface of the membrane. 
Here, we used a modified Boyden chamber assay to evaluate the migratory response of 
HAECs to 2dDR in comparison with VEGF.  
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Figure 12. Schematic illustration of the modified Boyden chamber assay 
Briefly, 800 µL of chemoattractant solutions (80 ng/mL VEGF, 1 mM 2dDR, 100 µM 2dDR, 
and 10 µM 2dDR) and low serum EC GM (as control) were added to the 24-well plates 
(lower chamber), and 8 µm pore size cell culture inserts were placed into the 
chemoattractant solutions carefully to avoid bubble formation. HAECs were trypsinised, 
centrifuged, and 5x104 HAECs resuspended in 300 µL of low serum EC GM were seeded 
into the cell culture inserts (upper chamber). After incubation for 4 hours at 37°C, cells 
which were not migrated were removed from the upper surface of the cell culture insert 
by scratching with a cotton bud. Cell culture inserts were fixed with 3.7% FA for 10 
minutes, and the migrated HAECs were stained with 0.1% crystal violet solution for 10 
minutes before washing three times with deionized water.  
Bright-field images were taken with the fluorescent microscope, and the migration was 
quantified with a multi-step image processing of the green channel images exported from 
microscope software (NIS-Elements, Tokyo, Japan). Briefly, the raw image was split to its 
three main colour channels (red, green and blue (RGB) channels) using Adobe Photoshop 
CS6 (ADOBE Systems Inc., San Jose, California, USA). Only the green channel was exported 
as an image file and then imported to ImageJ (Wayne Rasband, National Institutes of 
Health, USA) for conversion to binary image. The black pixels in the binary image, which 
are accounting the cells, were counted using the histograms of each image. Four areas of 
interest were chosen randomly from each image, and the mean number of migrated cells 
was taken for each group. 
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 Assessment of the angiogenic activity of 2dDR on stimulating tube formation with 
Matrigel® tube formation assay 
In vivo, ECs are in direct contact with a basement membrane which is specific and 
biologically functional for enabling ECs to form tube structures [350]. Matrigel is the 
trade name of a gelatinous protein mixture which is rich in collagen IV, laminin, 
proteoglycans and growth factors. This biologically active protein mixture is a wonderful 
candidate for mimicking native basement membrane of ECs in vitro and promotes ECs to 
form tube-like capillary structures [221]. The tube formation assay is widely used for 
screening of first biological activity related to neovascularisation. The schematic 
illustration of the Matrigel tube formation assay and the quantification protocol followed 
are given in Figure 13. 
 
Figure 13. Schematic illustration of the Matrigel tube formation assay and the quantification 
protocol followed 
Using Matrigel tube formation assay, we examined whether 2dDR stimulates the tube 
formation of HAECs using Matrigel tube formation assay. Briefly, working on ice, 48-well 
plates were thickly coated with growth factor reduced Matrigel by adding 120 µL of 
Matrigel into each well. Well, plates were placed at 37°C for 60 minutes for solidifying of 
the Matrigel. HAECs were trypsinised, centrifuged and plated on Matrigel® coated plates 
at a density of 2.5x104 cells/well and treated with 100 µM of 2dDR in comparison with 
80 ng/mL VEGF and non-supplemented control EC GM. HAECs were incubated at 37°C 
for 18 hours before fixing them in 2% PFA solution containing 0.1% glutaraldehyde for 
15 minutes. Tube formation was quantified using Angiogenesis Analyzer plugin of ImageJ 
[351]. 
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 Assessment of the VEGF-dependency and the stability of 2dDR-related angiogenic 
activity 
Human VEGF ELISA MAXTM Deluxe Set was used for the quantification of VEGF production 
of HAECs when treated with either 100 µM or 1 mM of 2dDR. 80 ng/mL VEGF was used 
as a positive control. The assay was conducted according to the manufacturer 
instructions. The contents of the Human VEGF ELISA MAXTM Deluxe Set and the 
preparation of the working solutions of the reagents (dilutions of the stock reagents) are 
given in Table 9. 
Table 9. The contents of the Human VEGF ELISA MAXTM Deluxe Set and the preparation of the 
working solutions of the reagents (dilutions of the stock reagents) 
Material Dilute with Dilution 
Coating Buffer A (5x) Deionised water 1:5 
Capture antibody (200x) 1x Coating Buffer A 1:200 
Assay Diluent A (5x) PBS 1:5 
Detection Antibody (200x) 1x Assay Diluent A 1:200 
Avidin-HRP (1000x) 1x Assay Diluent A 1:1000 
Assay Diluent D (1x) - - 
Substrate Solution D (1x) - - 
Human VEGF standard (18ng) 1x Assay Diluent A 
1:2, 1:4, 1:8, 1:16, 
1:32, 1:64 
Wash buffer (1x) - - 
Stop Solution (1x) - - 
 
To investigate the VEGF production of HAECs in response to 2dDR treatment, cells were 
incubated in low serum EC GM supplemented with 100 µM of 2dDR, 1 mM of 2dDR, and 
80 ng/mL VEGF. Non-supplemented low serum EC GM was used as a control. Growth 
media of the cells were collected at day 1, 3 and 5, centrifuged at 1000 rpm for 5 minutes, 
and stored at -20°C.  
For quantification of the samples, first, a human 1 mL of VEGF stock solution was 
prepared as 1500 pg/mL in 1x Assay Diluent A, and then six serial dilutions were done 
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down to 750, 375, 187.5, 93.8, 46.9, and 23.4 pg/mL in order to draw a reference curve 
for converting readings to concentrations. 
On day 1, 100 µL of 1x Capture antibody was added to each well to coat the well plate 
with the anti-VEGF antibody. The plate was then sealed using Parafilm® and incubated 
overnight at 4°C. 
On day 2, the plate was washed 4 times with 1x wash buffer, and blocked by adding 200 
µL of 1x Assay Diluent A to each well and incubating at RT for 1 hour on a shaker. The 
plate was then washed 4 times with 1x wash buffer, and 50 µL of 1x Assay Diluent D was 
added to each well. 50 µL of the samples (growth media from HAECs) and 50 µL of the 
prepared VEGF concentrations (reference standards) were added to wells, the plate was 
then sealed and incubated at RT for 2h on a shaker. The plate was washed 4 times with 
1x wash buffer, and 100 µL of 1x Detection Antibody was added to each well and 
incubated at RT for 1 hour on a shaker. The plate was washed 4 times with 1x wash buffer, 
and 100 µL of 1x Avidin-HRP was added to each well and incubated at RT for 30 minutes 
on a shaker. The plate was washed 5 times with 1x wash buffer (at least for 30 seconds 
for each wash), and 100 µL of 1x Substrate Solution D was added to each well and 
incubated at RT in the dark for 10 minutes. 100 µL of 1x Stop Solution was then added to 
each well to stop the reaction. The absorbance was read at 450 nm and 570 nm, the 
reading at 570nm was subtracted from that at 450 nm. The absorbance values were 
converted to concentrations using the reference curve drawn from the standard VEGF 
concentrations.  
2dDR has many hydroxyl (OH) groups present which are highly reactive and may 
undergone chemical transformations [352,353]. Thus, the stability of 2dDR in an aqueous 
environment was assessed using Bial’s Orcinol assay as described previously [90]. 
Briefly, two defined concentrations (100 µM and 1 mM) of 2dDR was prepared in EC GM. 
The solutions were incubated at 37°C in the presence and absence of HAECs. For this, 
HAECs were seeded to 24-well plates with a seeding density of 4x104 cells/cm2 and 
incubated with EC GM supplemented with 2dDR. On days 1, 4, 7, and 14, the growth 
medium was collected, and Bial’s assay was performed [354]. The principle of this test is 
the formation of furfural (an organic compound: C4H3OCHO) by the dehydration of 
pentoses (sugars with five carbon atoms) with Bial’s reagent. Furfural will then react with 
orcinol and generate a substrate with a blue colour. Briefly, Bial’s reagent was prepared 
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by combining 0.4 g of orcinol, 200 mL of 37% concentrated hydrochloric acid, and 0.5 mL 
of a 10% solution of ferric chloride. 2 mL of media collected from 6-well plate were placed 
in a test tube, and 2 mL of Bial’s reagent was added. The solution was heated to boil using 
a hot plate, and the sample tubes were then submerged into the boiling Bial’s reagent 
solution for 1 minute. Absorbance was measured using a UV-VIS spectrophotometer at 
630 nm. 
 Assessment of the angiogenic activity of 2dDR on stimulating angiogenesis using 
an ex-ovo CAM assay 
 Ex-ovo CAM assay 
The protocol of ex-ovo CAM assay consists of four main steps: (i) incubation of the 
fertilised eggs in a humidified rotating incubator, (ii) transferring embryos into petri 
dishes to start the ex-ovo culture, (iii) implantation of the agent/scaffold onto CAM, and 
(iv) analysis of the results. The schematic illustration of the steps is given in Figure 14. 
 
Figure 14. Schematic illustration of the steps of the direct application of the substances and 
implantation of the substance releasing scaffolds on chorioallantoic membrane. This figure shows the 
basic methodology of ex-ovo chorioallantoic membrane assay and quantification of the macro and 
microimages 
 Incubation of eggs 
All CAM experiments were carried out according to the Home Office, UK guidelines. 
Fertilised chicken eggs (Gallus domesticus) were carefully wiped with 20% industrial 
methylated spirit solution using hand paper towels to remove dirt and feathers from the 
shell. The eggs were then incubated at 37.5 °C until embryonic development day (EDD) 
3, lying horizontally in a humidified egg incubator. 
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 Transferring the embryos into petri dishes 
On EDD 3, the upper surface of the eggs was marked with a felt pen. The eggs were held 
horizontally (with the marked surface on top) and cracked on the edge of a 1000 mL glass 
beaker and kept close to the bottom surface of the petri dishes. The embryos were then 
transferred gently into sterile petri dishes and kept in a humidified incubator at 38°C. 
(Figure 15) 
 
Figure 15. Graphical demonstration of egg cracking technique. (1) The egg is kept in a stationary 
position, and the top surface is marked with a pen. The marked surface stays at the top at all times. 
(2) The eggshell is cracked at the bottom by hitting it onto a hard surface. The cracked egg is 
immediately brought into the weighing boat. (3) The eggshell is separated into two halves by pulling 
it sideways and upward using the thumbs. The eggshell is kept very close to the bottom of the 
weighing boat during this manoeuvre so that the egg white forms a cushion around the egg yolk. (4) 
All the egg content is smoothly transferred into the weighing boat. 
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Examples of the successful and unsuccessful transferring of embryos into petri dishes are 
given in Figure 16. 
 
Figure 16. Observation of a successful embryo transfer with an intact egg yolk and live embryo on 
embryonic development day 3 (left-hand image). An unsuccessful embryo transfer with a live embryo 
(middle image) and a successful embryo transfer with an intact egg yolk but a dead embryo 
(righthand image) can also be observed. Error bars represent 1 cm 
The normal development of the chick embryo from day 3, the start of ex-ovo culture, until 
day 14, the day of euthanisation, is given in Figure 17. 
 
Figure 17. The development of the chick embryo from day 3, the start of ex-ovo culture, until day 
14, the day of euthanising 
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 Determination of the optimum concentration of E2 and 2dDR on angiogenesis 
using the CAM assay 
 Preparation of drug solutions 
Three concentrations of E2 and 2dDR were screened in these experiments. E2 was 
dissolved in methanol then working solutions were prepared with PBS so as to be (a) 100 
ng/day (E2-100), (b) 200 ng/day (E2-200), and (b) 600 ng/day (E2-600) concentrations. 
2dDR solutions were prepared by dissolving in PBS so as the final concentrations to be 
(a) 20 µg/day (2dDR-20), (b) 200 µg/day (2dDR-200), and (c) 1000 µg/day (2dDR-
1000). VEGF was used as a positive control at a concentration of 80 ng/day (VEGF-80) 
whereas Sunitinib, an inhibitor of multiple receptor tyrosine kinases, was used as a 
negative control at a 2 µg/day concentration. Working solutions of all substances were 
prepared freshly at the beginning of each experiment. 
 Application of drugs onto the CAM 
Plastic rings (~6.5 mm in diameter), as a reservoir for the drugs and a marker for the 
implantation area, were placed on the CAM. The substances were applied as 20 µL volume 
onto the CAM twice a day for 3 days starting from EDD 7. On EDD 11, images of the CAM 
area circumscribed by the plastic rings were acquired using a digital microscope and 
embryos were sacrificed immediately after image acquisition. 
 Quantification of angiogenesis 
Digital images were used for quantification of the results. Multiple image processing steps 
were applied following previously described protocols [237,355,356]. Firstly, the 
internal area of the ring was cropped, and the raw image was split to its three main colour 
channels (red, green and blue (RGB) channels) using Adobe Photoshop CS6 (ADOBE 
Systems Inc., San Jose, California, USA). Only the green channel was exported as an image 
file and then imported to ImageJ (Wayne Rasband, National Institutes of Health, USA) for 
further analysis including unsharp mask filtering, enhancing the local contrast, noise 
removal, converting the image to binary and segmentation. The green channel was 
selected because it gave the most accurate and detailed results for blood vessels when 
converted to binary [357]. Finally, the number of branch points was quantified using 
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quantification software (AngioTool, National Cancer Institute, USA) and average blood 
vessel lengths were calculated by using binary image histograms with known pixel/mm 
ratios in ImageJ (Wayne Rasband, National Institutes of Health, USA). Image processing 
steps followed for quantification of the results are given in Figure 18. 
 
Figure 18. Flowchart detailing the image analysis technique that can be used to quantify the results 
of the angiogenesis experiments. The final image that results from each step is demonstrated on the 
right-hand side 
 Evaluation of the effect of E2 and 2dDR on microvasculature 
For these experiments only, one concentration of E2 (E2-200) and 2dDR (2dDR-200) 
were used as these concentrations were the most effective ones in terms of stimulating 
angiogenesis in CAM assay. The drugs were applied following the steps described 
previously. 
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Microinjection 
At EDD 11, a 20% solution of rhodamine labelled LCA was injected into the circulation of 
CAM using 30 G needles under a dissection microscope (Wild Heerbrugg, Heerbrugg, 
Switzerland) to visualize the microvasculature. After 1 minute of incubation, embryos 
were sacrificed, and the areas on the CAM under the plastic rings were removed and fixed 
in 3.7% FA solution. Fixed CAM samples were then imaged under a confocal microscope 
(Zeiss LSM 510 Meta, Jena, Germany) for investigating the effect of substances on the 
microvascular structure of the CAMs. 
Quantification of the vascular area  
The percentage vascular areas (VA%) of the microvasculature of CAMs were quantified 
using confocal images of rhodamine-labelled LCA injected CAM samples, as shown in 
Figure 3. The images were then imported to ImageJ and converted to binary images after 
filtering and smoothing processes prior to quantification. VA% was calculated using the 
histogram list of black and white areas in the image. 
 Construction of E2 and 2dDR releasing PHBV scaffolds  
 Electrospinning E2 and 2dDR loaded PHBV scaffolds 
Preparation of the solutions 
10% (w/w) PHBV solution was prepared prior to electrospinning. 1 g of PHBV granules 
were dissolved in 1 g of methanol and 8 g of DCM in a fume hood. Four 10% of PHBV 
solutions were prepared prior to the addition of the drugs. Finally, 25 mg E2, 50 mg of E2, 
250 mg of 2dDR and 500 mg of 2dDR were then added to each solution per 1 g of PHBV. 
The solutions were mixed using a magnetic stirrer overnight. 
Electrospinning 
Solutions (~10 mL) were loaded into 10 mL syringes fitted with 0.6 mm inner diameter 
syringe tips. Syringes were then placed in a syringe pump (GenieTMPlus, KentScientific, 
Connecticut, USA). Aluminium foil was used as the collector and placed at a distance of 
17 cm from the needle tips. The pump was set to 40 µL/minutes, and a 17 kV voltage was 
applied both to the collector and the tips using a high voltage power supply (Genvolt, 
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Shropshire, United Kingdom). Electrospinning was done at room temperature until all 
the polymer solution was used. 
 Characterisation of the scaffolds 
Scanning electron microscopy (SEM) 
The surface morphology of E2 and 2dDR releasing scaffolds were observed under SEM 
(FEI Inspect F, Orlando, USA). The samples were coated with gold using a gold sputter 
(Edwards sputter coater S150B, Crawley, England) prior to imaging. Fibre diameter and 
pore sizes were measured using ImageJ. At least 100 measurements were taken from the 
different areas of each sample, and at least three samples were used for each group. 
E2 and 2dDR release from the scaffolds 
Scaffolds were cut into pieces to fit into a 6-well plate (20 mm x 20 mm), weighed and 
submerged in 4 mL of PBS. The accumulative E2 and 2dDR concentrations released from 
each group (25 mg E2, 50 mg E2, 250 mg 2dDR, 500 mg 2dDR) were measured 
fluorometrically using an ultraviolet-visible (UV-VIS) spectrophotometer (Thermo 
Fischer Evolution 220, Massachusetts, USA) at 238 nm for 2dDR and 220 nm for E2. 
Absorbance values were converted into concentrations using a standard curve of known 
concentrations of E2 and 2dDR. 
Effect of additives on mechanical properties of the scaffolds 
Biomechanical testing samples were prepared by cutting 20 mm x 10 mm pieces from dry 
scaffolds. The clamps of the device were positioned 10 mm away from each other, and the 
width and thickness of each scaffold were measured. Test samples were clamped with 
two grips in a tensiometer (BOSE Electroforce Test Instruments, Minnesota, USA). Tensile 
tests were performed on each sample at a rate of 0.1 mm/s until the samples failed (n=4). 
The raw data of these tests were used for drawing stress-strain and load-displacement 
graphs. Ultimate tensile strength (UTS) and the Young’s modulus were calculated from 
stress (σ) and stress (ε) curves of each sample.  
Wettability tests of drug-releasing electrospun scaffolds were also undertaken using a 
drop shape analyser (Krüss DSA100, Germany) under ambient laboratory conditions in 
order to see the effect of E2 and 2dDR on wettability of the scaffolds. In brief, a 5 µL water 
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droplet was dropped onto the scaffold surface, and the retention times of the droplet on 
scaffolds before complete absorption were calculated from recorded movies of the tests. 
At least nine measurements (three drops on three different substrates) were taken for 
measuring the water retention time on each sample. 
 Evaluation of the angiogenic potential of the E2 and 2dDR releasing 
electrospun PHBV scaffolds 
 Implantation of the E2 and 2dDR releasing scaffolds on CAM 
Scaffolds were cut into 5.5 mm diameter circles using a laser cutting machine (Epilog 
Laser Cutter, Clevedon, UK) and sterilised under UV light for 1 hour prior to implantation. 
Two circular scaffolds were placed on CAM at EDD 7 and embryos were cultured for 
further 7 days. The correct placement of the test sample on the CAM is demonstrated in 
Figure 19. 
 
Figure 19. Correct placement of the test sample on the CAM. The dashed arrows show the borders 
of the CAM and coloured circles show the possible locations for implantation of the biomaterial 
 Quantification of the angiogenic activity of the drug-releasing scaffolds 
Images of the scaffolds implanted on CAM were acquired using a digital microscope at 
EDD 14. Embryos were then sacrificed, and scaffolds were cut together with a rim of 
surrounding CAM tissue and fixed in 3.7% FA solution. Angiogenesis was quantified by 
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counting all blood vessels growing towards the scaffolds in a spoke wheel pattern, as 
described previously [69]. 
 Histological evaluation of the E2 and 2dDR releasing scaffolds on CAM 
Haematoxylin and Eosin (H&E) staining was performed on cell impregnated scaffolds by 
modifying a standard protocol [358]. Briefly, fixed samples were embedded in optimal 
cutting temperature tissue freezing medium (OCT-TFM) and frozen in liquid nitrogen for 
3 minutes. Sections were cut 8-10 µm thick using a cryostat (Leica Biosystems, Nussloch, 
Germany) at -20°C. Sections were then stained with haematoxylin for 90 seconds and 
eosin for 5 minutes. Finally, H&E images were acquired under a light microscope (Motic 
DM-B1, Xiamen, China). The total number of blood vessels adjacent to the scaffolds were 
quantified by counting blood vessels in H&E sections [359]. Briefly, all discernible blood 
vessels adjacent to the scaffolds were counted by two independent researchers using two 
independent microscopes at 10× magnification. Three independent CAM experiments 
were conducted, and in each independent experiment, six embryos were used for each 
group. For histological analysis of a single group, three embryos were randomly selected 
out of six embryos from each independent experiment. Six sections were taken on a slide 
from each of the nine samples, and each slide was investigated under a microscope 
making a total of 54 counts per group for quantification of the results. The steps of the 
H&E staining protocol are summarised in Table 10. 
Table 10. The steps of the H&E staining protocol 
  Step Reagent Time  
1 
Removal of OCT Distilled water 5 minutes 
Removal of wax Xylene 3 minutes  
2 Cell nuclei staining Haematoxylin 90 seconds 
3 Staining Tap water (running) 4 minutes 
4 Intracellular and extracellular staining Eosin 5 minutes 
5 Staining Tap water 30 seconds 
6 Dehydration IMS (70%) 30 seconds 
7 Dehydration IMS (100%) 30 seconds 
8 Dehydration Xylene 30 seconds 
9 Mounting the sample DPX - 
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 Statistics 
Statistical analysis was carried out using either one-way or two-way analysis of variance 
(ANOVA) using statistical analysis software (GraphPad Prism, San Diego, CA). Where 
relevant, n values are given in figure captions. Error bars indicate standard deviations in 
the graphs unless otherwise stated. The degree of significance was indicated with number 
of stars, **** P ≤ 0.0001, *** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05, ns P ≥ 0.05. 
 Assessment of the angiogenic activity of 2dDR on stimulating angiogenesis and 
wound healing using a diabetic rat wound healing model 
Please note that the in vivo assessment of the angiogenic activity of 2dDR on stimulating 
angiogenesis and promoting wound healing using a diabetic rat wound healing model 
was conducted in collaboration with Dr Muhammad Yar of the Interdisciplinary Research 
Centre in Biomedical Materials (IRCBM), COMSATS University Islamabad, Lahore, 
Pakistan. The preparation of the 2dDR loaded alginate dressings, stability, sterilisation, 
2dDR release tests, and implantation were conducted in Pakistan. The histological 
evaluation of the wounds was performed at the University of Sheffield. The schematic 
illustration of the diabetic rat wound healing model is given in Figure 20. 
 
Figure 20. Schematic illustration of the diabetic rat wound healing model 
 Loading of 2dDR into alginate dressings 
2dDR was loaded into alginate dressings under sterile conditions. For this 20 mm patches 
of pre-sterilised alginate dressings were cut and syringe filtered solutions of 2dDR (5% 
and 10%) were loaded onto alginate dressings by submerging dressings into solutions in 
a sterile environment and then dried at room temperature. In another approach, 5% and 
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10% 2dDR solutions were prepared and loaded onto 20 mm patches of alginate dressings 
without filter sterilisation. Once 2dDR loaded dressings were dried at room temperature, 
gamma sterilisation was conducted with an irradiation dosage of 25 KGy. 
 Sterilisation test 
Confirmation of sterilisation of dressings loaded with filter-sterilised 2dDR solutions was 
performed by culturing these in Luria Bertani (LB) agar broth. For this, sterile alginate 
dressings (without 2dDR) and alginate dressings loaded with 2dDR (both 5% and10%) 
were placed in sterilised LB broth and incubated overnight at 37oC. LB broth (without 
dressings) was used as a negative control. After overnight incubation, 250 µL of each 
sample group was spread on LB agar plates and incubated at 37oC for 1 week.  
 Scanning electron microscopy (SEM)  
The surface morphology of the 2dDR loaded alginate dressings was examined using SEM. 
The samples were coated with gold prior to examination at a range of magnifications. 
Fibre diameter was measured using Image J.  
 Assessment of release of 2dDR  
To evaluate 2dDR release from alginate dressings 20 mm patches of 5% and 10% 2dDR 
loaded alginate dressings were placed in a 6 well plate containing 4 mL PBS solution and 
maintained at 37oC for 8 days. At each time interval (4-hr, 1-day, 2-day, 3-day, 5-day and 
8-day) when media was removed to measure absorbance, another 4 mL of fresh PBS was 
added. Also, the plates had parafilm stretched tightly over the lids to avoid evaporation 
loss of PBS.  
The accumulative concentration of 2dDR released from both groups was measured using 
Bial’s Orcinol assay as described [354]. The principle of this test is the formation of 
furfural (an organic compound: C4H3OCHO) by the dehydration of pentoses (sugars with 
five carbon atoms) with Bial’s reagent. Furfural will then react with orcinol and generate 
a substrate with a blue colour. Briefly, Bial’s reagent was prepared by combining 0.4 g of 
orcinol, 200 mL of 37% concentrated hydrochloric acid, and 0.5 mL of a 10% solution of 
ferric chloride. 2 mL of media collected from 6-well plate were placed in a test tube, and 
2 mL of Bial’s reagent was added. The solution was heated to boil using a hot plate, and 
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the sample tubes were then submerged into the boiling Bial’s reagent solution for 
1 minute. Absorbance was measured using a UV-VIS spectrophotometer at 630 nm. The 
release of 2dDR at each time interval (4-hr, 1-day, 2-day, 3-day, 5-day and 8-day) was 
calculated by converting the absorbance value into a concentration using a standard 
curve of known concentrations of 2dDR.  
 Stability studies 
The stability of 2dDR was assessed as described previously in Section 2.5.5. Briefly, three 
defined concentrations (1, 2 and 3 mg/mL) of 2dDR was prepared in distilled water and 
incubated at RT for 14 days. At days 0, 7 and 14, Bial’s orcinol assay was performed to 
measure the amount of 2dDR. A detailed protocol of Bial’s orcinol assay was described in 
Section 2.5.7.4. The absorbance values were measured at 630 nm and converted into 
concentrations using a standard curve of known concentrations of 2dDR. 
 In vivo evaluation of the effect of 2dDR on diabetic wound healing 
 Diabetes induction 
This in vivo study was carried out using male Wistar rats, aged 10-12 weeks of 180-220 g 
weight. Animals were kept in an animal care facility at CEMB, Lahore, Pakistan according 
to procedures approved by the Institutional Animal Ethics Committee under maintained 
pathogen-free controlled climate conditions (humidity 50% to 70% and temperature 
25°C) with free access to both filter-sterilised water and food. 
Type I DM was induced chemically by using streptozotocin (STZ). Briefly, after a 12-hr 
fast, rats received a single intraperitoneal injection of STZ (40 mg/kg) freshly prepared 
in 0.1 M sodium citrate buffer. Normal blood sugar levels of all rats before diabetes 
induction was in the range of 80-120 mg/dl. Blood glucose was monitored regularly using 
tail-vein blood using a glucometer (Accu-Chek Aviva Nano, Roche Diagnostics, Penzberg, 
Germany). At 8 days after STZ injection, rats whose fasting blood glucose levels exceeded 
250 mg/dL were considered diabetic and selected for wound creation.  
For this, all diabetic rats were randomly divided into four groups. Study groups were (i) 
Sham-operated (diabetic control with no treatment) (ii) Alginate control (alginate 
dressing without 2dDR) (iii) Alginate + 5% 2dDR (alginate dressing loaded with 5% 
2dDR) and (iv) Alginate + 10% 2dDR (alginate dressing loaded with 10% 2dDR).  
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 Wound creation and treatment 
For wound creation, rats were anaesthetised with ketamine (100 mg/kg body weight) 
and xylazine (10 mg/kg body weight). The desired surface area on the dorsal surface was 
shaved using electric hair clippers (Oster heavy duty 97-60, UK). A sterilised circular 
template (20 mm) was placed on the shaved area of the skin, and a full-thickness 
excisional wound (1.2 mm thickness) was created carefully using sterilised surgical 
scissors (Noorani Surgical Medical Supplies, Pakistan). Following the skin excision, 
alginate dressings (without 2dDR) and 2dDR loaded alginate dressings (5% and 10%) 
were placed on the wounds and sutured in place for 4 days only (by which time most of 
the 2dDR will have been released). Dressings were then removed. Sham wounds were 
dressed with Mepore bandage only while in other groups Mepore was used as a 
secondary bandage to keep the alginate dressings in place. All animals were kept in 
separate cages and were allowed free access to both water and food. The wounds were 
photographed on day 0, 4, 7, 11, 14, 17 and 20 post-wounding to analyse the percent 
wound closure in each group. The percentage of wound closure was calculated using 
following formula:  
 
 % of wound closure =  
Wound Area at Day 0 − Open Wound Area 
Wound Area at Day 0
 𝑥 100           (1) 
 
On day 20, all experimental rats were euthanised with an anaesthesia overdose to collect 
skin tissue from the wound bed sites. The samples were preserved in 10% neutral buffer 
formalin for histological study. Following formalin fixation, tissues were dehydrated by 
placing in graduated series of increasing ethanol concentration from 70% to 100% and 
paraffin blocks were prepared. 
 Histological evaluation of the angiogenesis, macrophage response and wound 
healing 
The 6 μm thick sections were taken from the paraffin-embedded skin biopsies with a 
microtome (Leica RM2145, Nussloch, Germany) and the sections were collected on 
Superfrost®Plus slides (Thermo Fisher, Massachusetts, USA). The H&E staining protocol 
was adapted from a previously described protocol [358], and DPX mounting medium was 
used to adhere the coverslip to the slides. For immunohistochemistry (IHC), sections of 
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the skin biopsies were processed with a mouse/rabbit specific horseradish peroxidase 
(HRP)/ 3,3′-Diaminobenzidine (DAB) Detection IHC Kit. Briefly, sections were 
deparaffinised with xylene and re-hydrated with serial alcohol washes. Sections were 
then incubated with hydrogen peroxide to quench endogenous peroxidase activity and 
later treated with 0.05% trypsin (v/w) and 0.1% Calcium Chloride (v/w) for antigen 
retrieval. To avoid non-specific binding, sections were incubated with 1% bovine serum 
albumin (BSA) before the addition of the primary antibodies. The sections were 
incubated for 2 hours with 3 different monoclonal antibodies, rabbit anti-CD34 (1:1000 
in PBS), mouse anti-CD80 (1:100) and mouse anti-CD163 (1:200) diluted in 1% BSA. This 
was followed by incubation with biotinylated goat anti-polyvalent antibody (from Abcam 
Detection IHC Kit) for 10 minutes. Following the incubation of the slides with avidin and 
biotinylated horseradish peroxidase, the target proteins were visualised by incubation 
with peroxidase substrate and DAB chromogen (Abcam Detection IHC Kit). Sections were 
finally counterstained with haematoxylin, dehydrated, and mounted. Samples incubated 
without primary and secondary antibodies or only without primary antibodies were used 
as controls. 
For quantification of the histological analysis, a semi-quantitative assessment was 
performed by observers who were blind to the samples presented to them using a 
qualitative grading scale; 0 = absent, 1 = weak staining, 2 = mild staining, 3 = some 
staining, 4 = extensive staining. One representative image of the three animals from each 
group at each time point was assessed by three blinded researchers (n=9). Images 
describing the grading scales (0, 1, 2, 3, and 4) as references were provided to blind 
scorers. The M2/M1 ratio was calculated using the values from the blind scoring of the 
IHC images. The steps of the IHC protocol are summarised Table 11. 
Table 11. The steps of the IHC protocol 
 Step Reagent Time Temperature 
1 Removal of wax Xylene 3 minutes RT 
2 Removal of wax Xylene 3 minutes RT 
3 Rehydration 100% ethanol 3 minutes RT 
4 Rehydration 100% ethanol 3 minutes RT 
5 Rehydration 95% ethanol 10 minutes RT 
6 Rehydration Deionised water 3 minutes RT 
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7 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
8 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
9 Blocking endogenous peroxidase 
Hydrogen peroxide 
solution 
10 minutes RT 
10 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
11 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
12 Antigen retrieval 
0.05% trypsin + 
0.1% CaCl2 solution 
20 minutes 37°C 
13 Antigen retrieval 
0.05% trypsin + 
0.1% CaCl2 solution 
10 minutes RT 
14 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
15 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
16 Blocking unspecific binding 1% BSA 10 minutes RT 
17 Primary antibody labelling 
Primary antibody 
solution 
2 hours RT 
18 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
19 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
20 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
21 
Secondary antibody 
(biotinylated) 
Secondary antibody 
solution 
10 minutes RT 
22 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
23 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
24 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
25 Avidin-biotin detection Streptavidin solution 10 minutes RT 
26 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
27 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
28 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
29 Visualisation Chromogen solution 10 minutes RT 
30 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
31 Washing 
PBS/Tween 20 
solution 
2 minutes RT 
32 Counterstaining  
Hematoxylin 
solution 
3-5 seconds RT 
33 Washing Distilled water 4 times RT 
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34 Dehydration 95% ethanol 10 minutes RT 
35 Dehydration 100% ethanol 2 minutes RT 
36 Dehydration 100% ethanol 2 minutes RT 
37 Dehydration Xylene 2 minutes RT 
38 Dehydration Xylene 2 minutes RT 
 Statistical analysis 
The quantitative data were analysed using Graph Pad Prism-5 software (USA). Analysis 
of variance (ANOVA) followed by Bonferroni post-test was used for multiple comparisons 
between individual groups. All experiments were performed in triplicate, and data were 
presented as the mean ± standard deviation of the mean.  
For statistical analysis of the qualitative blind scoring of the histological images, the 
statistical differences between groups at each time point were tested with the multiple 
comparisons between each group using a non-parametric one-way ANOVA test. 
 Results 
 2dDR improves the metabolic activity and proliferation of HAECs in a dose-
dependent manner in comparison with other small sugar molecules 
The results of metabolic activity assays showed that VEGF at 80 ng/mL concentration 
increased metabolic activities and the total number of cells as expected. The effect of 
VEGF was evident even at day 1 (but not statistically significant) but clearly significant by 
days 4 and 7. By day 7, cell number essentially doubled by the addition of 80 ng/mL of 
VEGF (Figure 3). At 100 µM, 2dDR was as effective as VEGF in stimulating metabolic 
activity and cell number without any adverse effect on the appearance of cells. Lower 
concentrations were found less effective. At higher concentrations, 1 mM 2dDR was 
slightly less effective when compared with 100 µM, and at 10 mM concentration cells 
detached from the culture wells by day 4. 
The results of the fluorescent staining at day 7 showed that cell proliferation was 
correlated with the metabolic activities of HAECs. The quantification of the fluorescent 
images demonstrated that when cells were treated with VEGF for 7 days, the number of 
cells was increased approximately 2.2-fold in comparison with the controls. Similarly, 
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100 µM 2dDR almost doubled the cell number at the end of day 7. No statistical difference 
was observed for other concentrations of 2dDR apart from 10 mM. HAECs detached from 
the surface of the well plate when which cells were treated with 10 mM of 2dDR for 4 or 
7 days. 
The treatment of HAECs with VEGF and 2dDR did not affect CD31 expression of HAECs. 
All groups apart from 10 mM of 2dDR showed similar levels of expression of CD31, which 
correlated with the number of cells at the end of day 7. No expression of CD31 was 
observed for 10 mM 2dDR groups, as all cells had detached. Accordingly, for the following 
migration experiments, 1 µM and 10mM 2dDR concentrations were excluded as 1 µM was 
too low to be effective and 10mM detached cells after exposure for several days. 
The results of the (A) fluorescent staining (DAPI/phalloidin-TRITC), (B) CD31 expression, 
(C) cell viability and normalised cell count of HAECs over 7 days are given in Figure 21. 
77 
 
 
Figure 21: (A) DAPI/Phalloidin staining and (B) CD31 expressions of HAECs at the end of day 7 
when treated with different concentrations of 2dDR compared to VEGF and controls. (C) The 
metabolic activities of HAECs over 7 days and the normalised number of HAECs at the end of day 7.  
(***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, not significant (ns) p ≥ 0.05, n = 3) 
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Following the determination of the effective concentration range of 2dDR on stimulating 
HAEC’s proliferation, other small sugar molecules were used at the same concentrations 
to compare their angiogenic potential with 2dDR. 
The results of the metabolic activities showed that none of the other small sugar 
molecules increased the activity of HAECs over 7 days (Figure 22).  
At day 1, only the VEGF group showed a significant increase in the metabolic activity of 
HAECs while 2dDG reduced the activity when given at higher doses (1 mM and 10 mM). 
No significant difference was found between the other groups.  
By day 4, VEGF and lower concentrations of 2dDR (100 µM and 1mM) showed a 
significant increase in the metabolic activities of HAECs whereas highest concentrations 
of 2dDR (10 mM), 2dLR (10 mM), and 2dDG (1 mM and 10 mM) dramatically reduced the 
metabolic activity. DG at any concentration did not show either a positive or negative 
effect on the growth of cells by day 4. 
On day 7, the only two groups increasing the metabolic activities of HAECs were VEGF 
(80 ng/ mL) and 2dDR (100 µM and 1 mM). All three concentrations of 2dDG were found 
to reduce the metabolic activity by day 7. None of the concentrations of DG were found to 
increase or decrease the activity of cells. Lower concentrations of 2dLR (100 µM and 
1 mM) were found to slightly increase the activity (but not significantly when compared 
to controls) while 10 mM of 2dLR significantly decreased the activity similar to 10 mM of 
2dDR. 
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Figure 22. Metabolic activities of HAECs over 7 days when treated with other sugar molecules 
(2dLR, 2dDG, and DG) used at same concentrations (10 mM, 1 mM, and 100 µM) in order to compare 
their angiogenic potential with 2dDR. The table shows the statistical differences between groups 
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 2dDR enhances the chemotactic migration of HAECs 
All three concentrations of 2dDR and VEGF significantly enhanced the chemotactic 
migrations compared with the control group. VEGF showed a slightly better performance 
over 2dDR at all three concentrations (Figure 23). Quantification of the results indicated 
that the increase in the number of migrated cells was significantly different for 100 µM in 
comparison with the other two concentrations of 2dDR. The addition of VEGF 
significantly increased the number of migrated HAECs when compared with 100 µM 
2dDR, which was also selected for further tube formation experiments.  
 
Figure 23: The migratory effect of different concentrations of 2dDR in comparison with VEGF and 
controls was evaluated by using a modified Boyden chamber assay. The quantified results were given 
in the graph bottom-right (***p≤0.001, **p ≤ 0.01, *p ≤ 0.05, not significant (ns) p ≥ 0.05, n = 3). Scale 
bars represent 250 µm 
  2dDR improves the capability of HAECs to form tube-like structures 
The administration of 2dDR and VEGF significantly improved the ability of HEACs to form 
tubes in Matrigel®, whereas cells were partly capable of forming these structures in the 
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control group (Figure 24). The results indicated that the inclusion of 2dDR and VEGF 
significantly increased the number of branch points to 86 ± 7 and 100 ± 13, respectively 
from controls (average number of branch points: 38 ± 10). Similarly, the number of tubes 
per field was increased 1.8-fold and 2.3-fold with the administration of 2dDR and VEGF, 
respectively, when compared with control. 
 
Figure 24: The effect of 2dDR (100µM) and VEGF (80 ng/ml) on tube formation was assessed with 
Matrigel tube formation assay. The quantified results of the average number of branch points and 
the number of tubes per field were given in the graphs given (***p≤0.001, **p ≤ 0.01, *p ≤ 0.05, not 
significant (ns) p ≥ 0.05, n = 3). Scale bars represent 250 µm 
 2dDR increases the VEGF production of HAECs  
The results of the VEGF quantification demonstrated that the administration of either 100 
µM or 1 mM of 2dDR to HAECs growth media led an increase in the amount of VEGF 
produced by the cells over 5 days (Figure 25). No VEGF production was observed in 
control group at any of the time points, where HAECs were incubated with non-
supplemented EC GM.  
The VEGF production by HAECs in response to 2dDR treatment was statistically 
significant even at day 1. The amount of VEGF rose up to 871.4 ± 361.7 pg/mL and 
82 
 
1284.5 ± 683.1 pg/mL, respectively for 100 µM and 1 mM of 2dDR treated groups when 
compared to controls (average VEGF amount: 18.3 ± 1.9 pg/ mL).  
By day 5, the amount of VEGF was significantly increased to 1140.6 ± 441.8 pg/mL and 
1233.4 ± 384.1 pg/mL, respectively when treated with 100 µM and 1 mM of 2dDR 
whereas the control group showed almost no change compared to VEGF production on 
day 1 (15.3 ± 4.4 pg/ mL).  
The VEGF added group had significantly higher amount of VEGF than other groups at all 
time points as expected (3669.2 ± 559.0 pg/mL and 3930.9 ± 850.5 pg/mL of VEGF by 
days 1 and 5, respectively). 
 
Figure 25. Quantification of VEGF production by HAECs in response to 2dDR treatment 
The results of the stability studies showed that there was a decrease of 2dDR in the media 
for over 7 days, either in the presence or absence of HAECs. The percentage reductions of 
2dDR on both day 4 and 7 were higher in the presence of HAECs when compared to 
control groups (no cells). 
For 100 µM 2dDR treatment, on day 4, the amount of 2dDR was reduced by 23.6 ± 8.2% 
and 11.5 ± 2.7% in the presence and absence of HAECs, respectively. On day 7, this further 
reduced by 37.4 ± 9.5% (with HAECs) and 21.5 ± 6.6% (without HAECs). On day 14, the 
percentage reductions in the amount of 2dDR were 41.2 ± 9.9% and 37.1 ± 3.5%, 
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respectively, for cellular ad acellular groups with no statistically significant difference 
(Figure 26A). 
For 1 mM 2dDR treatment, on day 4, the amount of 2dDR was reduced by 28.7 ± 7.7% 
and 12.8 ± 6.3% in the presence and absence of HAECs, respectively. On day 7, this further 
reduced by 31.5 ± 4.4% (with HAECs) and 18.5 ± 5.9% (without HAECs). By day 14, the 
percentage reductions in the amount of 2dDR were 47.1 ± 10.2% and 37.2 ± 10.3%, 
respectively, when HAECs existed and not existed in the well plates. (Figure 26B). 
 
 
Figure 26. Bial’s Orcinol Assay for the assessment of the stability of 2dDR. (A) 100 µM 2dDR and (B) 1 
mM 2dDR in the presence or absence of HAECs over 14 days. (**p ≤ 0.01, *p ≤ 0.05, n = 3) 
 2dDR promotes vascularisation in ex-ovo CAM assay 
 The results of the angiogenic potential of 2dDR when administered to CAM  
 Effect of E2 and 2dDR on the macrostructure of CAM 
Quantification of the macroimages of CAMs showed that E2-100, E2-200 and E2-600 
groups increased the number of branch points 1.3-fold, 1.5-fold and 1.4-fold respectively 
and, all concentrations increased the average vessel length approximately 1.2-fold 
compared to controls over 4 days. In the same way, 2dDR-20 and 2dDR-200 increased 
the number of branch points by 1.3 times and 1.4 times, respectively. Both concentrations 
increased the average vessel length approximately 1.2 times while there was no 
significant difference for the 2dDR-1000 group compared to control scaffolds. VEGF 
increased the number of branch points by 1.4-fold and the average vessel length by 1.7-
fold. Quantification of the branch points and average vessel lengths and the macroimages 
A B 
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of the CAMs with the most effective concentrations of E2 (E2-200) and 2dDR (2dDR-200) 
are shown in Figure 27. 
 
Figure 27. Evaluation of different concentrations of Estradiol (E2) and 2-deoxy-ribose (2dDR) to 
stimulate new blood formation in a CAM assay. Three concentrations of both drugs were compared 
against a negative (SM), PBS and positive (VEGF) control in these experiments. A normal angiogenic 
response can be seen in the PBS group. A significant increase in the average length of blood vessels 
and the number of branch points compared to PBS can be observed for both E2 and 2dDR groups 
(upper row). Representative images are given for E2 (200 ng/day) and 2dDR (200 µg/day). 
Processed images used for quantification of results are given for each group (middle row). **** P ≤ 
0.0001, *** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05, ns P≥0.05, n=9±SD. The number of branch points and 
average macrovessel lengths seen in response to different concentrations of E2 and 2dDR were 
calculated and compared to PBS controls over 4 days (lower row). Values represent mean ± SD. Scale 
bars represent 1 mm 
 Effect of E2 and 2dDR on the microstructure of CAM 
Microvascular evaluation of the CAM samples showed that VA% was increased from 
55.3% ± 3% to 79.5% ± 5% and 71.7% ± 3% for E2 and 2dDR applied groups respectively 
compared to controls over 4 days. VEGF and Sunitinib were used as positive and negative 
controls. Although the vascular area was significantly higher in VEGF groups when 
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compared with 2dDR and E2 applied CAMs, VEGF also resulted in smaller lacunae 
formation. Sunitinib, as an inhibitor of angiogenesis, led to much larger lacunae (Figure 
28). 
 
Figure 28. Demonstration of the effect of Estradiol (E2) and 2-deoxy-D-ribose (2dDR) on 
microvasculature compared to the application of PBS (Control). Rhodamine-labelled Lens culinaris 
agglutinin (LCA) was injected into the circulation of the CAM to visualize microvasculature (A). Similar 
to VEGF group, endothelial cell hypertrophy together with smaller lacunae compared to PBS can be 
observed for both E2 and 2dDR groups (B). Percentage area covered by endothelial cells was calculated 
for each group and compared (C). 2dDR was applied as 200 µg/day and E2 as 200 ng/day. **** P ≤ 
0.0001, *** P ≤ 0.001 compared to PBS, n=9±SD. Scale bars represent 50 µm 
 The results of the angiogenic potential of 2dDR when released from PHBV 
fibres 
 Characterisation of E2 and 2dDR releasing PHBV scaffolds 
Effect of including E2 and 2dDR on the ultrastructure of the PHBV scaffolds 
SEM images of the E2 and 2dDR releasing PHBV scaffolds can be seen in Figure 4. The 
diameters of the fibres were significantly increased by the addition of substances in all 
groups (25 mg E2 (0.83 ± 0.17 µm), 50 mg E2 (0.98 ± 0.35 µm), 250 mg 2dDR (0.89 ± 0.19 
µm), 500 mg 2dDR (1.22 ± 0.28 µm)) added PHBV scaffolds when compared with the 
PHBV control group (0.66 ± 0.16 µm) as shown in the graph on the bottom right corner 
of Figure 29. 
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Figure 29. SEM images of the scaffolds. (A) Plain PHBV, (B) PHBV + 25 mg E2, (C) PHBV + 50 mg 
E2, (D) PHBV + 250 mg 2dDR, (E) PHBV + 500 mg 2dDR. The graph on the bottom left corner shows 
the distribution of fibre diameters for each scaffold, **** P ≤ 0.0001, *** P ≤ 0.001. Scale bars 
represent 100 µm 
Release of E2 and 2dDR from PHBV scaffolds over 30 days 
The rate of release of E2 and 2dDR from scaffolds was assessed over 30 days as shown in 
Figure 30A. By 7 days, 2dDR release from the scaffolds was 81.3% and 86.5% of the 2dDR 
present in the polymer solution for 250 mg and 500 mg 2dDR scaffolds, respectively. In 
contrast the total E2 release from scaffolds within 7 days represented 1.3% and 1.6% of 
the initial E2 present in the polymer solution for 25 mg and 50 mg E2 scaffolds 
respectively. 
Comparison of effects of E2 and 2dDR on the mechanical properties of scaffolds 
The thicknesses of the scaffolds were 105 ± 22 µm, 84 ± 13 µm, 62 ± 10 µm, 136 ± 12 µm, 
and 124 ± 13 µm for plain, E2 25, E2 50, 2dDR 250, and 2dDR 500 PHBV scaffolds 
respectively. As can be seen from Figure 30B, the addition of all substances significantly 
increased the UTS of PHBV scaffolds when compared with plain PHBV scaffolds. Addition 
of E2 increased the UTS of the scaffolds more when compared with 2dDR added groups. 
Similarly, the Young’s modulus of the scaffolds loaded with 2dDR and E2 was significantly 
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higher compared to unloaded PHBV scaffolds. 250 mg 2dDR loading increased the 
Young’s modulus of PHBV scaffolds to the greatest extent, as shown in Figure 30B. The 
wettability of the drug-releasing scaffolds was investigated through a droplet retention 
time which is calculated using a drop shape analyser. The retention time of the water 
droplet on drug released scaffolds was given in Figure 30C. This showed that the addition 
of 2dDR made the scaffolds more wettable while the addition of E2 made the scaffolds 
less wettable. 
 
Figure 30. (A) Release of 2dDR and E2 from PHBV scaffolds over 30 days, n=6±SD. (B) comparison 
of UTS and Young’s modulus and (C) droplet retention time on the scaffolds, **** P ≤ 0.0001, *** P ≤ 
0.001, ** P ≤ 0.01, * P ≤ 0.05, n=6±SD 
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 Assessment of the angiogenic potential of the E2 and 2dDR releasing scaffolds 
Assessment of E2 and 2dDR releasing scaffolds on CAM demonstrated that all groups at 
least doubled the number of discernible blood vessels growing towards the scaffolds in 
comparison with plain PHBV scaffolds as can be seen in Figure 31. Mean vessel counts for 
25 mg E2 loaded scaffolds and 50 mg E2 loaded scaffolds were 49.5 (±0.92) (**** P ≤ 
0.0001) and 37.9 (±1.05) (**** P ≤ 0.0001) respectively, while it was 48.6 (±1.02) (**** P 
≤ 0.0001) and 37.1 (±1.37) (**** P ≤ 0.0001) for 250 mg and 500 mg 2dDR loaded 
scaffolds respectively when compared with control groups (mean vessel count: 23.1 
(±1.24)). None of the loaded substances affected the embryo survival rate, which was 
over 75% for each group. 
 
Figure 31. Representative images demonstrating the angiogenic potential of 2dDR (250 mg and 
500 mg) and E2 (25 mg and 50 mg) releasing scaffolds in comparison with PHBV scaffolds. The 
graph on the bottom left shows the quantitative data from these experiments-mean vessel counts, 
**** P ≤ 0.0001. Scale bars represent 3mm, n=6±SD 
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 Histological analysis of the E2 and 2dDR releasing scaffolds on CAM 
All groups showed good biocompatibility and similar changes in the structure of CAM 
with a small increase in cell density in the mesoderm layer in all scaffold groups. The 
mean number of blood vessels adjacent to the scaffolds was significantly increased in 
response to all concentrations of both E2 and 2dDR releasing scaffolds when compared 
with controls and CAM only groups (see Figures 32 and 33). 
All scaffolds, whether loaded with pro-angiogenic agents or unloaded showed good 
attachment to the CAM, and all membranes showed similar cellular infiltration. Figure 30 
shows representative histology images.  
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Figure 32. Histological analysis (H&E staining) of CAMs after 7days of incubation with or without 
scaffolds in different magnifications. The orientation of the scaffold (s), CAM ectoderm (*), 
mesoderm (**), and endoderm (***) layers were indicated in the images. Green arrows show the 
blood vessels. Scale bars = 0.2 mm (10×), 0.1 mm (20×), 0.05 mm (40×) 
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Groups Mean vessel count 
 
CAM only 6.85 ± 0.31 
PHBV 6.90 ± 0.39 
PHBV + E2 25mg 10.59 ± 0.75 
PHBV + E2 50mg 11.35 ± 0.79 
PHBV + 2dDR 250mg 10.32 ± 0.97 
PHBV + 2dDR 500mg 11.52 ± 0.75 
 
Figure 33. Quantification of the discernible blood vessels adjacent to the scaffolds at 10× 
magnification from a total of six different slides for each group and six different areas of interest 
from each slide. (*** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05, ns P≥0.05) 
 2dDR promotes wound healing and angiogenesis in the diabetic rat model 
 Confirmation of diabetes induction of diabetes in rats 
Post-wounding diabetes (induced by intraperitoneal administration of streptozotocin) 
was confirmed by monitoring the blood glucose levels (mg/dl) at day 4, 8, 14 and 20 using 
Accu Check Active plus by a needle prick at the tip of the rat’s tail. Blood glucose levels in 
all rats (n=32) before administration of STZ injection were in the range of 107 – 140 
mg/dl. As shown in Figure 34 blood glucose monitoring at day 4, 8, 14 and 20 post 
diabetes induction (STZ injection) showed blood glucose levels in the range of 350 to 450 
mg/dl. 
 
Figure 34. Blood glucose level (mg/dl) in rats monitored at days 4, 8, 14 and 20 post diabetes 
induction. Results presented as mean ± SD, n=4 
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 Confirmation of sterilisation of 2dDR loaded dressings 
To confirm sterility of 2dDR loaded alginate dressings, these were incubated in LB agar 
broth for 24 hr. Alginate dressings loaded with filter-sterilised solutions of 2dDR both pre 
and post gamma irradiation were confirmed to be sterile on the basis that there was no 
bacterial growth after 7 days culture in bacterial broth. 
In this study, the alginate dressings used were those loaded with a filter-sterilised 
solution of 2dDR. 
 Morphological characterisation of the alginate dressings before and after 2dDR 
loading 
 Scanning Electron Microscopy (SEM) 
SEM was performed to examine the morphology of alginate dressings both simple and 5 
or 10% 2dDR loaded before and after gamma sterilisation. As can be seen in Figure 35, 
micrographs showed that more sugar (2dDR) content was present on the surface of 
alginate fibres in the case of 10% loading than 5%.  
 
Figure 35. Scanning electron microscope (SEM) images of alginate dressing loaded with 5 and 10% 
2dDR before and after gamma sterilisation at different magnifications. 
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 Release of 2dDR from alginate dressing 
The release rate of 2dDR from alginate dressings over 8 days was determined following 
their immersion in PBS at 37o C. Figure 35 shows the cumulative 2dDR release from 5% 
and 10% loaded alginate dressings before (Figure 36A) and after gamma sterilisation 
(Figure 36B). Alginate exhibited a steady release of 2dDR over 3 days. Almost all (>90%) 
loaded 2dDR was released by day 3 with a similar pattern before and after gamma 
sterilisation.  
 
Figure 36. Drug release study: (a) cumulative release of 2dDR from alginate dressing before and 
(b) after gamma sterilisation over eight days. Results are presented as mean ± SD, n=3 
 Assessment of 2dDR stability in water 
To evaluate the stability of 2dDR, solutions of 2dDR were kept in distilled water at room 
temperature over 14 days as shown in Figure 37. As can be seen, there was no significant 
change in the absorbance measured for all three concentrations of 2dDR (1, 2 and 3 mg/ 
mL) at different time intervals (0, 7 and 14 days) confirming the sugar stability at room 
temperature over 2 weeks. 
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Figure 37. Stability test of 2dDR over 14 days at room temperature. Results presented as mean ± 
SD, n=3 
 Evaluation of wound healing responses to 2dDR loaded alginate dressings on 
the diabetic rat model 
Wound healing in the diabetic rat model was assessed by using a single application of 
2dDR loaded alginate dressings kept in place for 4 days. At day 4, when wounds were 
photographed the dressings were removed as studies had demonstrated over 90% 
release of 2dDR within three days from our in vitro studies.  
Figure 39 shows representative macroscopic images of different experimental group 
wounds at the time of wounding (Day 0) and then at days 4, 7, 11, 14 and 17 until the 
wound in the first group had healed (Day 20).  
Wound areas were assessed by photographing the wounds and then using image J was 
used to analyse areas. As previously shown, Figure 34 confirms that the rats were diabetic 
throughout the study as assessed by their elevated blood glucose levels. 
The first thing to note is that wounds were slow to heal in these diabetic animals and had 
failed to heal completely in the control animals by day 20. Alginate treated rats showed 
slightly better healing than sham operated animals, but wounds were still open at day 20. 
While the addition of alginate hydrogel did significantly stimulate wound healing 
compared to the sham operated control the addition of 2dDR at either 5 or 10% 
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significantly improved the wound healing response in all experimental rats. The rats 
treated with 2dDR loaded alginate dressings (both 5% and 10%) showed complete 
wound closure by day 20.  
Figure 38 shows the percentage of wound closure in all study groups at 4, 7, 11, 14, 17, 
and 20 days post-transplantation. Results demonstrated that wound closure was 
significantly faster overall in both 2dDR treated groups than applying simple alginate and 
sham operated control except at day 4. Furthermore, no significant difference was 
observed in the groups treated with either 5% or 10% 2dDR loaded alginate dressing.  
Statistical analysis showed the inclusion of 2dDR in alginate dressings improved the rate 
of wound healing compared to the use of alginate dressings on their own.  
 
Figure 38. Graphical representation of wound closure analysis at days 4, 7, 11, 14, 17 and 20 of 
sham (without any dressing), alginate (without 2-dDR), alginate + 2dDR (5%) and alginate + 2dDR 
(10%). *** P ≤ 0.001, not significant (ns) P≥0.05, n=4 ± SD 
 
96 
 
 
Figure 39. Representative macroscopic analysis of wounds; sham (without any dressing), alginate 
(without 2dDR), alginate + 2dDR (5%) and alginate + 2dDR (10%) are shown at days 0, 4, 7, 11, 14, 
17 and 20 post wounding 
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 Histological and Immunohistochemistry analysis of wound beds 
Skin wound samples from all groups were harvested on day 7 and 20, for comparison 
between treated and non-treated diabetic wounds. At day 7 H&E staining demonstrated 
there was no evident epithelium in any of the wound areas (Figure 40) whereas by day 
20 it was possible to see the formation of a new stratified epithelium covering the whole 
area that was previously wounded for wounds treated with 5% and 10% 2dDR loaded 
alginate dressings (Figure 41). In contrast, non-treated wounds and wounds treated with 
the alginate dressing showed disorganised granulation by 20 days (Figure 41).  
The samples were then stained for three different antigens (CD34 for progenitor 
endothelial cells, and CD80 and CD163 for M1 and M2 macrophages, respectively). At 
both time points, blind scoring of CD34 staining for 5% and 10% 2dDR loaded alginate 
groups showed a similar significant increase in neovascularisation in the healed areas 
compared to the non-treated and alginate dressing treated groups (Figure 40 and 41). At 
both time points, the M1 response did not differ significantly between groups, and 
similarly, the M2 response was similar between all groups with no significant differences 
by day 7. By day 20, a significantly higher M2 response was observed for all treated 
groups compared with the non-treated group (Figure 41).  
The ratio of M2 to M1 was above 1 for all groups at both time points as the M2 response 
was consistently much higher than the M1 response (Figure 40 and 41). 
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Figure 40. From top to bottom; images of H&E and immunostaining of CD34, CD80 and CD163 at 
day 7. Assessment of the immunostainings was done by a blind scoring system. 0 =absence; 1= mild 
presence; 2 =large presence; 3 =abundance; 4= large abundance. The ratio of M2/M1 is given in the 
table. *** P ≤ 0.001, ** P ≤ 0.01, ns P≥0.05, n=9±SD. Scale bars represent 500μm for H&E and 200μm 
and 100μm for lower and higher magnifications of the IHC images 
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Figure 41. From top to bottom; images of H&E and immunostaining of CD34, CD80 and CD163 at 
day 20. Assessment of the immunostainings was done by a blind scoring system. 0 =absence; 1= mild 
presence; 2 =large presence; 3 =abundance; 4= large abundance. The ratio of M2/M1 is given in the 
table. *** P ≤ 0.001, ** P ≤ 0.01, ns P≥0.05, n=9±SD. Scale bars represent 500μm for H&E and 200μm 
and 100μm for lower and higher magnifications of the IHC images 
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 Discussion 
As laboratory production of TE materials has progressed to the clinic, it has become clear 
that one of the critical barriers to their success is the need to achieve rapid 
neovascularisation post-implantation. Rapid ingrowth and infiltration of blood vessels 
are crucial for biomaterials to be able to survive in vivo [360]. The need for improved 
neovascularisation is crucial for tissue engineering, and our laboratory has been seeking 
to develop biomaterials to promote angiogenesis.  
VEGF is a crucial angiogenic factor that plays a key role in promoting angiogenesis [38]. 
ECs are sensitive to VEGF signalling, which regulates proliferation, migration and their 
survival [41,361]. Although VEGF is accepted as the gold standard for promoting 
angiogenesis, the use of exogenous VEGF can promote the formation of leaky [362], 
permeable [335] and haemorrhagic [336] vessels when administered in an uncontrolled 
manner. The MacNeil group and many others have sought to deliver materials which bind 
heparin and are therefore attractive to the binding of VEGF [344,345]. However, 
introducing VEGF with the TE scaffolds requires multistep actions and a long process. 
Moreover, the administration of large amounts of exogenous VEGF can lead to the 
formation of leaky and haemorrhagic vessels [334]. Thus, exploring new alternatives to 
the use of exogenous VEGF has critical importance. VEGF is a widely studied pro-
angiogenic factor, and several reports established the signalling pathway responsible for 
its angiogenic activity [38,363]. Molecular mechanism of VEGFR-2 dependant 
angiogenesis is given in Section 1.3.1.1.1. 
2dDR is a promising alternative which has been reported to have chemotactic and 
angiogenic activity by our group and other researchers using current angiogenic assays, 
Boyden chamber assay [83], tube formation assay [83], CAM assay [81,89] and rat wound 
healing models [87,90]. However, the dose-dependent response of 2dDR still remained 
to be investigated in vitro to learn what is the effective concentration range to drive 
angiogenesis at the cellular level. 
First, I investigated the effect of 2dDR on proliferation, chemotactic migration and tube 
formation ability of HAECs. The results of the metabolic activity assay showed a dose-
dependent response in the metabolic activity of HAECs. It was not effective when used at 
low concentrations (1 µM) but significantly improved metabolic activity and proliferation 
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of HAECs when used at 100 µM and to a lesser extent 1 mM. It inhibited cellular 
proliferation at higher concentrations (10 mM) by detaching the cells. The 100 µM 2dDR 
was found approximately 95% as potent as VEGF in terms of enhancing the proliferation 
of HAECs over 7 days. Following the metabolic activity assay, three concentrations of 
2dDR (10 µM, 100 µM and 1mM) were further examined for enhancing the chemotactic 
migration of HAECs using a modified Boyden chamber assay. All the 2dDR concentrations 
and VEGF showed a statistical difference when compared with controls in terms of 
migration of HAECs from the upper chamber to the lower one where the chemoattractant 
was located. The 100 µM group was then selected for further experiments to evaluate 
how the addition of 2dDR and VEGF influences the formation of capillary tube-like 
structures using a well-established method of assessing angiogenesis, Matrigel® tube 
formation assay [364]. The administration of 100 µM 2dDR and VEGF increased the 
number of capillary tubes formed and the number of branch points. 
The comparison of 2dDR with 2dLR, 2dDG and DG showed that none of the other small 
sugar molecules increased the activity of HAECs over 7 days. Instead, I demonstrated that 
2dDG (when administered at 100 µM, 1 mM and 10 mM) and 2dLR (when used at 10 mM) 
had an anti-angiogenic effect on HAECs proliferation. The anti-angiogenic impact of 2dDG 
and 2dLR has been reported by several groups. Uchimiya et al. reported TP-mediated 
angiogenesis could be suppressed by 2dLR [83]. Similarly, Nakajima et al. showed that 
2dLR reduces the vascular area increased by TP-mediated tumour angiogenesis in 
metastatic nodules [86]. Merchan et al. reported that 2dDG reduces the tube formation in 
vitro and inhibits angiogenesis in vivo [365]. Likewise, Chuang et al. reported the 
inhibition of new tube formation in 2dDG treated rat aortic rings and showed that 2dDG 
reduced cell viability, tube formation capability, and VEGFR-2 expression of HUVECs in 
vitro [366]. 
In summary, the in vitro assessment of the angiogenic activity of 2dDR showed it to be 
dose-dependent reproducing all of the actions of VEGF with 2dDR stimulating 
proliferation, migration and tube formation of HAECs. 100 µM concentration was 
essentially equivalent to 80 ng/mL of VEGF. None of the other small sugar molecules 
(2dLR, 2dDG, and DG) were found to be effective for inducing angiogenesis in vitro. 
Following the in vitro assessment of 2dDR, I aimed to investigate the angiogenic potential 
of 2dDR and E2 either applied as solutions or released from fibrous TE constructs and to 
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explore if it is possible to define certain concentrations of either 2dDR or E2 which are as 
effective as VEGF in stimulating angiogenesis in CAM assay. To date, there have been no 
studies conducted on the effective angiogenic dose range of 2dDR, which is proangiogenic 
in vivo. Therefore, for the first time in this study, I demonstrated the reliable 
concentration ranges for both 2dDR and E2 for stimulating angiogenesis in CAM assay 
and compared their proangiogenic activities with the VEGF used as a positive control. 
The key findings from this study were that 2dDR and E2 showed dose-dependent 
angiogenic responses, and our results demonstrate that both were found to be 
approximately 80% as potent for the production of new blood vessels in vivo when 
compared with VEGF as a positive control. The results of the dose response studies 
showed that the most effective doses were 200μg/day/embryo and 200ng/day/embryo 
for 2dDR and E2, respectively. Higher and lower doses of the drugs showed less 
angiogenic activity in the CAM assay. These results were further confirmed with the 
investigation of the microvascular structures of CAM when treated with the drugs. In 
VEGF treated groups, the VA% was far higher than in other groups. However, 
microvessels upregulated by VEGF showed smaller lacunae formation due to endothelial 
cell hypertrophy when assessed with confocal microscopy, while a more consistent and 
stable microvessel structure with a significantly increased VA% was found in 2dDR and 
E2 treated CAMs. This, we suggest, is important as VEGF has been reported to lead to the 
formation of leaky and haemorrhagic vessels [334]. Although angiogenic activities of 
2dDR and E2 were evaluated with the direct applications of those to CAM, this 
administration method is only used for determination of the most angiogenic 
concentrations of the drugs.  
The effective concentrations of 2dDR and E2 were then loaded into electrospun PHBV 
constructs to stimulate angiogenesis with the sustained release of both agents from 
fibres. PHBV is a natural, biocompatible and biodegradable biopolymer [367]. Although 
the biodegradability of PHBV is relatively slow when compared to PLA [368], it is still an 
attractive material for drug release studies because of its excellent biocompatibility, 
biodegradability, and easy processing properties [369].  
Incorporation of 2dDR and E2 into the PHBV scaffolds resulted in some alterations in 
fibre morphology and hydrophobicity of the scaffolds although no technical problems or 
adverse effects of introducing E2 and 2dDR into fibres were experienced. 
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Introduction of both drugs significantly increased fibre diameters in accordance with the 
increasing concentrations of the drugs, and a change in the fibre structure of electrospun 
PHBV scaffolds that contain higher concentrations of E2 was observed. Physical 
crosslinking of electrospun fibres (or fibre fusion) was observed in PHBV scaffolds loaded 
with a higher dose of E2. The fibre fusion can be explained with the decrease in viscosity 
of the electrospinning solution with the addition of E2, a highly plasticizing agent [370]. 
This decrease in viscosity leads to slow evaporation of the solvent during electrospinning 
[371] which results in fused fibres. Unnithan et al. also reported similar changes in 
fibrous morphology of E2 loaded electrospun polyurethane (PU) scaffolds due to a 
change in the viscosity of the electrospinning solution [372]. On the other hand, the 
incorporation of 2dDR into the electrospun PHBV scaffolds did not affect fibre 
ultrastructure. However, although the SEM images did not show any change in fibre 
structure, I did observe reduced structural integrity of the fibres in histologic sections of 
2dDR releasing scaffolds. These alterations occurred after the scaffolds were implanted 
on CAM. Therefore, it is likely that this change was due to rapid deformation of the fibres 
after the rapid release of 2dDR resulting in an increased surface area for cellular 
attachment and infiltration. 
Addition of E2 significantly increased the hydrophobicity of the scaffolds in a dose-
dependent manner. This is not surprising as E2 is known to be highly hydrophobic [373]. 
In contrast to E2, the addition of 2dDR significantly decreased the hydrophobic character 
of the PHBV fibres which can be explained by the high solubility of 2dDR in water. The 
estimated solubility of E2 in water is approximately 30000 times lower than sugars 
[374,375]. Thus, the addition of these drugs with different solubilities significantly 
changed the hydrophilicity of the PHBV scaffolds. Furthermore, this influenced the 
release characteristics. As can be expected, I observed significantly lower and slower 
release of E2 in comparison with the release of 2dDR from the PHBV fibres. In contrast to 
the lower and more sustained release of E2 from PHBV fibres, a burst release of 2dDR 
was observed within 7-days.  
Incorporation of both drugs enhanced both the UTS and Young’s modulus of the PHBV 
scaffolds compared with plain PHBV controls. Similarly, Huang et al. reported a similar 
change in tensile properties of their drug-loaded PCL electrospun scaffolds. They 
demonstrated that the diameters of the fibres were increased with the addition of higher 
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concentrations of the resveratrol (a type of antioxidant), and the addition of the drug led 
to the increased ultimate strength and decreased Young’s modulus of their scaffolds 
[376]. 
Although both of the factors stimulated angiogenesis when applied directly onto the CAM, 
a more dramatic increase in the number of discernible blood vessels was seen when 2dDR 
and E2 releasing PHBV scaffolds were implanted to CAM. E2 was found to be slightly more 
effective in both application procedures when compared with 2dDR loaded and plain 
PHBV control groups. This study also established effective concentrations of E2 (25mg/g 
of PHBV) and of 2dDR (250mg/g of PHBV) to be loaded into scaffolds to achieve a reliable 
stimulation of neovascularisation. Higher doses of both drugs were found to be less 
effective in promoting the angiogenesis in CAM assay. The dose dependence of E2 has 
been studied by many groups. In 2004, Seo et al. reported E2 caused increased angiogenic 
activity in vivo in a dose-dependent manner [347]. Pence et al. studied the endogenous 
VEGF production of epithelial cells when treated with different doses of E2 in vitro. They 
found that the treatment of cells with 10 nM and 1000 nM E2 stimulated the production 
of VEGF where addition of 100 nM E2 showed no significant effect on cells [348]. Liu et 
al. examined the effect of E2 on rat cardiac microvascular endothelial cell (CMEC) 
proliferation and tube formation in vitro. With regards to the proliferation of CMECs, they 
reported a biphasic response to E2. The lowest and the highest doses of E2 were less 
effective compared to the optimal dose [349]. In contrast to studies of dosage response 
of E2, to date, there have not been any such studies exploring the angiogenic response to 
different doses of 2dDR. In view of the comparatively few studies on this small sugar, not 
all of which agree, I conducted a dose-dependence study of 2dDR for promoting 
angiogenesis. While lower doses of promoted angiogenesis, higher doses were found to 
be less effective. Drug releasing scaffold assays further confirmed these findings. The 
scaffolds loaded with the higher doses of 2dDR and E2 showed reduced angiogenic 
activity when compared with the scaffolds loaded with lower doses.  
These results were then compared with the histologically stained sections of the 
scaffolds. In these, more blood vessels were counted adjacent to 2dDR and E2 releasing 
scaffolds. However, in contrast to the results from the quantified macro images, in 
histological analysis, the number of blood vessels adjacent to the scaffolds loaded with 
the higher doses of 2dDR (2dDR 500) and E2 (E2 50) were not significantly but slightly 
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greater than lower doses. These different results might be caused by our ability to see 
and count the smaller diameter blood vessels that may not be discernible in the digital 
CAM analysis used for quantification. Additionally, the histological sections also show 
blood vessels from different orientations which might not have been detectable on digital 
CAM images. This might increase the results seen for higher doses of the drugs. 
E2 has previously been reported as angiogenic both in vitro and in vivo by many groups 
as well as our research group. Albrecht et al. suggested that E2 promotes angiogenesis 
through up-regulation of VEGF. They reported rapidly increased VEGF expression and 
cell permeability by E2 administration to ovariectomised baboons [377]. Similarly, 
elevated VEGF mRNA expression levels were observed in ovariectomised rats after E2 
treatment by Hyder et al. [378]. Morales et al. reported that E2 promoted migration of 
HUVECs and formation of capillary-like networks on Matrigel [63]. Pence et at. indicated 
that exogenous E2 promoted endogenous production of VEGF by endometrial epithelial 
cells [348]. More recently, our group has demonstrated the release of E2 from both 
biodegradable PLA fibres [69] and from nondegradable PU fibres [379] with both 
electrospun scaffolds showing good proangiogenic activity in the CAM assay. 
In contrast to VEGF and E2, there is relatively little literature on the angiogenic activity 
of 2dDR, and the mechanism of action of 2dDR remains still unclear. Only a few studies 
have proposed a pathway to explain the angiogenic mechanism behind this small sugar 
molecule. Briefly, two main mechanisms have been proposed when it comes to the 
angiogenic activity of 2dDR at the molecular level. In the first proposed mechanism, 
researchers suggest the endogenous production of 2dDR by enzymatic degradation of 
thymidine to thymine promotes oxidative stress and consecutively stimulates the 
secretion of angiogenic factors such as VEGF and interleukin-8 (IL-8) which can be 
internalised by ECs and promote angiogenesis [82,84,380]. In the second mechanism, 
which has been recently studied by Vara et al. [381], the 2dDR-1-phosphate (2dDRP) is 
produced either internally by cells which express TP such as macrophages, platelets and 
cancer cells and then secrete this extracellularly, or TP may be released from injured cells 
to act on enzymatic degradation of thymidine and generation of 2dDR extracellularly. 
2dDRP then can be taken up by endothelial cells, and this then activates NADPH oxidase 
2 (NOX2) which later acts on nuclear factor kappa B (NF-κB). NF-κB then upregulates the 
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VEGFR2 and thus drives VEGF-dependent angiogenesis. Both mechanisms are 
summarised in Figure 42. 
As must be evident in these early days of studying 2dDR, the clarification of the 
mechanism of action of 2dDR remains to be definitely established. Herein, I wished to 
learn more about the biological activity of this sugar using a range of well-established in 
vitro models and in particular to establish the effective concentration range of this small 
sugar. Throughout, I have used VEGF as a comparator so that I can answer how 
biologically effective 2dDR is compared to this well documented major pro-angiogenic 
factor.  
Although I have not primarily aimed to establish a mechanism of action for the angiogenic 
activity of 2dDR, I investigated whether this activity is VEGF-dependent or not. For this, 
HAECs were incubated in low serum EC GM supplemented with 100 µM of 2dDR, 1 mM 
of 2dDR, and 80 ng/mL VEGF. Non-supplemented low serum EC GM was used as a control. 
The analysis of the collected media at day 1, 3 and 5 demonstrated that the VEGF 
production by HAECs in response to direct treatment of 2dDR was statistically significant 
even at day 1. The amount of VEGF rose up by approximately 48-fold and 70-fold, 
respectively by 100 µM and 1 mM 2dDR treatment. At the end of day 5, VEGF production 
of HAECs was increased by 74-fold and 80-fold, respectively by the addition of 100 µM 
and 1 mM 2dDR. This data was in support with the current literature, which hypothesises 
that an increase in the level of VEGF expression of endothelial cells in the presence of 
2dDR [82,84].  
The stability studies demonstrated that there was a gradual decrease in the amount of 
2dDR presented in the growth medium over 14 days either in the presence or absence of 
HAECs. This decrease has been found to be higher when HAECs were presented in the 
well plates. This higher decrease is likely to be due to that 2dDR is internalised by HAECs 
and used to increase the production of VEGF. At the end of day 14, there was 
approximately 40% to 50% reduction in the amount of 2dDR in the culture medium in 
the presence of HAECs. The drop of 2dDR amount in culture medium over 7 days is in 
compliance with the decrease in the amount of VEGF produced by HAECs in response to 
2dDR treatment from day 4 to 7. Thus, these data may reveal important information 
about the safety of 2dDR treatment since both 2dDR and its angiogenic effect is burning 
out over time. 
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Figure 42: Proposed pathways for VEGF and 2dDR to promote angiogenesis. (1) endogenous 
generation of 2dDR stimulates the production of angiogenic factors via stimulation of oxidative 
stress. (2) 2dDR takes a role in the upregulation of VEGFR2 via generation of ROS and NF-κB  
Alongside with the 2dDR, the literature on small sugars is very limited and conflicting. 
Uchimiya et al. demonstrated that TP-induced angiogenesis could be reversed by the 
addition of 2dLR [83]. Nakajima et al. reported that 2dLR inhibits VEGF production and 
TP-related angiogenesis in metastatic nodules [86] and inhibits Matrigel invasion of 
tumours [382]. Ikeda et al. showed that 2dLR promotes hypoxia-induced apoptosis of HL-
60 cells [383]. Uchimiya et al. demonstrated the inhibition of angiogenesis in a rat corneal 
assay by 2dLR [83]. Although all these studies reported the anti-angiogenic activity of 
2dLR, Yar et al. previously showed the promotion of angiogenesis by the release of 2dLR 
from hydrogels in CAM assay [87]. Similarly, Sengupta et al. also suggested that 2dLR 
showed an angiogenic response in sponge granuloma model of angiogenesis [82]. Similar 
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conflicting literature can be seen for DG, which has previously been reported to induce 
proliferation, migration and tube formation of ECs by many groups [384–386]. On the 
contrary, several reports asserted that DG inhibits tube formation in vitro [387] and anti-
angiogenic in vivo [388]. In order to better understand this conflicting literature, I 
summarised the studies on some of the small sugars that have been found to promote or 
inhibit angiogenesis in Table 12.
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Table 12. Summary of the studies on some small sugars that have been found to promote or inhibit angiogenesis 
Sugars Assay Result Effective Doses Reference 
2-deoxy-D-ribose 
(2dDR) 
In vitro 
Promotes proliferation, migration and tube formation of ECs 100 µM to 1 mM [88] 
Inhibits hypoxia-induced apoptosis 10 µM [383] 
Induces Matrigel invasion 100 µM [382] 
Stimulates proliferation and migration of ECs 100 µM to 1 mM [82] 
Activates NOX2 → NF-κB and upregulates VEGFR2 8 µM to 1 mM [389] 
Increases VEGF production of ECs 100 µM to 1 mM [390] 
CAM assay Promotes angiogenesis 
200 µg/day [89] 
1 mg/mL  [87] 
In vivo 
Promotes angiogenesis and wound healing 
1 mg/mL  [87] 
5% or 10% (w/v) [90] 
Promotes angiogenesis 2 nmol [82] 
2-deoxy-L-ribose 
(2dLR) 
In vitro 
Inhibits migration and tube formation and tumour invasion 100 µM [83,84,382] 
Inhibits VEGF production 10 µM to 100 µM [86] 
Promotes hypoxia-induced apoptosis 30 µM to 50 µM [383] 
CAM assay Stimulates angiogenesis 1 mg/mL  [87] 
In vivo 
Inhibits angiogenesis in a rat corneal assay 200 ng/pellet [83] 
Promotes angiogenesis 2 nmol [82] 
2-deoxy-D-
glucose 
(2dDG) 
In vitro 
Inhibits the proliferation, migration and tube formation of ECs 60 µM to 9 mM [365] 
Inhibits proliferation of cells and reduces ATP levels 3 mM [391] 
Inhibits the proliferation, migration and tube formation of ECs 50 µM to 1 mM [366] 
Downregulates AKT and ERK pathways and inhibits tube 
formation  
600 µM [392] 
Rat aortic ring Inhibits tube formation of ECs 50 µM to 1 mM [366] 
In vivo Inhibits angiogenesis 6 mM [365] 
D-Glucose 
(DG) 
In vitro 
Induces migration and tube formation of ECs 25 mM [384] 
Inhibits proliferation, migration and tube formation of ECs 5 mM to 30 mM [385] 
Promotes tube formation of ECs and COX-2 expression 25 mM to 30.5 mM [386] 
Inhibits the tube formation of ECs in a dose-dependent 
manner 
10 mM to 16 mM [387] 
In vivo Reduced angiogenesis 22 mM [388] 
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In the assessment of these approaches to overcome delayed angiogenesis in TE 
constructs, I have made extensive use of the ex-ovo CAM assay to evaluate angiogenesis. 
It is an excellent bioassay for assessing the angiogenic response to materials allowing 
direct imaging and comparison of the newly formed blood vessels. It can also be used as 
a low cost, rapid and simple tool for testing very early tissue reactions to biomaterials 
[228]. The CAM assay has been used by our group in recent years to evaluate the 
biocompatibility and proangiogenic response to a range of different polymers 
encompassing PLA, PU, PHBV, and CS/collagen.  
To place the current results in context, I summarised these preceding studies in a table 
which summarises the response of the ex-ovo CAM assay to these materials in terms of 
their effect on the structure of the underlying membrane, the infiltration of cells into the 
material and their effect on angiogenesis in the CAM. Cellular infiltration in the table 
describes the migration of cells from CAM to biomaterials. In general, highly porous, 
biocompatible structures, where pore sizes are large enough to allow cellular ingrowth, 
lead to good cellular/tissue infiltration to a biomaterial [393,394]. Because the diameter 
of the fibres and the pore size of electrospun PHBV were much smaller, less cellular 
infiltration was observed in all PHBV scaffold groups than for other polymers studied in 
the CAM assay (Table 13). 
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Table 13. Comparison of the response of CAM to different polymer systems, assessing 
biocompatibility and proangiogenic activity 
Polymer Agent 
Average 
Pore size 
Effect on 
embryo 
survival 
Cell 
infiltration 
Angiogenic 
activity on 
CAM 
PLA [69] 
None 
< 5 µm 
None ++++ - 
Vitamin C None ++++ ++ 
E2 None ++++ ++++ 
PU [379] 
None 
< 25 µm 
None +++ - 
E2 None +++ ++++ 
CS/PVA/PCL 
[345] 
Heparin < 1 µm None +++ ++++ 
CS/PVA [346] Heparin < 6 µm None +++ ++++ 
CS/Collagen [87] 2dDR < 105 µm None +++ ++++ 
PHBV 
None < 3 µm None ++ - 
2dDR < 4 µm None ++ +++ 
E2 < 3 µm None ++ ++++ 
 
As the next step in our investigations, we sought to assess whether 2dDR can stimulate 
wound healing in a compromised wound model in animals. Healing is a multifaceted 
process in which the development of new blood vessels plays a major role. This is 
particularly critical in chronic non-healing wounds. By the time a wound has failed to 
respond to conventional best practice clinical treatment- often for an arbitrary period of 
3 months- they are classified as chronic non-healing wounds. Investigation of the 
underlying wound beds will often show poor vascularisation, abnormal often 
exacerbated inflammation and very often some level of bacterial infection. 
Impaired wound healing is a major complication endured by patients with diabetes and 
is the leading cause of non-traumatic lower limb amputation in these patients. 
Accordingly, the current study aimed to examine to what extent release of this sugar 
might promote wound healing in a compromised diabetic wound model. To do this, we 
loaded the sugar into an alginate hydrogel and used it to treat skin wounds in a diabetic 
rat model. 
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Alginate dressings are in clinical use for the treatment of heavily exudative, chronic 
wounds [395] as well as for diabetic wounds. As such, they are a logical choice to use to 
deliver this sugar. The sugar was loaded on highly absorbent alginate dressings under 
sterile conditions.  
Our findings were that 2dDR was straightforward to load into alginate dressings- these 
were then air-dried, and when placed in a wet environment, they released approximately 
90% of their sugar load within 3 days. The amount released was proportional to the 
amount loaded. The fibre structure of alginate dressings was retained after deoxy sugar 
loading. The sugar itself was stable over 3 weeks as assessed at RT.  
A well-established diabetic rat model was used in which a full thickness of 20 mm 
diameter skin wound was made. While the area of these wounds reduced by 
approximately 70% by 20 days they were still not fully healed. Addition of alginate did 
significantly accelerate wound healing, but macroscopic wound closure analysis (Figure 
37) clearly showed that 2dDR released from alginate further accelerated the wound 
healing. By day 20, wounds treated with 2dDR were essentially fully healed. Similar 
results were seen whether alginate was loaded with 5 or 10% sugar. The histological 
assessment also demonstrated better healing of the skin wounds treated with 2dDR 
loaded alginate as evidenced by the presence of new epithelium.  
We looked for the immune response to the dressings and whether the dressings had any 
effect on angiogenesis. Overall there was a vigorous M2 macrophage response which is 
indicative of macrophages promoting new tissue formation [396] -while an M1 response 
is associated to encapsulation and chronic inflammation with the rejection of the implant 
[397]. This response was very low for all groups. The addition of the sugar did, however, 
lead to increased CD34 positive cells in the wound bed indicative of better 
neovascularisation. This was observed at day 7 for the 2dDR loaded alginate groups and 
maintained throughout the 20 days of the study. We suggest that the increased 
vascularisation will have contributed to the accelerated wound healing. Both 5% and 
10% loading were effective. 
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 Conclusions and Future Work 
In this chapter, the angiogenic potential of 2dDR and its effective concentrations range 
were revealed using established in vitro and in vivo angiogenesis assays.  
First, it has been shown that the most effective dose range of 2dDR to promote the 
proliferation, migration and tube formation of HAECs was between 100 µM and 1 mM. 
When used within this range 2dDR was found approximately 90% as effective as VEGF 
for promoting angiogenesis in vitro. Administration of 2dDR at higher concentration (10 
mM) resulted in the detachment of ECs and led to cell death. 
Then, an ex-ovo CAM assay was used to define a certain concentration range of 2dDR, and 
it has been found to be 80% as potent as VEGF for inducing angiogenesis in CAM assay 
when given at the dose of 200 µg/day/embryo. In addition, loading of 250 mg of 2dDR 
per 1 g of polymer significantly increased the angiogenic activity in the area of 
implantation when compared to controls. 
Finally, the potential of 2dDR for stimulating wound healing and angiogenesis when 
released from commercially available alginate dressing was demonstrated using a 
diabetic rat model. The incorporation of 5% and 10% 2dDR to the alginate dressings not 
only stimulated wound healing and showed a full wound closure (100%) at the end of 20 
days when the wound closure was only 70% in the alginate control group but also 
stimulated angiogenesis in the wound area by day 7 and 20. 
In the scope of this chapter, I did not primarily aim to explore the mechanism of action of 
this small sugar. However, our results clearly showed that 2dDR achieves angiogenesis 
by upregulating the production of VEGF. It’s encouraging performance in vitro, in the CAM 
assay and in a diabetic wound model shows the potential value of this small sugar. In the 
future, experiments need to be carried out to explore the mechanism of action of this 
small deoxy sugar molecule to understand what is happening in the molecular level 
behind the scene. The literature on the mechanism of action of 2dDR still remains unclear, 
and studies suggest only a few potential pathways mostly focusing on VEGF-R2 
dependent signalling.  
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CHAPTER III 
Development of the PHBV synthetic vascular 
networks to study angiogenesis 
 Aims and Objectives 
The aims of this chapter are to design and produce synthetic vascular networks and to 
investigate its potential to be used as an in vitro platform to study angiogenesis. In order 
to satisfy these aims; the objectives of this chapter are to: 
• Compare two widely-used polymers (PHBV and PCL) which are suitable for the 
manufacturing of vascular networks in terms of their physical, mechanical, and 
biological performances. 
• Design and manufacture the PHBV synthetic vascular networks using a four-step 
fabrication technique, which combines 3D printing and electrospinning. 
• Investigate the biomechanical properties of the scaffolds. 
• Evaluate the optimal cell types and co-culture systems for improved survival and 
growth of the endothelial cells within these channels. 
• Investigate the outgrowth of endothelial cells from pre-formed endothelial cell 
monolayer inside the channels towards Matrigel and reconstructed skin model in 
the presence and absence of pro-angiogenic agents. 
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 Chapter III by Pictures 
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 Introduction 
Angiogenesis is a sophisticated process regulated by a complex web of interactions of 
endothelial cells (ECs) with their extracellular matrix (ECM) and with biochemical and 
mechanical factors as previously explained in Section 1.3. The delayed neovascularisation 
of tissue-engineered (TE) constructs post-implantation can cause them to fail clinically 
[398]. Thus, investigating the factors that regulate angiogenesis is particularly important 
to understand how they are involved in this complex process.  
Angiogenesis assays are powerful tools to study aspects of angiogenesis and can be 
categorised into three main categories: (i) in vitro, (ii) ex vivo, and (i) in vivo [399]. In vivo 
assays are the most representative of native angiogenesis, but since healthy animals are 
used to perform these assays, they are ethically questionable, require considerable 
technical skills, and expensive [204]. In contrast, in vitro assays are inexpensive and 
relatively easy to perform. However, the majority of them are based on two-dimensional 
(2D) cell culture systems which lack the physiological relevance that three-dimensional 
(3D) structures can provide [400]. Thus, it is important to develop better in vitro 
platforms that enable the study of angiogenesis under more physiologically relevant 
conditions.  
Skin tissue engineering has gained great momentum over the years. However, developing 
biologically relevant in vitro tissue models as alternatives to animal models or as 
physiologically relevant tissue substitutes for clinical use is always open for 
improvement. Several in vitro skin models have been developed over the last years as 
alternatives to animal testing, to study wound healing, pigmentation, contraction, tumour 
invasion, barrier function, and bacterial infection [401,402]. Facy et al. created a 
reconstructed epidermis model with Langerhans cells and used this model to test the 
reactivity of these cells to known allergens and UV [403]. Kandarova et al. studied skin 
irritation using two reconstructed human skin equivalents as an alternative to animal 
testing [404]. To study pigmentation, Bessous et al. developed an in vitro reconstructed 
epidermis using autologous keratinocytes and melanocytes [405]. Meier et al. developed 
a human skin equivalent to study melanoma progression, and they reported a close 
correspondence between the growth of melanoma into engineered skin construct and in 
vivo [406]. Admane et al. reported the direct 3D bioprinting of full-thickness skin 
constructs that mimics the signalling pathways of skin [407]. Similarly, Kim et al. 
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developed a 3D printed skin model with perfusable vascular channels to create a 
vascularised skin model [408]. Kolesky et al. developed a platform using a multi-material 
3D bioprinting method, which enables researchers to create thick tissue models with 
engineered matrix and embedded vasculature [409]. Recently, John et al. demonstrated 
the regeneration of TE skin substitute on human amniotic membrane [410]. Our 
laboratory has previously reported a 14-day protocol for the reconstruction of a 3D 
human skin model that is suitable for clinical use [411], and have previously explored 
adding Human Dermal Microvascular Endothelial Cells (HDMEC) to TE skin model with 
very little success-the cells struggled to enter the TE skin and showed no signs of being 
organised when they did enter [412]. Although TE skin was being studied for a long time 
to be used as skin substitutes in the clinic or in vitro models for research, the main 
challenge remains the same: studying and improving angiogenesis/vascularisation of a 
TE skin for translation of it to clinic or for doing research on understanding the basic 
principles of skin vascularisation. Either for implanting or for in vitro laboratory research, 
developing a vascularised 3D human skin model is highly important for the successful 
take of TE skin substitute after implantation or studying the effect of chemical, 
mechanical and environmental factors on neovascularisation of skin. Thus, there is a need 
to develop new platforms that enable to study vascularisation of complex tissues such as 
skin.  
In this chapter, I initially compared physical, mechanical, and biological performances of 
two widely-used polymers, Poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV), a 
biocompatible and biodegradable polyester, belongs to the polyhydroxyalkanoate family. 
3-hydroxybutanoic acid, one of its degradation products that are also a natural product 
produced in the human body [413] which can be linked with its high biocompatibility and 
polycaprolactone (PCL), another biocompatible and bioresorbable synthetic polymer, 
which does not produce an overly acidic environment in the degradation process and has 
been approved by the United States Food and Drug Administration (FDA) as a material 
for the fabrication of several biomedical devices [414,415]. Then, I selected PHBV as the 
material for the development of synthetic vascular networks (SVN) by combining two 
scaffold manufacturing techniques, electrospinning and 3D printing. 
The main aim of this study was to create a unique in vitro platform that enables 
researchers to study more than one aspect of angiogenesis both at cellular and tissue 
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levels. PHBV channels were used as physical support and a structural guide for ECs to 
create a pre-formed endothelium-like structure. This endothelium-like structure was 
then used to study the migratory response and tube-forming capability of ECs in response 
to pro-angiogenic agents in vitro and to explore how synthetic channels can be used as a 
model for the vascularisation studies at tissue level. The CAM assay has been used for the 
first time as a surrogate for a well-vascularised wound bed to provide the source of blood 
vessels to grow into the 3D human skin as a positive control to the PHBV SVN 
vascularisation studies [416]. 
 Materials 
Chemical / Reagent 
Catalogue 
Number 
Supplier 
Thrombin (human) 228-11508 Cayman Chemical 
Matrigel® (Growth Factor Reduced) 356231 Corning 
Chloroform 10784143 
Fisher Scientific 
Dichloromethane (DCM) 10127611 
Dimethylformamide (DMF) 15562393 
DPX mounting medium D/5319/05 
Industrial methylated spirit (IMS) M/4450/17 
Methanol 10626652 
Triton X-100 BP151 
Xylene X/0100/17 
Poly3-hydroxybutyrate-co-3-hydroxyvalerate 
(PHBV) (PHV content 12 mol %) 
BV326301 GoodFellow 
Optimum cutting temperature tissue freezing 
medium (OCT-TFM) 
14020108926 Leica Biosystems 
Fertilised chicken eggs - MedEggs 
RCOM King SURO humidified egg incubator MX-SURO P&T Poultry 
EC GM MV Supplement Pack (For HDMECs) C-39220 
PromoCell Endothelial Cell Growth Medium MV (EC GM) 
(for HDMECs) 
C-22220 
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Human Dermal Microvascular Endothelial Cells 
(HDMECs) 
C-12210 
Epidermal growth factor (EGF) 236-EG R&D Systems 
2-deoxy-D-ribose (2dDR) 121649 
Sigma Aldrich 
37% formaldehyde (FA) solution F8775 
4',6-diamidino-2-phenylindole (DAPI) solution  D8417 
Adenine A5665 
AlamarBlue Cell Metabolic Activity Assay R7017 
Alginic acid sodium salt 180947 
Amphotericin B A2942 
Anti-CD31 (PECAM-1) antibody produced in 
mouse 
P8590 
Bovine serum albumin (BSA) A7030 
Calcium chloride dihydrate 223506 
Chlorotoxin C5238 
Collagenase A COLLA-RO 
D-glucose G7021 
Dimethyl sulphoxide (DMSO) 472301 
Dulbecco’s Modified Eagle’s Medium (DMEM) D6546 
Ethylenediaminetetraacetic acid (EDTA) E6758 
Eosin Y solution HT110232 
Ethanol 51976 
F-12 HAM nutrient mixture N4888 
Fetal calf serum (FCS) F9565 
Fibrinogen from human plasma F3879 
Glutaraldehyde (25%) G5882 
Glycerol G5516 
Hematoxylin solution HHS16 
Hydrocortisone H0888 
Insulin (human recombinant) 91077C 
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L-glutamine G3126 
Methylene blue M9140 
Penicillin / Streptomycin P0781 
Phalloidin, fluorescein isothiocyanate (FITC)  P5282 
Phalloidin, tetramethylrhodamine 
isothiocyanate (TRITC) 
P1951 
Polycaprolactone (PCL) (Mn: 80.000 g/mol) 440744 
Sodium hydroxide pellets 795429 
Trypan blue T6146 
Trypsin EDTA T3924 
Tween®20 P1379 
Vascular endothelial growth factor (VEGF) V7259 
CellTracker™ Green C2925 
ThermoFisher 
CellTracker™ Red C34552 
Goat anti-Human IgG (H+L) Cross-Adsorbed 
Secondary Antibody, Alexa Fluor 546 
A-21089 
 
 Methods 
 Comparison of two polymers that are widely used in tissue engineering 
applications: PHBV and PCL 
 Comparing the hydrophobicity of the polymers with contact angle 
measurements 
 Preparation of the polymer solutions 
The polymer solutions were prepared before contact angle measurements. Firstly, PHBV 
(10% (w/w)) granules were dissolved in DCM:methanol (90:10 w/w) solvent blend in a 
fume hood. Then PCL (10% (w/w)) granules were dissolved in and chloroform:DMF 
(70:30 w/w) solvent blend. The DCM:methanol (90:10 w/w) solvent blend for 
electrospinning PHBV has previously been found the best composition in our lab 
[417,418]. The solvent mixture for electrospinning PCL has been optimised in the scope 
of this thesis and will be explained in Chapter VI. We have recently reported that 
122 
 
chloroform:DMF (70:30 w/w) composition was the best mixture for electrospinning PCL 
nanofibres [419]. 
 Contact angle measurements 
PHBV and PCL thin films from the polymer solutions were prepared using a spin-coater 
(Laurell WS-400B, North Wales, Pennsylvania, USA). Contact angle measurements of the 
PHBV and PCL were performed using a drop shape analyser (Krüss DSA100, Germany) 
under ambient laboratory conditions. A 5 µL water droplet was dropped onto the 
polymer films, and the contact angles of the droplet on samples were recorded from the 
software. The measurements of at least three drops on three different samples were 
taken for each polymer. 
 Electrospinning PHBV and PCL solutions 
PHBV and PCL polymer solutions were loaded into two separate 5 mL syringes fitted with 
0.6 mm inner diameter syringe tips. Syringes were then placed in a syringe pump 
(GenieTMPlus, KentScientific, Connecticut, USA). Aluminium foil was used as the collector 
and placed at a distance of 17 cm from the needle tips. The pump was set to 40 
µL/minutes, and 17 kV voltage was applied both to the collector and the tips. 
Electrospinning was done at room temperature until all the polymer solution was used. 
 Biomechanical testing of PHBV and PCL electrospun scaffolds 
Biomechanical testing samples were prepared by cutting 20 mm x 10 mm pieces from dry 
electrospun scaffolds. The clamps of the device were positioned 10 mm away from each 
other, and the width and thickness of each scaffold were measured. Test samples were 
clamped with two grips in a tensiometer (BOSE Electroforce Test Instruments, 
Minnesota, USA). Tensile tests were performed on each sample at a rate of 0.1 mm/s until 
the samples failed (n=4). UTS and Young’s modulus were calculated from stress (σ) and 
stress (ε) curves of each sample. 
 Comparing the microstructures of the electrospun PHBV and PCL using SEM 
The surface morphology of PHBV and PCL electrospun nanofibres were observed under 
SEM (FEI Inspect F, Orlando, USA). The samples were coated with gold using a gold 
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sputter (Edwards sputter coater S150B, Crawley, England) prior to imaging. Fibre 
diameter and pore sizes were measured using ImageJ software. At least 100 
measurements were taken from the different areas of each sample, and at least three 
samples were used for each polymer group.  
 Comparing the biocompatibility of the polymers in vitro and in vivo 
 Assessment of the activities of HDFs growing on PHBV and PCL with 
AlamarBlue® metabolic activity assay  
AlamarBlue® Cell Viability Assay (ThermoFisher Scientific, USA was used to compare the 
biocompatibility of the PHBV and PCL electrospun scaffolds by measuring the metabolic 
activity of Human Dermal Microvascular Endothelial Cells (HDMECs) cultured on either 
PHBV or PCL over 11 days.  
HDMECs were used between P2 and P4. Cells were thawed and cultured until reaching 
80-90% confluency. Following sterilisation of the PHBV and PCL scaffolds with 70% 
ethanol for 45 minutes, HDMECs were trypsinised and counted. 4 x 104 cells were 
resuspended in 0.25 mL of EC GM (PromoCell, Heidelberg, Germany) and then seeded 
onto the scaffolds in 12-well plates. Before adding culture medium, scaffolds were 
returned to the incubator for an hour to allow HDMECs to attach. Then, 4 mL of HDMECs 
culture medium was added to each well, and they were incubated at 37°C overnight. 
Scaffolds were kept in culture for 11 days by changing the culture medium every 2-3 days. 
AlamarBlue® Cell Viability Assay was performed at days 1, 4, 7 and 11. Briefly, 0.1 mM 
AlamarBlue® working solution was prepared by 10x dilution of the 1 mM AlamarBlue® 
stock solution with growth medium. Growth media were removed, and the scaffolds were 
washed with PBS. 1 mL of AlamarBlue® working solution was added to each well and 
incubated at 37°C for 4 hours. After an incubation period, 200 µL of the solution was 
transferred into 96-well plate, and the fluorescence readings were done at an excitation 
wavelength of 540 nm and an emission wavelength of 635 nm.  
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 Assessment of the biocompatibility of the PHBV and PCL using ex-ovo CAM 
assay 
To evaluate the initial response of CAM to both polymers, electrospun PHBV and PCL 
were implanted to CAM. The response of CAM to the polymers was evaluated with 
macroscopic and histological evaluation of the CAMs after the incubation period. A 
detailed procedure of the CAM assay, scaffold implantation and histological analysis of 
electrospun scaffolds is given in Chapter 2. 
 Manufacturing of SVN from the selected polymer: PHBV 
Following the 3D design of SVN using computer-aided design (CAD) software 
(SolidWorks 2012, Massachusetts, USA), synthetic scaffolds were manufactured via the 
four-step process as shown in Figure 43. First, a layer of PHBV was electrospun on 
aluminium foil coated collector using the parameters given in Section 3.5.1.2. Alginate 
was then used as a sacrificial substrate and 3D printed on to PHBV using a 3D bioprinter 
(BioBots, Philadelphia, USA). Following that, another layer of PHBV was electrospun on 
top of the alginate using same parameters. Finally, sacrificial alginate channels were 
removed via 0.5 M of EDTA solution. 
 
Figure 43. Schematic illustration showing the four-step manufacturing process of synthetic 
vascular channels 
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 Computer-aided design (CAD) of the 3D vascular channels 
Various designs of synthetic vascular networks (Figure 44) were created using CAD 
software (SolidWorks 2012, Massachusetts, USA). Once the models were prepared, they 
were exported as standard tessellation language (STL) format for 3D printing.  
  
Figure 44. The CAD of synthetic vascular channels 
 Electrospinning PHBV 
 Preparation of PHBV solution for electrospinning 
10% (w/w) PHBV solution was prepared prior to electrospinning. 6 g of PHBV granules 
were dissolved in 3 g of methanol and 24 g of DCM in a fume hood, and the mixture was 
magnetically stirred overnight.  
 Electrospinning PHBV 
Approximately 10 mL of PHBV solution was transferred into 4x5 mL syringes with 0.6 
mm blunt tips, and the syringes were placed to a syringe pump (GenieTMPlus, Kent 
Scientific, Connecticut, USA). Aluminium foil coated collector was placed at a distance of 
17 cm from needle tips, and the pump was set to deliver 40 µL/minute. A voltage of 17 
kV was applied to the collector as well as the needle tips. The polymer was electrospun 
on the collector with the parameters given above for an hour. 
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 3D printing of alginate as a sacrificial material 
 Preparation of alginate paste for 3D printing 
1.5 % alginate paste was produced by dissolving 0.2g of calcium chloride dihydrate 
(CaCl2.2H2O) into a 72.7 g of distilled water (dH2O) while continuously stirring. The 
solution was then heated up to 60°C prior to adding 1.5 g of alginic acid sodium salt while 
continuously stirring on a hot plate magnetic stirrer. Once fully dissolved and dehydrated, 
24.25 g (approximately 19.25 mL) of glycerol was added and mixed until a smooth 
viscous paste was obtained. 
 Alginate printing 
Prior to 3D printing, the desired numbers of 3D models were oriented and sliced using g-
code generator software (Repetier-Host, Willich, Germany). The model was then 
exported as g-code using the following parameters: 0.4 mm layer height, 0,40 mm nozzle 
diameter and 2 mm/s speed. The alginate paste was transferred into a 10mL syringe with 
0.40mm blunt tip, and the syringe was inserted to the extruder of 3D bioprinter (BioBots, 
Philadelphia, USA). The aluminium foil containing electrospun PHBV layer was placed 
onto the lid of a 6-well plate and fixed using adhesive paper tape. G-code was then 
uploaded to the 3D printing software (Bioprint, Philadelphia, USA), and the pressure was 
adjusted between 11-20 psi. Finally, the extruders were calibrated, and the alginate was 
3D printed on the PHBV electrospun sheet. Following the 3D printing process, the 
electrospinning process was repeated using the same parameters to create synthetic 
vascular channels inside two layers of PHBV. 
 Removal of alginate 
 Preparation of EDTA solution 
0.5 M EDTA solution was prepared adding 74.46 g of EDTA (MW: 372.24) to 320 mL of 
dH2O. The pH was then adjusted to 8.0 using sodium hydroxide (NaOH) beads whilst 
stirring continuously. Once fully dissolved, the final volume was adjusted to 400 mL. 
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  Alginate removal 
The synthetic vascular scaffolds were submerged in 0.5 M EDTA solution on a gel-shaker 
(Fisher Scientific, Massachusetts, USA) set to 70 rpm overnight to create hollow channels 
between two layers of PHBV sheets by removing alginate. Two ends of the scaffolds were 
pierced to allow alginate to be removed prior to submerging it into EDTA solution. 
 Biomechanical testing of PHBV SVN 
Tensile testing was carried out for the dry (n=4) and wet (n=4) scaffolds using a 
mechanical testing machine equipped with a 22 N load cell. Scaffolds were submerged in 
PBS for 1 hour before testing to be wetted. The clamps of the device were positioned 15 
mm away from each other, and the width and thickness of each scaffold were measured. 
Test samples either dry or wet were clamped with two grips in a tensiometer (BOSE 
Electroforce Test Instruments, Minnesota, USA). Tensile tests were performed on each 
sample at a rate of 0.1 mm/s until the samples fail (n=4). The raw data of the tests were 
taken and tabulated before converting them into stress-strain curves. Stress and strain 
values were calculated using Equation 2 and 3: 
𝑆𝑡𝑟𝑒𝑠𝑠 (𝜎) =  
𝐹𝑜𝑟𝑐𝑒 (𝐹)
𝐴𝑟𝑒𝑎 (𝐴)
   (2) 
𝑆𝑡𝑟𝑎𝑖𝑛 (𝜀) =  
𝐿𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑠𝑡𝑟𝑒𝑡𝑐ℎ (𝛥𝐿)
𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑙𝑒𝑛𝑔𝑡ℎ (𝐿0)
 (3) 
UTS, yield strength (YS) and Young’s modulus parameters were calculated using stress 
(σ) and stress (ε) curves (Figure 45) of each sample.  
 
Figure 45. The mechanical testing of the PHBV SVN scaffolds. Placement of the scaffolds (A) before, 
(B) after the test to the uniaxial testing machine. (C) A representative stress-strain curve showing 
relevant parameters and calculations 
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Suture retention tests were performed based on the BS EN ISO 7198:2017, which is the 
standard for testing vascular grafts and patches. Before clamping the samples to a 
uniaxial testing device, scaffolds were sutured from 2 mm away from the upper end as 
can be seen in Figure 46 with a suture (Ethicon, New Jersey, USA) which is for use in 
general soft tissues. To prepare the wet group, the scaffolds were hydrated by 
submerging in PBS for 1 hour. The distance between clamps was then adjusted, and the 
tests were conducted at a rate of 0.1 mm/second until the samples fail. Suture retention 
strength was calculated using Equation 4: 
𝑆𝑢𝑡𝑢𝑟𝑒 𝑟𝑒𝑡𝑒𝑛𝑡𝑖𝑜𝑛 =  
𝑆𝑢𝑡𝑢𝑟𝑒 𝑟𝑒𝑡𝑒𝑛𝑡𝑖𝑜𝑛 𝑓𝑜𝑟𝑐𝑒
𝑆𝑢𝑡𝑢𝑟𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 𝑥 𝑆𝑎𝑚𝑝𝑙𝑒 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 
  (4) 
 
 
Figure 46. Placement of the scaffolds for the measurement of their suture retention strength 
 Cannulation and sterilisation of the synthetic vascular channels 
Prior to cell seeding into PHBV SVN, channels were cannulated with a 25 G cannula by 
perfusing PBS into the channels under a dissection microscope (Wild Heerbrugg, 
Heerbrugg, Switzerland). Methylene blue was then injected into channels to test the 
channel structure and patency. Scaffolds were then sterilised using 70% IMS (by 
submerging in 70% IMS solution for approximately 45 min) and washed 3 times with PBS 
prior to cell seeding. 
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 Cellularisation of synthetic vascular channels 
 General cell culture procedures 
Cells at the desired passage were taken from liquid nitrogen (LN2) and immediately 
thawed at 37°C. Once cell suspension was thawed, it was transferred into a container with 
10 mL of appropriate growth medium (the type of culture medium will be revealed in the 
following sections). Cells were centrifuged at 1000 rpm for 5 minutes, and the cells were 
resuspended in the growth medium. The suspension of cells was the split into the desired 
number of T75 flasks (VWR International, Pennsylvania, USA), and the total volume was 
adjusted to 12 mL with culture medium. T75 flasks were then incubated at 37°C (Sanyo, 
Osaka, Japan). The culture media was replaced every 2-3 days until they reached ~80-
90% confluency. Once the culture was confluent (around 80-90%), the cell culture 
medium was removed from the flask, and flasks were washed with PBS. Following that, 5 
mL of trypsin/EDTA solution was added to each flask, and flasks were incubated at 37°C 
for 5 minutes. When cells were detached from the surface, trypsin was neutralised with 
culture medium containing 10% FCS (approximately 15 mL) and the cell suspension was 
centrifuged at 1000 rpm for 5 minutes. The supernatant was removed, and the cell pellet 
was homogenised by tapping the bottom of the universal container gently. Cells were 
then resuspended in growth medium and split into flasks.  
To find the cell concentration required for cellularisation of scaffolds, cells were counted 
under an inverted microscope (Olympus CK40, Tokyo, Japan) using a haemocytometer 
(Hawksley, London, UK). After resuspending the cells in a certain volume, 50 µL of cell 
suspension was pipetted into a haemocytometer. The grid lines of the haemocytometer 
were imaged under a microscope, and cells were counted in a set of 16 squares. To 
calculate the total cell number, Equation 5 was used. 
 
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 =  
𝑁𝑜. 𝑜𝑓 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑥 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 104 𝑥 𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
 (5) 
  
 Cellularisation of the PHBV channels with HDFs in isolation 
HDFs were thawed, cultured, passaged and counted as given in Section 3.5.9.1. Following 
sterilisation, scaffolds were transferred to petri dishes. 0.5 x 106 cells were resuspended 
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in 0.25 mL of culture medium (DMEM containing 10% (v/v) FBS, 100 IU mL –1 penicillin, 
100 µg mL –1 streptomycin, 2mM L-glutamine and 0.625 µg mL −1 amphotericin B) and 
then perfused into the SVN using 1mL syringe with 25 G cannula. Before adding culture 
medium, scaffolds were returned to the incubator (Sanyo, Osaka, Japan) for an hour to 
allow fibroblasts to attach to the inside of the channels. Then, 10 mL of culture medium 
was added to each petri dish, and they were incubated at 37°C overnight. Scaffolds were 
flipped over, and the seeding protocol was repeated to cellularise the other side of the 
channels on the following day. Scaffolds were kept in culture for 7 days by changing the 
culture medium every 2-3 days. The cell seeding process is shown in Figure 47. 
 
 
Figure 47. Illustration showing the steps of cellularisation of synthetic vascular channels with HDFs 
 Cellularisation of the PHBV channels with HDMECs in isolation 
HDMECs were thawed, cultured, passaged and counted as described in Section 3.5.9.1. 
Following sterilisation, scaffolds were transferred to petri dishes. 0.5 x 106 HDMECs were 
resuspended in 0.25 mL of EC GM (PromoCell Endothelial Cell Growth Medium MV basal 
medium supplemented with 2% FCS, 0.4% EC growth supplement, 10 ng/mL EGF, 90 
µg/mL heparin, 1 µg/mL hydrocortisone) and then perfused into the SVN using a 1 mL 
syringe with a 25 G cannula. Before adding culture medium, scaffolds were returned to 
the incubator for an hour to allow HDMECs to attach to the inside of the channels. Then, 
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10 mL of HDMECs culture medium was added to each petri dish, and they were incubated 
at 37°C overnight. Scaffolds were flipped over, and the seeding protocol was repeated to 
cellularise the other side of the channels on the following day. Scaffolds were kept in 
culture for 7 days by changing the culture medium every 2-3 days. The cell seeding 
process was shown in Figure 48. 
 
Figure 48. Illustration showing the steps of cellularisation of synthetic vascular channels with 
HDMECs 
 Cellularisation of the PHBV channels with HDMECs (inner surface of the 
vascular channels) and HDFs (exterior surface of the vascular channels) 
HDMECs and HDFs taken from LN2 were thawed, cultured, passaged and counted as given 
in Section 3.5.9.1. To image them separately under a fluorescent microscope, each cell 
type was marked using CellTracker™ Fluorescent Probes. To label the HDMECs, 50 µg of 
CellTracker™ Red dry powder was dissolved in 7.3 µL of dimethyl sulfoxide (DMSO) 
(Sigma Aldrich, Missouri, USA). Then 3 mL of serum-free HDMECs culture medium was 
added to prepare a ~25 µM working dye solution. The pre-warmed dye solution was then 
added gently to T75 flask, and HDMECs were incubated ~1 h under growth conditions. 
To label the HDFs, 50 µg of CellTracker™ Green dry powder was dissolved in 10.75 µL of 
DMSO. Then 4.3 mL of serum-free HDFs culture medium was added to prepare ~25 µM 
working dye solution. The pre-warmed dye solution was then added gently to T75 flask, 
and HDFs were incubated ~1h under growth conditions. Following the labelling of cells, 
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sterile scaffolds were transferred to petri dishes. 0.5 x 106 HDMECs were trypsinised, 
centrifuged and resuspended in 0.25 mL of culture medium and then perfused into the 
synthetic vascular channels using 1 mL syringe with 25 G cannula. Following that, 0.5 x 
106 HDFs were then trypsinised, centrifuged and resuspended in 200 µL of HDMEC 
growth medium and pipetted on the outer surface of the channels. Before submerging the 
scaffolds into HDMECs culture medium, scaffolds were incubated at 37°C for 2 hours in 
order to allow HDFs to be attached on the outer surface. 10 mL of HDMECs culture 
medium was then added to each petri dish, and they were incubated at 37°C overnight. 
Scaffolds were flipped over, and the same CellTracker™ labelling and seeding protocol 
was followed in order to cellularise the other side of the channels on the following day. 
Scaffolds were kept in culture for 7 days by changing the culture medium every 3 days. 
The seeding process of HDMECs into the channels and HDFs onto the exterior surface of 
the channels is shown in Figure 49. 
 
Figure 49. Illustration showing the steps of cellularisation of synthetic vascular channels with 
HDMECs in co-culture with HDFs. The seeding process of HDMECs into the channels and HDFs onto 
the exterior surface of the channels 
In order to verify the presence and check the distribution of the HDMECs in the PHBV 
vascular network prior to further experiments, scaffolds were fixed in 3.7% FA. Fixed 
PHBV scaffolds were embedded in OCT freezing medium and frozen in liquid nitrogen for 
3 minutes. Sections were cut 5-10 µm thick using a cryostat (Leica Biosystems Nussloch, 
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Germany) at -20°C and immunostained for the expression of CD31 and counterstained 
with DAPI after 7-day culture of HDMECs and HDFs in PHBV synthetic scaffolds. Briefly, 
a hydrophobic barrier PAP pen was used to create a water repellent barrier as a reservoir 
on sections for staining reagents. First, cells were incubated in 0.1% Triton-X 100 for 20 
minutes at RT for permeabilisation and then in 7.5% BSA at RT for 1 hour to block 
unspecific binding of the antibodies. The samples were then washed once with 1% BSA 
and incubated with the primary antibody (1:50 dilution in 1% BSA was used for Anti-
CD31 primary antibody) overnight at 4 °C. Next day, samples were washed with 3 x PBS 
prior to incubating with the diluted secondary antibody (1:500 dilution in 1% BSA is used 
for AlexaFluor®546 conjugated secondary antibody) for 1 hour at RT. Samples were then 
washed with 3 x PBS before counterstaining with DAPI (diluted 1:1000 in PBS) for 20 
minutes at RT. Slides were washed 3 x PBS and imaged using a fluorescent microscope. 
The steps of the immunofluorescent staining using unconjugated antibody are 
summarised Table 14. 
Table 14. The steps of the immunofluorescent staining using unconjugated antibody 
 Step Reagent Time Temperature 
1 Removal of OCT Distilled water 1 minute RT 
2 Permeabilisation Triton-X 100 20 minutes RT 
3 Blocking unspecific binding 7.5% BSA 60 minutes RT 
4 Washing 1% BSA 1 minute RT 
5 Primary antibody labelling 
Primary antibody 
solution 
Overnight 4°C 
6 Washing PBS 3 times RT 
7 Secondary antibody labelling 
Secondary antibody 
solution 
60 minutes RT 
8 Washing PBS 3 times RT 
9 Counterstaining with DAPI DAPI solution 20 minutes RT 
10 Washing PBS 3 times RT 
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 Fluorescent staining 
For PHBV SVN cellularised with HDMECs in isolation, the scaffolds were fixed with 3.7% 
FA for 1 hour and sectioned using a cryostat as described in Section 3.5.9.4. For analysing 
the distribution of the cells in the PHBV SVN, the sections were stained with Phalloidin 
tetramethylrhodamine (TRITC) (1:500 diluted in PBS) (or Phalloidin fluorescein 
isothiocyanate (FITC) (1:500 diluted in PBS) in some of the experiments) to stain 
cytoskeleton. Sections were then stained with DAPI (1:1000 diluted in PBS) to stain cell 
nuclei. Briefly, 0.1% (v/v) Triton X 100 (in PBS) was added on samples, and the samples 
were incubated for 20-30 minutes at room temperature. After three times washing with 
PBS, either Phalloidin TRITC or FITC (1:500 diluted in PBS from stock solution) solution 
was added to cells and incubated for 30 minutes at RT at dark. Sections were then washed 
with 3 x PBS. DAPI solution (1:1000 diluted in PBS) was added and incubated for 10-15 
minutes at room temperature in the dark prior to washing with 3 x PBS. Finally, DPX 
mountant was pipetted on the slides, and samples were covered with a coverslip. Cells 
were then examined under a fluorescent microscope (Olympus IX3, Tokyo, Japan). 
 Direct imaging of pre-labelled cells 
While investigating HDMECS in co-culture with HDFs, cells were pre-labelled using 
CellTracker™ Fluorescent Probes with the intent of distinguishing them during 
fluorescent imaging. Use of fluorescent probes prior to cultivating cells in the scaffolds 
enabled us to image HDMECs and HDFs directly under a fluorescent microscope following 
the sectioning step.  
 Development of a TE 3D skin model 
 Isolation of human foreskin keratinocytes and HDFs from skin grafts 
Skin grafts were obtained from patients who were informed of the use of their skin for 
research purposes according to a protocol approved by the Sheffield University Hospitals 
NHS Trust Ethics Committee. Fibroblasts and keratinocytes were isolated from the skin 
as described by Ghosh et al. [420]. Briefly, skin samples were cut into 0.5 cm2 pieces and 
incubated overnight in Difco-trypsin (0.1% (w/v) trypsin, 0.1% (w/v) D-glucose in PBS, 
pH 7.45) before being washed and maintained in PBS.  
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For isolating keratinocytes, skin samples were taken from the solution and transferred 
into a petri dish filled with growth media. The epidermis was peeled off, and the surface 
of the epidermis (papillary surface) was gently scraped, and basal keratinocytes were 
collected into the growth media. Cells were then harvested by centrifuging at 1000 rpm 
for 5 minutes, resuspended and seeded into 75 cm2 tissue culture flasks with the presence 
of a feeder layer (irradiated mouse 3T3 (i3T3) cells) and cultured in Green’s media (66% 
DMEM (v/v), 21.6% F12-HAMS (v/v), 10% FCS (v/v), 0.5% insulin, 0.5% adenine, 0.1% 
T/T, 0.1% chlorotoxin, 0.016% hydrocortisone, 0.01% EGF, 100 IU mL –1 penicillin, 100 
µg mL –1 streptomycin, 2mM L-glutamine and 0.625 µg mL −1 amphotericin B). 
HDFs were isolated by mincing the dermis with into 10 mm2 pieces. The pieces were then 
incubated overnight at 37 °C in 0.5% (w/v) collagenase A solution. The suspension of 
fibroblasts was centrifuged at 1000 rpm for 5 minutes and resuspended in DMEM 
containing 10% (v/v) FBS, 100 IU mL –1 penicillin, 100 µg mL –1 streptomycin, 2mM L-
glutamine and 0.625 µg mL −1 amphotericin B. 
 Preparation of acellular de-epidermised dermis (DED) 
DED was prepared from skin grafts according to a modified method described by 
Chakrabarty et al. [421]. Briefly, the skin graft was treated in 1 M NaCl solution for 24 h 
at 37ºC and then washed with PBS for 40 minutes. The epidermis was removed by peeling 
off or scraping gently (if epidermal layer remains, and cells have not been harvested 
before). DED was kept in media at 37ºC for 2 days to check its sterility.  
 Construction of a 3D TE human skin model 
A 3D human skin model was reconstructed in vitro to study vascularisation of the skin 
using a well-established protocol [411]. Briefly, 1 cm2 pieces were cut from DED, and a 
stainless-steel ring (0.79cm2) was placed onto the papillary side. HDFs were trypsinised 
and centrifuged at 1000 rpm for 5 minutes before being resuspended in DMEM. 1 x 105 
HDFs were seeded into the stainless-steel ring and kept in 37°C while preparing 
keratinocytes for seeding. The i3T3 feeder layer was removed first using 5 mL of 0.5 M 
sterile EDTA solution with 3-5 minutes incubation at 37°C. After removal of the feeder 
layer, keratinocytes were then trypsinised and centrifuged at 1000 rpm for 5 minutes and 
resuspended in Green’s media. 3 x 105 HDFs were seeded into the stainless-steel ring as 
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a co-culture with HDFs. TE skin models were incubated overnight at 37°C before 
removing the ring and addition of Green’s media. 3D skin models were incubated in 
Green’s media for another day (two days in total) and then raised to air-liquid interface 
by using a sterile stainless-steel grid and cultured for a total of fourteen days in order to 
ensure differentiation of the layers of the epidermis. The protocol of the reconstruction 
of a tissue-engineered skin model is given in Figure 50. 
 
Figure 50. Schematic illustration of the reconstruction of a 3D tissue-engineered human skin model. 
K = keratinocytes, F = fibroblasts, DED = de-epidermised dermis 
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 Use of the PHBV SVN to study angiogenesis in vitro and to investigate the 
vascularisation of a reconstructed skin model 
Two separate experiments were designed to investigate the potential of the developed 
PHBV SVN to be used as an in vitro platform to study angiogenesis and vascularisation of 
a TE skin model: (i) Matrigel outgrowth experiments and (ii) TE skin vascularisation 
studies (Figure 51). 
 
Figure 51. Designed experiments showing the investigation of the potential of the PHBV SVN to be 
used as an in vitro platform to study angiogenesis and vascularisation of a TE skin model. Purple 
dotted lines represent pierced holes. Matrigel and TE skin were indicated with blue and orange color, 
respectively 
 Investigating the endothelial outgrowth from PHBV channels to Matrigel and 
to TE 3D skin equivalent 
For Matrigel outgrowth experiments, PHBV SVN repopulated with HDMECs (1x106 
HDMECs per scaffold) were incubated for 7 days as described in Section 3.5.9.3 and then 
transferred into 6-well plates in a laminar hood. Once an endothelium-like monolayer 
was obtained, escape holes were pierced on the channels using sterile 30 G syringe 
needle. Matrigel (protein concentration > 10.8g/ mL) was purchased from Corning. The 
final concentrations of VEGF and 2dDR within the Matrigel were 80 ng/mL and 1.34 
μg/mL respectively. 100 μl of Matrigel was pipetted into hexagonal wells formed by 
synthetic channels and 200 μl into the well between two hexagonal wells (Figure 52). 
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Scaffolds were then returned to the incubator for Matrigel to set at 37 °C for 15 minutes. 
PHBV scaffolds were then cultured in EC GM for 7 days. 
For analysing the HDMEC outgrowth through Matrigel after culturing HDMECs in the 
synthetic PHBV vascular scaffolds, the scaffolds were fixed with 3.7% FA and stained with 
Phalloidin--TRITC for 30 minutes and DAPI for 15 minutes following permeabilisation of 
the cells with 0.1% Triton-X100 for 30 minutes. The hydrogels were peeled off from the 
surface of the PHBV SVN, and fluorescent images were taken within the Matrigel. Tube 
formation and the number of branch points was quantified as described previously using 
Angiogenesis Analyzer plugin of ImageJ [351] and AngioTool software, respectively. The 
results were then statistically analysed using GraphPad Prism software 
 
Figure 52. Schematic illustration of the Matrigel outgrowth experiments showing the pierced holes 
and loading of Matrigel shown with purple and light blue colour, respectively 
 Investigating the endothelial outgrow from PHBV channels to reconstructed 
3D skin equivalent 
For TE skin outgrowth experiments, PHBV synthetic vascular scaffolds repopulated with 
HDMECs (1x106 HDMECs per scaffold) and HDFs (1x106 HDMECs per scaffold) were 
incubated for 7 days and then transferred into 6-well plates in a laminar hood. Escape 
holes were pierced on the channels with 30 G syringe needle. TE skin equivalent models 
were prepared as described in section 3.5.12 and cut circularly at day-7 prior to 
implantation. A fibrin glue was used to glue TE skin to PHBV SVN. Use of fibrin glue in 
skin grafts and TE skin replacements has previously been reported [422]. Fibrin glue was 
prepared by mixing fibrinogen from human plasma (20 mg/mL in 0.9% NaCl solution in 
dH2O) and human thrombin (25 units/mL in 0.1% BSA). Briefly, 50 μl of fibrinogen was 
pipetted over the surface of the PHBV SVN channels. Then 50μl of thrombin was pipetted 
over fibrinogen, and TE skin models were glued immediately on channels (Figure 53). 
PHBV scaffolds with TE skin models on them were then submerged in EC GM either 
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supplemented with 80 ng/mL VEGF or non-supplemented (control) and cultured for a 
further 7 day at the air-liquid interface. Throughout the experiment duration, EC GM 
either non-supplemented or supplemented with VEGF (80 ng/ mL) was pipetted from the 
top of the TE skin model twice per day. 
 
Figure 53. Schematic illustration of the TE skin outgrowth experiments showing the pierced holes 
and the placement of the TE skin models shown with purple and orange colour, respectively 
For the investigation of the HDMEC outgrowth through reconstructed TE skin models, 
scaffolds with TE skin on top of them were fixed in with 3.7% FA. Fixed PHBV scaffolds 
with TE skin models were then embedded in OCT freezing medium and frozen in liquid 
nitrogen for 3 minutes. Sections were cut 5-10 µm thick using a cryostat (Leica 
Biosystems Nussloch, Germany) at -20°C and stained with Phalloidin-TRITC for 30 
minutes and DAPI for 15 minutes following permeabilisation of the cells with 0.1% 
Triton-X100 for 30 minutes in order to see the general appearance of the PHBV SVN and 
TE skin together. The sections were then immunostained for anti-CD31 and 
counterstained with DAPI as described at the beginning of this section. The samples were 
further investigated histologically by staining the sections with haematoxylin for 
1.5 minutes and eosin for 5 minutes as described previously. The outgrowth distance of 
HDMECs was determined using ImageJ software, and the results were then statistically 
analysed using GraphPad Prism software. 
 Investigating the vascularisation of the reconstructed 3D skin equivalent using ex-
ovo CAM assay  
Ex-ovo CAM assay was used to evaluate the vascularisation of the TE skin model as a 
positive control. The protocol of ex-ovo CAM assay was explained in detail in Section 2.5.6. 
Briefly, fertilised chicken eggs (Gallus domesticus) were purchased from Henry Stewart 
& Co. MedEggs (Norwich, UK) and cleaned with 20% industrial methylated spirit solution. 
140 
 
Eggs were incubated at 37.5°C for 3 days in a rocking egg incubator (RCOM King SURO, 
P&T Poultry, Powys, Wales). On day 3, the embryos were transferred gently into sterile 
petri dishes and incubated at 38°C in a cell culture incubator (Binder, Tuttlingen, 
Germany). CAM assay was conducted in care of the guidelines of the Home Office, UK. On 
day 7, reconstructed human skin equivalents (14-day cultured) were cut circular (0.8 mm 
diameter) using a biopsy punch and implanted to CAMs for a further 7 days. In order to 
study the effect of proangiogenic drugs, VEGF and 2dDR were added twice a day dropwise 
throughout the assay duration. The concentrations of the drugs were 80 ng/day/embryo 
and 200 µg/day/embryo for VEGF and 2dDR, respectively. The preparations of the 
proangiogenic solutions were described in Section 2.5.4. 
Images of the reconstructed skin equivalents implanted on CAM were taken using a 
digital USB microscope at day 14. Embryos were then sacrificed, and the skins cut with a 
rim of surrounding CAM tissue and fixed in 3.7% FA solution. Angiogenesis was 
quantified by counting all blood vessels growing towards the scaffolds in a spoke wheel 
pattern, as described previously [89]. Histological analysis of the samples was performed 
with H&E staining as described previously in Section 2.5.4. 
 Statistical analysis 
Statistical analysis was carried out using either student t-test or one-way analysis of 
variance (ANOVA) using statistical analysis software (GraphPad Prism, CA, USA). Where 
relevant, n values are given in figure captions. Error bars indicate standard deviations in 
the graphs unless otherwise stated. 
 Results 
 Comparison of PHBV vs PCL in terms of their physical, mechanical and biological 
performances in vitro and in CAM assay 
The results of the contact angle measurements showed that the contact angle of the water 
droplet on PCL was lower than the one on PHBV, indicating a less hydrophobic surface. 
SEM images of the electrospun PHBV and PCL showed that use of both polymers resulted 
in smooth and beadless nanofibrous fibre formation. Fibre diameters of PHBV and PCL 
were 0.67 ± 0.13 µm and 0.47 ± 0.1 µm, respectively. No statistically significant difference 
was found between UTS of the scaffolds (3.62 ± 0.22 MPa and 3.94 ± 0.35 MPa, 
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respectively for PHBV and PCL). The Young’s modulus of the electrospun PHBV scaffolds 
was found approximately 5-times higher when compared with PCL electrospun scaffolds 
(67.56 ± 11.36 MPa and 13.14 ± 1.73 MPa, respectively for PHBV and PCL). The results of 
contact angle measurements, stress-strain curves, and SEM images are given in Figure 54.  
 
Figure 54. (A) Contact angle measurements, (B) representative stress-strain curves, (C) 
Ultrastructure of PHBV and PCL 
The results of the mechanical comparison of PHBV and PCL are summarised in Table 15. 
Table 15. Mechanical properties of PHBV and PCL electrospun fibres. ( asignificantly different 
(p<0.05), bsignificantly different (p<0.001), ns= not significant, n=4) 
Polymer 
Fibre Diameter 
(µm) 
UTS 
(MPa) 
Young’s Modulus 
(MPa) 
Electrospun PHBV 0.67 ± 0.13a 3.62 ± 0.22ns 67.56 ± 11.36b 
Electrospun PCL 0.47 ± 0.12a 3.94 ± 0.35ns 13.14 ± 1.73b 
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Metabolic activities of HDMECs on both polymers showed a regular increase over 11 days. 
By day 1, attachment of HDMECs was approximately 3.4-fold higher on PHBV fibres when 
compared with PCL fibres. Moreover, no statistically significant difference was found 
between the metabolic activities of HDMECs on PHBV and TCP by day 1. At each time 
point, the metabolic activities of HDMECs on PHBV fibres were significantly greater when 
compared with the activities on PCL fibres. By day 11, the activity of cells on PHBV fibres 
was 1.1-fold higher than that measured on PCL fibres. Although both PHBV and PCL 
showed that they are both capable of providing a suitable environment for culturing 
HDMECs on them, PHBV gave better results in terms of metabolic activity of cells (Figure 
55). 
 
Figure 55. The metabolic activity of HDMECs cultured on PHBV and PCL over 11 days in comparison 
with that on TCP. *** p ≤ 0.001, * p ≤ 0.05, ns p ≥ 0.05, error bars indicate SD 
Following the in vitro assessment of the PHBV and PCL, both polymers showed good 
biocompatibility on CAM with no adverse effects on embryo survival rates which were 
78.8 % and 76.5 %, respectively for PHBV and PCL implanted groups. The histological 
evaluation of both implanted scaffolds showed similar changes in the structure of CAM 
with a small increase in cell density in the mesoderm layer in all scaffold groups. Both 
electrospun PHBV and PCL scaffolds showed good attachment to the CAM, and they 
showed similar cellular infiltration from the chick membrane (Figure 56). 
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Figure 56. Macro and the histological images showing the evaluation of biocompatibilities of PHBV 
and PCL using ex-ovo CAM assay 
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 Results of the characterisation of the PHBV SVN 
Following the comparison of PHBV and PCL in terms of their physical, mechanical and 
biological properties, PHBV was selected as the material for the production of synthetic 
vascular networks using electrospinning and 3D printing techniques together. 
 Macrostructure and microstructure of the PHBV SVN 
Combination of electrospinning and 3D printing allowed the production of a number of 
replicate scaffolds in a short period of time (in less than 2 hours). The 4-step fabrication 
route of PHBV SVN is shown in Figure 57. 
 
Figure 57. Production of synthetic scaffolds via electrospinning and 3D printing. 3D printing of 
alginate to obtain controlled synthetic channel structures can be seen in A and B. Electrospinning of 
another layer of PHBV on top the alginate channels is given in C and D 
The SEM images of the PHBV SVN showed that it was possible to obtain a connected 
network of hallow channels after removal of the alginate. The PHBV SVN scaffolds used 
in this study were approximate ~30 mm in length and ~18 mm wide. For each production 
batch, approximately 12 scaffolds were produced, and 100% of these was used. The 
macrostructure and the microstructure of the PHBV SVN scaffolds were given in Figure 
58. 
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Figure 58. The macrostructure and the microstructure of the PHBV SVN scaffolds 
 Mechanical Properties of the PHBV SVN 
The average diameter of the fibres and the average pore size between the fibres were 
calculated as 0.76 ± 0.22 µm and 2.73 ± 1.47 µm, respectively. PHBV fibres in these 
diameters allow transportation of nutrients through fibres while preventing cells from 
escaping through them for up to 6 weeks [417,423]. In order to determine the mechanical 
properties of the dry and wet scaffolds such as UTS, YS, Young’s modulus, and suture 
retention, tensile tests were performed using a uniaxial mechanical testing machine. As 
expected, average UTS was higher under dry conditions (0.87 ± 0.14 MPa) compared to 
wet scaffolds (0.48 ± 0.12 MPa). The Young’s modulus of the PHBV scaffolds dramatically 
reduced from 80.5 ± 7.71 MPa to 12.80 ± 1.77 MPa when moistened. Similarly, suture 
retention of the scaffolds in dry state was double of that in wet state (1.70 ± 0.05 MPa and 
0.89 ± 0.11 MPa, respectively for dry and wet scaffolds). The results of the mechanical 
tests are summarised in Table 16. 
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Table 16. Morphological and mechanical properties of the PHBV SVN under dry and wet conditions. 
(a,dsignificantly different (p<0.05), b,csignificantly different (p<0.005), n/a= not applicable, n=4) 
Condition 
Fibre Diameter 
(µm) 
Pore Size 
(µm) 
UTS 
(MPa) 
Yield Strength 
(MPa) 
Young’s 
Modulus 
(MPa) 
Suture 
Retention (MPa) 
Dry 0.76 ± 0.22 2.73 ± 1.47 0.87 ± 0.14 
a
 0.58 ± 0.09
b
 80.5 ± 7.71
c
 1.70 ± 0.05
d
 
Wet n/a n/a 0.48 ± 0.12 
a
 0.12 ± 0.03
b
 12.80 ± 1.77
c
 0.89 ± 0.11
d
 
       
A representative stress-strain graph for dry and wet scaffolds is shown in Figure 59.  
 
Figure 59. Representative stress-strain graphs of dry and wet scaffolds 
 Confirmation of the channel patency of the PHBV SVN 
The removal of the sacrificial alginate was confirmed by the cannulation of the PHBV SVN 
with methylene blue dye. The dye reached all the channels within the network, and the 
channels, which allowed the perfusion of methylene blue, were found open and 
interconnected (Figure 60). 
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Figure 60. The macrostructure and the microstructure of the PHBV SVN scaffolds (A) before and 
(B) after removal of the 3D printed alginate 
 Results of the cellularisation of the PHBV SVN 
 Cellularisation of the PHBV SVN with HDF in isolation  
To investigate the biological characteristics of synthetic vascular scaffolds, synthetic 
channels were seeded with HDFs in order to determine cellular attachment, proliferation, 
survival, and formation of tube-like structure. HDFs were cultured inside the channels for 
7 days under static conditions (no perfusion). Scaffolds were then analysed for survival 
and distribution of fibroblasts inside the channels. Different sections of H&E stained 
scaffolds and cells after 7 days cultivation are shown in Figure 61. To verify the H&E 
results, phalloidin and DAPI stained sections of scaffolds were given in Figure 62.  
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Figure 61. Histological evaluation of the sections of the synthetic vascular channels cellularised 
with HDFs. (Scale bars = 100 µm) 
 
Figure 62. Phalloidin-FITC and DAPI stained scaffolds cellularised with HDFs only. (A) F-actin staining 
using phalloidin, (B) cell nuclei staining using DAPI, (C) A merged image showing both green and blue 
channels. (Scale bars = 100 µm) 
 Cellularisation of the PHBV SVN with HDMECs in isolation 
To investigate the survival of HDMECs inside the vascular channels without HDFs as 
supporter cells, HDMECs were seeded inside the PHBV SVN and cultured for 7 days under 
static conditions. A complete formation of the HDMEC monolayer within the PHBV SVN 
has been confirmed with fluorescent and H&E staining. Fluorescent and H&E images of 
the sections of the PHBV SVN cellularised with HDMECs in isolation showing the complete 
coverage of the channels are given in Figure 63. 
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Figure 63. Fluorescent staining of the sections taken from scaffolds cellularised with HDMECs in 
isolation. (A) DAPI (blue), (B) phalloidin-TRITC (red) and (C) combined red and blue channels, and 
(D) H&E staining of the sections from PHBV SVN. (Scale bars = 100 µm) 
 Cellularisation with HDMECs in the presence of helper HDFs 
To investigate the formation of a continuous EC monolayer inside the synthetic vascular 
channels, HDMECs were seeded inside the channels in co-culture with HDFs on the 
exterior surface. Cells were cultured for 7 days, and then the scaffolds were directly 
imaged under a fluorescent microscope following the sectioning step for survival and 
distribution of HDMECs and HDFs. Fluorescent and H&E images of cells are given in 
Figure 64. 
150 
 
   
Figure 64. Sections of scaffolds with HDMECs labelled with CellTracker™Red (inside the channels) 
and HDFs labelled with CellTracker™Green (seeded onto the outer surface of the channels) on the 
left. The image on the right shows the histological evaluation (H&E staining) of the scaffolds 
populated with HDMECs and HDFs. (Scale bars = 100 µm) 
In order to verify the formation of the HDMEC monolayer in the synthetic vascular 
channels, sections were immunostained for the expression of CD31 and counterstained 
with DAPI after 7-day culture of HDMECs and HDFs in PHBV synthetic scaffolds.  
A merged image of CD31+ (Red) and DAPI (blue) staining of the HDMECs growing on TCP 
is given in Figure 65. CD31 stained (counterstained with DAPI) sections of the PHBV SVN 
cellularised with HDMECs and HDFs cultured over 7-days are given in Figure 66. CD31 
staining showed an evenly distributed HDMEC monolayer within the channels in both 
curved and flat surfaces.  
  
Figure 65. A merged image of CD31 positive (red) and DAPI-stained (blue) HDMECs growing on TCP. 
(Scale bars = 20 µm) 
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Figure 66. Immunostained sections of PHBV synthetic vascular scaffolds populated with HDMECs 
(inner surface of the channels) and HDFs (on the outside of the channels). Stained cell nuclei with 
DAPI (blue) and CD31+ staining (red) is given in the figure. (Scale bars = 100 µm) 
 Results of HDMEC outgrow from PHBV SVN to Matrigel 
HDMECs were observed as outgrowing and forming interconnected tube-like structures 
within the Matrigel close to edges of the pierced synthetic PHBV channels by day 7 
(Figure 67). Inclusion of both 2dDR and VEGF increased the tube-like formed structures. 
However, tube-like structures were more obvious and well-organised in VEGF loaded 
Matrigel groups when compared with 2dDR loaded and control groups. These 
experiments were repeated 3 times, and 5 replicates were used for each repeat. Please 
note that the formation of tube-like structures was witnessed only 20% of the 
experiments for VEGF loaded Matrigel and 13.3% of the 2dDR loaded and control groups. 
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Figure 67. The figure shows the outgrowing HDMECs from PHBV channels to Matrigel either loaded 
with VEGF and 2dDR or non-treated groups. tube-like formed structures were obvious and well-
organised in VEGF loaded Matrigel groups when compared with 2dDR loaded and control groups 
The quantification of the fluorescent images showed that inclusion of 2dDR and VEGF in 
Matrigel increased the number of tubes formed within the gel up to 3.5 ± 1.1 and 8.2 ± 
4.0, respectively where the number of tubes per field was 1.0 ± 0.9 in control group. 
Similarly, average branch points were increased from 3.1 ± 1.9 (control) to 12.3 ± 4.4 and 
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27.6 ± 8.2, respectively, when 2dDR and VEGF loaded to Matrigel. 80 ng/mL VEGF was 
found significantly more effective for stimulating tube formation and for increasing 
branch points when compared to 100 µM 2dDR (Figure 68). 
  
Figure 68. Quantified results of the Matrigel outgrowth experiments. The graphs show the increase 
in the number of tubes formed (on the left) and branch points (on the right) within Matrigel when 
VEGF and 2dDR were loaded. (***p≤0.001, *p ≤ 0.05, n = 6) 
Tube-like connections between HDMECs witnessed only a minority of the 2dDR and VEGF 
loaded Matrigel groups. The formation of the tube-like structures was pretty similar to 
those which can be observed in Matrigel tube formation assays. A representative image 
of tube-like capillary structures formed by HAECs growing on Matrigel basement 
membrane is given in Figure 69.  
  
Figure 69. HAECs cultured on Matrigel for 1 hour (A) starting to align themselves and after 18 hours 
(B) forming tube-like capillary structures. Scale bars represent 200 μm 
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 Results of HDMEC outgrowth from PHBV channels to 3D tissue-engineered skin 
equivalent 
 The appearance of skin-derived cells used in this study under a light 
microscope 
Light microscope images of fibroblasts (Figure 70A) and keratinocytes before and after 
removal of i3T3 feeder layer are given in Figure 70B and 70C, respectively.  
 
Figure 70. Light microscope images of the (A) HDFs and (B) keratinocytes (dark cells) growing on 
i3T3 feeder layer (bright spider web-like cells colonies) and (C) keratinocytes after removal of the 
feeder layer. Scale bars represent 500 µm for A and 200 µm for B and C. 
 
 
 
 General appearance and histological evaluation of the 3D tissue-engineered 
skin models 
TE skin model was successfully developed by co-culturing human dermal keratinocytes 
and HDFs on DED for 14 days (2 days as submerged in media and 12 days at the air-liquid 
interface). The macro images of the developed skin model showed that the colour of the 
circular area seeded with HDFs and keratinocytes started to change to a yellowish colour 
which identifies the formation of a new epithelium on DED (Figure 71). The histological 
evaluation of the reconstructed TE skin models showed that developed TE skin model 
achieved a normal-looking gross skin morphology in 14 days. A multi-layered epithelium 
was formed and found to be well attached to the dermis (Figure 72).  
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Figure 71. (A) STSG taken from patients, (B) circular area (on DED) where HDFs and keratinocytes 
were seeded (papillary surface) is shown with a black dashed circle. Colour change within the circle 
indicates the formation of a new epithelium on DED 
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Figure 72. Histological evaluation of the TE skin equivalent models incubated 2 days in Green’s 
media and 12 days at the air-liquid interface. Black and green arrows indicate the dermal layer and 
differentiated epidermal layers, respectively. Scale bars represent 100 µm 
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 The results of the endothelial outgrow from PHBV channels to 3D tissue-
engineered skin equivalent 
Following the encouraging results of HDMEC outgrowth through Matrigel, PHBV scaffolds 
repopulated with HDMECs and HDFs were investigated for HDMECs outgrowth through 
reconstructed TE skin equivalent model. After 7-day culture at the air-liquid interface, TE 
skin equivalent was attached to the top surface of the PHBV SVN (Figure 73) and cultured 
for a further 7 days at the air-liquid interface.  
  
Figure 73. After 7-day culture at the air-liquid interface, TE skin equivalent was attached to the top 
surface of the PHBV SVN  
Phalloidin-FITC and DAPI staining of the PHBV SVN repopulated with HDMECs and HDFs 
and cultured with TE skin on it for 7 days showed that there was a formed monolayer 
within the scaffold channels and some cells were localised on the outer surface of the 
scaffolds. There were also some cells outgrowing from PHBV SVN towards reconstructed 
TE skin. However, it was not possible to identify the type of cells presented in this system 
(Figure 74). Thus, the sections were immunostained against CD31 to identify HDMECs.  
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Figure 74. DAPI (blue) and Phalloidin-FITC (green) staining of the PHBV SVN repopulated with 
HDMECs and HDFs and cultured with TE skin on it for 7 days. The orientations of the PHBV SVN 
scaffold and TE skin are highlighted with white dashed lines 
Immunostained (Anti-human CD31+) sections showed that HDMECs were evenly 
distributed within the channels and formed a monolayer (CD31+ cells are shown with 
red colour), and the outer surface of the PHBV SVN was covered with HDFs (CD31+ cells 
shown with blue colour). High magnification images of the immunostained sections 
revealed that the outgrowing cells from the PHBV channels towards the reconstructed 
skin models were CD31 positive HDMECs. The outgrowth of HDMECs was mostly 
observed from the connection edges of two separate electrospun sheets (Figure 75). 
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Figure 75. H&E and immunostained (CD31/DAPI) sections show that HDMECs were outgrowing 
from the PHBV channels through skin models. The outgrowth was mostly observed from the 
connection edges of two separate electrospun sheets. Inclusion of VEGF in the growth medium 
enhanced the outgrowth distance of the HDMECs 
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Higher magnification of the H&E and CD31 staining showed that the addition of VEGF to 
the growth media significantly increased the outgrowth distance of HDMECs towards the 
reconstructed TE skin model. The distance of migration went up to 121.7 ± 6.3 µm in the 
VEGF group when compared to non-supplemented controls, where the outgrowth 
distance was 27.9 ± 11.9 µm (Figure 76). 
 
Figure 76. The graph shows the quantification of the HDMEC outgrowth distance from PHBV SVN 
to TE skin models when the growth medium was supplemented with VEGF or non-supplemented as 
control group. (*p ≤ 0.05, n = 6) 
 The results of the vascularisation study of the tissue-engineered skin 
equivalent on CAM 
In order to assess the effect of the presence of cells and pro-angiogenic factors on 
vascularisation of TE skin equivalents, DEDs and developed skin models were assessed 
using an ex-ovo CAM assay. The results showed that the mean number of blood vessels 
were the highest in 2dDR added TE skin equivalents, whereas the least blood vessels 
were observed in DED groups. The presence of cells and the addition of 2dDR significantly 
increased the mean vessel count growing through the samples (Figure 77). Mean vessel 
counts for TE skin models (no pro-angiogenic agent added), TE skin models administered 
with 2dDR added and TE skin models administered with VEGF were 27.0 ± 1.3, 34.4 ± 1.9, 
and 45.6 ± 2.0, respectively compared to control DED group (Mean vessel count: 19.2 ± 
1.5). None of the implanted groups affected the embryo survival rate, which was over 
70% for each group. 
161 
 
 
Figure 77. Representative macroimages given in top row show the angiogenic activity of DED, TE 
skin only and TE skin with daily addition of 2dDR at the end of EDD14 of chick embryos. Scale bars 
represent 3mm for macroimages. Histological appearance of the samples can be seen in the middle 
row. Although no complete integration was shown in any of the groups, DED only group was 
completely separable from CAM where TE skin samples were partly attached to CAMs. Addition of 
2dDR and VEGF increased the number of blood vessels 1.3 and 1.7 fold, respectively when compared 
with TE skin only group. Black, red, green and blue arrows indicate the CAM, dermal layer, epidermal 
layer and blood vessels respectively. The graph in the bottom row demonstrates the quantification 
of blood vessels growing towards the samples. Presence of cells (Keratinocytes and HDFs) increased 
the mean vessel count by 42% when compared with DED control groups. The total number of blood 
vessels was 27% higher when 2dDR was added daily to TE skin samples when compared with TE 
skin only controls. Scale bars for the histological images represents 200 µm. (***p≤0.001, **p ≤ 0.01, 
n = 4) 
 Discussion 
PHBV and PCL are widely-used and biocompatible polymers in tissue engineering 
applications [419,424,425], and both of the polymers are suitable to fabricate tissue 
engineering scaffolds using electrospinning technique [426,427]. In this chapter, I 
compared both polymers in terms of their physical, mechanical and biological 
performances in order to select one of them for the production of synthetic vascular 
networks.  
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Our results showed that PCL was slightly less hydrophobic than PHBV, and SEM images 
of the electrospun PHBV and PCL showed that electrospinning of both polymers resulted 
in smooth and beadless nanofibre formation. In line with our findings, the high 
hydrophobicity of PHBV has previously been reported by several groups [425,428]. 
However, despite the more hydrophobic characteristics of it, the biological evaluation of 
the polymers showed that the attachment of HDMECs onto PHBV nanofibres was 
approximately 3.4-fold higher compared to cell attachment to PCL fibres. This might be 
likely due to that the Young’s modulus of the PHBV was approximately five times and the 
average fibre diameter of PHBV was approximately 1.4-fold higher than those of PCL. 
Jalali et al. have previously reported that substrate Young’s modulus has an effect on the 
adhesive behaviour of vascular ECs. Their results indicated that the adherence of ECs and 
their exhibition of dense actin structures were higher when cultured on high Young’s 
modulus surfaces compared to lower ones, although no difference was observed in EC 
viability [429]. Similarly, Ataollahi et al. showed that the attachment and proliferation of 
ECs in stiff substrates were higher than those of soft substrates [430]. The average fibre 
diameter of electrospun fibres has also been shown to have an effect on EC attachment. 
Rüder et al. reported that EC adhesion was facilitated by increasing fibre diameters [431]. 
Ko et al. demonstrated that ECs more homogeneously proliferated on the electrospun 
scaffolds with higher than 600 nm fibre diameter than on the scaffolds with smaller 
diameters [432]. 
Although the attachment of HDMECs on PCL was dramatically lower than that on PHBV, 
on day 11, the metabolic activity of HDMECs on PCL was lower but quite close to that 
measured on PHBV, but it was still statistically significant. This is likely because the 
contact inhibition of the growth as the surface area of the scaffolds that cells can attach 
and grow were almost the same [433,434]. After cells become confluent on the growth 
area, a reduced metabolic activity, as an indirect measure of proliferation, and cell 
migration can be observed [435]. Throughout the experiments, the metabolic activities 
of HDMECs on TCP were significantly higher at all time points. This is an expected 
outcome since TCP is an optimised material for cell culture, which is positively charged 
to improve the attachment and consequently, the proliferation of cells on it [436,437]. 
Further evaluations of PHBV and PCL on CAM indicated that both polymers had similar 
degrees of biocompatibilities without any adverse effects on embryo survival (78.8 % and 
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76.5 %, respectively for PHBV and PCL implanted groups) and caused similar changes in 
the histological structures of CAMs. We have previously reported the average survival 
rates of the chick embryos when cultured ex-ovo (shell-less) as 25%, 68%, and 83% by 
beginner, intermediate, and experienced users, respectively [241]. In addition, the 
survival rates of the chicks were between 73-75% when we implanted biphasic PCL 
barrier membranes [419] and 75% when we implanted drug releasing PHBV scaffolds 
[89]. Ex-ovo CAM assay has many advantages over in-ovo CAM assay such as accessibility 
of the CAM during the implantation period, monitoring of angiogenesis, and quality of 
imaging of angiogenesis. However, the major drawback of shell-less culture is the 
comparably lower survival rates than in-ovo CAM assay [241]. 
The favourability of PHBV by HDMECs has previously been demonstrated by our group 
[143,323], and as can be seen from the results of this chapter, its slightly better biological 
performance over PCL led us to select this polymer for the fabrication of synthetic 
vascular networks. 
Both electrospinning and 3D printing have various advantages and are frequently used 
techniques in tissue engineering. In previous studies, our group combined these two 
methods to benefit from both of the advantages they have [143]. 3D printing technique 
allows us to control the production of a large number of scaffolds with exactly the same 
geometries in a short time. On the other hand, electrospinning is a method where we are 
able to produce tissue-engineered scaffolds with a wide range of properties in terms of 
material composition, fibre diameter, thickness, porosity, and degradation rates [438–
441]. The PHBV polymer was chosen for synthetic vascular scaffolds not only because of 
the previous experiences of our research group [143,417,423] , but also electrospinning 
nanofibers which are desirable in this study for creating a barrier for cells which is easier 
with this material. Furthermore, the comparison of biological performance of the two 
widely-used polymers, PHBV and PCL, showed us that PHBV was better for supporting 
ECs to attach and proliferate on it. PHBV SVN was found to be suitable for satisfying the 
initial requirements of this study, to provide an environment where ECs can attach and 
form an endothelium-like structure. 
Initially, PHBV electrospun fibres with a diameter of ~0.75 µm were successfully 
manufactured via electrospinning. Each scaffold was designed as ~30 mm in length and 
~18 mm wide with two synthetic vascular branches. PHBV nanofibres were successfully 
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manufactured via electrospinning, and alginate, a natural and biocompatible 
polysaccharide that is largely preferred for biomaterial applications [442,443], was used 
as a sacrificial substrate to create temporary support as interconnected networks. PHBV 
solution was then electrospun on top of the 3D printed alginate channels, and the alginate 
was removed using an EDTA solution. The perfusion of the channels with methylene blue 
dye showed that the channels were interconnected, and no leakage was observed neither 
between the two layers of electrospun PHBV nor through the small pores between fibres. 
The average fibre diameter and pore size were 0.76 ± 0.22 µm and 2.73 ± 1.47 µm, 
respectively. PHBV fibres in these diameters have been shown to allow transportation of 
nutrients through fibres while preventing cells from escaping through them for up to 6 
weeks [417,423]. This manufacturing technique is useful because a large number of 
scaffolds with exactly the same geometries can be produced in a short time. The 
production errors reported previously by our group caused a 30% reduction in 
production efficiency [21]. However, using our new bioprinter, four scaffolds were 
produced successfully in each production batch, which took ~5 minutes, and after three 
production batches were completed, I was able to use 12 out of 12 scaffolds (100% 
production efficiency).  
For mechanical characterisation of the dry and wet scaffolds, uniaxial tensile tests were 
performed using a uniaxial mechanical testing unit. The results were found similar with 
previous PHBV study in our group [143] and showed that dry scaffolds have an average 
UTS of 0.87 MPa and average UTS of wet scaffolds was 0.48 MPa. The mechanical 
properties of the synthetic vascular scaffolds were also compared with other polymeric 
scaffold materials. Steele et al. reported a tensile stress of 0.4 MPa for their bilayer PCL 
scaffolds [444]. Sant et al. reported a range of UTS between 1.5-2.5 MPa according to the 
ratio of their PGS-PCL scaffolds [445]. Hong et al., UTS of poly(ester urethane)urea 
(PEUU)/ECM scaffolds ranged from 0.08 to 0.19 MPa in the longitudinal axis and from 
0.04 to 0.09 MPa in the circumferential axis [446]. Tong et al. evaluated the mechanical 
properties of electrospun PHBV sheets with different diameters and orientations and 
showed the tensile strengths of the sheets ranged approximately from 0.45 to 3 MPa 
[447]. The suture retention test results demonstrated that the PHBV SVN was suitable to 
be used by suturing the tissue models onto the scaffold. The scaffolds were resistant to 
suture up to 1.70 MPa and 0.89 MPa pull out strength, respectively under dry and wet 
conditions without any tearing. DuRaine et al. reported the suitability of their TE 
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constructs with a suture retention strength of 1.45 MPa for in vivo implantation by 
suturing them in place [448]. Selders et al. demonstrated that the suture retention 
strength of the developed polymer templates was between 0.40 - 1.20 MPa under dry 
conditions [449]. Similarly, Syedain et al. showed that acellular vascular grafts with a 
suture retention of approximately 0.15 MPa (reported as 175 g for a 12.1 mm2 graft area) 
were suitable for suturing in vivo as pulmonary artery replacements [450]. 
A comparison of UTS of the synthetic vascular scaffolds produced with PHBV and other 
TE scaffold materials studied by other groups is given in Table 17.  
Table 17. Comparison of UTS of synthetic vascular scaffolds produced with PHBV and other scaffold 
materials studied by several groups 
Polymeric Scaffold 
Material 
UTS (MPa) Reference 
PHBV SVN 
Dry 0.87 MPa 
This study 
Wet 0.48 MPa 
Bilayer-PCL 0.4 MPa Steele et al. [444] 
PGS-PCL 1.5-2.5 MPa Sant et al. [445] 
PEUU 
Longitudinal axis 0.08 to 0.19 MPa 
Hong et al. [446] Circumferential 
axis 
0.04 to 0.09 MPa 
PHBV (Sheet) 0.45 to 3 MPa Tong et al. [447] 
PHBV (Bulk) 0.60 MPa Ortega et al. [322] 
 
Following the design, production and mechanical characterisation of the scaffolds, HDFs 
were seeded to both sides of channels and cultivated for 7 days in order to initially 
investigate biological performances of the scaffolds. The results of the H&E and 
fluorescent stainings showed the formation of a monolayer of HDFs inside the channels, 
and that the distribution of cells was continuous on the upper and lower wall of the 
channels.  
Following the cellularisation of the PHBV SVN with HDFs, synthetic channels were then 
cellularised with HDMECs in isolation, and the cells were kept in culture for 7 days. At the 
end of the culture period, scaffolds were fixed, stained with phalloidin and DAPI. The 
results showed that HDMECs adhered and proliferated within the channels and formed a 
monolayer. However, the seeding density was found as an important factor that affects 
the survival and growth of HDMECs inside the synthetic channels. High seeding density 
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(~1 x 106 HDMECs / scaffold) was found essential to be able to obtain a successful 
formation of the HDMEC monolayer. 
In the body, vascular cells are in contact with perivascular cells such as pericytes, smooth 
muscle cells, fibroblasts or mural cells [451]. Fibroblasts have previously been reported 
to play a key role in the angiogenic process by producing considerable amounts of ECM 
molecules (i.e. collagen, fibronectin and other molecules), growth and pro-angiogenic 
factors which control the shape and density of blood vessels [452,453]. Although 
fibroblasts secrete some VEGF, the main role of these cells is to create an ECM in which 
endothelial cells can be embedded to form tubules. This ECM structure is rich in collagen 
I and fibronectin [454,455]. Based on this knowledge, PHBV synthetic vascular channels 
were then cellularised with HDMECs, whereas the outer surface of the channels was 
seeded with HDFs as co-cultures. The introduction of HDFs as supporter cells slightly 
improved the coverage of the channels with HDMECs. This is more likely due to the 
secretion of ECM components by fibroblasts, which might provide a more suitable 
environment for the attachment, survival and growth of HDMECs within the channels. 
The positive influence of HDFs on the survival and growth of HDMECs has previously 
been reported by other groups as well as our laboratory [21,143].  
Cell culture experiments showed that PHBV SVN could provide a suitable environment 
for HDMECs to attach, grow and form a monolayer either in the presence or absence of 
HDFs. However, the use of HDFs was found to be desirable depending on the intended 
use of the PHBV SVN. 
For the use of PHBV SVN as an in vitro angiogenesis model, two separate studies were 
conducted; the outgrowth of HDMECs was investigated; (i) towards the Matrigel loaded 
with pro-angiogenic agents and (ii) towards a reconstructed TE skin model as a more 
physiologically relevant tissue model. 
The Matrigel experiments, the PHBV SVN was cellularised with HDMECs in isolation, and 
the outgrowth of HDMECs was investigated towards the Matrigel. 2dDR and VEGF were 
selected as the pro-angiogenic agents to stimulate HDMECs outgrowth from the pre-
formed EC monolayer within the channels.  
VEGF is an effective and well-established pro-angiogenic factor [38] which has been 
proven to be a regulator of EC proliferation, migration and survival [41,361]. 2dDR is a 
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small sugar that naturally occurs in the body as a result of the enzymatic degradation of 
thymidine to thymine [71]. As an alternative to the use of exogenous VEGF, we have 
recently reported the angiogenic potential of 2dDR in vitro [88], in ex-ovo CAM assay [89], 
and in diabetic rats [90].  
Nanofibres have been shown to provide better surface properties for ECs to adhere and 
proliferate on them over microfibres [456–458]. This is likely due to the nanofibres being 
structurally similar to the ECM of natural tissue with their submicron-scale topography 
and highly packed morphology [456,459]. Furthermore, PHBV nanofibres have 
previously been shown to be a suitable environment for ECs to form an endothelial 
monolayer [323]. However, nanofibres also create a physical barrier for cells, which 
limits the infiltration [460]. Thus, prior to the outgrowth experiments, holes had to be 
pierced onto the channels of the scaffolds. The results of the Matrigel experiments 
showed that HDMECs were outgrowing and forming interconnected tube-like structures 
within the Matrigel (either loaded with VEGF or 2dDR) close to edges of the pierced 
synthetic PHBV channels. The tube-like formed structures were more obvious and well-
organised in 80 ng/mL loaded VEGF loaded Matrigel groups when compared with 100 
µM 2dDR loaded and control groups. The formation of the tube-like structures was pretty 
similar to those which can be observed in Matrigel tube formation assays. In vivo, 
endothelial cells are in direct contact with a basement membrane which is specific and 
biologically functional for enabling endothelial cells to form tube structures [350]. This 
biologically active protein mixture is a wonderful candidate for mimicking native 
basement membrane of endothelial cells in vitro and promotes endothelial cells to form 
tube-like capillary structures [221]. Kubota et al. seeded endothelial cells on a mimicked 
basement membrane and reported that endothelial cells could attach and form tube-like 
capillary structures within 2-3 hours [461]. Our observations were validated with the 
literature, which reports that VEGF regulates the endothelial outgrowth [462–464]. 2dDR 
also improved the tube formation, which is in correlation with our in vitro tube formation 
results presented in Chapter 2.  
Matrigel-HDMEC outgrowth experiments were repeated 3 times, and at least 5 replicates 
were used for each experiment. It is important to note that the outgrowth of HDMECs was 
witnessed only 20% of the experiments for VEGF loaded Matrigel and 13.3% of the 2dDR 
loaded and control groups, respectively. Formation of complete tube-like structures by 
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HDMECs witnessed only a minority of the VEGF-loaded Matrigel groups. This variability 
demonstrates that the proposed PHBV SVN model as an in vitro platform to study 
angiogenesis is not reliable enough to investigate angiogenesis by its own. There are 
several factors that might be the reasons for this variability;  
(i) the Matrigel is a protein gel mixture which is rich in ECM proteins such as laminin, 
collagen heparin sulphate, proteoglycans etc. However, the exact concentrations of the 
ingredients are not clearly defined, and it shows high batch‐to‐batch variations [465].  
(ii) the thickness of Matrigel was not possible to control very well due to the complex 
geometry of the PHBV SVN scaffolds even though the same volume was used for each 
experiment. The effect of gel thickness on EC survival has been studied, and the thickness 
of gels has been shown to have a negative impact on the survival of ECs and HDFs [205]. 
(iii) HDMECs are very sensitive to culture conditions and show batch to batch variations 
[466]. These variations of ECs have been previously shown to be a cause for not being 
reproducible for in vitro angiogenesis models [467] 
(iv) the holes pierced on SVN channels were randomly oriented, and their positions and 
diameters might have an impact on the variations in the outgrowth of HDMECs.  
Following the Matrigel® experiments, a more physiologically relevant tissue model, TE 
skin model, was used with PHBV SVN to study vascularisation of a reconstructed human 
skin model. TE skin model was successfully developed using a well-established protocol 
[420]. The air-liquid interface has previously been confirmed to provide a stimulus for 
the gradual differentiation of keratinocytes [411]. The histological evaluation of the 
reconstructed TE skin models showed that developed TE skin model achieved a normal-
looking gross skin morphology in 14 days. A multi-layered epithelium was formed and 
found to be well attached to the dermis. Following the reconstruction of TE skin, after 7-
day culture at the air-liquid interface, TE skin equivalent was attached to the top surface 
of the PHBV SVN and cultured for further 7 days at the air-liquid interface.  
The outgrowth of HDMECs towards the TE skin model was mostly observed from the 
connection edges of two separate electrospun sheets, and the inclusion of VEGF to the 
growth media significantly increased the outgrowth distance of HDMECs approximately 
4.4-fold when compared to controls. However, cells were not found to be invading into 
the dermal layer of the developed skin models either supplemented with VEGF or not. 
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Santos et al., previously demonstrated that starch-based scaffolds combined with growth 
factors and fibrin sealant (fibrinogen 75–115 mg/mL, thrombin 4 IU/ mL) were capable 
of promoting vascular infiltration to newly formed tissue in vivo [468]. In addition, the 
concentration of fibrin glue used in this study is also approximately 3-4 times lower than 
some commercially available skin graft sealant fibrin glues [469,470]. We have 
previously demonstrated that fibrin glue with a fibrinogen concentration of 18.75 
mg/mL, a similarly high concentration as used in this study, did not hinder cell outgrowth 
from tissue explants [471]. Thus, the concentration of fibrin glue does not seem to be the 
major cause of the prevention of cell penetration. The most probable explanations for this 
are that the outgrowth direction of HDMECs was against gravity; the rate of outgrowth of 
HDMECs from PHBV channels was low. Furthermore, the orientations, positions and 
diameters of the manually pierced random holes might also have negatively affected the 
outgrowth of HDMECs. Our group had previously explored the endothelialisation of a TE 
skin model and reported that the cells struggled to enter the TE skin and showed no signs 
of being organised when they did enter [412]. 
CAM is a well-vascularised membrane, and I hypothesised that CAM might represent a 
very well-vascularised wound bed. Thus, as a positive control experiment, I implanted 
the TE skin models to assess the vascularisation of reconstructed skin models from CAM. 
The results of the ex-ovo CAM assay were in compliance with the results obtained from 
PHBV SVN studies. Although CAM is a highly vascularised and dynamic environment with 
fast proliferating embryonic cells [472], the results showed that there was no sign of 
blood vessel or tissue integration into the dermal layer of the reconstructed skin 
substitutes. However, the presence of dermal cells (fibroblasts and keratinocytes) 
significantly improved the vascularisation in the area of implantation (towards the 
implanted TE skin) in comparison with DED (with no cells). In addition, the 
administration of VEGF and 2dDR showed a further increase in angiogenic activity. 
Although the major function of fibroblasts is to synthesise and maintain ECM structure, 
they have been reported to produce collagen, fibronectin, proteoglycans, and connective 
growth factors, especially in response to wounding [473,474]. They have also been 
reported as producing soluble angiogenic growth factors such as VEGF [475], 
transforming growth factor-beta (TGF-β) [476], and Platelet-derived growth factor 
(PDGF) [477]. Furthermore, keratinocytes have previously been reported to improve the 
proliferation of endothelial cells and to express VEGF [478]. Recently, the presence of 
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cells and in vitro generated ECM has also been shown to improve angiogenesis in the ex-
ovo CAM assay [479,480]. The enhanced angiogenic properties of TE skin over DED on 
CAM might be validated by the studies given above.  
While an increased angiogenic activity was observed when cells and drugs were 
presented to CAMs, the histological evaluation of the implanted TE skin models showed 
that there was no tissue infiltration and vascularisation through the dermal layer of the 
reconstructed TE skin models. Although no vascularisation was observed in any of the 
implants, one important thing to note was that the inclusion of dermal cells (fibroblasts 
and keratinocytes) and pro-angiogenic agents (VEGF and 2dDR) improved the “take” of 
TE skin model by CAM when compared to DED with no cells. The attachment of TE skin 
model to CAM (either supplemented with pro-angiogenic agents or not) was stronger 
whereas the DED showed no integration with CAM, and it was easily separable from the 
surface of the membrane after the implantation period. 
The developed platform showed encouraging results to be used as an in vitro platform to 
study angiogenesis either at cellular or tissue levels. Future studies need to be conducted 
to improve the reliability of the proposed in vitro platform to and to standardise the 
methodology for seeding of the cells, loading of Matrigel® to the synthetic vascular 
scaffolds, piercing holes, and assessing the angiogenesis. In the scope of this study, only 
one tissue model was developed and assessed on PHBV SVN. However, promising results 
have shown that through further improvements, the PHBV SVN can offer a great platform 
for studying in vitro vascularisation of tissue models. 
 Conclusions and Future Work 
A synthetic vascular network made of PHBV nanofibres was fabricated successfully via 
combining electrospinning and 3D printing to be used as an in vitro platform to study 
angiogenesis. Initial characterisation of PHBV SVN showed that a network with hollow 
channels was produced, and the mechanical properties of the scaffolds were similar to 
those used in vascular tissue engineering. The results showed that PHBV SVN could be 
cellularised with evenly distributed HDMECs either in isolation or in the presence of 
HDFs. The physical appearance of HDFs improved the survival and homogeneous 
distribution of ECs within the channels. The developed PHBV SVN showed promising 
results to be used as an in vitro model to study angiogenesis. Matrigel experiments 
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demonstrated that the platform could be used to study sprouting angiogenesis in 
response to pro-angiogenic agents that were loaded into Matrigel. 80 ng/mL of VEGF and 
100 µM of 2dDR promoted HDMECs to migrate towards the Matrigel loaded with 
chemoattractants. In order to study vascularisation of a more physiologically relevant 
and complex structure, a tissue-engineered skin model was developed successfully. The 
outgrowth of HDMECs from the channels towards the skin model was mostly observed 
from the connection edges of two separate electrospun sheets. 80 ng/mL VEGF 
significantly increased the outgrowth distance of HDMECs towards the TE skin model. 
However, no cells reached to the DED and were found to be invading into the dermal layer 
of the developed skin models. 
In the future, studies could focus on the standardisation of the manufacturing method in 
an attempt to increase the reproducibility of the model by optimising the thickness of 
Matrigel, orientation and the diameters of the holes. Use of ECs in co-culture with 
different cell types and investigating their interaction might also bring a new perspective 
to the use of the developed platform. Further experiments with other pro-angiogenic 
factors and flow conditions could be performed to study their relation to angiogenesis 
using the developed model to increase the reliability of the model. Furthermore, the 
inclusion of flow might increase the reliability of the results obtained from tissue-
engineered skin model experiments. The positive influence of shear stress on EC 
outgrowth has been demonstrated in Chapter V. Finally, the majority of results obtained 
from these experiments was qualitative results. Future studies could focus on obtaining 
more quantitative results such as cell viability, expression of angiogenic markers and 
factors. 
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CHAPTER IV 
Development of a 3D natural scaffold by 
decellularising baby spinach leaves to study and 
promote angiogenesis 
 Aims and Objectives 
The aim of this chapter is to explore a plant-based natural TE scaffold with an intrinsic 
3D vascular architecture by decellularising spinach leaves and to investigate its potential 
to study and stimulate angiogenesis. In order to satisfy this aim; the objectives of this 
chapter are to: 
• Fabricate natural vascular networks via the retention of the intrinsic 3D vascular 
architecture of baby spinach leaves by decellularising them. 
• Investigate the biocompatibility of the decellularised spinach leaves. 
• Recellularise natural vascular networks with endothelial cells to create a 
prevascularised construct. 
• Assess the angiogenic potential of prevascularised spinach leaves using ex-ovo 
CAM assay 
• Evaluate the potential of decellularised baby spinach leaves to be used as a 
model to study angiogenesis in vitro. 
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 Introduction 
Prevascularisation is a promising approach to circumvent slow neovascularisation upon 
implantation of TE constructs. For prevascularisation of the TE scaffolds, the selection of 
scaffold material is critical, and several factors need to be considered, such as 
biocompatibility, degradation time of the material in vivo and integrity of the biomaterial 
in terms of structure and function [129]. A variety of materials can be used as TE scaffolds, 
and an ideal scaffold biomaterial is expected to be non-toxic and biocompatible, and 
biodegradable while providing adequate mechanical support and encouraging cellular 
interactions for tissue development [481]. Synthetic polymers are preferred to be used 
in TE applications because of their tunability according to the desired mechanical and 
physical properties without possible immunological concerns [482], whereas natural 
scaffolds are attractive because of their good biological performance for supporting cell 
adhesion and function, but care must be taken to remove all bioactive compounds and 
epitopes to avoid an immune reaction [481,483]. 
Use of decellularised biological constructs has become an emerging strategy for 
producing physiologically relevant scaffolds for use in both pre-clinical and clinical 
applications [304,305]. The main principle of decellularisation is to remove the cellular 
content of the tissue or organ while preserving the 3D architecture and key ECM elements 
[164,308]. The methodology for decellularisation of tissues and organs is well-
established, and several studies have reported on the use of this approach for generating 
patches for tissue regeneration, as in vitro models or drug screening platforms. For 
example, Sarig et al. successfully decellularised a porcine heart and constructed an 
acellular matrix to be repopulated with progenitor cells and used as an ex vivo drug 
screening platform, as an in vitro model for studying human cardiac tissue and 
transplantable patches. [164] Similarly, Dew et al. generated a decellularised rat intestine 
and repopulated it with human microvascular endothelial and stromal cells successfully 
as an in vitro model to study aspects of neovascularisation [306]. Melo et al. established 
an in vitro multicellular bronchial model using decellularised porcine luminal trachea 
membrane [307]. Uygun et al. developed a decellularised liver matrix and recellularised 
it with adult hepatocytes as a transplantable liver graft [308]. Mertsching et al. developed 
an acellular porcine small bowel segment and conducted a pilot trial for evaluating the 
tissue capabilities in terms of vessel patency and tissue viability by clinical 
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transplantation of their bioartificial vascularised scaffold repopulated with patient’s 
peripheral blood cells [309]. Recently, Zhang et al. developed vascularised soft tissue 
flaps as an alternative to autografting. They generated an acellular skin/adipose tissue 
and repopulated it with human adipose-derived stem cells and HUVECs [310].  
Thus, the use of acellular mammalian scaffolds has great potential in TE applications, but 
they are expensive and difficult to obtain. It also requires experience to harvest tissues or 
organs from man or animals and prepare these to completely remove cells and cell 
epitopes to avoid them causing immune reaction following implantation [311]. On the 
other hand, decellularised plant tissues and organs are promising possible alternatives 
to explore as tissue engineering scaffolds. They are readily available, cost-effective and 
safe to use. Cellulose, the important structural component of plant tissues, is a 
biocompatible natural polysaccharide which has the potential to be used as tissue 
engineering scaffolds in vitro and in vivo.  
The in vivo biocompatibility of plant-derived cellulose has previously been proven by 
Modulevsky et al. by implanting a decellularised McIntosh Red apple section into mice 
subcutaneously [312]. Helenius et al showed the biocompatibility of the BC when 
implanted subcutaneously in rats [313]. The use of cellulose in tissue engineering 
applications has also been reported as a TE scaffold for cartilage tissue engineering [314] 
and temporary skin substitute [315]. Recently, Gershlak et al. successfully developed a 
prevascularised acellular plant-based scaffold by benefiting from some similarities in the 
vascular organisation in animal and plant tissues. Although their study proposed the 
potential of a decellularised spinach leaf to be used in the field of biomaterials and TE as 
a prevascularised construct, they have not yet assessed the angiogenic potential of the 
prevascularised acellular spinach leaf scaffolds using any of the well-established 
angiogenesis assays [166]. Accordingly, in this study, I seek to recapitulate their findings 
and go beyond this to further explore to what extent plant-based biomaterials may offer 
significant alternatives to the conventional scaffold materials used in TE applications. 
Accordingly, I have explored the angiogenic potential of the prevascularised 
decellularised spinach leaves using an ex-ovo CAM assay which is a very useful and 
reliable platform to study initial responses to biomaterials and to quantitatively study the 
angiogenic potential of biomaterials. In addition to its use as a prevascularised construct, 
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I have also assessed the potential use of acellular spinach leaves as a platform which 
enables us to study angiogenesis in vitro.  
In addition to spinach, the feasibility of using different types of decellularised plant leaves 
has been further confirmed by several studies as TE scaffolds for various applications 
[166,167,316]. All the studies above concluded that cellulose is inexpensive, 
biocompatible and therefore a good candidate for use in tissue engineering applications. 
 Materials 
Chemical / Reagent 
Catalogue 
Number 
Supplier 
Baby spinach leaves - Co-op Food 
Matrigel® (Growth Factor Reduced) 356231 Corning 
Industrial methylated spirit (IMS) M/4450/17 
 
Methanol 10626652 
Sodium dodecyl sulphate (SDS) 15865308 
Sodium hypochlorite 11448842 
Triton X-100 BP151 
Fertilised chicken eggs - MedEggs 
RCOM King SURO humidified egg incubator MX-SURO P&T Poultry 
EC GM MV Supplement Pack (For HDMECs) C-39220 
PromoCell 
Endothelial Cell Growth Medium MV (EC GM) 
(for HDMECs) 
C-22220 
Human Dermal Microvascular Endothelial Cells 
(HDMECs) 
C-12210 
37% formaldehyde (FA) solution F8775 
Sigma Aldrich 
4',6-diamidino-2-phenylindole (DAPI) solution  D8417 
Adenine A5665 
AlamarBlue Cell Metabolic Activity Assay R7017 
Amphotericin B A2942 
Calcium chloride dihydrate 223506 
Collagenase A COLLA-RO 
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D-glucose G7021 
Dulbecco’s Modified Eagle’s Medium (DMEM) D6546 
Ethylenediaminetetraacetic acid (EDTA) E6758 
Ethanol 51976 
Fetal calf serum (FCS) F9565 
Gelatin from porcine skin G1890 
Glutaraldehyde (25%) G5882 
Glycerol G5516 
Hexamethyldisilazane (HMDS) 440191 
L-glutamine G3126 
Penicillin / Streptomycin P0781 
Phalloidin, fluorescein isothiocyanate (FITC)  P5282 
Phalloidin, tetramethylrhodamine 
isothiocyanate (TRITC) 
P1951 
Sodium hydroxide pellets 795429 
Tris-EDTA buffer solution (TrE) T9285 
Tris hydrochloride (Tris-HCL) 10812846001 
Trypsin EDTA T3924 
Vascular endothelial growth factor (VEGF) V7259 
Zinc chloride (ZnCl2) 746355 
CellTracker™ Green C2925 
ThermoFisher CellTracker™ Red C34552 
Quant-iTTM Picogreen® (PG) dsDNA Kit P7589 
 
 Methods  
 Preparation of the acellular spinach leaves for cell culture: Decellularisation, 
cannulation, sterilisation, and gelatin coating 
Baby spinach leaves (Spinacia oleracea) were purchased from a local market. A 7-day 
immersion decellularisation protocol was adapted and modified from well-established 
protocols [166,167]. Briefly, the leaves were immersed into a mixture of hexane isomers 
for 1 hour to remove the cuticles and washed with PBS. The vascular structure was 
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cannulated and perfused with PBS using a 30G syringe needle (BD Microlance™ 
Hypodermic Needle, Becton–Dickinson, UK). The leaves were then submerged in 10% 
sodium dodecyl sulphate (SDS) solution for 5 days, 1% Triton-X100 for 1 day, 0.1% 
Triton-X100 for 1 day and 10% sodium hypochlorite solution for 4 hours. Leaves were 
kept on an orbital shaker (PSU-10i, Grant Instruments, Cambridge, UK) at 60 rpm. 
Solutions were changed daily in order to enhance decellularisation efficiency. After 
detergent washing steps, decellularised leaves were rinsed using sterile PBS and washed 
with sterile PBS + antibiotic (1% Penicillin/Streptomycin and 0.25% Fungizone solution 
prepared in PBS) for 2 days. Intrinsic vascular structures of the decellularised leaves 
were then cannulated by infusing PBS through the midrib of the leaves, and the leaves 
were submerged into 0.2% (w/v) porcine gelatin solution and incubated at 37°C for 4 
hours. Finally, decellularised leaves were washed with PBS, cannulated, and conditioned 
with warm Endothelial Cell Growth Medium (EC GM) prior to cell culture. Approximately 
30 leaves can be processed as a batch over 9 days including the final detergent removal 
steps. The decellularisation protocol used in this study is summarised in Table 18. 
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Table 18. The summary of the step-by-step protocol of the decellularisation protocol followed in this 
study 
Step Agent Duration Temperature 
Cuticle Removal Hexane Isomers 1 hour on shaker RT 
Washing PBS 5 minutes RT 
Pre-cannulation PBS - RT 
Anionic Detergent Wash SDS 
5 days on shaker by 
refreshing the solution 
daily 
RT 
Non-ionic Detergent 
Wash 
1% Triton-X100 1 day on shaker RT 
0.1% Triton-
X100 
1 day on shaker RT 
Sterilisation 
10% sodium 
hypochlorite 
4 hours on shaker RT 
Rinsing PBS - RT 
Washing PBS + antibiotic 
2 days on shaker by 
refreshing the solution 
daily 
RT 
Gelatin coating 0.2% Gelatin 4 hours 37°C 
Washing PBS 5 minutes RT 
Conditioning EC GM 30 minutes 37°C 
 
For the evaluation of the vascular patency of the decellularised spinach leaves, blue food 
dye was injected through the cannula of the leaves under a dissection microscope (Wild 
Heerbrugg, Switzerland). 
SEM (FEI Inspect F, Orlando, USA) imaging was used to investigate the microstructural 
alterations between fresh and decellularised spinach leaves. For SEM imaging of the fresh 
and acellular spinach leaves, the leaves were fixed in 2.5% glutaraldehyde and washed 
gently with PBS prior to dehydration with serial ethanol (EtOH) washes (35%, 60%, 80%, 
90%, and 100%). Hexamethyldisilazane (HMDS) is used as a chemical drying agent, and 
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the leaves were soaked in HMDS:EtOH (1:1) solution for 1 hour and then transferred into 
100% HMDS for 5 minutes. The protocol of biological sample preparation for SEM is 
summarised in Table 19. The leaves were air-dried overnight in a fume hood and gold-
coated at a current of 15 mA for 2.5 minutes with a gold sputter (Edwards sputter coater 
S150B, Crawley, England) prior to imaging under SEM (FEI Inspect F, Orlando, USA). The 
SEM images were false coloured using Adobe Photoshop CS6 (Adobe Systems 
Incorporated, California, USA) in order to emphasize the structural alterations when the 
leaf is decellularised.  
Table 19. The protocol of biological sample preparation for SEM 
Step Solution Duration 
Washing PBS x 3 times 4 minutes 
Fixation 2.5% Glutaraldehyde 60 minutes 
Washing PBS x 3 times 15 minutes 
Washing dH2O 5 minutes 
Serial alcohol washes 
for dehydration 
35% EtOH 15 minutes 
60% EtOH 15 minutes 
80% EtOH 15 minutes 
90% EtOH 15 minutes 
100% EtOH 15 minutes 
Chemical dehydration 
HMDS:EtOH (1:1) 60 minutes 
100% HMDS x 2 times 5 minutes 
Drying Air Drying 60 minutes 
 Quantification of DNA content 
Quant-iTTM Picogreen® (PG) dsDNA Kit was used to quantify the DNA content and 
determine the effectiveness of the decellularisation protocol. Fresh and decellularised 
spinach leaves were washed with PBS three times and equal circular pieces were cut 
using a 10 mm biopsy puncher (Stiefel Laboratories, Offenbach, Germany) and the leaves 
were transferred into 24-well plates. 500 µL of cell digestion buffer (10 mM Tris-HCl, 1 
mM ZnCl2 and 1% Triton-X100 in distilled water (dH2O)) was added onto the samples 
and incubated for 30 minutes at RT. Samples were then vortexed for 60 seconds and kept 
182 
 
overnight at 4°C. PG working solution was prepared by diluting 20× Tris-EDTA (TrE) 1:20 
in dH2O (1×TrE) and diluting PG reagent 1:200 in 1× TE. The leaf samples then underwent 
3 x freeze-thaw (FT) cycle (10 minutes at - 80°C and 20 minutes at 37°C, 15 seconds 
vortex between FT the cycles). 100 µL of the lysate was mixed with 100 µL PG working 
solution in 96-well plates wrapped in foil and incubated at RT for 10 minutes. 
Fluorescence reading was done at an excitation wavelength of 485 nm and an emission 
wavelength of 528 nm. The efficiency of decellularisation was determined by comparing 
%DNA content in fresh and decellularised leaves. The step-by-step summary of the DNA 
quantification protocol is given in Table 20. 
Table 20. The step-by-step summary of the DNA quantification protocol with Quant-iTTM Picogreen® 
(PG) dsDNA Kit 
Step Agent Duration Temperature 
Sample preparation - - RT 
Cell Digestion 
Cell Digestion 
Buffer 
30 minutes RT 
Vortex 1 minutes RT 
Incubation Overnight 4°C 
Freeze 10 minutes - 80°C 
Thaw 20 minutes 37°C 
Vortex 15 seconds RT 
Freeze 10 minutes - 80°C 
Thaw 20 minutes 37°C 
Vortex 15 seconds RT 
Freeze 10 minutes - 80°C 
Thaw 20 minutes 37°C 
Mixing samples with PG 
working solution 1:1 (vol/vol)  
PG working 
solution 
- RT 
Incubation 10 minutes RT 
Fluorescence Reading - RT 
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 Biocompatibility of the decellularised spinach leaves and the effect of gelatin 
coating 
AlamarBlue® Cell Viability Assay (ThermoFisher Scientific, California, USA), fluorescent 
microscopy and SEM were performed in order to evaluate the performance of the gelatin 
coated (G+) and non-coated (G-) acellular spinach leaves in terms of cell attachment and 
proliferation.  
Human dermal fibroblasts (HDFs) isolated as described previously [484] were used to 
evaluate the biological performance of the G+ and G- decellularised leaves. Briefly, HDFs 
were isolated from human skin taken from patients by mincing the dermis with into 10 
mm2 pieces. The pieces were then incubated overnight at 37 °C in 0.5% (w/v) collagenase 
A solution. The suspension of HDFs was centrifuged at 1000 rpm for 5 minutes and 
resuspended and cultured in HDF GM. Ethical approval for the use of skin excised in 
routine surgical operations and not needed for treatment of patients was granted by the 
local ethical approval committee of National Health Service Trust, Sheffield, UK (Ethics 
reference: 15/YH/0177). All patients provided written informed consent. For these 
experiments, HDFs were used between passage 3-6. 
G- and G+ acellular spinach leaves were cut circular using a 10 mm biopsy puncher, 
transferred into 24-well plates and conditioned with warm HDF growth medium (HDF 
GM) (DMEM with 10% (v/v) FBS, 100 IU mL –1 penicillin, 100 µg mL –1 streptomycin, 
2 mM L-glutamine and 0.625 µg mL −1 amphotericin B for 30 minutes at 37°C. 2.5 x 104 
HDFs resuspended in 100 µL of HDF GM were seeded onto each leaf and incubated for 2 
hours before the addition of HDF GM. The same cell seeding procedure was repeated for 
G+ and G- TCP. AlamarBlue® Cell Viability Assay was performed at days 1, 4, 7, and 11. 
Briefly, 0.1 mM AlamarBlue® working solution was prepared by 10x dilution of the 1mM 
AlamarBlue® stock solution with HDF GM. HDF GM was removed, and the leaves were 
washed with PBS. 1 mL of AlamarBlue® working solution was added to each well and 
incubated at 37°C for 4 hours. After an incubation period, 200 µL of the solution was 
transferred into a 96-well plate, and the fluorescence readings were done at an excitation 
wavelength of 540 nm and an emission wavelength of 635 nm. Metabolic activity 
measurement experiments were set up in triplicate in three independent assays. 
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For visualisation of the HDFs growing on acellular spinach leaves, G+ decellularised 
leaves were repopulated with HDFs at a density of 2 x 105 cells/cm2.  
After 3-day and 7-day culture, the leaves were fixed with 2.5% GA for SEM imaging. The 
samples were prepared for SEM as summarised in Table 19. Briefly, leaves were washed 
with PBS and dehydrated with serial EtOH washes, and HMDS was used as a chemical 
drying agent. The leaves were then air-dried overnight in a fume hood and gold-coated 
prior to imaging the scaffolds under SEM. 
For fluorescent staining, leaves were fixed in 3.7% FA after 7-day culture and washed 
gently with PBS and submerged into 0.1% (v/v) Triton X 100 (in PBS) solution for 
20 minutes. After serial PBS washes, phalloidin-FITC (1:500 diluted in PBS from stock 
solution) solution was added onto samples to visualize F-actin and incubated for 
30 minutes at RT in the dark. The samples were washed three times with PBS. In order to 
stain cell nuclei, 4',6-diamidino-2-phenylindole (DAPI) solution (1:1000 diluted in PBS) 
was added onto leaves and incubated for 10-15 minutes at RT in the dark, samples were 
then washed 3 times with PBS and directly imaged under a fluorescent microscope 
(Olympus IX3, Tokyo, Japan). 
 Recellularisation of the vascular structure with human ECs 
HDMECs derived from juvenile foreskin were cultured and proliferated according to the 
manufacturer's instructions and used between passage 2 and 4. Briefly, EC GM with 5% 
FBS and microvascular endothelial cell supplement mix (EC growth supplement (0.004 
mL / mL), epidermal growth factor (10 ng/ mL), heparin (90 µg/ mL), hydrocortisone 
(1 µg/ mL)) were used for culturing HDMECs. HDFs were isolated as described in section 
2.3 and used between passage 3-6. 
Our group has previously reported that the presence of HDFs while culturing HDMECs is 
crucial for cell attachment and proliferation [143,306]. Thus, I set up two scenarios for 
recellularisation of the vascular channels. (i) HDMECs by their own were infused through 
the cannula and (ii) HDMECs were infused through the channels in the presence of HDFs 
seeded to the outer layer of the decellularised spinach leaves, as indirect co-culture. Both 
types of cells were prelabelled using CellTracker™ Fluorescent Probes in order to 
visualise the cells in channels. For seeding HDMECs only, HDMECs were prelabelled with 
CellTracker™Red. Briefly, cells were incubated at 37 °C for 45 minutes with 10 µM 
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CellTracker™ working solution, washed with PBS. Decellularised leaves were transferred 
into petri dishes, prelabelled HDMECs were trypsinised, and 3 x 105 HDMECs were 
resuspended in 250 µL of EC GM and infused through the cannula into the leaves and 
incubated 37°C for 1 hour prior to addition of EC GM. For indirect co-culture of HDMECs 
and HDFs, HDMECs were labelled with CellTracker™Red and HDFs were labelled with 
CellTracker™Green as described above. Prelabelled HDMECs were trypsinised, and 3 x 
105 HDMECs were resuspended in 250 µL EC GM, and prelabelled HDFs were trypsinised, 
and 3 x 105 HDFs were resuspended in 200 µL of EC GM. HDMECs were perfused into 
channels, and HDFs were seeded onto the surface of the decellularised leaves. The leaves 
seeded with cells were then incubated at 37°C for 2 hours before adding EC GM. 
Recellularised decellularised leaves were incubated for 4 days, and the images were 
taken using a fluorescent microscope. 
 Assessment of the angiogenic potential of endothelialised leaves in ex-ovo CAM 
assay 
HDMECs were cultured for 7 days in the channels, and HDFs were cultured on the exterior 
surface of the decellularised spinach leaves prior to implantation to CAM as described in 
section 2.5.4. 
To assess the potential angiogenic effect of decellularised spinach leaves containing 
HDMECs and HDFs were assessed using an ex-ovo CAM assay [89]. In brief, fertilised 
chicken eggs (Gallus domesticus) were purchased from Henry Stewart & Co. MedEggs 
(Norwich, UK) and cleaned with 20% industrial methylated spirit solution. Eggs were 
incubated at 37.5°C for 3 days (until embryonic development day (EDD) 3) in a rocking 
egg incubator (RCOM King SURO, P&T Poultry, Powys, Wales). On EDD 3, the embryos 
were transferred gently into sterile petri dishes and incubated at 38°C in a cell culture 
incubator (Binder, Tuttlingen, Germany). CAM assay was conducted in care of the 
guidelines of the Home Office, UK. 
On EDD 7, the main channel lying through the midrib of the acellular spinach leaves 
repopulated with HDFs only, HDMECs and HDFs together and with no cells were cut into 
1 cm pieces using a sterile scalpel blade, and two pieces were implanted onto a single 
CAM. Images of the blood vessels growing towards leaf pieces were acquired using a 
digital USB microscope at EDD 14 before sacrificing the embryos.  
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The angiogenic activity was quantified by counting the blood vessels that converged 
towards the leaves [89]. Briefly, all discernible blood vessels that are growing towards 
the scaffolds in a spoke wheel pattern within a 1-mm imaginary circle drawn around the 
scaffold were carefully counted. As described by Ribatti et al., the blood vessels branching 
inside of the imaginary circle are counted as one blood vessel whereas they are counted 
as two or more if the branching occurs outside the circle [237]. For testing the angiogenic 
activity of each group, at least 8 embryos were used in each of the three replicates. 
 Assessment of HDMEC outgrowth from decellularised spinach leaves to vascular 
endothelial growth factor (VEGF) loaded Matrigel 
With the aim of assessing the potential of decellularised spinach leaves to be used as an 
in vitro model to study angiogenesis, I studied the potential of endothelial outgrowth from 
the leaf channels. 
Decellularised spinach leaves repopulated with HDMECs (1.5 x 106 cells per scaffold) 
were incubated for 7 days at 37ºC. Using sterile 30G syringe needle approximately 10 - 
15 holes were pierced on the main channel (midrib) of each leaf in a class II biological 
safety cabinet. The aim of piercing the holes was to facilitate the outgrowth of HDMECs 
from the channels as no outgrowth was observed from unpierced channels. 
Reduced growth factor Matrigel (protein concentration > 10.8 g/ mL) was purchased 
from Corning. The final concentration of VEGF within the Matrigel was adjusted to be 80 
ng/mL, and 200 μl of Matrigel either plain (no VEGF) or loaded with VEGF was pipetted 
onto the midrib of the decellularised spinach leaves (Figure 78). Leaves were then 
returned to the incubator for gels to set at 37°C for 15 minutes. Decellularised leaves were 
then submerged in EC GM and cultured statically for further 7 days. The leaves were fixed 
3.7% FA as a whole, and, stained with Phalloidin-TRITC and DAPI. Briefly, after fixation 
and three times PBS washing, phalloidin-TRITC (1:500 diluted in PBS from stock 
solution) solution was added to cells in order to stain F-actin filaments of cells and 
incubated for 30 minutes at RT in the dark. Cells were then washed three times with PBS. 
In order to stain cell nuclei, DAPI solution (1:1000 diluted in PBS) was added and 
incubated for 15 minutes at RT in the dark, and cells were then washed 3 times with PBS. 
Matrigel was then carefully peeled from the surface of the spinach leaves, and the 
outgrowth of the HDMEC was then examined under a fluorescent microscope. The 
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outgrowth distances of HDMECs through plain and VEGF loaded Matrigel were quantified 
from fluorescent images of the gels using ImageJ (NIH, Maryland, USA). For the 
assessment of the HDMEC outgrowth, the experiments were repeated 4 times with at 
least 7 replicates per experiment. 
Decellularised spinach Piercing escape holes Pipetting Matrigel® 
   
Figure 78. Schematic illustration of the Matrigel outgrowth experiments. The outgrowth of 
HDMECs localised within the main channel of the decellularised spinach leaves to Matrigel was 
assessed. The pierced holes and Matrigel were shown with purple and light blue color 
 Statistical analysis 
Statistical analysis was carried out using one-way analysis of variance (ANOVA) using 
statistical analysis software (GraphPad Prism, CA, USA). Where relevant, n values are 
given in figure captions. Error bars indicate standard deviations in the graphs unless 
otherwise stated. 
 Results 
 Preparation of the acellular spinach leaves for cell culture 
After initiation of decellularisation, leaves started to lose their green colour gradually, 
and by the end of day 7, they were colourless and translucent as can be seen in Figure 
79A.  
Decellularised leaves maintained their intrinsic 3D vascular architecture seen in native 
spinach leaves, and SEM images showed that the surface structure of the decellularised 
leaves was sinuous compared to the surface of the fresh spinach leaves (Figure 79B). PG 
assay was used to quantitatively confirm the success of the decellularisation protocol by 
showing an approximately 98% drop in the DNA content (Figure 79C). 
The patency of the 3D architecture was evaluated using blue food dye prior to cell seeding 
into this natural vasculature. Although a minor leakage was observed, the food dye was 
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able to reach to the smaller branch points showing that the 3D vascular architecture was 
well-maintained after decellularisation, and the smaller channels were connected and 
accessible via the main channel (midrib) (Figure 79D). 
 
Figure 79. (a) Colour changes during washing steps for decellularisation can be seen from day 0 to 
7. The unit seen on the ruler indicates centimetres. (b) False coloured SEM images showing the 
microstructure of fresh (on the left) and decellularised (on the right) leaves. (c) DNA content of fresh 
and decellularised spinach leaves and (d) blue food dye injection through vascular channels is 
illustrated in the bottom row. Error bars represent SD. 
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 Results of the biocompatibility of the decellularised spinach leaves and the effect 
of gelatin coating 
The results showed a regular increase in the metabolic activities of HDFs from day 1 to 
day 11 in all groups. Although there was a significant stimulatory effect of gelatin coating 
on cell attachment and proliferation of the HDFs growing on the decellularised spinach 
leaves at each time point, gelatin coating did not enhance the metabolic activities of HDFs 
grown on TCP at any of the time points. The metabolic activity of HDFs on decellularised 
leaves achieved approximately 60% of that observed in TCP group by 11 days. The results 
of the AlamarBlue® cell viability assay are shown in Figure 80A. 
Phalloidin-FITC and DAPI staining of the HDFs cultured on G+ and G- decellularised 
leaves for 7 days are given in Figure 80B and 80C, respectively. The morphology of the 
HDFs showed the usual fibroblast-like spreading structure as observed for cells grown 
on TCP. 
The SEM images of the HDFs growing on G+ and G- decellularised spinach leaves on day 
3, 7 and 11 further confirmed the gradual proliferation of HDFs on both surfaces over 
time. While the surface of the decellularised spinach leaf was partly covered by HDFs on 
day 3, the HDFs became fully confluent on day 11, as shown in Figure 80D. 
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Figure 80. (A) The metabolic activity of HDFs growing on G+ and G- decellularised scaffolds over 11 
days in comparison with HDFs growing on G+ and G- TCP. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, ns p ≥ 
0.05, error bars indicate standard deviation (SD). (B) Phalloidin-FITC and DAPI staining of HDFs 
cultured on G+ decellularised leaves for 7 days. Scale bar represents 100 µm. (C) SEM images 
showing the growth of HDFs on G+ decellularised spinach leaf over 11 days are given. Scale bars 
represent 50 μm 
 Results of the recellularisation of the vascular structure with HDMECs 
The results of the recellularisation showed that the growth of HDMEC was very poor in 
G- leaf channels, and no cells were observed as proliferating in the channels when 
HDMECs were seeded in isolation. In contrast, when HDMECs were co-cultured with 
HDFs, they showed greater attachment and proliferation in the channels in G+ 
decellularised spinach channels while only several HDMECs and HDFs were found to be 
attached and proliferating in the G- group.  
The distribution of prelabelled HDMECs and HDFs was visualised with fluorescent 
microscopy in G- (Figure 81A) and G+ (Figure 81B) decellularised spinach leaves at the 
end of 7 days. HDMECs were found localising mostly along the main vein of the spinach 
leaf (midrib) only and did not penetrate into the smaller branches although these 
capillary branches were found to be accessible by the infusion of food dye (Figure 79D). 
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Figure 81. Distribution of HDMECs (red) growing in the main channel and HDFs (green) growing 
on the upper surface of the (A) G- and (B) G+ decellularised spinach leaves. Scale bar is 0.5 mm 
 Results of the assessment of the angiogenic potential of endothelialised leaves in 
ex-ovo CAM assay 
A significant increase in the number of blood vessels growing towards the leaves 
containing HDMECs and HDFs was observed at the end of 7 days. The macro images of 
the blood vessels in the surrounding area of spinach leaves either without or with cells 
are given in Figure 82. The mean vessel counts for acellular spinach leaves repopulated 
with HDFs only, and HDMECs in co-culture with HDFs were 22.1 ± 1.0 and 31.0 ± 1.6, 
respectively compared with decellularised spinach leaf controls (13.1 ± 4.3). The 
presence of the HDFs and HDMECs did not affect the embryo survival rate, which was 
over 77% for this study. 
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Figure 82. Representative macroimages demonstrating the angiogenic potential of decellularised 
spinach leaves repopulated with HDFs only and HDMECs and HDFs in co-culture in comparison with 
plain decellularised spinach leaves with no cells (control). Quantification of the blood vessels is given 
with the graph given bottom-right (n=3). Scale bar represents 0.5 cm. *** p ≤ 0.001, ** p ≤ 0.01, error 
bars indicate SD 
 Results of the assessment of HDMEC outgrowth from decellularised spinach leaves 
to VEGF loaded Matrigel 
The results of phalloidin-TRITC and DAPI staining showed that HDMECs could, on 
occasion, grow out from the main channel of the decellularised spinach leaves towards 
both plain and VEGF loaded Matrigel. However, the outgrowth of HDMECs was rare and 
witnessed in the range of 15-30% of samples per experiment. The outgrowth distances 
from the leaves were 81.7 ± 58.6 μm and 339.5 ± 163.3 μm for cells migrating towards 
plain and VEGF loaded Matrigel, respectively (Figure 83). 
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Figure 83. The images of DAPI (blue) and phalloidin-TRITC (red) fluorescent staining of the 
outgrowing HDMECs from the decellularised spinach leaves into Matrigel without or with VEGF. 
Scale bar represents 100μm. The outgrowth distances of HDMECs are given. (n=4, * p ≤ 0.05, error 
bars indicate SD) 
 Discussion 
A major barrier to translating TE constructs to the clinic is achieving rapid 
neovascularisation in the post-implantation period [23,24]. Although significant progress 
has been made, this problem with TE constructs still remains challenging. 
Neovascularisation is based on the formation of new blood vessels after implantation, 
and these must form within a few days to ensure graft survival. 
Use of proangiogenic drugs is a well-established technique to overcome slow 
neovascularisation post-implantation, and VEGF is well-known and recognised as the 
gold standard in the field of these agents [14]. However, besides being a potent stimulator 
of angiogenesis, it has also been demonstrated to be possibly unsafe when given in high 
doses and in a non-regulated manner [334–336]. Thus, it is very timely to explore 
different strategies for promoting neovascularisation.  
In-vitro prevascularisation of the TE constructs, which can be derived from synthetic or 
natural sources prior to implantation is a promising approach to overcome the slow 
vascularisation problem. The idea of this prevascularisation technique is to shorten the 
time required for neovascularisation in the post-implantation period by establishing a 
connection between existing vessels and the cultured ECs [485,486]. 
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Accordingly, in this study, I aimed to explore a recent plant-based naturally-derived TE 
scaffold with an intrinsic 3D vascular architecture by decellularising spinach leaves and 
investigating their potential to promote angiogenesis when repopulated with HDMECs.  
An immersion decellularisation protocol was adapted and modified from previously 
published protocols [166,167]. After initiation of decellularisation, leaves began to lose 
their green colour over time and became translucent by the end of day 7 (Figure 1A). The 
loss of colour is likely to be due to the removal of chlorophyll [487], which is linked with 
the chloroplast removal from the leaf tissue during washing steps. Some alterations have 
been observed in the microstructure of the spinach leaf with the decellularisation 
procedure. The surface became more sinuous due to burst plant cells and bigger stomatal 
pores (Figure 1B). The decellularisation protocol used in this study contained high 
concentrations of detergents which were found to be toxic to mammalian cells [488,489]. 
Thus, the washing steps after decellularisation are crucial, and no cytotoxic effect was 
observed in this study. Decellularisation was verified by quantification of the DNA 
content (Figure 1C). The remnant DNA remaining at the end of decellularisation was low 
enough to satisfy the suggested criteria for a successful decellularisation [490].  
Cellulose is the major component of the plant cell wall [491], and in vitro and in vivo 
biocompatibility of the plant-derived cellulose has been previously studied by several 
groups recently. Modulevsky et al. reported the in vitro biocompatibility of decellularised 
McIntosh Red apple slices by assessing the proliferation of mammalian cells on them 
[316] They further assessed the biocompatibility of the decellularised apple scaffolds in 
vivo by implanting them into mice subcutaneously, and reported that only low levels of 
macrophages and foreign body multinucleated cells were visible within the scaffold after 
8-weeks of implantation[312]. Recently, Gershlak et al. assessed the feasibility of 
decellularised spinach and parsley to be used as TE scaffolds. They demonstrated that 
hPS-CMs were viable and contracting five days after initial seeding [166]. All of these 
studies concur that cellulose is a readily available, inexpensive, and a biocompatible 
biomaterial that may prove a good candidate to be used in tissue engineering 
applications.  
In this study, I explored the biocompatibility of decellularised spinach leaves in vitro and 
using an ex-ovo CAM assay and demonstrated the usefulness of gelatin coating for 
enhancing the attachment and proliferation of HDFs. The results demonstrated an 
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increase in the metabolic activities of HDFs growing on decellularised spinach leaves 
from day 1 to 11, showing that the material shows no toxicity to cells. This data was 
further confirmed by a fluorescent image showing the well-spread HDFs in an elongated, 
flattened morphology (Figure 2B), and with the SEM images showing the proliferation of 
the HDFs over 11 days (Figure 2C) on decellularised spinach scaffolds. The results of the 
CAM assay also demonstrated that decellularised spinach leaves showed no toxicity to 
chick embryos. 
In vivo, ECs are in contact with an ECM mostly composed of collagen and laminin which 
is critical for ECs adhesion and formation of a smooth endothelium layer, and fibronectin 
which plays a major role in adhesion and restoration following vascular injury [492,493]. 
Beside the adhesion of ECs, the ECM plays an important role in cell migration, 
morphogenesis, survival, and vessel stabilisation [494]. Many methods have been 
described to grow ECs in vitro using different culture conditions and systems for culturing 
ECs efficiently. These culture systems are mostly focused on the surface coating with 
fibronectin, collagen and gelatin and the availability of growth factors and the presence 
of stromal cells such as HDFs in contact with ECs [37,495,496].  
Gelatin, denatured collagen, has been used as an inexpensive alternative for promoting 
cell attachment and proliferation in vitro. In order to assess the efficiency of gelatin 
coating on cell attachment and proliferation, I compared the metabolic activities of HDFs 
growing on surfaces coated with gelatin and uncoated. Although gelatin coating showed 
no significant difference for HDFs growing on TCP, it significantly enhanced the 
attachment and proliferation of HDFs to decellularised spinach leaf at all time points. The 
coating procedure used in this study did not include any cross-linking step, and the 
remarkable effect of gelatin coating was observed at day 1 by which time the non-cross-
linked gelatin might be expected to have largely detached from the surface fairly quickly. 
Non-cross-linked gelatin has previously been reported as dissolvable in aqueous solution 
at 37°C [497]. Lai et al. showed the degradation of non-cross-linked gelatin membranes 
within 30 minutes at 37°C in physiological medium containing collagenase [498]. 
Similarly, Kuijpers et al., reported that although they studied the stability of cross-linked 
gelatin at 40°C, the stability of non-cross-linked gelatin was not tested as it will dissolve 
in aqueous solution at that temperature. 
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The positive influence of gelatin coating on the proliferation of HDFs is most likely to be 
due to the increased initial cell attachment on acellular spinach leaves. Similar to our 
results, Vleggeert-Lankamp et al. demonstrated the positive influence of gelatin coating, 
either cross-linked or non-cross-linked, on attachment and proliferation of human 
Schwann cells. They demonstrated that the non-cross-linked gelatin coating significantly 
enhanced the attachment of the cells on day 1, and from day 3 to day 6, the proliferation 
rate of the cells increased approximately 6 times with the help of non-cross-linked gelatin 
coating [499].  
HDFs were used initially to assess the effect of gelatin coating on cell attachment and 
proliferation prior to assessing its effect on HDMECs in the recellularisation experiments. 
Similar to its effect on HDFs, the gelatin coating was found to be crucial for HDMECs. They 
survived only in 10% of the G- scaffolds (in only 1 out of 10 scaffolds) when seeded by 
their own. However, the survival of HDMECs in G+ scaffolds (without HDFs) was 
increased to 50% (in 5 out of 10 scaffolds). 
For endothelialisation of the leaf channels, HDMECs were then cultured in indirect 
contact with HDFs. It was previously reported that fibroblasts have a key role to play in 
the angiogenic process by producing considerable amounts of ECM molecules (i.e., 
collagen, fibronectin, and other molecules), growth and pro-angiogenic factors which 
control the shape and density of blood vessels [452,453]. Although fibroblasts secrete 
some VEGF, the main role of these cells is to create collagen I and fibronectin rich ECM in 
which ECs can be embedded to form tubules [454,455]. I confirmed this key feature with 
that the presence of HDFs enhanced the attachment and survival of HDMECs in the 
channels of the decellularised leaves even if they were seeded at lower concentrations 
(less than 1x 106 HDMECs per scaffold) (Figure 3). The survival of HDMECs in the 
channels increased to approximately 70% (7 out of 10 scaffolds) with the presence of 
HDFs. The culture of HDMECs in isolation without HDFs was only possible when the 
initial cell seeding concentration was high enough (more than 1 x 106 cells per scaffold), 
and the leaves were coated with gelatin. The culture of HDMECs in the acellular spinach 
channels was found to be the most efficient with the G+ scaffolds and when HDFs were 
presented in indirect contact.  
In vitro prevascularisation is a promising technique for the survival of engineered tissue 
constructs in the early phases of implantation by shortening the time required for 
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neovascularisation [500]. The effectiveness of the prevascularisation technique has 
previously been studied by many groups. Tremblay et al. reconstructed an 
endothelialised skin model repopulated with HUVECs and reported the inosculation of 
HUVECs with the host mice vasculature during the first 4 days [485]. Similarly, Nor et al. 
implanted biodegradable poly-L-lactic acid scaffolds prevascularised with HDMECs 
subcutaneously into immunodeficient mice and demonstrated the differentiation of 
HDMECs into functional human microvessels which anastomosed with the host 
vasculature in less than 7 days [501]. Schechner et al. reported the formation of primitive 
capillary-like structures by HUVECs cultured within a 3D gel and showed successful 
inosculation of HUVECs with the host vasculature when implanted into mice [118]. Unger 
et al. investigated the functionality of in vitro pre-formed microvasculature in vivo and 
reported that co-culture of HDMECs with osteoblasts stimulated the ingrowth of host’s 
blood vessels into TE construct, and chimeric vessels were also observed at the end of 
14-day period [493].  
I have shown the stimulatory effect of the prevascularised TE constructs on 
neovascularisation by implanting the endothelialised acellular spinach leaves into the 
CAM and investigating angiogenesis over 7 days in the area of implantation. Acellular 
leaves with no cells and repopulated with HDFs were used as controls. The results 
showed that there was an increase in the number of newly formed blood vessels towards 
the leaves containing either only HDFs or HDMECs plus HDFs. The most dramatic 
increase was observed in the HDMECs plus HDFs group in comparison with 
decellularised leaves repopulated with HDFs only. The mean number of blood vessels was 
31.0 ± 1.6 and 22.1 ± 1.0, respectively. They were both compared with the acellular 
spinach leaves with no cells as controls (number of blood vessels: 17.9 ± 1.1) (Figure 82). 
The results demonstrated that the presence of HDMECs enhanced angiogenesis in CAM 
assay. This data provides evidence on prevascularisation stimulating new blood vessel 
growth at the site of implantation, further investigation of the inosculation of HDMECs 
with host vasculature needs to be investigated. Furthermore, even if the leaves were 
gelatin coated and the HDFs were used as helper cells, HDMECs were not found to 
penetrate into the smaller branches of the acellular spinach leaves. In considering the 
potential use of the decellularised spinach leaves as prevascularised constructs, this lack 
of homogeneity in the distribution of HDMECs might prove a problem for establishing a 
connection with the endothelial cells of the host tissue. Further developments on 
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endothelial cell distribution in the scaffolds may lead to a better angiogenic response 
from a host tissue. In the field of decellularisation of the native tissues and organs, the 
complete recellularisation of the acellular 3D scaffolds in vitro is a long-standing problem, 
and further investigations are needed to improve the cell distribution in the scaffolds 
[502]. 
In vitro models are important tools to understand the angiogenic process and assess the 
activities of anti and pro-angiogenic agents. To date, many migration and differentiation 
assays have been developed and used to study angiogenesis in vitro. Alessandri et al. used 
a modified Boyden chamber to study endothelial capillary mobilisation in response to a 
pro-angiogenic agent [215]. Obesso et al. developed a new technique to study endothelial 
movements by attaching beads to the bottom of a 96-well plate and screening the tracks 
generated by ECs [503] Liang et al. used an in vitro scratch assay based on creating a 
wound by scraping the ECs in a designated area, to study endothelial migration in 2D 
[504]. Bach et al. studied the formation of capillary-like structures in the fibrin and 
collagen gels to address the potential role of the endothelial cadherins [505]. Similarly, 
Grant et al. studied endothelial tube formation using laminin and Matrigel [506]. 
Recently, Dew et al. developed a biodegradable synthetic vascular scaffold and assessed 
its potential use as an in vitro model of angiogenesis by investigating the outgrowth of 
HDMECs into a VEGF loaded collagen gel [507]. In the current study, I combined two in 
vitro approaches (migration and tube formation) and investigated the potential of 
decellularised spinach leaves to be used as an in vitro platform in which I can study 
angiogenesis in response to exogenous inhibitory or stimulatory agents. Briefly, I 
explored the outgrowth behaviour of HDMECs from the natural vascular network of 
decellularised spinach leaves to Matrigel either plain or loaded with VEGF (Figure 83). 
Unfortunately, our results demonstrated that the outgrowth of the HDMECs from the 
channels was extremely rare (outgrowing HDMECs were witnessed only in 5% of the 
experiments). However, the outgrowth distance of the HDMECs through VEGF loaded 
Matrigel was higher, and a more organised structure was observed when compared with 
non-loaded Matrigel groups. Obviously, further developments on this assay would be 
required to increase its reproducibility. It possibly merits more development as it 
combines both migration and cell differentiation in a 3D environment. 
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Although the CAM assay is a useful platform to study biocompatibility and angiogenicity 
of materials in vivo, one of its drawbacks is that the chick does not have a fully developed 
immune system during the period of use for the CAM assay [69,89]. Thus, comparison of 
plant-derived and animal-derived decellularised constructs using an animal model with 
a competent immune system will be interesting in the future to compare the relative 
merits of both.  
 Conclusions and Future Work 
In this chapter, I successfully developed natural vascular networks by decellularising 
baby spinach leaves. The decellularisation protocol enabled the removal of the 98% of 
DNA of the baby spinach leaves by serial detergent washes without any damage to the 
structural integrity of the leaves. The biocompatibility of the acellular spinach leaves was 
confirmed in vitro and in vivo. An intrinsic 3D vascular architecture was maintained after 
decellularisation, and the midrib of the spinach leaf was completely open and suitable for 
culturing ECs in it. Gelatin coating significantly enhanced the attachment and growth of 
HDFs on acellular spinach leaves. Gelatin coated acellular spinach leaves repopulated 
with HDMECs promoted neovascularisation in the CAM assay over 7 days, and the 
number of blood vessels growing towards the endothelialised leaves was doubled when 
compared with plain decellularised leaf controls without cells. I also demonstrated that 
the decellularised baby spinach leaves have some potential to be used as an in vitro 
angiogenesis model to study angiogenesis in response to exogenous inhibitory or 
stimulatory agents. 
In future, further investigation of the inosculation of HDMECs with host vasculature 
needs to be investigated. Furthermore, even if the leaves were gelatin coated and the 
HDFs were used as helper cells, HDMECs were not found to penetrate into the smaller 
branches of the acellular spinach leaves. In considering the potential use of the 
decellularised spinach leaves as prevascularised constructs, this lack of homogeneity in 
the distribution of HDMECs might prove a problem for establishing a connection with the 
endothelial cells of the host tissue. Further developments on endothelial cell distribution 
in the scaffolds may lead to a better angiogenic response from a host tissue. In the field of 
decellularisation of the native tissues and organs, the complete recellularisation of the 
acellular 3D scaffolds in vitro is a long-standing problem, and further investigations are 
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needed to improve the cell distribution in the scaffolds [502]. Although the CAM assay is 
a useful platform to study biocompatibility and angiogenicity of materials in vivo, one of 
its drawbacks is that the chick does not have a fully developed immune system during the 
period of use for the CAM assay [69,89]. Thus, comparison of plant-derived and animal-
derived decellularised constructs using an animal model with a competent immune 
system will be interesting in the future to compare the relative merits of both. When it 
comes to use the developed scaffolds as an in vitro platform to study angiogenesis, further 
developments on this assay would be required to increase its reproducibility. It possibly 
merits more development as it combines both migration and cell differentiation in a 3D 
environment.  
201 
 
 
CHAPTER V 
Development of a novel in vitro 3D dynamic 
platform to study angiogenesis under 
physiologically more relevant conditions 
 Aims and Objectives 
The aim of this chapter is to develop a 3D dynamic in vitro model by combining emulsion 
templating and electrospinning techniques to study angiogenesis in a more 
physiologically relevant environment. In order to satisfy the aim; the objectives of this 
chapter are to: 
• Manufacture the PCL PolyHIPE outer tube by emulsion templating 
• Manufacture the PHBV inner tube by electrospinning 
• Design and manufacture the flow chamber 
• Recellularise the 3D model by rotational seeding 
• Study the impact of flow and pro-angiogenic agents on proliferation and migration 
of ECs 
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 Introduction 
Angiogenesis models are important tools to study the angiogenic activity of agents, 
biomechanical stimulus and cells [205]. Although in vivo assays are the most 
representative and reliable models for the evaluation of angiogenesis, they are also 
expensive, technically difficult, time-consuming, and ethically questionable [204]. On the 
other hand, in vitro angiogenesis assays are inexpensive, quick, technically simple, and 
reproducible, but they are usually based on evaluating only one aspect of angiogenesis 
(for example, proliferation, migration or differentiation), and they may produce false 
results due to the nonspecific reaction of cells [508]. Moreover, most of the in vitro 
angiogenesis assays are limited to static, two-dimensional (2D) cell culture systems 
where culturing cells on stiff and flat substrates is a simplified method and does not 
represent the dynamic and highly complex tissue systems [400,509]. 2D culture of cells 
distorts cell-cell and cell-matrix interactions which affects cell proliferation, migration 
and differentiation [510,511], whereas 3D in vitro models better represent the in vivo 
situation in a cost-effective way and with no ethical concerns [400]. To date, none of the 
studies demonstrated an in vitro model which allows researchers to evaluate 
angiogenesis assessing both proliferation and migration of ECs in a 3D dynamic 
environment. 
In this study, we developed a bilayer tubular model as a platform to be used in the 
evaluation of two phases of angiogenesis together; cell proliferation and migration in a 
dynamic environment under physiologically more relevant conditions. The nanofibrous 
structure of the inner tube mimics the basement membrane and provides a suitable 
environment for EC attachment and formation of an endothelial monolayer whereas the 
highly porous and interconnected outer polymerised high internal phase emulsion 
(PolyHIPE) tube enables cell infiltration and migration through the pores. 
The experimental procedures in this chapter have been conducted in collaboration with 
my co-worker Betül Aldemir Dikici during our collaboration with Massachusetts Institute 
of Technology (MIT). Betül was responsible for the production of PCL PolyHIPE tube 
including the synthesis of PCL methacrylate, preparation of PCL HIPEs, and 
polymerisation of the PCL PolyHIPE tubes. 
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 Materials 
Chemical / Reagent 
Catalogue 
Number 
Supplier 
Alexa Fluor® 594 anti-human CD31 Antibody 303126 Biolegend 
Hypermer B246 - Croda 
Chloroform 10784143 
Fisher 
Scientific 
Dichloromethane (DCM) 10127611 
DPX mounting medium D/5319/05 
Industrial methylated spirit (IMS) M/4450/17 
Methanol 10626652 
Toluene 10102740 
Triton X-100 BP151 
Xylene X/0100/17 
Poly3-hydroxybutyrate-co-3-hydroxyvalerate 
(PHBV) (PHV content 12 mol %) 
BV326301 GoodFellow 
Optimum cutting temperature tissue freezing 
medium (OCT-TFM) 
14020108926 
Leica 
Biosystems 
Fertilised chicken eggs - MedEggs 
Hydrochloric acid fuming 37% 100317 Merck 
RCOM King SURO humidified egg incubator MX-SURO P&T Poultry 
EC GM 2 Supplement Pack (for HAECs) C-39211 
PromoCell 
Endothelial Cell Growth Medium 2 (EC GM) (for 
HAECs) 
C-22211 
Human Aortic Endothelial Cells (HAECs) C-12271 
2-deoxy-D-ribose (2dDR) 121649 
Sigma Aldrich 
37% formaldehyde (FA) solution F8775 
4',6-diamidino-2-phenylindole (DAPI) solution  D8417 
AlamarBlue Cell Metabolic Activity Assay R7017 
Amphotericin B A2942 
Bovine serum albumin (BSA) A7030 
Collagenase A COLLA-RO 
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Dimethyl sulphoxide (DMSO) 472301 
Eosin Y solution HT110232 
Ethanol 51976 
Fetal calf serum (FCS) F9565 
Glutaraldehyde (25%) G5882 
Goat serum G9023 
Hematoxylin solution HHS16 
Methacrylic anhydride (MAA) 276685 
Paraformaldehyde (PFA) 158127 
Penicillin / Streptomycin P0781 
Pentaerythritol (98%) P4755 
Photoinitiator (PI) (2,4,6-Trimethylbenzoyl 
Phosphine Oxide/2-Hydroxy-2-
Methylpropiophenone blend) 
405663 
Polydimethylsiloxane (PDMS) (SYLGARD®184) 761036 
Tin (II) 2-ethylhexanoate S3252 
Triethylamine (TEA) 471283 
Trypan blue T6146 
Trypsin EDTA T3924 
Vascular endothelial growth factor (VEGF) V7259 
ε-caprolactone 704067 
Alexa Fluor 594 Phalloidin A12381 
ThermoFisher 
Scientific 
 Methods 
 Design and manufacturing of the 3D dynamic system 
The 3D system was designed to be two-layers; the inner tube of nanofibres to serve as a 
suitable environment for HAECs to attach, proliferate and form a monolayer to represent 
an endothelium, and the outer tube of the highly porous and interconnected environment 
to enable proliferation and migration of HAECs from the formed endothelial monolayer. 
3D bilayer tubes used in this study were manufactured combining two manufacturing 
206 
 
methods; emulsion templating and electrospinning, and they were characterised using 
scanning electron microscopy. 
 Manufacturing of the PCL PolyHIPE outer tube by emulsion templating 
The manufacturing of the PCL PolyHIPE outer tube has been carried out in collaboration 
with my colleague, Betül Aldemir. More information about the details of the following 
protocols can be found elsewhere for further reading [424]. 
 Synthesis of PCL methacrylate 
The PCL used in this study is 4-arm PCL methacrylate (4PCLMA) which we have 
previously reported the detailed synthesis [424]. Throughout the paper, the term `PCL 
polymerised high internal phase emulsion (PolyHIPE)` will be used to describe 4PCLMA 
PolyHIPE, unless otherwise stated. 
Briefly, pentaerythritol (12 g, 0.088 mol) and ε-caprolactone (80.49g, 0.705 mol) were 
mixed in a round flask at 160°C while stirring continuously at 200 rpm. When 
pentaerythritol was dissolved, tin (II) 2- ethylhexanoate (as a catalyst) was added, and 
the system was left for reaction overnight with stirring. Then, stirring was stopped, and 
the system was removed from the oil bath to cool down in the ambient atmosphere. 
Hydroxyl-terminated 4-arm PCL was obtained, and to methacrylate functionalise, it was 
dissolved in 300 mL of DCM, and then TEA (52.65 g, 0.52 mol) was added. The flask was 
placed in an ice bath. MAAn (80.22 g, 0.52 mol) was dissolved in 100 mL DCM and 
transferred into a dropping funnel. When the addition of MAAn was completed, the ice 
bath was removed, and the system was kept at RT overnight with stirring at 375 rpm. To 
remove the TEA, MAAn and the salts formed, the methacrylated PCL was washed three 
times with HCl solution (1 M, 1000  mL), separated using a separating funnel, and then 
washed three times with pure deionised water. Almost all solvent was evaporated using 
a rotary evaporator. PCL was then dissolved in methanol, then precipitated out of 
methanol by placing in -80 °C freezer. Three methanol washes were used, and any 
remaining solvent was removed by using the rotary evaporator. 4PCLMA was stored in 
an appropriate vessel in the freezer (-20 °C) for further use. 
 Preparation PCL HIPEs 
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4PCLMA (0.4 g) and the surfactant Hypermer (10% w/w of polymer) were added into a 
glass vial and heated to 40°C to dissolve surfactant. The effect of different solvents and 
solvent blends on the structural parameters of PolyHIPE has recently been demonstrated 
[424]. In this study, solvent blend (150% w/w of polymer, 80% chloroform, 20% toluene 
(w/w)) and PI (10% w/w of polymer) were added in the 4PCLMA-surfactant mixture, 
respectively and mixed at 375 rpm using a magnetic stirrer for 1 minute at RT. Once the 
homogeneous mixture formed, 2.5 mL of water (internal phase volume 80% v/v) was 
added dropwise in 3 minutes, and the emulsion was mixed further 30 seconds more. The 
protocol of HIPE preparation is given in Figure 84. 
 
Figure 84. Preparation of PCL HIPEs. The steps shown are (i) Addition of aqueous phase to organic 
phase, (ii) creating a stable emulsion suing a surfactant, and (iii) the resultant emulsion that can be 
defined as HIPE when the aqueous phase content is over 74% 
 
 The polymerisation of PCL HIPEs 
A mould made of silicone tubes, stoppers, and a copper rod was assembled (Figure 85A). 
PCL HIPE was injected into the mould by using a syringe and polymerised for 3 minutes 
on both sides using a UV curer with a 100 W.cm-2 UV bulb (Omnicure Series 1000, Lumen 
Dynamics, Canada).  
The resulting parts were recovered, soaked in 100% methanol for 24 hours with four 
changes to remove any remaining contaminants of surfactant, solvent or uncured 
material. Then the samples were left in methanol (50% (v/v) in water) for 24 hours and 
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then in water for a further 24 hours. Finally, the samples were taken out from the water 
and left in the freezer (-80°C) for an hour then transferred into a vacuum oven and left 
for a day to preserve the porous structure of PCL PolyHIPE without any collapse. 
 
Figure 85: Manufacturing route of the polymeric bilayer tubes (A) Developed moulding system to 
manufacture PCL PolyHIPE tubes, (B) Electrospinning setup for manufacturing of PHBV electrospun 
tubes 
 Manufacturing of the PHBV inner tube by electrospinning 
PHBV (10% (w/w)) pellets were dissolved in DCM:methanol (90:10 w/w) solvent blend, 
and the solution (~5  mL) was loaded into 5 mL syringes fitted with 0.6 mm inner 
diameter blunt syringe tips. The syringe was then placed in a syringe pump 
(GenieTMPlus, KentScientific, Connecticut, USA). L-Shape T9 Torx key (~2.5 mm 
diameter) (purchased from a local supplier) was used as the mandrel and placed at a 
distance of 17 cm from the needle tip (Figure 83B). The rotator and the pump were set to 
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250 rpm and 40 µL/minutes, respectively. A 17 kV voltage was applied to both the 
collector and the tips. The solution was then electrospun at RT for ~10 minutes. 
 Assembling of PCL PolyHIPE and PHBV electrospun tubes 
PCL PolyHIPE tube was soaked in ethanol, removed and the excess alcohol was shaken 
off. Without letting it dry, the PHBV electrospun tube was inserted into PCL PolyHIPE 
tube, and they were soaked in ethanol and gradually transferred into 70% ethanol for 
sterilisation and then transferred into PBS for complete integration of two layers which 
occurred due to the shrinkage of PCL PolyHIPE layer (Figure 86). Then 80 holes per tube 
were pierced using 23 G syringe needles as escape holes as described previously [507] 
for enabling the migration of the ECs from the inner PHBV tube to the outer PCL PolyHIPE 
layer. 
 
Figure 86. Assembling of PCL PolyHIPE and PHBV electrospun tubes 
 Scanning electron microscopy 
Micro-architectures of PCL PolyHIPE, PHBV electrospun, and the bilayer tubes were 
examined using an SEM. All samples were gold-coated with a voltage of 15 kV for 
2.5minutes using a gold sputter coater (Edwards sputter coater S150B, Crawley, UK) to 
increase conductivity. SEM (FEI Inspect F, Orlando, USA) was used with 10 kV power.  
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 Design and manufacturing of the chamber 
A chamber with a lid was manufactured using 3D printing technique to serve as a 
reservoir for culture media and to enable the connection of the 3D bilayer tubes to lateral 
flow.  
The 3D models of the chamber and the lid were designed using Autodesk Inventor 
Professional 2020 (San Rafael, CA, USA). The chamber had inner dimensions of 70x25x25 
mm with 2 mm material thickness and with input and output holes which have an inner 
diameter of 3 mm. The lid had 75x30x5 mm inner dimensions with 2 mm material 
thickness. The model was then saved as a standard tessellation language (STL) file. The 
design of the chamber is given in Figure 87. 
 
Figure 87. The design of the chamber. The figure illustrates the connection of the scaffolds to the 
designed chamber and the chamber to the pump for the introduction of flow to the system 
The STL file was imported into Formlabs Form 2 printer (Somerville, MA, USA) and 
printed using the resin; Dental LT Clear (Figure 88A). Following this, the chamber and lid 
were washed with isopropanol, post-cured at 60oC for 1 hour and washed with ethanol. 
Then the chambers were air-dried, and silicone tubes were sealed into the input and 
output holes of the chambers (Figure 88B). Chamber systems were sterilised using 70% 
(v/v) ethanol solution (in deionised water). Briefly, they were soaked in the ethanol 
solution in the laminar hood and left for 2 hours, air-dried in the hood for 1 hour and 
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washed with PBS three times for 2 hours. The connectors and the silicone tubing were 
sterilised by using an autoclave, and the whole system was assembled in a laminar hood 
under sterile conditions using sterile forceps. 
 Testing the diffusion pattern between the tube and the chamber 
The bilayer tube was connected to the chamber, and the chamber was filled with 30 mL 
of DI water. Trypan blue was injected into the silicone tube to be circulated, and 
10 dyn/cm2 flow was applied to the system. Macroscopic images of the system were 
captured at the end of 1, 5 and 10 minutes to observe the diffusion of the trypan blue. At 
the end of the experiment, deionised water in the chamber was collected, and the volume 
was measured. 
 Rotational cell seeding into bilayer tubes 
One end of the tubes was occluded, as shown in Figure 88C and bilayer tubes were left in 
70% ethanol for 2 hours and then washed with PBS three times in sterile conditions. 
Finally, they were conditioned with media for an hour in the incubator in 24 well plates. 
HAECs were trypsinised, counted, and centrifuged. The cell pellet was re-suspended in 
fresh media, and 106 cells/300 µL were injected into tubes using a syringe, as shown in 
Figure 88D. Once all the cell suspension was injected, the other end was closed using a 
cap (Figure 88E). Tubes were transferred in a 15 mL centrifuge tube with 10 mL EC GM 
and placed in a cylindrical rotator turning at 1 rpm in a 37 °C, 5% CO2 humidified 
incubator for 4 hours for the attachment of HAECs (Figure 88F). 
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Figure 88: Protocols we followed starting from the chamber manufacturing to the implementation 
of the tubes to the fabricated chamber. (A) Manufactured chamber using 3D printing, (B) 
implementation of the tubing to the chamber, (C) preparation of the tubes for seeding, (D) 
administration of the cell suspension into tubes using a syringe, (E) closing the other end with a cap 
to prevent leakage of the cells from the tube upon seeding, (F) rotational incubation of the tubes, 
and (G) implementation of the cellularised tube to the chamber 
 3D culture of HAECs in the newly developed dynamic model for the assessment of 
angiogenesis 
Following cell seeding, caps in both ends of the tubes were removed, and bilayer tubes 
were connected to silicone tubing in the printed chamber using sterile forceps (Figure 
88G). HAECs in bilayer tubes were cultured for a week. In 3D experiments, the individual 
effect of flow, pro-angiogenic agents and their combined effect on EC infiltration were 
investigated. Flow experimental groups were static (control), 1 dyn/cm2, 2 dyn/cm2 and 
10 dyn/cm2. Then, drug experimental groups; 100 µM 2dDR and VEGF were investigated 
under static conditions. Finally, 100 µM 2dDR and VEGF were further investigated under 
2 dyn/cm2 flow and compared with the static conditions.  
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 Hematoxylin and Eosin (H&E) staining 
Bilayer tubes cultured with HAECs for a week were stained with H&E using a standard 
protocol [358]. Briefly, samples were washed with PBS and fixed with 3.7% FA. They 
washed with PBS, and excess water was removed using filter paper. Meanwhile, 
cryomoulds were filled with OCT-TFM. Samples were embedded into it, and the rest of 
the volume was then filled with OCT-TFM to the top. Cryomoulds were placed into -80 °C 
freezer and incubated for 30 minutes until solidified. Frozen blocks were fixed on 
mounting platforms, and placed into a cryostat (Leica CM1860 UV, Milton Keynes, UK) 
before sections were sliced at 5-10 µm and immediately mounted onto Thermo 
SuperFrost® Plus slides. For H&E staining, slides were stained with hematoxylin for 90 
seconds and eosin for 5 minutes and they were dehydrated, cleared and mounted the 
slide using the permanent mounting medium. 
 Fluorescent staining 
Bilayer tubes were fixed with 3.7% FA for 30 minutes and washed gently with PBS prior 
to submerging into 0.1% (v/v) Triton X 100 (in PBS) solution for 20 minutes and stained 
in the same way explained in the Section 3.1.4. Then, the stained scaffold was sectioned, 
as explained in Section 3.2.7 and imaged under a fluorescent microscope (Olympus IX3, 
Tokyo, Japan). 
 Statistical analysis 
Statistical analysis was carried out using one-way and two-way analysis of variance 
(ANOVA) using statistical analysis software (GraphPad Prism, CA, USA). Where relevant, 
n values are given in figure captions. Error bars indicate standard deviations in the graphs 
unless otherwise stated. 
 Results 
 Design, production and characterisation of the PCL polyHIPE & PHBV electrospun 
tubes 
The 3D bilayer tubes consist of an inner PHBV electrospun tube for ECs to attach and form 
an endothelial monolayer and an outer PCL PolyHIPE tube which provides a highly 
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porous and interconnected environment for ECs to infiltrate was developed successfully 
following the manufacturing route illustrated in Figure 86.  
The surface morphology of PHBV electrospun was beadless with random (non-aligned 
fibres) fibre orientation where the average fibres and pore sizes were 0.70 ± 0.25 µm and 
3.64 ± 2.16 µm, respectively (Figure 89D). The outer layer, PCL PolyHIPE, had an average 
pore size of 30 ± 13 µm (Figure 89E).  
 
Figure 89: (A,B) SEM image of the cross-section of the bilayer tube, (C) Macroscopic image of the 
bilayer tube, (D) SEM images of the surface topology of PHBV electrospun and (E) PCL PolyHIPE 
The 3D culture chamber manufactured using 3D printing was capable of supporting the 
culture of HAEC in bilayer tube for periods of 7 days. There was no leakage or 
contamination throughout the experiments. The connection of the scaffolds to the 
fabricated chamber and the whole system to the flow are given in Figure 90A-C. The resin, 
Dental LT Clear, used for manufacturing of the chamber was reported to be biocompatible 
by the manufacturer. It was resilient to 70% ethanol for sterilisation of the chamber. Its 
transparency was advantageous for bioreactor chambers to be able to allow the visual 
inspection of the media colour without opening the lid, which reduces the risk of 
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contamination throughout the culture. This petri-dish inspired design is reproducible, 
cost-effective ($15/chamber) and allows gas exchange. Its small dimensions enable 
multiple chambers to be used in the same incubator at the same time. 
 
Figure 90. (A) The connection of the scaffolds to the chamber, (B) the connection of chamber to the 
pump prior to starting experiments, and (C) the connection of multiple chambers to the pump in a 
cell culture incubator 
 
 
 
 
A B 
C 
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 Flow mediates proliferation and outgrowth of ECs: Low shear stress promotes 
proliferation and migration of HAECs 
HAECs were seeded in bilayer tubes and cultured under static, 1 dyn/cm2 flow, and 
2dyn/cm2 flow formed a continuous endothelial monolayer at the end of a 1-week culture 
period (Figure 90). The cells cultured in tubes under 10 dyn/cm2 flow showed relatively 
poor cell distribution, which is likely due to cells were washed out because of the 
comparably high flow rate which gave the lowest cell density observed amongst all of the 
groups. However, migration of HAECs through electrospun fibres was higher under 10 
dyn/cm2 shear stress (202.6 ± 107.7 µm) compared with the static group where no 
outgrowth was observed. HAEC outgrowth and cell density in tubes cultured under 2 
dyn/cm2 flow were significantly higher and statistically different than other groups. 
HAECs migrated approximately 533 ± 90.8 µm in 7 days under 2 dyn/cm2 shear stress 
while the outgrowth was 231.5 ± 70.1 µm when 1 dyn/cm2 shear applied. Moreover, at 
day 7, the normalised density of cells in the tubes was significantly increased under 2 
dyn/cm2, and it was approximately 2-fold, 1.4-fold, and 12-fold higher in comparison 
with static, 1 dyn/cm2, and 10 dyn/cm2 shear stress conditions, respectively. Fluorescent 
and H&E staining of the HAECs under static and flow conditions are given in Figure 91.  
217 
 
 
Figure 91: Effect of flow on the outgrowth distance, cell density and the cell monolayer formation 
of HAECs. (Top) Phalloidin TRITC, (Bottom) H&E staining of the sections of the bilayer tubes cultured 
with HAECs for a week under static culture and dynamic culture with 1 dyn/cm2, 2 dyn/cm2 and 10 
dyn/cm2 flow from left to right, respectively 
 Testing the diffusion pattern between the tube and the chamber 
To test the diffusion behaviour between the chamber and the tube visually, the trypan 
blue dye was circulated in the system, and macroscopic images of the chamber were 
captured at 1, 5 and 10 minutes (Figure 92A). Images showed the gradual release of the 
dye from the inner tube to the chamber. Also, the volume of the liquid in the chamber was 
500µm 
200µm 
100µm 
200µm 
100µm 
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measured both at the beginning of the experiment and at the end of 10 minutes of 
circulation, and it was 30 mL at both time points. 
 
Figure 92: (A) The diffusion of trypan blue dye from flow system to the outer chamber, (B) 
Schematic diagram of the system and (C) cross-sectional view of the tube showing the dye gradient 
between bioreactor chamber and inside of the tube at any point till balance point 
 2dDR and VEGF promotes proliferation and outgrowth of HAECs under static 
conditions  
In 2dDR and VEGF supplemented groups, HAECs in the electrospun tube formed a dense-
packed endothelial monolayer inside the tube. No HAEC infiltration was observed in the 
control group which was not supplemented with any drug under static conditions 
whereas in 2dDR and VEGF supplemented groups, HAECs were able to migrate through 
PCL PolyHIPE layer approximately 182.2 ± 81.6 µm and 264.9 ± 88.1 µm, respectively. 
There was no statistically significant difference between VEGF and 2dDR supplemented 
tubes under static conditions in terms of HAEC outgrowth. The cellular densities in the 
tubes under static conditions were increased 1.2-fold and 1.5-fold by the addition of 
2dDR and VEGF, respectively. 
 Pro-angiogenic agents (2dDR and VEGF) and fluid forces cooperate to improve the 
outgrowth and proliferation of HAECs  
The highest distance of outgrowth and a dramatic increase in the cellular density was 
observed when HAECs were exposed to the simultaneous application of the angiogenic 
drugs and the flow. HAECs cultured under 2 dyn/cm2 shear stress with a growth medium 
supplemented with either 2dDR or VEGF migrated up to 779.8 ± 110.3 µm and 797.3 ± 
72.5 µm, respectively. Furthermore, the cellular densities in the tubes were increased 3.8-
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fold and 3.2-fold, respectively for 2dDR and VEGF groups under 2 dyn/cm2 shear stress 
when compared with the drug including static controls. There was no statistically 
significant difference observed between 2dDR and VEGF groups under 2 dyn/cm2 shear 
stress in terms of HAEC outgrowth. Fluorescent and H&E staining of the HAECs under 
static and flow conditions either administered with drugs or non-treated are given in 
Figure 93. The graph showing the quantified results of flow and drug experiments and 
the statistical analysis is given in Figure 94. 
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Figure 93: The combined effect of 2dDR, VEGF, and flow (2dyn/cm2) on the outgrowth distance, cell 
density and the cell monolayer formation of HAECs. (Top) Phalloidin TRITC, (Bottom) H&E staining 
of the sections of the bilayer tubes cultured with HAECs under static culture and dynamic culture 
with 2 dyn/cm2 flow and with the implementation of the angiogenic agents (VEGF and 2dDR) 
500µm 
200µm 
100µm 
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Figure 94: Quantification of the outgrowth (µm) distance and the cell density (normalised to the 
static alone group) of HAECs to show the effect of flow and drugs either in isolation or combined 
(***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, not significant (ns) p ≥ 0.05, n = 3) 
 Discussion 
To test the angiogenic activity of added pro-angiogenic factors, biomechanical stimulus 
and cells, angiogenesis models are important tools [205], and the current angiogenesis 
assays can be divided into three categories: in vitro assays which focus on evaluating 
proliferation, migration, and tube formation capabilities of ECs [512], ex-vivo assays and 
in vivo assays [399]. Although in vivo, assays are the most representative and reliable 
models for the evaluation of angiogenesis, they are also expensive, technically difficult, 
time-consuming and ethically questionable. On the other hand, in vitro angiogenesis 
assays are inexpensive, quick, technically simple, and reproducible, but they are usually 
based on evaluating only one aspect of angiogenesis, and as such do not represent the 
complexity of angiogenesis which occurs in vivo. A comparison of current angiogenesis 
assays in terms of cost-effectivity, ethical concerns, reproducibility, the requirement of 
special skills, representations of the physiological angiogenesis and the duration of the 
assay are given in Table 21.  
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Table 21. Comparison of current in vitro, ex vivo and in vivo angiogenesis assays with the developed dynamic 3D angiogenesis model. (- = absence, + = very 
low, ++ = low, +++ = low / medium, ++++ = medium, +++++ = medium / high, ++++++ = high) 
 Models Cost 
Ethical 
concerns 
Reproducibility 
Special skill 
requirement 
Representation of the 
physiological angiogenesis 
Duration of the 
assay 
References 
In
 v
it
ro
 
Proliferation assays + - ++++++ + + ++ / +++ [513–516] 
Migration assays ++ - ++++++ + + + [514,515,517] 
Tube formation assays ++ - ++++ ++ + + [518–520] 
3D dynamic angiogenesis 
model 
+ - ++++++ + ++ / +++ ++ this study 
E
x 
v
iv
o
 Aortic ring/arch assays ++ ++ +++ +++ +++ +++ [225,521,522] 
Retinal assay ++ ++ +++ +++ +++ ++ [523,524] 
In
 v
iv
o
 
In-ovo CAM assay ++ +++ +++ ++++ ++++ ++++ [238,525] 
Ex-ovo CAM assay ++ +++ +++ +++++ ++++ ++++ [89,241,419,480] 
Dorsal skinfold chamber 
assay 
++++++ ++++++ ++ ++++++ ++++++ +++ [526,527] 
Sponge/Matrigel® plug 
assay 
++++++ ++++++ ++ ++++++ ++++++ ++++ [528,529] 
Corneal assay +++++ ++++++ ++ +++++ +++++ +++ [516,530] 
Zebrafish assay ++ +++ ++ ++++ ++++ ++ [531,532] 
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When all the drawbacks of these methods are considered, there is a need for a 3D dynamic 
system which enables the study of angiogenesis in vitro in a more physiological complex 
3D environment which includes the introduction of flow which is a major stimulus for 
neovascularisation in vivo. 
Experiments in this study were designed with two key objectives; (i) to develop a 3D 
dynamic system to be used for testing of angiogenic drugs, (ii) to evaluate the efficiency 
of 2dDR on encouraging proliferation and infiltration of HAEC using in vitro 3D dynamic 
system we designed for the assessment of the suitability of our model to be used as a 3D 
in vitro angiogenesis model. Throughout these experiments, we have used VEGF as a 
comparator. 
The 3D dynamic system was designed in a tubular form as seen in tissue engineering 
vascular graft design to enable the application of lateral flow [533–535]. It was designed 
to be two-layers and manufactured by combining two different manufacturing methods, 
electrospinning and emulsion templating.  
The inner tube was manufactured using electrospinning, and it is made of nanofibres to 
serve as a suitable environment for HAECs to attach, proliferate and form a monolayer to 
represent an endothelium. Nanofibres have been shown to provide better surface 
properties for ECs to adhere to and to proliferate on than microfibres [456–458]. This is 
likely due to the nanofibres being structurally similar to the ECM of natural tissue with 
their submicron-scale topography and highly packed morphology [456,459]. 
Furthermore, nanofibres made of PHBV have previously been shown to be a suitable 
environment for ECs to form an endothelial monolayer [323]. Although nanofibres are 
favourable for the formation of the endothelium layer, these close-packed fibres act as a 
barrier to cell infiltration [419]. 
In contrast, the outer tube was designed to serve as a suitable environment for cell 
infiltration. An emulsion templating method was used for the manufacturing of the outer 
layer as it enables fabrication of the scaffolds with high interconnectivity and up to 99% 
porosity. We have recently reported the manufacturing route of PCL based PolyHIPEs, 
and we have also shown the biocompatibility and structural suitability of these scaffolds 
in terms of cell infiltration [419,424].  
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Moulding was used for the fabrication of the PolyHIPE tubes. The manufacturing route of 
PolyHIPE tubes using 3D laser patterning has previously been reported [536]. However, 
the production of PolyHIPE based 3D structures needs bespoke stereolithography set-
ups and careful optimisation of the printing ink, the print speed of the stage and 
irradiation intensity, to produce good quality prints with PolyHIPEs. Thus, the use of 
moulds is a practical and convenient method to fabricate PolyHIPEs with uncomplicated 
designs. 
Following the fabrication of the individual layers separately, we combined them by taking 
advantage of the high swelling degree of PolyHIPEs in organic solvents [537]. The outer 
diameter of the PHBV electrospun tube and the inner diameter of the PCL PolyHIPE tube 
were designed to be 2.4 mm when they were soaked in water or culture media. When the 
PCL PolyHIPE tube was transferred from water to ethanol, the diameter increased by 
more than 10% and enabled the insertion of the PHBV tube into the PolyHIPE tube. Then, 
the bilayer tube was transferred into the water, and a shrink-fit connection between the 
two layers was obtained. After combining PHBV electrospun and PCL PolyHIPE tubes, 
they maintained their structural integrity, and no delamination was observed at any stage 
of the experiments over 7 days.  
3D experiments were conducted to investigate the effect of (i) flow, (ii) angiogenic agents, 
and (iii) their combined effect on cellular density and the outgrowth distance of HAEC 
from the inner tube to PCL PolyHIPE layer. The inner diameter of the 3D tube was 2.4 mm 
to partially represent the diameter of big blood vessels such as arteries or veins, and 
accordingly, the shear rates used in this study ranged between 1-10 dyn/cm2 to mimic 
the physiological shear rates observed in some arteries and veins [538,539]. 
The results of the 3D flow experiments showed that static culture and lower shear 
stresses (1 dyn/cm2 and 2 dyn/cm2) enabled the formation of a continuous endothelial 
monolayer, but the application of higher stress (10 dyn/cm2) resulted in a discrete 
monolayer of HAECs. This is possibly due to the cells being washed out at the high rate of 
flow. Similarly, Kitagawa et al. demonstrated a rapid decrease in the number of cells 
attached to their tubular scaffolds due to the high flow shear stress [540]. Low shear 
stress promoted the outgrowth of HAECs over 7 days. 2 dyn/cm2 shear stress 
significantly increased the outgrowth distance of HAECs and normalised cell density 
when compared with 1 dyn/cm2 and 10 dyn/cm2, whereas no outgrowth was observed 
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under static culture conditions. Our findings of the effect of flow experiment on ECs are 
consistent with the literature [541,542]. ECs are mechanosensitive, and they have been 
reported to show phenotypic and functional changes based on various flow patterns 
[112]. Shear stress caused by laminar flow has been reported to reduce the apoptosis 
while increasing the VEGF expression [113] and demonstrated to regulate EC migration 
[114]. Barron et al. reported a higher EC number and infiltration under flow conditions 
compared to static culture [543]. Similarly, Sprague et al. demonstrated that the 
migration of HAECs onto a prosthetic material was positively influenced by shear stress 
[544]. Urbich et al. showed that the application of shear stress stimulates migration of 
human umbilical vein ECs in a flow rate dependent manner being at least as effective as 
VEGF [545]. Mohan et al. reported an increased angiogenesis-related nuclear factor-kB 
(NF-kB) activity when HAECs were exposed to low shear in comparison with high shear 
stress conditions [546]. 
Under static conditions, administration of 2dDR and VEGF stimulated EC outgrowth and 
cell density when compared with the static control group (no agents administered). 
However, the most dramatic increase in outgrowth distance and cell density was 
observed when the pro-angiogenic agents (2dDR and VEGF) were administered under 2 
dyn/cm2 shear conditions. The outgrowth distance and cell density of HAECs under flow 
conditions and when treated with VEGF and 2dDR were significantly higher when 
compared to that observed when VEGF and 2dDR were administered under static 
conditions. Similarly, Song et al. reported that VEGF and fluid forces cooperate to improve 
endothelial invasion into collagen gel matrix [547]. Studying EC outgrowth is particularly 
important because the formation of new blood vessels involves budding of endothelial 
cells from established vasculature towards an area of hypoxia and increased the release 
of pro-angiogenic factors such as VEGF. 
Alongside the mechanotactic stimulus, the chemotactic stimulus is the other factor that 
causes a migratory response of ECs [43]. In our system, an external media reservoir was 
not used as the media in the chamber was sufficient to keep the cells alive for a 7-day 
culture period. The bilayer tubes were porous enough to enable the application of flow 
and the diffusion of the media between the media the inside of the tube and the media in 
the chamber, as shown in the time-lapse figure (Figure 92A), the trypan blue dye was 
spread over the chamber by this time and as there was no volume change observed in the 
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chamber, which indicates the liquid transport both from the tube to the chamber and the 
chamber to the tube. But as this transportation takes time, even after 10 minutes trypan 
blue did not cover the top of the tube. During the culture of HAECs in the tubes, there was 
a continuous nutrient consumption in the inside of the tube by the cells, which probably 
creates a concentration gradient between the circulating media (in the tube) and the 
media in the chamber. As the circulating media (represented with trypan blue, Figure 
92B,C) was comparably exhausted in terms of supplemented angiogenic agents (2dDR 
and VEGF) compared to media in the chamber (represented with water, Figure 92B,C), 
the migration of HAECs from the inner surface of the electrospun tube towards outside 
PolyHIPE layer can be explained by the chemotactic stimulus for ECs due to the 
abundance of the drugs in the chamber when compared with the inner tube where 
perfusion occurs. 
The current study makes a novel contribution by demonstrating a novel 3D model which 
can be used to study angiogenesis in vitro in a 3D dynamic environment. Herein, we 
showed that the 3D in vitro model we developed gave results consistent with the 
established angiogenesis assays for testing of the angiogenic effect of 2dDR in comparison 
with VEGF. Our model enables users to monitor cell proliferation and migration 
simultaneously under more physiologically relevant conditions. Our bilayer tubular 
system will also enable the future co-culture of endothelial cells with another cell line; for 
example, seeding bone cells into the PolyHIPE tube while ECs are in the electrospun tube 
to study angiogenesis in bone tissue engineering. This new 3D dynamic model will be 
suitable for studying several aspects of angiogenesis. For instance, quantitative 
assessment of angiogenesis markers may give a better insight into the response of ECs to 
an external stimulus and to flow. 
 Conclusion and Future Work 
In the present study, a 3D bilayer dynamic system which enables one to study 
angiogenesis in vitro was successfully fabricated by combining electrospinning and 
emulsion templating. The angiogenic activity of 2dDR was evaluated in the 3D dynamic 
system compared to VEGF under static and flow conditions. Both agents improved 
endothelial cell density in the tube and the outgrowth of cells under either static or 
2 dyn/cm2 shear stress conditions. We conclude that the developed 3D dynamic system 
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offers the potential to be used as a powerful in vitro platform which allows to study more 
than one aspect of vascularisation in a more physiologically relevant environment. 
In the future, studies trying to include quantitative assessment of angiogenesis markers 
could be trialled in an attempt to give a better insight into the response of ECs to an 
external stimulus and to flow. This will clearly increase the reliability of the developed 
model and increase the accuracy of the results obtained. In addition, further studies 
exploring co-culture of ECs with another cell line could bring a whole new perspective to 
the use of this model. For example, inclusion of bone cells in the PolyHIPE layer in co-
culture with ECs (in the electrospun layer) could enable users to study the aspects of 
vascularisation in bone tissue engineering. Finally, the assessment of different cell 
combinations, pro-angiogenic factors, and flow regimes could be studied in relation to 
angiogenesis in future studies. 
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CHAPTER VI 
Seeding of simple electrospun scaffolds with a 
combination of endothelial cells and fibroblasts 
to promote angiogenesis 
 Aims and Objectives 
The aim of this chapter is to investigate the practicability of the prevascularisation 
approach to induce angiogenesis by pre-seeding simple electrospun PHBV scaffolds with 
a combination of endothelial cells and fibroblasts. In order to satisfy the aim; the 
objectives of this chapter are to: 
• Manufacture simple nanofibrous PHBV scaffolds by electrospinning 
• Investigate the effect of gelatin coating and the presence of human dermal 
fibroblasts (HDFs) as helper cells on human dermal microvascular endothelial 
cells (HDMECs) growth and survival.  
• Evaluate the angiogenic activity of the PHBV scaffolds when cellularised with 
HDFs in isolation, HDMECs in isolation, and HDMECs in indirect co-culture with 
HDFs using an ex-ovo chick chorioallantoic membrane (CAM) assay. 
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 Introduction 
Tissue and organ failure or losses are major problems that are seen in human health, and 
tissue engineering offers an opportunity to develop functional substitutes for damaged 
tissues. Most of the conventional tissue engineering approaches have mainly focused on 
attachment and proliferation of cells, and their formation of ECM prior to implantation 
[22]. However, the lack of blood vessels in tissue-engineered constructs is one of the most 
critical challenges in the survival of engineered tissue substitutes [23,24]. Although 
significant progress has been made, the main problem with tissue engineering constructs 
still remains the same, and it is the slow formation of new blood vessels, also known as 
neovascularisation, post-implantation. When a TE substitute is implanted, nutrients and 
oxygen must be provided to enable the cells to survive in vivo, and the formation of a 
vascular network within TE substitutes can take weeks, which leads to the failure of the 
constructs [26].  
The majority of the current strategies to circumvent delayed neovascularisation focus on 
the addition of pro-angiogenic factors to TE constructs (functionalisation strategy) [22], 
but the use of laboratory expanded pro-angiogenic cells such as endothelial cells (ECs), 
endothelial progenitor cells (EPCs), and stem cells to the tissue engineering systems 
(prevascularisation strategy) prior to implantation is also a well-established approach 
[125,327]. The successful prevascularisation of a tissue-engineered construct depends on 
three primary parameters: (i) cell type (single or co-culture of vessel-forming cells), (ii) 
scaffold material selection (synthetic, natural or composite materials), and (iii) culture 
conditions [202,548]. 
Accordingly, in this study, I evaluated the effect of gelatin coating and the presence of 
human dermal fibroblasts (HDFs) as helper cells on human dermal microvascular 
endothelial cells (HDMECs) growth and survival. Then, I fabricated simple electrospun 
scaffolds made of PHBV to study the angiogenic activity of the scaffolds when cellularised 
with HDFs in isolation, HDMECs in isolation, and HDMECs in indirect co-culture with 
HDFs using an ex-ovo CAM assay [549]. 
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 Materials & Methods  
 Materials 
37% formaldehyde (FA) solution, 4',6-diamidino-2-phenylindole (DAPI) solution, 
AlamarBlue Cell Metabolic Activity Assay, Amphotericin B, Dimethyl sulphoxide (DMSO), 
Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal calf serum (FCS), Hematoxylin 
solution, Penicillin / Streptomycin, Phalloidin-fluorescein isothiocyanate (FITC), 
Phalloidin-tetramethylrhodamine isothiocyanate (TRITC), and Trypsin EDTA were 
purchased from Sigma Aldrich. Dichloromethane (DCM), DPX mounting medium, 
Industrial methylated spirit (IMS), Methanol, and Xylene were purchased from Fisher 
Scientific. Human Dermal Microvascular Endothelial Cells (HDMECs), EC GM MV 
Supplement Pack (For HDMECs), and Endothelial Cell Growth Medium MV (EC GM) (for 
HDMECs) were purchased from PromoCell. CellTracker™ Green and CellTracker™ Red 
were purchased from ThermoFisher. Poly3-hydroxybutyrate-co-3-hydroxyvalerate 
(12%) (PHBV) was purchased from GoodFellow. Optimum cutting temperature tissue 
freezing medium (OCT-TFM) was purchased from Leica Biosystems. 
 Methods 
 Assessing the effect of gelatin coating on the attachment of cells to electrospun 
PHBV nanofibres  
 Preparation of the PHBV scaffolds 
Electrospun PHBV scaffolds were manufactured as described. Briefly, 10% PHBV was 
dissolved in DCM:Methanol (90:10) mixture, and then electrospun on an aluminium foil 
coated collector for random nanofibers from 17cm distance with a rate of 40 µL/minutes 
at 17kV voltage. PHBV scaffolds were cut into circular pieces and sterilised with 70% 
ethanol solution for 45 minutes. 
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 Gelatin coating and cellularisation of the PHBV scaffolds with HDMECs and 
HDFs 
For gelatin coating of the PHBV scaffolds, they were submerged in a sterile 0.2% gelatin 
solution (w/w in PBS) and incubated at 37°C for 4 hours prior to washing with PBS three 
times. 
For co-culture groups, the PHBV scaffolds were cellularised with HDFs in direct contact 
with HDMECs. Briefly, HDFs were isolated from human skin grafts taken from patients as 
described previously [480]. Ethical approval for the use of skin excised in routine surgical 
operations and not needed for treatment of patients was granted by the local ethical 
approval committee of National Health Service Trust, Sheffield, UK (Ethics reference: 
15/YH/0177). All patients provided written informed consent. HDFs were used between 
passage 3-6. 
HDMECs were purchased from PromoCell and used between passage 2-4. Once both cells 
reached 80-90% confluency. 2 x 104 HDFs were resuspended in 0.1 mL of EC GM 
(PromoCell Endothelial Cell Growth Medium MV basal medium supplemented with 2% 
FCS, 0.4% EC growth supplement, 10 ng/mL EGF, 90 µg/mL heparin, 1 µg/mL 
hydrocortisone) and then seeded onto the one side of the PHBV scaffolds. Before seeding 
HDMECs, scaffolds were returned to the incubator for two hours to allow HDFs to attach. 
Then scaffolds were taken from the incubator and flipped over. 2 x 104 HDMECs were 
resuspended in 0.1 mL of EC GM and then seeded onto the other surface of the PHBV 
scaffolds. Before adding culture medium, scaffolds were returned to the incubator for an 
hour to allow HDMECs to attach. Then, 2 mL of culture medium was added to each well, 
and they were returned to the incubator. 
 AlamarBlue® Cell Viability Assay to evaluate the metabolic activities of 
HDMECs on PHBV scaffolds 
AlamarBlue® Cell Viability Assay was performed to evaluate the effect of gelatin coating 
and co-culture with HDFs on HDMECs growth. In brief, 0.1 mM AlamarBlue® working 
solution was prepared by 10x dilution of the 1mM AlamarBlue® stock solution with EC 
GM. At days 1, 4 and 7, growth media were removed, and the scaffolds were washed with 
PBS. 1 mL of AlamarBlue® working solution was added to each well and incubated at 
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37°C for 4 hours. After the incubation period, 200 µL of the solution was transferred into 
a 96-well plate, and the fluorescence readings were done at an excitation wavelength of 
540 nm and an emission wavelength of 635 nm. 
 Preparation of cellularised electrospun PHBV scaffolds for implantation 
 Electrospinning PHBV 
10% (w/w) PHBV solution was prepared prior to electrospinning. 6 g of PHBV granules 
were dissolved in 3 g of methanol and 24 g of DCM in a fume hood, and the mixture was 
magnetically stirred overnight. For gelatin coating of the PHBV scaffolds, they were 
submerged in a sterile 0.2% gelatin solution (w/w in PBS) and incubated at 37°C for 4 
hours prior to washing with PBS three times. 
Approximately 10 mL of PHBV solution was transferred into 5 mL syringes with 0.6 mm 
blunt tips, and the syringes were then placed onto the syringe pump (GenieTMPlus, Kent 
Scientific, Connecticut, USA). An aluminium foil coated collector was placed at a distance 
of 17 cm from needle tips, and the pump was set to deliver 40 µL/minutes. A voltage of 
17 kV was applied to the collector as well as the needle tips. The polymer was electrospun 
on the collector with the parameters given above for an hour. 
 Cellularisation of the electrospun PHBV scaffolds 
For cellularisation of the PHBV scaffolds, three cell systems were used: (i) HDFs, (ii) 
HDMECs, and (Iii) HDMECs seeded on the lower surface of the PHBV fibres followed by 
HDFs seeded on the upper surfaces of the scaffolds. 
Cellularisation of the scaffolds with HDFs in isolation 
HDFs were used between passage 3-6 when they had reached 80-90% confluency. The 
PHBV scaffolds were disinfected by submerging them in 70% ethanol for 45 minutes 
prior to wash with PBS three times. 0.5 x 105 HDFs were resuspended in 0.1 mL of EC GM 
(PromoCell Endothelial Cell Growth Medium MV basal medium supplemented with 2% 
FCS, 0.4% EC growth supplement, 10 ng/mL EGF, 90 µg/mL heparin, 1 µg/mL 
hydrocortisone) and then seeded onto the PHBV scaffolds. Before adding EC GM, scaffolds 
were returned to the incubator for an hour to allow HDFs to attach. Then, 2 mL of culture 
235 
 
medium was added to each well, and they were incubated at 37°C overnight prior to 
implantation. 
Cellularisation of the scaffolds with HDMECs 
HDMECs were used between passage 2-4 and were used at 80-90% confluency. The PHBV 
scaffolds were sterilised by submerging them in 70% ethanol for 45 minutes prior to 
washing with PBS three times. Following sterilisation, scaffolds were transferred to 24-
well plates. 0.5 x 105 HDMECs were resuspended in 0.1 mL of EC GM and then seeded onto 
the PHBV scaffolds. Before adding EC GM, scaffolds were returned to the incubator for an 
hour to allow HDMECs to attach. Then, 2 mL of culture medium was added to each well, 
and they were incubated at 37°C overnight prior to implantation. 
Cellularisation of the scaffolds with HDMECs in indirect contact with HDFs 
HDMECs and HDFs were cultured as described above and at 80-90% confluency. The 
PHBV scaffolds were sterilised by submerging them in 70% ethanol for 45 minutes prior 
to washing with PBS three times. Following sterilisation, scaffolds were transferred to 
24-well plates. 0.25 x 105 HDFs were resuspended in 0.1 mL of EC GM and then seeded on 
one side of the PHBV scaffolds. Before seeding HDMECs, scaffolds were returned to the 
incubator for two hours to allow HDFs to attach. Then scaffolds were taken out from the 
incubator and turned over. 0.25 x 105 HDMECs were resuspended in 0.1 mL of EC GM and 
then seeded onto the other surface of the PHBV scaffolds. Before adding EC GM, scaffolds 
were returned to the incubator for an hour to allow HDMECs to attach. Then, 2 mL of 
culture medium was added to each well, and they were incubated at 37°C overnight prior 
to implantation. 
Pre-labelling of cells for the confirmation of cell seeding 
For imaging cells on the scaffolds prior to implantation, HDFs and HDMECs were pre-
labelled with CellTracker™ Green and CellTracker™ Red prior to seeding. In brief, to label 
HDMECs, 50 µg of CellTracker™ Red dry powder was dissolved in 7.3 µL of dimethyl 
sulfoxide (DMSO) to prepare 10 mM stock solution. Then, 7 mL of serum-free EC GM was 
added to prepare a ~10 µM working dye solution. The pre-warmed dye solution was 
added gently to T75 flask, and HDMECs were incubated ~1 hour under growth 
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conditions. To label HDFs, 50 µg of CellTracker™ Green dry powder was dissolved in 
10.75 µL of DMSO to prepare 10 mM stock solution. Then 10 mL of serum-free EC GM was 
added to prepare ~10 µM working dye solution. The pre-warmed dye solution was added 
gently to T75 flask, and HDFs were incubated ~1 hour under growth conditions. Both 
flasks were washed three times with PBS prior to cell seeding onto PHBV scaffolds as 
described above.  
After incubation of the HDMECs and HDFs on the scaffolds overnight either in isolation 
or in co-culture, PHBV scaffolds were fixed in 3.7 % formaldehyde for 30 minutes, and 
the fixed samples were embedded in optimal cutting temperature tissue freezing medium 
and frozen in liquid nitrogen for 3 minutes. Sections were cut 5-10 µm thick using a 
cryostat (Leica Biosystems, Nussloch, Germany) at -20°C. Sections were then directly 
imaged under a fluorescent microscope (Olympus IX3, Tokyo, Japan). 
 Evaluation of the angiogenic activity of the cellularised scaffolds using ex-ovo 
CAM assay 
To evaluate the angiogenic activity of cellularised PHBV scaffolds, they were implanted 
on the CAM for 7 days. Briefly, circles of 7 mm diameter were cut from the scaffold and 
cellularised with HDMECs, HDFs and HDMECs in indirect culture with HDFs prior to 
implantation as described above.  
Fertilised chicken eggs were incubated at 37.5°C for three days in a rocking egg incubator 
(RCOM King SURO, P&T Poultry, Powys, Wales). On day 3, the embryos were transferred 
into sterile petri dishes to start ex-ovo culture and incubated at 38°C in a cell culture 
incubator (Binder, Tuttlingen, Germany) until day 7. On day 7, cellularised PHBV scaffolds 
were implanted onto the CAM and incubated for a further 7 days. The EC GM was added 
to the scaffolds twice a day. On day 14, the embryos were euthanised, and the 
angiogenesis was evaluated macroscopically and histologically. 
For histological evaluation, the CAMs were fixed in 3.7% formaldehyde for 30 minutes, 
and the fixed samples were embedded in optimal cutting temperature tissue freezing 
medium and frozen in liquid nitrogen for 3 minutes. Sections were cut 5-10 µm thick 
using a cryostat (Leica Biosystems, Nussloch, Germany) at -20°C. Sections were then 
stained with haematoxylin for 90 seconds and eosin for 5 minutes, as described 
previously [89]. 
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 Quantification of angiogenesis 
For the quantification of angiogenesis from macroscopic images, macro images of the 
scaffolds implanted on CAM were taken using a digital microscope at day 14, and the 
number of blood vessels was quantified by counting all blood vessels growing towards 
the scaffolds in a spoke wheel pattern, as described previously [69]. 
For the quantification of angiogenesis from histological images, the total number of blood 
vessels adjacent to the scaffolds were quantified by counting blood vessels in H&E 
sections [345]. Briefly, all discernible blood vessels adjacent to the scaffolds were 
counted by two independent researchers using two independent microscopes. 
 Statistical analysis 
Statistical analysis was carried out using one-way analysis of variance (ANOVA) using 
statistical analysis software (GraphPad Prism, CA, USA). Where relevant, n values are 
given in figure captions. Error bars indicate standard deviations in the graphs unless 
otherwise stated. 
 Results 
 The effect of gelatin coating and co-culture with HDFs on HDMECs attachment and 
proliferation 
The results of the AlamarBlue assay showed that there was an increase in the activity of 
HDMECs from day 1 to 7 in all scaffold groups. TCP groups either coated or non-coated 
with gelatin showed higher activity when compared with the PHBV scaffold groups 
(Figure 95).  
Gelatin coating of TCP did not significantly affect the growth of HDMECs at any of the time 
points. However, gelatin coating significantly improved the activity on HDMECs seeded 
on PHBV scaffolds at day 1 and 4. The increases in the metabolic activity with the gelatin 
coating were 1.9-fold and 1.4-fold at days 1 and 4, respectively. Although the difference 
was not statistically significant at day 7, gelatin coating improved the activity of HDMECs 
on PHBV scaffolds 1.2-fold when compared to control PHBV scaffolds. 
238 
 
The presence of HDFs in indirect contact with HDMECs significantly improved the 
metabolic activity of HDMECs at all time points. The activity of HDMECs was increased 
2.7-fold, 2.1-fold, and 1.6-fold at day 1, 4, and 7, respectively. 
 
Figure 95. The results of AlamarBlue® Assay showing the effect of gelatin coating and indirect co-
culture with HDFs on HDMECs metabolic activity over 7 days 
Sections of the cellularised scaffolds with CellTracker™ labelled HDFs and HDMECs were 
directly investigated under a fluorescent microscope prior to implantation to CAMs. The 
results showed that both types of cells were attached to the surfaces of the scaffolds 
either when seeded in isolation or in indirect co-culture. Fluorescent images of the 
scaffold sections are shown in Figure 96.  
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Figure 96. Cross-sections of the cellularised PHBV scaffolds with HDFs (labelled with CellTracker™ 
Green) and HDMECs (labelled with CellTracker™ Red) either in isolation or in co-culture prior to 
implantation to CAM for the evaluation of angiogenic activities. Scale bars represent 100 µm 
 Evaluation of the angiogenic activity of cellularised PHBV scaffolds in ex-ovo CAM 
assay 
The ex-ovo CAM assay results showed that the presence of both HDFs and HDMECs either 
in isolation or when co-cultured together significantly increased the angiogenic activity 
in the area of implantation. None of the implanted scaffolds affected the embryo survival 
rate, which was over 77 % for all groups. The presence of HDFs and HDMECs increased 
the angiogenic activity 1.7-fold and 2.3-fold, respectively. The results showed that when 
HDMECs were seeded on PHBV scaffolds, they stimulated angiogenesis significantly 
greater than when HDFs were used on their own. However, the most significant 
angiogenic response was observed when scaffolds were seeded with both HDMECs and 
HDFs. PHBV scaffolds cellularised with HDMECs and HDFs increased the number of blood 
vessels from 17.5 ± 1.9 to 46.0 ± 3.4 compared to PHBV controls. The macroscopic and 
histologic evaluations of the CAM assay results are summarised in Figure 97. 
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Figure 97. Representative images demonstrating the angiogenic potential of PHBV scaffolds 
cellularised with HDMECs or HDFs or HDMECs in indirect culture with HDFs. The graphs below show 
the quantified results from the macroscopic and histological analysis of the scaffolds. Scale bars 
represent 3 mm and 250 µm for macroimages and histological images, respectively. Black and green 
arrows indicate PHBV scaffolds and blood vessels, respectively. *** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05, 
n=6±SD 
 Discussion 
I have previously compared PHBV and PCL, two widely used polymers in tissue 
engineering applications, in terms of their physical, mechanical and biological 
performances in order to select one of them for further endothelialisation studies in 
Chapter III. Although biological evaluation of the polymers showed similar degrees of 
biocompatibility in vitro and in vivo, the attachment and growth of HDMECs onto PHBV 
nanofibres was higher compared to cell attachment to PCL fibres. The favourability of 
PHBV by HDMECs over PCL led us to select this polymer also for further 
prevascularisation studies. 
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Electrospinning is a method that enables to produce TE scaffolds with a wide range of 
properties in terms of material composition, fibre diameter, thickness, porosity, and 
degradation rates [438–441]. Electrospun nanofibres have been shown to provide better 
surface properties for ECs to adhere and proliferate on compared to microfibres [456–
458]. This is likely due to the nanofibres being structurally similar to the ECM of natural 
tissue with their submicron-scale topography and highly packed morphology [456,459]. 
Accordingly, I successfully fabricated PHBV electrospun fibres with a diameter of ~0.67 
µm via electrospinning. Our laboratory has previously shown that PHBV nanofibrous 
scaffolds allow the diffusion of oxygen and nutrients while supporting cell attachment 
and growth [417,507]. Although PHBV nanofibres provide a relatively favourable 
environment to ECs, in their natural environment, ECs are in contact with collagen, 
laminin and fibronectin rich ECM [492,550]. It is known that ECM plays a key role also in 
EC migration, morphogenesis, survival, vessel stabilisation [494]. Several studies have 
been reported on how ECs can be grown efficiently in vitro. These culture systems are 
mostly focused on surface coating with fibronectin, collagen and gelatin, and providing 
essential growth factors and the presence of stromal cells in contact with ECs [495,496]. 
Communication of ECs with surrounding stromal cells such as SMCs, fibroblasts or 
pericytes has also been proven to have significant importance for the angiogenic process 
[551,552].  
Our group has previously reported the positive influence of fibroblasts on improving the 
survival and growth of ECs in polymeric scaffolds when cultured in indirect contact [323]. 
Recently, I have demonstrated how non-cross-linked gelatin coating can be used to 
improve the attachment and growth of ECs to biomaterials that have relatively weak 
biological properties [480]. In line with our results, Ma et al. reported that surface 
modification of electrospun PCL scaffolds with gelatin coating enhances the EC spreading 
and proliferation [553]. The positive impact of either non-cross-linked or cross-linked 
gelatin coating on attachment and proliferation of human Schwann cells has been shown 
by Vleggeert-Lankamp et al. [499]. Accordingly, in this study, I showed that gelatin 
coating and co-culture with HDFs are both practical approaches to improve the viability 
of HDMECs in synthetic nanofibrous channels with an ultimate aim of stimulating 
angiogenesis as a prevascularisation approach. Our results demonstrated that gelatin 
coating did not affect the attachment and proliferation of HDMECs on TCP, whereas the 
metabolic activity of HDMECs grown on gelatin coated PHBV fibres at days 1 and 4 was 
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significantly higher when compared to controls. Similarly, the presence of HDFs 
significantly improved the activity of HDMECs at all time points.  
The use of pro-angiogenic agents is a well-established approach to promote 
neovascularisation [37,326], and VEGF is recognised as the most effective stimulator of 
angiogenesis [41,361] by taking key roles in the angiogenic cascade [38]. However, the 
exogenous use of VEGF has also been shown to cause leaky [362], permeable [335], and 
haemorrhagic [336] blood vessels, which is highly observed in tumorigenesis [337]. In 
addition, the exogenous use of the pro-angiogenic agents is expensive, highly dose-
dependent, and the delivery of them requires a very-well controlled system for the 
administration of the agents at the effective doses [26]. Thus, seeking alternative 
approaches such as the use of pro-angiogenic cells for the prevascularisation of the tissue 
engineering scaffolds to promote angiogenesis is crucial to circumvent the delayed 
neovascularisation of these constructs [117]. Prevascularisation is based on shortening 
the time required for neovascularisation in the post-implantation period by the 
inosculation of the pre-formed vasculature with the existing vessels of host tissue [7,122]. 
To date, the use of several cell types has been reported in prevascularisation studies. Nor 
et al. prevascularised poly-L-lactic acid (PLLA) scaffolds with HDMECs and showed the 
anastomosis of them with the natural vasculature of mice [501]. Similarly, Unger et al. 
reported that co-culture of HDMECs with osteoblasts induced the migration of the host’s 
blood vessels into developed TE construct [493]. Duttenhoefer et al. showed the 
formation of tubular structures by co-culturing EPCs and mesenchymal stem cells (MSCs) 
in polyurethane scaffolds for 7 days [125]. Hadjizadeh et al. demonstrated the formation 
of a network between two neighbouring fibres when PLLA fibres prevascularised with 
HUVECs were embedded in a fibrin gel and revealed that the presence of fibroblasts was 
seen on top of the fibrin gel [554]. 
Following the determination of the optimal culture conditions for HDMECs, three 
different cell culture systems were investigated in ex-ovo CAM assay in terms of 
improving the angiogenic activity, as a prevascularisation approach. The results of the 
CAM assay revealed that both HDFs and HDMECs either in isolation or when co-cultured 
together significantly increased the angiogenic activity in the area of implantation. 
HDMECs were found to be more effective for stimulating angiogenesis. However, the most 
significant angiogenic response was observed when HDFs were also present in indirect 
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contact with HDMECs. This increase in the angiogenic activity is more likely due to the 
growth factors that are released from cultured ECs in the scaffolds. ECs have previously 
been shown to secrete VEGF [555,556] and bFGF [557] even under normoxic culture 
conditions. In addition, co-culture of ECs with the stromal cells has been shown to 
increase the secretion of more VEGF when compared to mono-cultured cells [558]. 
Similarly, fibroblasts have previously been reported to play a crucial role in the 
angiogenic process by generating ECM molecules such as collagen and fibronectin 
[454,455], growth factors, and pro-angiogenic factors [452,453]. They have previously 
been shown to secrete VEGF, and fibroblast conditioned media has been reported to 
enhance the capillary development of ECs [559]. In vitro generated ECM has also been 
demonstrated to increase the neovascularisation of the implanted constructs to a rat 
animal model, and the researchers hypothesised that this is more likely due to the 
angiogenic factors that are released to and stored in the generated ECM [560].  
The current study reveals essential information about culturing HDMECs in TE constructs 
and about the angiogenic potential of different types of cell culture systems. The 
observations made in this study suggest that gelatin coating and co-culture of HDFs both 
showed a positive impact on HDMECs viability and growth and the physical presence of 
HDMECs and HDFs either in isolation or in co-culture induced angiogenesis in ex-ovo CAM 
assay.  
 Conclusion and Future Work 
A critical issue in the translation of tissue engineering substitutes into the clinic is the 
neovascularisation post-implantation. Here, I compared two biocompatible polymers, 
PHBV and PCL, which are widely used in tissue engineering applications, and selected 
PHBV for the study of prevascularisation in ex-ovo CAM assay. The gelatin coating and co-
culture with HDFs were both found to be practicable to increase the favourability of PHBV 
nanofibres by HDMECs. The results of the CAM assay demonstrated that the presence of 
HDMECs showed a stronger angiogenic reaction than the introduction of HDFs alone, but 
the use of HDMECs and HDFs together gave the most significant angiogenic activity.  
In future studies, investigating the anastomosis of HDMECs with the host vasculature to 
confirm the effectivity of prevascularisation technique might be interesting. In addition, 
the use of patient’s stem cells in this prevascularisation system could also provide more 
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reliable information as the ultimate goal of this technique relies on the use of autologous 
cells and expansion of them on TE constructs to create a prevascularised construct to 
shorten the time required for neovascularisation post-implantation [117,561]. 
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CHAPTER VII 
Development of a bilayer PCL barrier membrane 
for guided bone/tissue regeneration (GBR/GTR) 
applications: combining electrospinning and 
emulsion templating 
 Aims and Objectives 
The aim of this chapter is to develop a bilayer PCL barrier membrane for guided 
bone/tissue regeneration applications by combining electrospinning and emulsion 
templating. In order to satisfy the aim; the objectives of this chapter are to: 
• Manufacture the PCL PolyHIPE layer by emulsion templating 
• Manufacture the PHBV nanofibrous layer by electrospinning 
• Investigate the bone promoting properties of PCL PolyHIPE layer 
• Evaluate the performance of PCL PolyHIPE for supporting blood vessel ingrowth 
using ex-ovo CAM assay  
• Investigate the barrier properties of PHBV electrospun layer 
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 Introduction 
Periodontal regenerative procedures require the use of guided tissue 
regeneration/guided bone regeneration membranes (GTR/GBR) in various conditions 
such as socket preservation, grafting, maxillary sinus elevation and the treatment of the 
chronic periodontitis [562]. The main principle of the GTR/GBR procedure is to place a 
barrier membrane (BM) between epithelial tissue and bone or bone graft to prevent 
migration of the fast-proliferating epithelial cells into the defect site to be able to preserve 
a space for infiltration of bone cells into periodontal defect site [563,564].  
The earliest developed membranes were made of non-resorbable materials such as 
cellulose filters, polytetrafluoroethylene (e-PTFE), and titanium meshes but the necessity 
of a second surgery for removal led to the development of resorbable membranes [565]. 
The most common natural membranes are made of porcine, bovine, or human collagen. 
Despite their high biocompatibility, the main disadvantages of collagen membranes are 
their potential for antigenicity, poor mechanical properties, and rapid degradation 
[566,567]. Alternatively, synthetic polymers such as PGA and PLLA have been commonly 
investigated for the fabrication of BMs. Although they are biodegradable and non-
cytotoxic, their rapid degradation can generate an acid environment around the implant, 
which may cause adverse inflammatory tissue reactions [568,569].  
PCL is another biocompatible and bioresorbable synthetic polymer, which degrades more 
slowly and consequently does not produce an overly acidic environment in the 
degradation process [568]. FDA approved biomedical devices made of PCL are already on 
the market, which makes PCL a promising material for other biomedical applications. 
Additionally, due to its ease of fabrication in different forms, PCL is used as a scaffold 
material for both hard and soft tissue engineering [570]. It has previously been reported 
for various biomedical applications including drug delivery applications [571,572], 
periodontal regeneration [573,574], vascular grafts [575], bone tissue engineering 
applications [576,577], and wound healing [578,579]. One of the main drawbacks of PCL, 
as with many other synthetic polymers is that it is hydrophobic, which limits the polymer-
cell interaction [580,581]. Plasma treatment is one of the most common and effective 
ways to promote hydrophilicity of the polymer surfaces by adding polar groups to the 
surface of the material without altering the bulk properties [460,582–585]. 
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A BM is expected to be in contact with both hard and soft tissues, and it has different 
functions on each side. While being cell occlusive on the side in contact with soft tissue, it 
should encourage bone regeneration on the other side. There many methods used in 
barrier membrane fabrication; such as solvent casting [586,587], electrospinning 
[417,574,588–590], phase inversion, freeze-drying [591,592], and 3D printing [593,594]. 
Electrospinning is a simple, rapid and versatile technique for fabricating fibres with 
varying diameters from a few nanometres to several micrometres from a wide variety of 
materials [595]. PCL is also one of the widely-used polymers that have been electrospun 
for its use in numerous applications [596]. Several solvents and solvent blends have been 
reported to be used to dissolve PCL for preparing the electrospinning solution [597]. 
Although several parameters have been associated with the size of fibres [598], the 
composition and the ratio of solvents have been demonstrated to have a significant effect 
on fibre diameters [599]. As electrospun nanofibers are shown to prevent cell infiltration 
without limiting the diffusion of oxygen and nutrients [22], electrospinning is a promising 
method to manufacture a physical barrier. 
Emulsion templating is another scaffold manufacturing technique where polymer 
solution and water are mixed in the presence of surfactants to form an emulsion. When 
the water droplets are encapsulated in a polymer solution, it is called water in oil (w/o) 
emulsion. If the internal phase volume (water content) is increased over 74% (v/v), the 
emulsion is called a high internal phase emulsion (HIPE) [536,600–602]. After 
solidification of the polymer phase (continuous phase) by thermal curing or photo-curing 
or solvent evaporation, the structure is locked, and water droplets are removed. The 
resulting porous structure is defined as PolyHIPE. PolyHIPEs are favourable as a tissue 
engineering scaffolds because of their highly interconnected porous structures which 
have been previously demonstrated as promoting cell migration and tissue ingrowth 
[424,603–607]. 
Manufacturing of scaffolds made of photocurable PCL by using emulsion templating 
technique is challenging because of the high viscosity of the polymer, which makes it 
difficult to mix two phases during emulsion formation [53–56]. We have recently 
developed and reported a production route of PolyHIPEs made of photocurable PCL and 
showed the biocompatibility of the material by using human dermal fibroblasts [48]. 
However, this developed composition has not been used for any specific application yet, 
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and the use of emulsion templated PolyHIPEs in GBR/GTR barrier membrane 
applications has not previously been reported. 
In this study, we combined two methods; emulsion templating and electrospinning to 
manufacture a bilayer, bioresorbable BM made of polycaprolactone. Emulsion templating 
is selected for manufacturing of the layer, which will be in contact with bone/bone graft. 
250 μm thick PCL PolyHIPE layer was manufactured and treated with air plasma to 
enhance the cellular infiltration. Following the in vitro evaluation of the biological 
performance, the suitability of PCL PolyHIPE morphology for blood vessel infiltration 
through the pores was further investigated using an ex-ovo CAM assay. Electrospinning 
was selected to manufacture the nanofibrous barrier layer. Four different solvent 
compositions were tested in terms of their abilities to enable nanofiber production. The 
biocompatibility and the barrier properties of the electrospun layer were tested over four 
weeks in vitro by histological staining.  
The experimental procedures in this chapter have been conducted in collaboration with 
my co-worker Betül Aldemir Dikici. Betül was responsible for the production of PCL 
PolyHIPE layer including the synthesis of PCL methacrylate, preparation of PCL HIPEs, 
and polymerisation and sectioning of the PCL PolyHIPE layer. She has also conducted the 
experiments about the biological evaluation of PCL PolyHIPE layer. 
 Materials 
Chemical / Reagent 
Catalogue 
Number 
Supplier 
Alexa Fluor® 594 anti-human CD31 Antibody 303126 Biolegend 
Hypermer B246 - Croda 
Acetone 10554634 
Fisher 
Scientific 
Chloroform 10784143 
Dichloromethane (DCM) 10127611 
Dimethylformamide (DMF) 15562393 
DPX mounting medium D/5319/05 
Industrial methylated spirit (IMS) M/4450/17 
Methanol 10626652 
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Toluene 10102740 
Triton X-100 BP151 
Xylene X/0100/17 
Optimum cutting temperature tissue freezing 
medium (OCT-TFM) 
14020108926 
Leica 
Biosystems 
Minimum Essential Alpha Medium (α-MEM) BE02-002F Lonza 
Fertilised chicken eggs - MedEggs 
Hydrochloric acid fuming 37% 100317 Merck 
RCOM King SURO humidified egg incubator MX-SURO P&T Poultry 
EC GM 2 Supplement Pack (for HAECs) C-39211 
PromoCell 
Endothelial Cell Growth Medium 2 (EC GM) (for 
HAECs) 
C-22211 
Human Aortic Endothelial Cells (HAECs) C-12271 
2-deoxy-D-ribose (2dDR) 121649 
Sigma Aldrich 
37% formaldehyde (FA) solution F8775 
4',6-diamidino-2-phenylindole (DAPI) solution  D8417 
AlamarBlue Cell Metabolic Activity Assay R7017 
Alizarin Red S A5533 
Amphotericin B A2942 
Ascorbic acid 2-phosphate (AA2P) A8960 
Beta-glycerolphosphate (βGP) 50020 
Bovine serum albumin (BSA) A7030 
Collagenase A COLLA-RO 
Dimethyl sulphoxide (DMSO) 472301 
Direct Red 80 (Sirius Red) 365548 
Eosin Y solution HT110232 
Ethanol 51976 
Fetal calf serum (FCS) F9565 
Gelatin from porcine skin G1890 
Glutaraldehyde (25%) G5882 
Goat serum G9023 
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Hematoxylin solution HHS16 
L-glutamine G3126 
Methacrylic anhydride (MAA) 276685 
Paraformaldehyde (PFA) 158127 
Penicillin / Streptomycin P0781 
Pentaerythritol (98%) P4755 
Perchloric acid 244252 
Picric acid 197378 
Photoinitiator (PI) (2,4,6-Trimethylbenzoyl 
Phosphine Oxide/2-Hydroxy-2-
Methylpropiophenone blend) 
405663 
Polycaprolactone (PCL) (Mn: 80.000 g/mol) 440744 
Polydimethylsiloxane (PDMS) (SYLGARD®184) 761036 
Tin (II) 2-ethylhexanoate S3252 
Triethylamine (TEA) 471283 
Trypan blue T6146 
Trypsin EDTA T3924 
Vascular endothelial growth factor (VEGF) V7259 
ε-caprolactone 704067 
Alexa Fluor 594 Phalloidin A12381 
ThermoFisher 
Scientific 
 Methods 
 Manufacturing of the PCL PolyHIPE, PCL electrospun, and bilayer membrane 
 Preparation PCL HIPEs 
The PCL used in this study is 4-arm PCL methacrylate (4PCLMA), and the detailed 
synthesis of 4PCLMA (Figure 98A) is described in Section V. 4PCLMA (0.4 g) and the 
surfactant Hypermer (10% w/w of polymer) were added into a glass vial and heated to 
40°C to dissolve surfactant which is crucial for emulsion stability. Solvent blend (150% 
w/w of polymer, 80% chloroform, 20% toluene (w/w)) and PI (10% w/w of polymer) 
were added in the 4PCLMA-surfactant mixture, respectively and mixed at 375 rpm using 
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a magnetic stirrer for 1 minute at RT. Once the homogeneous mixture formed, 2.5 mL of 
water (internal phase volume 85% v/v) was added dropwise in 2 minutes, and the 
emulsion was mixed further 2 minutes, as illustrated in Figure 98B. 
 Optimisation of manufacturing of PCL PolyHIPEs 
The emulsion templating technique was selected due to its ability to manufacture 
scaffolds with interconnected architecture. However, during the polymerisation, the 
material in contact with emulsion has been reported to have a significant effect on 
PolyHIPE morphology [608].  
To find the best manufacturing method in terms of creating interconnected scaffolds, we 
briefly polymerised PCL HIPEs in PDMS moulds, with the upper surface in contact with 
air, glass, and PDMS, and we investigated the morphology of the surface and transverse 
sections with SEM. 
 Manufacturing of PCL PolyHIPE layer 
PCL HIPEs were manufactured by either polymerisation in silicone moulding and 
sectioning of 250 µm samples using a vibratome (Bio-Rad Polaron Division) or syringe 
moulding and sectioning of 1 mm samples using a scalpel. For the fabrication of a bilayer 
BM, 250 µm sections of PCL PolyHIPE were used. 1 mm thick PCL PolyHIPE samples were 
used alone for MLO-A5 cell culture, measurements of their metabolic activity, Alizarin 
Red and Sirius Red staining, histological evaluation of infiltration of MLO-A5s and CAM 
experiments. 
Briefly, PCL HIPE was pipetted into either silicon templates or 2.5 mL syringes (diameter 
of 6 mm) and cured 3 minutes to both sides using a UV belt curer with a 100 W.cm-2 UV 
bulb (Figure 98C). The resulting parts were recovered, soaked in 100% methanol for 24 
hours with four changes to remove any remaining contaminants of surfactant, solvent or 
uncured material. Then the samples were left in methanol (50% (v/v) in water) for 24 
hours and water for a further 24 hours. Finally, the samples were taken out from the 
water and left in the freezer (-80°C) for an hour then transferred into a vacuum oven and 
left for a day to preserve the porous structure of PCL PolyHIPE without any collapse.  
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Figure 98: Summary of the manufacturing process of the bilayer membrane. (A) Synthesis of 4-arm 
hydroxyl-terminated PCL and methacrylate terminalisation reaction (B) PCL PHIPE preparation 
process, (C) the polymerisation of PCL HIPEs to obtain PCL PolyHIPE and slicing the samples, (D) air 
plasma treatment of PCL PolyHIPE, (E) electrospinning of PCL on 250 µm thick PCL PolyHIPE layer, 
(F) Final representation of the bilayer BM 
For the fabrication of bilayer BM, 250 µm sections of PCL PolyHIPE layer were obtained 
using a vibratome (Bio-Rad Polaron Division). For metabolic activity, Alizarin red, Sirius 
red, and CAM experiments, 1 mm sections of dry samples (obtained from syringe 
moulding) were taken using a scalpel, and these monolayer PCL PolyHIPE samples were 
used.  
Air plasma (Diener Electronic, Ebhausen, Germany) was applied on both surfaces of the 
PCL PolyHIPE with a power of 50 W and a pressure of 0.8 mbar for 60 seconds to improve 
cell attachment to the hydrophobic surfaces as demonstrated in our previous work 
(Figure 98D) [609]. 
 Assessment of solvent compositions in terms of their ability to form the 
nanofibrous structure  
Four solvent compositions were investigated in terms of their ability to form the 
nanofibrous structure. PCL (10% (w/w)) pellets were dissolved in acetone (100%), 
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acetone:chloroform (30:70 w/w), DCM:methanol (90:10 w/w), and chloroform:DMF 
(70:30 w/w). The mixtures were magnetically stirred overnight. 
Solutions (~5  mL) were loaded into 5 mL syringes fitted with 0.6 mm inner diameter 
(ID) blunt syringe tips. The syringe was then placed in a syringe pump (GenieTMPlus, 
KentScientific, Connecticut, USA). Aluminium foil was used as the collector and placed at 
a distance of 17 cm from the needle tips. The pump was set to 40 µL/minutes, and 17 kV 
voltage was applied both to the collector and the tips. Solutions of PCL prepared with 
various solvent blends were then electrospun at RT for 40 minutes. 
Single-layer of electrospun PCL (without PolyHIPE layer) manufactured using each 
polymer solutions were morphologically investigated, as explained in Section 3.1.3. In the 
rest of the text, the following nomenclatures are used for electrospinning groups. Acetone 
(100) defines acetone (100%). Acetone:chloroform (30:70) refers to acetone:chloroform 
(30:70 w/w). DCM:methanol (90:10) denotes DCM:methanol (90:10 w/w), and 
chloroform:DMF (70:30) refers to chloroform:DMF (70:30 w/w). 
 Manufacturing of bilayer PCL BM 
The aluminium foil collector was sprayed with methanol, and 250 µm thick sections of 
PCL PolyHIPE layer were placed onto it. This step was performed immediately before 
electrospinning of the PCL barrier layer. Chloroform:DMF (70:30) solvent blend was used 
for the production of PCL electrospun barrier layer as explained in Section 3.1.3. 10% PCL 
solution was loaded into 5 mL syringes fitted with 0.6 mm ID blunt syringe tip. PCL was 
then electrospun onto PCL PolyHIPE layers with a rate of 40 µL/minutes and a voltage of 
17 kV for 40 minutes (Figure 98E, F). 
 Morphological, mechanical and surface characterisation 
 Morphological characterisation 
Micro-architectures of PCL PolyHIPE, PCL electrospun, and bilayer BM were examined 
using a SEM. All samples were gold-coated with a voltage of 15 kV for 2.5 minutes using 
a gold sputter coater (Edwards sputter coater S150B, Crawley, UK) to increase 
conductivity. SEM (FEI Inspect F, Orlando, USA) was used with 10 kV power. 
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SEM images of the PCL fibres and PCL PolyHIPE were analysed for the determination of 
the fibre diameters, pore size distributions, and window size using ImageJ software 
(Bethesda, MD, USA). Total of 54 different fibre diameters and 54 pore sizes were 
measured for each group of PCL electrospun layers, 100 pores and 150 windows were 
measured for PCL PolyHIPE. All measurements were taken from three different areas of 
three different samples. 
 Mechanical characterisation 
The bilayer BM was mechanically tested under dry and wet conditions using a mechanical 
testing unit (BOSE Electroforce Test Instruments, Minnesota, USA) equipped with a 22.5 
N load cell. Briefly, mechanical testing samples were cut into 10 mm x 3 mm pieces and 
clamped to the device with two tensile grips, and the tensile tests were performed on 
each sample at a rate of 0.1 mm/s until the samples failed. Elastic modulus (E), UTS and 
elongation (%) values were calculated from stress (σ) and strain (ε) curves of each 
sample. The elastic modulus was determined as the slope of the initial linear section of 
the curve. UTS was obtained from the curve as the maximum stress that the samples could 
withstand. Ultimate elongation was measured as the percentage elongation of the 
samples at the break. 
 Contact angle measurements 
Contact angle measurements were conducted to evaluate the effect of air plasma 
treatment on the hydrophilicity of PCL PolyHIPE. In brief, a 5 µL water droplet was 
dropped onto the surface of the either non-treated or plasma-treated PCL PolyHIPE, and 
the water contact angles were determined via drop shaper analyser (Krüss DSA100, 
Germany) under ambient laboratory conditions.  
 Assessment of the biological performance of the developed barrier membrane 
 Cell culture of HDFs 
HDFs were isolated from STSGs taken from patients using a well-established protocol 
[484]. Briefly, the dermis was minced into 10 mm2 pieces, and the pieces were incubated 
overnight at 37°C in 0.5% (w/v) collagenase A solution. The cell suspension was then 
centrifuged at 1000 rpm for 5 minutes and resuspended and cultured in DMEM 
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containing 10% (v/v) FBS, 100 IU mL –1 penicillin, 100 µg mL –1 streptomycin, 2mM L-
glutamine and 0.625 μg mL -1 amphotericin B. HDFs were used between passage 4-8. The 
investigations were carried out following the rules of the Declaration of Helsinki of 1975. 
Ethical approval for the tissue acquisition was granted by the National Research Ethics 
Service (NRES) Committee Yorkshire & The Humber–Sheffield (REC ref: 15/YH/0177, 
REC opinion date: 03/06/2015). 
 Seeding of HDFs onto the PCL electrospun layer to confirm the barrier 
properties 
Bilayer BMs were used as test samples to measure the metabolic activity and for 
histological assessment of HDFs. BMs were cut into 10 mm circles using a biopsy punch 
(Stiefel, Slough, UK) and 70% ethanol solution was used as an antiseptic agent for 45 
minutes prior to cell seeding. 2×104 HDFs were trypsinised, centrifuged, and 
resuspended in 100 µL of DMEM growth medium and pipetted on PCL electrospun 
(barrier) side of the bilayer BM. Before submerging the BMs into HDFs culture medium, 
they were incubated at 37°C for 2 hours to allow HDFs to attach. BMs were kept in culture 
for 4 weeks by changing the culture medium every 2 days. 
 Cell culture of murine long bone osteocytes (MLO-A5) 
MLO-A5, murine osteoblast cell line (kindly donated by Dr Lynda Bonewald) was used to 
evaluate the potential of PCL PolyHIPE as GBR membrane as it was previously used for 
evaluation of bone tissue engineering applications [604]. The T75 flasks were coated with 
0.1% gelatin solution for 2 hours at 37°C and washed gently with PBS prior to cell culture. 
Cells were expanded on gelatine-coated T75 flasks in basal media containing α-MEM 
supplemented with 10% fetal bovine serum, 2mM L-glutamine and 100 mg/mL 
penicillin/streptomycin. MLO-A5s cultured until 90% confluence and media was changed 
in every 2-3 days. Cells were used between passages 35-36. 
 MLO-A5 cell seeding onto the PCL PolyHIPE layer 
To be able to test the full infiltration capacity of MLO-A5s through PCL PolyHIPE, 
monolayer, 1 mm PCL PolyHIPE samples (without electrospun layer) were used for 
biological assessment of PCL PolyHIPE. 
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Prior to cell seeding, PCL PolyHIPEs were left in 70% ethanol for 2 hours and then 
transferred into PBS in sterile conditions, 4 washes were applied in 24 hours to replace 
the ethanol with PBS. Finally, they were conditioned with basal media for an hour in the 
incubator in 24 well plates to remove the PBS completely and not to dilute the media used 
during the cell seeding stage with PBS. MLO-A5s were trypsinised, counted, and 
centrifuged. The cell pellet was re-suspended in fresh basal media (2.5 x 104 cells in 20 
µm). The cell suspension was placed over the surface of each PCL PolyHIPE 
homogenously. Before PolyHIPE layers were moved to the fresh wells, and 2 mL basal 
media was supplied into the wells, they were left for 2 hours in the incubator (37.5°C, 5% 
CO2) for cell attachment. 2 mL of media was supplied. A day after, basal media was 
replaced with supplemented media consisting of basal media supplemented with 5 mM 
β-glycerophosphate (βGP) and 50 μg/mL L-Ascorbic Acid 2-phosphate (AA2P). Media 
was changed every 2–3 days. 
 Assessment of metabolic activity of the cells seeded on both layers 
AlamarBlue® assay was performed in order to track the metabolic activities of HDFs on 
the PCL electrospun and MLO-A5s on PCL PolyHIPE. 0.1 mM AlamarBlue® working 
solution was prepared by 10× dilution of the 1 mM AlamarBlue® stock solution with 
growth medium. At days 1, 7, 14, 21, and 28 growth media were removed, and the 
samples were washed with PBS. 1 mL of AlamarBlue® working solution was added to 
each well and incubated at 37°C for 4 hours. After an incubation period, 200 µL of the 
solution was transferred into 96-well plate, and the fluorescence readings were done at 
an excitation wavelength of 540 nm and an emission wavelength of 635 nm. Fresh 
samples were used for the measurements at each time point. 
 Assessment of calcium deposition of MLO-A5s 
Alizarin red powder was dissolved in deionized water at 1 w/v% in a water bath and 
filtered to remove particles to make Alizarin red solution (ARS). PCL PolyHIPEs were 
submerged in 1 mL of ARS solution and incubated for 1 hour. ARS solution was removed, 
and the samples were washed every five minutes with deionized water and gentle orbital 
shaking until the water remains clear. They were submerged with 1 mL of 5% perchloric 
acid to destain and left for further 30 minutes with gentle orbital shaking. 150 μL of the 
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destain solution in triplicates were transferred into a clear 96 well plate and read at an 
absorbance of 405 nm. 
 Assessment of collagen deposition of MLO-A5s 
Sirius red (direct 80) powder was dissolved in saturated picric acid (1 w/v%) to form 
Sirius red solution (SRS) and filtered to ensure no particles remain. PCL PolyHIPE’s were 
submerged with 1 mL of SRS solution and left for 1 hour. SRS solution was removed, and 
the samples were washed every five minutes with deionized water and gentle orbital 
shaking until the water remains clear. They were submerged with 1 mL of 0.2 M sodium 
hydroxide (NaOH):methanol (1:1) to destain and left for 30 minutes with gentle orbital 
shaking. 150 μL of the destain solution in triplicates were transferred into a clear 96 well 
plate and read at an absorbance of 405 nm. 
 Haematoxylin & Eosin (H&E) and Alizarin red staining 
Bilayer BM and PCL PolyHIPE cultured with HDFs and MLO-A5s, respectively for 1-week 
and 4-week, and PCL PolyHIPE on CAM were stained with H&E using a standard protocol 
[358]. Briefly, samples were washed with PBS before (once) and after (three times) fixing 
them in 3.7% FA for 30 minutes at RT. Meanwhile, cryomoulds were filled with OCT-TFM. 
Samples were embedded into it, and the rest of the volume was then filled with OCT-TFM 
to the top. Cryomoulds were placed into liquid nitrogen and incubated for 5-7 minutes 
until solidified. Frozen blocks were fixed on mounting platforms, and placed into a 
cryostat (Leica CM1860 UV, Milton Keynes, UK) before sections were sliced at 5-10 µm 
and immediately mounted onto the surface of Thermo SuperFrost® Plus slides. For H&E 
staining, slides were stained with hematoxylin for 90 seconds and eosin for 5 minutes. 
For calcium staining, slides were stained with 2% (w/v, in water) ARS for 5 minutes. 
Excess dye is shaken off, and the slides were rinsed, dehydrated, cleared and mounted 
the slide using the permanent mounting medium. 
 Preparation of biological samples for SEM 
The protocol for the preparation of biological samples for SEM has previously been 
summarised in Table 19. On day 28, the PCL PolyHIPE discs seeded with MLO-A5s were 
washed 3 times with PBS and fixed with 2.5% glutaraldehyde at RT for 1 hour and rinsed 
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with PBS. Then the discs were soaked in deionised water for 5 minutes prior to 
dehydration of the samples with serial ethanol washes. Finally, HMDS is used as the 
chemical drying agent, and the discs were soaked in HMDS:ethanol (1:1) solution for 1 
hour and transferred into 100% HMDS for 5 minutes. The samples were then air-dried 
overnight in a fume hood and gold-coated at a current of 15 mA for 2.5 minutes with a 
gold sputter (Edwards sputter coater S150B, Crawley, England) prior to imaging under 
SEM (FEI Inspect F, Orlando, USA). 
 Fluorescent staining 
At days 7 and 28, PCL PolyHIPE discs were fixed with 3.7% FA for 30 minutes and washed 
gently with PBS prior to submerging into 0.1% (v/v) Triton X 100 (in PBS) solution for 
20 minutes. After serial PBS washes, phalloidin-TRITC (1:500 diluted in PBS from stock 
solution) solution was added onto samples to visualize F-actin filaments of the cells and 
incubated for 30 minutes at RT in the dark. Discs were washed 3 times with PBS. To stain 
the cell nuclei, DAPI solution (1:1000 diluted in PBS) was added onto the PolyHIPE discs 
and incubated for 10-15 minutes at RT in the dark; samples were then washed 3 times 
with PBS and imaged under a fluorescent microscope (Olympus IX3, Tokyo, Japan). 
 Ex-ovo CAM assay 
An ex-ovo CAM assay was used to evaluate the potential of PCL PolyHIPE layer for the 
suitability of blood vessel ingrowth, as described previously [89,241]. Briefly, fertilised 
chicken eggs (Gallus Domesticus) were purchased from Henry Stewart & Co. MedEggs 
(Norwich, UK) and cleaned with 20% IMS solution. Eggs were incubated at 37.5°C for 
3 days in an egg incubator (RCOM King SURO, P&T Poultry, Powys, Wales). At the end of 
day 3, the embryos were transferred gently into sterile Petri dishes and incubated at 38°C 
in a humidified cell culture incubator (Binder, Tuttlingen, Germany). On day 7, PCL 
PolyHIPE discs were implanted to CAM, and the chicks were incubated for further 7 days. 
On day 14, the chicks were euthanised, and the CAMs with the PolyHIPE discs integrated 
to them were removed and fixed in 3.7% FA solution. Sections of the CAMs were taken 
and stained with H&E as described previously. 
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 Statistical analysis 
Statistical analysis was carried out using one-way and two-way analysis of variance 
(ANOVA) using statistical analysis software (GraphPad Prism, California, USA). Where 
relevant, n values are given in figure captions. Error bars indicate standard deviations in 
the graphs unless otherwise stated. 
 Results and Discussion 
 Manufacturing and characterisation of the PCL PolyHIPE layer 
The surface of PCL PolyHIPEs polymerised in contact with air, glass, or PDMS showed 
different morphologies (Figure 99A-C). When the surface was not covered by any 
substrate, and UV was directly applied on PCL HIPEs, the surface was porous, but it did 
not have open interconnected cellular morphology (Figure 99A). When the surface of the 
HIPE was in contact with glass, the surface showed microscale roughness, rather than 
pores (Figure 99B). In terms of interconnectivity, the best surface morphology was 
obtained when the PDMS sheet was used as a cover. PCL PolyHIPE surfaces created this 
way had a mixture of open and closed porous morphology (Figure 99C).  
The significant influence of the mould material on PolyHIPE has been reported previously 
[608]. This study correlated the surface interconnectivity with the following potential 
scenarios on the PolyHIPE-mould interface; (i) PolyHIPE can potentially bind to mould 
surface leading to difficulties in demoulding, (ii) the mould can leach materials leading to 
contamination of the PolyHIPE surface, and (iii) partial phase separation of the emulsion 
which leads to closed-pore PolyHIPE surfaces. 
Figure 99D shows the transverse section of PCL PolyHIPE. It has a homogenous, open 
cellular architecture with interconnected porosity. Pore interconnects are pathways for 
cells, waste and nutrients, the interconnectivity of the scaffold is a crucial feature for cell 
invasion, tissue integration and vascularisation [610–613]. To be able to benefit from the 
interconnected inner morphology of the scaffolds, the PCL PolyHIPE layer was decided to 
be created by sectioning bulk pieces into slices as described in Section 3.1.4. 
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Figure 99: SEM images of the top surfaces PCL PolyHIPEs cured in contact with; (A) air, (B) glass, 
and (C) PDMS sheet. (D) SEM image of the transverse section of PCL PolyHIPEs. (E) Pore size and 
window size distributions of the inner section. (F) Contact angle measurements of a water droplet 
on PCL PolyHIPE before and after air plasma treatment (n=3) 
The pore sizes of the PCL PolyHIPE layer were distributed between 10-78 µm; the 
average pore size (D) was found 34±13 µm, 90% of the pores have the pore sizes between 
20-75 µm range (Figure 99E). The window sizes were distributed between 2-13 µm 
range, and the average window size (d) was measured as 6±2 µm (Figure 99E), which 
gives the degree of connectivity (d/D) as 0.18. In our previous study, when the same 
solvent composition was used to dilute PCL (80:20 chloroform:toluene (w/w)) the 
average pore size and the window size was found 20±7 µm and 4±2, respectively [424]. 
The difference between the pore and window size found in the previous study and the 
current work can be explained with the two main compositional changes; (i) increasing 
the internal phase volume from 82% to 85%, and (ii) increasing the total solvent volume 
from 0.40 mL to 0.46 mL. A higher internal phase volume is expected to reduce the 
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average pore size while increasing the average window diameter as water droplets will 
need to be more tightly packed. On the other side, the increasing solvent amount is 
expected to show a dramatic increase in the average pore diameter [614]. The overall 
effect of these two compositional changes resulted in approximately 50% increase in 
average pore size and window diameter. 
Oxidising the surface by plasma treatment is one of the most popular methods for 
enhancing cell attachment [609,615–619]. In this study, our finding also proved that air 
plasma treatment changes the surfaces from hydrophobic to hydrophilic and this change 
encourages the cell attachment and cellular infiltration on PCL PolyHIPE layer which will 
be further discussed following sections. Contact angles of the water droplets on non-
treated (P-) and air plasma treated (P+) PCL PolyHIPEs were measured as 67±4° and 
96±4°, respectively (Figure 99F). 
 Assessment of the metabolic activity of MLO-A5s on PCL PolyHIPE and the cellular 
infiltration through PCL PolyHIPE layer 
At all-time points, the metabolic activity of MLO-A5s cultured on P+ PCL PolyHIPEs was 
slightly higher than MLO-A5s cultured on P- PCL PolyHIPEs, but there was no statistical 
difference observed between these two groups (Figure 100A). Metabolic activities of 
MLO-A5s on both P+ and P- PCL PolyHIPEs increase from day 1 to day 28 gradually, but 
the dramatic decrease was observed in the metabolic activity of the MLO-A5s on TCP after 
day 7 which is also discussed in Section 4.4. 
Figure 99B and 99C clearly show the positive impact of air plasma treatment of PCL 
PolyHIPE on the attachment of MLO-A5s to the surface at day 28. While the layer of MLO-
A5s is peeled off from the surface of P- PCL PolyHIPE, cells on P+ PCL PolyHIPE are still 
integrated with the PolyHIPE layer. The preparation steps of the biological samples for 
SEM includes multiple washing steps and drying (Section 3.3.9). The loosely attached cell 
layer detached from P- PCL PolyHIPE at the end of all these steps, probably due to limited 
cell penetration into the pores. 
Although air plasma treatment seems as it has not had a significant effect on the metabolic 
activity of MLO-A5s, H&E and fluorescent images support the finding from SEM images, 
and they show that air plasma treatment has a huge impact on cell infiltration (Figure 
100D, E). At week 1, while MLO-A5s only accumulated on the surface of the P- PCL 
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PolyHIPE with nearly no infiltration, they were observed as migrating through the pores 
the P+ PCL PolyHIPE.  
Even during the seeding of the MLO-A5s on the PCL PolyHIPE layer, the positive effect of 
plasma treatment was observed. Once the cell suspension was placed on the top of the 
PCL PolyHIPE, it immediately absorbed by P+ PolyHIPE but stayed as a droplet on the 
P- layer. This indicates that even from the cell-seeding stage onwards, plasma treatment 
encourages cells to migrate into the pores of the PCL PolyHIPE layer. Although MLO-A5s 
tend to densely accumulate on the top of both PCL PolyHIPEs at week 4, cell migration up 
to 400 µm was observed on P+ PolyHIPEs. This positive influence of air plasma treatment 
on polymer scaffold has also been demonstrated in vivo. Valence et al. had reported 
improvement of cell attachment and infiltration within a vascular graft upon plasma 
treatment when materials were implanted subcutaneously [585]. 
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Figure 100: (A) Metabolic activity of MLO-A5s cultured on P-, P+ PCL PolyHIPEs, and TCP for 4 
weeks. SEM images of the top surfaces of (B) P+ and (C) P- PCL PolyHIPEs cultured MLO-A5s on for 
4 weeks (Scale bar represents 500 µm). (D) H&E and Alizarin Red, and (E) Fluorescent staining of 
MLO-A5s cultured on P+ and P- PCL PolyHIPEs for 1 week and 4 weeks (Scale bar represents 250 
µm, blue: DAPI, red: Phalloidin TRITC) 
Interestingly, on H&E slides, very small-sized haematoxylin-stained particles (different 
than haematoxylin stained cells) were observed only at week 4 at both P+ and P- PCL 
PolyHIPEs (Figure 100D). Fluorescent staining shows that they are not cells. It has been 
previously reported that haematoxylin selectivity stains calcium-containing particles 
[620]. Alizarin red staining images shows densely accumulated calcium on the top of P- 
PCL PolyHIPE and comparably less dense stains in deeper pores, while there is dense 
calcium deposition P+ PCL PolyHIPE up to 400 µm deep (Figure 100D). 
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 Assessment of the extracellular matrix (ECM) deposition of MLO-A5s on PCL 
PolyHIPE layer 
As MLO-A5s cultured in supplemented media, they were expected to deposit calcified 
ECM [604,621,622]. Prideaux et al. previously reported that supplementation of MLO-A5 
cell cultures with AA2P and βGP showed a significant increase in ECM mineralisation 
compared to the non-supplemented group [14]. 
Calcium and collagen deposition on P+ PCL PolyHIPE gradually increased from day 7 to 
day 28 (All subsequent studies were conducted on P+ PCL PolyHIPE only). ECM 
deposition, mineral nodules, and collagen fibres of MLO-A5s cultured on PCL PolyHIPE 
layer for 4 weeks are shown in Figure 101B. An SEM image of the cross-section of the PCL 
PolyHIPE shows the pores densely filled with cells and extracellular material (Figure 
101C). Additionally, sub-micrometric crystalline debris was observed in regions beyond 
the maximum cell ingrowth (Figure 101D, E), these indicate the existence of calcium 
deposits deep within the PolyHIPE layer, as also observed in on H&E and Alizarin red 
images. 
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Figure 101: (A) Assessment of calcium and collagen deposition of MLO-A5s after 7, 14, 21 and 28-
day culture on PCL PolyHIPE by using Alizarin Red and Sirius Red, respectively. (B) Surface (C, D, E) 
cross-section of PCL PolyHIPE cultured with MLO-A5s for 28 days in supplemented media 
These calcium deposits look similar to surfaces of PolyHIPE layer incubated in simulated 
body fluid, which is commonly used to test the ability of the formation of bone-like apatite 
or mineral deposition on scaffolds [623–625]. The source and mechanism of the 
formation of the deposited calcium-containing crystals will be investigated in future 
studies. 
 Assessment of the performance of PCL PolyHIPE for supporting blood vessel 
ingrowth using ex-ovo CAM assay  
The CAM assay is a well-established assay for the assessment of angiogenesis and initial 
response to biomaterials [89,241,480]. In an ex-ovo CAM assay, the embryos are 
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transferred into petri dish on day 3 (Figure 102A) and incubated until day 7 (Figure 
102B) which is the day of material implantation. At day 14, the following features can be 
assessed macroscopically (Figure 102C) and histologically (Figure 102D): (i) 
biocompatibility, (ii) cellular infiltration capacity and (iii) the performance of the PCL 
PolyHIPE layer for supporting vascularisation.  
Our laboratory has reported the average survival rate for the ex-ovo CAM assay as 68% 
for intermediate and 83% for experienced users [241]. The survival rate of the chicks was 
approximately 75% and 73% for non-implanted, and PCL PolyHIPE implanted groups, 
respectively, in line with previous investigations. Thus, the PCL PolyHIPE showed good 
biocompatibility, and the implantation of the material did not affect the survival rate of 
the chicks.  
The integration of the CAM tissue into PCL PolyHIPE was examined. Extensive cell 
infiltration was observed from the CAM tissue to PCL PolyHIPE, showing complete 
integration of the material with the membrane. During the isolation of the PCL PolyHIPE 
from the CAM, it was not possible to separate it from the CAM, which is also an indication 
of strong integration. This is in line with studies reported by other groups on the good-
integration of PCL porous scaffolds with CAM [626–628]. The infiltration capacity of the 
cells into PCL PolyHIPE was better in the ex-ovo CAM assay (Figure 102D) when 
compared with the in vitro histology data (Figure 100D). This is potentially due to the 
continuous contact of the PCL PolyHIPE with a dense and dynamic cell population in the 
CAM.  
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Figure 102: Chick embryos in a petri dish on (A) embryonic development day 3 and (B) embryonic 
development day 7 (Scale bar represents 10 mm). (C) PCL PolyHIPE on CAM at day 14 (Scale bar 
represents 2 mm). (D) H&E images of PCL PolyHIPE on CAM at day 14. (Green arrow indicates the 
blood vessel on CAM itself; yellow arrows indicate the blood vessels in PCL PolyHIPE. Scale bar 
represents 100 µm) 
Assessment of the PolyHIPE material on the CAM demonstrated that the structure and 
the pore size of the PolyHIPE were suitable for supporting blood vessel ingrowth through 
the PolyHIPE. H&E staining shows that alongside the high level of integration of the host 
CAM tissue with the PolyHIPE layer, many blood vessels were found growing into the 
pores of PCL PolyHIPE and through the interconnections (Figure 102D) in only 7 days.  
Current understanding of vascularisation of porous scaffolds indicates that the pore size 
should be at least 250 µm for vascularisation to occur [24,26], but some studies suggest 
smaller pore sizes can also allow for the ingrowth of blood vessels. Madden et al. have 
shown that 30-40 µm pore size with 15 µm interconnects are suitable for vascularisation 
in rats [629]. Similarly, Baker et al. reported that particulate-leached PCL scaffolds with 
5-200 µm pore range allowed extensive vascularisation in the scaffold when implanted 
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subcutaneously into rats [630]. Klenke et al. observed vascularisation in ceramic particles 
with macropores ranged from 40 to 280 μm [631]. Finally, our group has demonstrated 
the vascularisation of polylactic acid electrospun scaffolds with a mean pore size of 4.25 
µm in the CAM assay [69]. 
By using the CAM assay, we have shown the performance of the developed BM for 
supporting tissue integration and vascularisation. Both are critical factors in avoiding 
delay in osteogenesis and tissue regeneration and overcoming the rejection of an implant 
[632,633]. 
 Assessment of solvent compositions in terms of their ability to form the 
nanofibrous structure 
The mean diameters of the PCL fibres where polymer solutions were prepared with 
different solvents were 0.35 ± 0.10 µm, 0.74 ± 0.32 µm, 1.69 ± 0.75 µm, and 0.47 ± 0.22 
µm, and the average pore sizes were 6.28 ± 2.30 µm, 8.34 ± 4.96 µm, 9.84 ± 5.25 µm, and 
3.57 ± 2.08 µm for acetone (100), acetone:chloroform (30:70), DCM:methanol (90:10), 
and chloroform:DMF (70:30) groups, respectively (Figure 103). 
Except for the acetone (100) group, a decrease in the pore sizes was observed when the 
diameter of the PCL fibres gets smaller. Although the acetone (100) led to the formation 
of the smallest diameter PCL fibres, the smallest pore size was calculated for the 
electrospun layer prepared with chloroform:DMF (70:30). 
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Figure 103: Morphological characterisation of the electrospun PCL fibres, where polymer solutions 
were prepared with different solvents. SEM image of PCL electrospun prepared by dissolving PCL in 
(A) acetone (100), (B) acetone:chloroform (30:70), (C) DCM:methanol (90:10), (D) chloroform:DMF 
(70:30). The graphs show (E) the fibre diameter and (F) the pore size distributions, respectively. 
Yellow scale bars represent 20 µm 
When acetone was used as the sole solvent, it was difficult to electrospin the solution, and 
bead formation occurred. The undesirable bead formation during electrospinning is 
likely to increase pore size between the fibres [634]. One of the main reason for the 
formation of thinner fibres and beads has been reported as the lower viscosity of the 
electrospinning solution [635]. It has previously been shown that among the five solvents 
used in this study, acetone has the lowest viscosity [636]. Zverev et al. reported that the 
viscosity of the polymer solution changes with the solubility, and low viscosity is linked 
with poor solubility when other parameters kept constant [637]. 
The electrospinnability of the PCL solutions from high to low was: chloroform:DMF 
(70:30) > acetone:chloroform (30:70) > acetone (100) > DCM:methanol (90:10). The 
quality of the PCL electrospinning was assessed based on smooth fibre formation, bead 
or particle formation and continuous electrospinning of the solution, which depend on 
parameters such as solubility, viscosity, dielectric constant, and conductivity [638]. 
The solubility of the polymer in a solvent has a major effect on electrospinning 
nanofibres. DCM, methanol, chloroform, DMF and acetone (as single solvents or solvent 
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blends) are common solvents for dissolving PCL and widely used for the production of 
PCL fibres with electrospinning [597,639]. Among these solvents, PCL has a higher 
solubility in chloroform and DCM, whereas the solubility of PCL is poor in DMF, acetone, 
and methanol [640].  
When acetone was used as the single solvent to dissolve PCL, the solution resulted in poor 
electrospinnability and the formation of undesired beads during the electrospinning 
process. Using the acetone:chloroform (30:70) solvent blend significantly increased the 
electrospinnability of PCL, which can be explained by the addition of chloroform to the 
solvent mixture, in which PCL has higher solubility [641]. The ability to electrospin PCL 
dissolved in DCM:methanol (90:10) was very poor, and we did not manage to obtain 
nanofibers when this solvent used for electrospinning. This can be explained by the low 
dielectric constant and conductivity of the main solvent, DCM, in the solvent blend [642]. 
The best solvent blend for electrospinning PCL nanofibers was chloroform:DMF (70:30) 
solvent composition used. Although DMF is not classified as a good solvent for PCL, it has 
a high dielectric constant and, it is a polyelectrolyte [643]. Due et al. previously reported 
that the addition of DMF to the solvent blend improves the electrospinnability of PCL and 
leads to smaller diameter fibre formation. [644]. Kanani et al. had shown that when DMF 
was added to methylene chloride, and the solvent mixture used for electrospinning PCL, 
the spinning process was improved, and uniform nanofibers were obtained [599]. Hsu et 
al. demonstrated a reduction in the diameter of electrospun PCL fibres with the addition 
of DMF to chloroform [645]. Bolgen et al. observed a dramatic decrease in diameter (from 
1300 nm to 300 nm) when DMF was included in the solvent mixture up to 40% [646]. 
In this study, the chloroform:DMF (70:30) solvent blend was selected for the 
manufacturing of nanofibrous barrier layer due to multiple factors including the 
improved electrospinnability, the decreased fibre diameter, and the smaller pore size. 
 Manufacturing and characterisation of the PCL bilayer barrier membrane 
Following the optimisations of manufacturing of PCL electrospun and PCL PolyHIPE 
layers, two layers were combined to fabricate the bilayer BM (Figure 104A-D). The 
complete integration of both layers can be seen from SEM images. This is more likely due 
to the fact that both polymers are PCL, and the solvent composition used for 
electrospinning PCL can partially dissolve the surface of the PCL PolyHIPE layer. No 
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delamination of the two layers was observed, and the BM preserved its integrity during 
the experiments.  
Figure 104E-J shows the handling ability of the PCL bilayer BM. The resulting BM was 
very flexible and allowed manual handling, including bending and twisting without losing 
its structural integrity. Figure 104I shows the space making ability of the BM, which is 
defined as the ability to maintain a space for cells without any collapse. 
For this study, the thicknesses of the PCL electrospun and PCL PolyHIPE layers were 
determined as 200 µm and 250 µm, respectively. The thicknesses of the PCL electrospun 
and PCL PolyHIPE layers can be controlled easily by changing the electrospinning time 
and slicing thickness, respectively. To show the controllability of the thickness of the PCL 
electrospun layer, Figure 104B shows a bilayer membrane with a low thickness where 
PCL was electrospun on PolyHIPE for 20 minutes instead of 40 minutes. Thicker 
membranes are assumed to have better barrier performances in addition to higher 
mechanical strength [647] and a longer degradation time and which results in the GTR 
membrane being present during a longer time period [648]. The question of the optimum 
barrier membrane thickness can be answered to some extent, experimentally in vitro, but 
ideally, it needs to be investigated in vivo in future studies. Here, the tunability of the 
thickness of individual layers is an advantage in our manufacturing method as we can 
provide BMs of varying thicknesses for comparative evaluation of performance and rate 
of breakdown in vivo.  
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Figure 104: SEM images of (A) 250 µm sectioned PCL PolyHIPE layer, (B) 20 minutes PCL 
electrospun on PCL PolyHIPE, (C) 40 minutes PCL electrospun on PCL PolyHIPE, (D) Higher 
magnification SEM image showing the border of two layers. Macro images of the bilayer PCL BM to 
show the suitability of the design for (E-F) stretching in different axes, (G-H) bending, (I) space 
making, and (J) side view of the BM to show the integration of the two layers 
Tensile tests of the BMs were conducted on both dry and wet conditions. Biomedical 
implants are usually in contact with body fluids, which significantly influences their 
performance in comparison with their dry state. The mechanical behaviour of an implant 
under wet conditions is important for better representing the in vivo conditions [649].  
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Both the E and UTS values of dry BMs were significantly higher compared with the wet 
BM samples. But there was not any statistically significant difference between the 
elongation of the BMs in dry and wet state (Figure 105).  
The UTS of the BM s were measured as 137.3±6.7 KPa and 75.0±4.2 KPa for dry and wet 
samples, respectively. The elastic modulus and elongation of dry and wet BMs are 
452.1±24.5 KPa and 304.2±12.9 KPa; and 79.3 ± 3.5% and 83.2 ± 2.1%, respectively.  
 
Figure 105: Mechanical properties of the BM under dry and wet conditions. (A) Representative 
stress-strain curves, (B) Elastic modulus, (C) UTS of the BMs under dry and wet conditions (*** p ≤ 
0.001, ns p ≥ 0.05, n = 3) 
The mechanical properties of the developed membrane show similarities with other 
developed membranes in literature. Lee et al. reported tensile strength of commercial 
collagen membrane (Ossix plus) around 110 KPa and 20 KPa for the dry and wet state, 
respectively [647]. Poly(lactic-co-glycolic acid) (PLGA) membrane fabricated with 
freezing and lyophilisation has been reported to have similar UTS with our BM where the 
elongation of the PLGA membrane was approximately eight times lower [650]. Similarly, 
the tensile strength of the freeze gelated chitosan membrane has been demonstrated 
approximately four times and ten times lower, respectively under dry and wet conditions 
when compared with the developed BM in this study [592]. Electrospun chitosan 
membrane with random fibre orientation has been shown to have slightly higher UTS in 
wet state, but at the same time, it was approximately ten times less elastic than our BM, 
and the elongation was almost six times lower [651]. Another study has revealed that the 
polysaccharide/bioactive glass membrane produced using the layer by layer deposition 
technique has very similar mechanical properties in terms of UTS and E values with our 
BM [652]. 
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 Assessment of the metabolic activity of HDFs on PCL electrospun layer and the 
ability of the PCL electrospun layer to act as a cell barrier 
The metabolic activities of HDFs growing on the PCL electrospun layer gradually 
increased from day 1 to 28 (Figure 106) showing the biocompatibility of the bilayer PCL 
membrane. Although the metabolic activities of the HDFs growing on TCP were higher at 
each time point, they started to drop after day 14. This decrease is more likely to be due 
to contact inhibition of proliferation. Two dimensional structure of TCP may restrict the 
capacity of cells to expand further [653]. 
Histological analysis of the PCL electrospun layer showed that HDFs were not able to 
penetrate due to the small pore sizes of nanofibrous random PCL fibres. Instead, they 
were observed as growing on the surface of the electrospun barrier layer and not 
migrating towards the PolyHIPE layer (Figure 106) confirming the cell-occlusiveness 
properties of the electrospun PCL layer. Randomly orientated nanofibrous scaffolds have 
been demonstrated as a physical barrier to cell penetration while allowing the diffusion 
of nutrients. Previous work from our laboratory has shown that keratinocytes and 
fibroblasts were successfully segregated when separated by a nanofibrous Poly(3-
hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) layer [417]. Similarly, Vaquette et al. 
showed that fibroblasts seeded on a random fibre mat did not penetrate the scaffold and 
colonized on the surface and formed a 30 µm thick cell sheet [654].  
 
Figure 106: Evaluation of the biocompatibility and the barrier properties of the bilayer BM. The 
metabolic activity of the HDFs growing on PCL electrospun layer from day 1 to day 28 is given in the 
graph (*** and ΦΦΦ p ≤ 0.001, ** and ΦΦ p ≤ 0.01, * and Φ p ≤ 0.05, n = 3). Histological images 
demonstrate the barrier properties of the PCL electrospun layer over 4 weeks. ε and ρ indicate the 
electrospun layer and PCL PolyHIPE layer, respectively. Dotted line indicates the boundary of the 
two layers (Scale bar represents 200 µm) 
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As the crucial time for epithelial invasion has been reported as the first 14 days of 
implantation, then the barrier function limiting the epithelial invasion up to 14 days is 
considered sufficient for GBR applications [655,656]. 
 Conclusions and Future Work 
In the present study, a bilayer BM made of a biodegradable synthetic polymer, PCL was 
successfully fabricated by combining electrospinning and with emulsion templating. The 
resulting BM showed no delamination, and its structure was qualitatively resilient to 
torsion and stretching, and it was straightforward to handle. The electrospun layer of the 
BM has been confirmed for its barrier features for the prevention of soft tissue invasion 
whereas the interconnected PCL PolyHIPE layer has shown potential for use as the bone 
promoting layer providing the key requirements such as cell compatibility, supporting 
cellular infiltration, and promoting collagen and mineral deposition. Furthermore, the 
pore structure of the PCL PolyHIPE layer has been found to be suitable for blood vessel 
ingrowth. In conclusion, by combining two methods of fabricating an FDA approved 
polymer, PCL, a bilayer BM that is a good candidate for a diverse range of GTR 
applications can be fabricated.  
In future, studies could focus on culture of both cell types together to see the effect of cell-
cell interaction on the behaviour of both cells. The in vitro results were very encouraging 
for further assessments of the BM. Thus the assessment of the in vivo performance of the 
BM could be really interesting and might potentially reveal the potential of the developed 
BM to be used in the clinic.  
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CHAPTER VIII 
Overall Discussion and Future Perspectives 
As laboratory production of TE materials has progressed to the clinic, it has become clear 
that one of the critical barriers to their success is the need to achieve rapid 
neovascularisation post-implantation. While relatively thin simple TE constructs can 
survive on well-vascularised wound beds, thicker constructs (>200 µm) usually fail to 
engraft due to lack of oxygen and nutrients in vivo [22,24]. Thus, rapid ingrowth and 
infiltration of blood vessels are crucial for biomaterials to be able to survive in vivo [360].  
Prevascularisation, the use of pro-angiogenic cells, and scaffold functionalisation, the use 
of pro-angiogenic agents, are viewed as promising approaches to accelerate vascular 
ingrowth into tissue engineering (TE) constructs to circumvent slow vascularisation after 
implantation [37,326]. 
When it comes to scaffold functionalisation, VEGF is a crucial pro-angiogenic factor that 
plays a key role in promoting angiogenesis [38]. ECs are known to be sensitive to VEGF 
signalling, which regulates proliferation, migration and their survival [41,361]. Although 
VEGF is accepted as the gold standard for promoting angiogenesis, the exogenous use of 
VEGF can promote the formation of leaky [362], permeable [335] and haemorrhagic 
[336] vessels when administered in an uncontrolled manner. Thus, the need for 
alternative pro-angiogenic drugs to promote neovascularisation is clear.  
2dDR is a promising alternative which has been reported to have chemotactic and 
angiogenic activity by our group and other researchers using current angiogenic assays; 
Boyden chamber assay [83], tube formation assay [83], CAM assay [81,89] and rat wound 
healing models [87,90]. However, the dose-dependent response of 2dDR still remained 
to be investigated in vitro to learn what is the effective concentration range to drive 
angiogenesis at the cellular level. 
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In Chapter II, I demonstrated the angiogenic potential of 2dDR and defined its effective 
concentration ranges in vitro and in vivo. The in vitro assessment of the angiogenic activity 
of 2dDR showed it to be dose-dependent reproducing all of the actions of VEGF with 2dDR 
stimulating proliferation, migration and tube formation of HAECs when used at 100 µM 
and 1 mM concentrations. Lower concentrations (1 µM) were not found effective and 
higher concentrations (10 mM) led the death of HAECs by day 4. The comparison of 2dDR 
with 2dLR, 2dDG and DG evidenced that none of the other small sugar molecules 
increased the activity of HAECs in vitro. Instead, 2dDG (when administered at 100 µM, 1 
mM and 10 mM) and 2dLR (when used at 10 mM) showed an anti-angiogenic effect on 
HAECs proliferation. Our results were in concordance with the literature. The anti-
angiogenic impact of 2dDG [365,366] and 2dLR [83,86] have previously been reported 
by several groups, mostly focusing their potential applications on the inhibition of 
tumour angiogenesis. Following the in vitro assessment of 2dDR, I explored that if it is 
possible to define certain concentrations of 2dDR which are as effective as VEGF in 
stimulating angiogenesis in ex-ovo CAM assay. To date, there have been no studies 
conducted on the effective angiogenic dose range of 2dDR, which is proangiogenic in vivo. 
Therefore, for the first time in this study, I demonstrated the reliable concentration 
ranges for 2dDR for stimulating angiogenesis in CAM assay and compared their 
proangiogenic activities with the E2 and VEGF as positive controls. The results of the CAM 
assay confirmed the dose-dependent angiogenic response of 2dDR, and 
200μg/day/embryo was at least 80% as effective as VEGF when given as solution for 
inducing angiogenesis in vivo. Higher and lower doses of the drugs showed less 
angiogenic activity in the CAM assay. Following the determination of the effective dose 
range, 2dDR was loaded into electrospun PHBV fibres to stimulate angiogenesis with the 
release of it in CAM assay over 7 days. PHBV is a natural, biocompatible and 
biodegradable biopolymer [367]. Although the biodegradability of PHBV is relatively 
slow when compared to PLA [368], it is still an attractive material for drug release studies 
because of its excellent biocompatibility, biodegradability, easy processing properties 
[369]. 
Incorporation of 2dDR into the PHBV scaffolds resulted in increased activity on CAM by 
the release of the agent from fibres. This study established an effective concentration 
range of 2dDR (250mg/g of PHBV) to be loaded into scaffolds to achieve a reliable 
stimulation of neovascularisation over 7 days. Higher doses of 2dDR were found to be 
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less effective in promoting the angiogenesis in ex-ovo CAM assay. These results were 
further confirmed with the histologically stained sections of the scaffolds. In these, more 
blood vessels were counted adjacent to 2dDR releasing scaffolds. However, in contrast to 
the results from the quantified macro images, in histological analysis, the number of 
blood vessels adjacent to the scaffolds loaded with the higher dose of 2dDR (2dDR 500) 
were not significantly but slightly greater than the lower dose. This differential result 
might be caused by our ability to see and count the smaller diameter blood vessels that 
may not be discernible in the digital CAM analysis used for quantification. Additionally, 
the histological sections also show blood vessels from different orientations which might 
not have been detectable on digital CAM images. This might increase the results seen for 
higher doses of the drugs. 
Finally, I evaluated the activity of 2dDR on enhancing angiogenesis and wound healing 
upon implantation using a diabetic rat wound healing model. The current study follows 
on from recent work from our group showing that a small sugar, 2dDR, is proangiogenic 
as demonstrated in a chick bioassay and that it stimulated wound healing in a 
full-thickness skin wound in a rat model [87]. Alginate dressings are in clinical use for the 
treatment of heavily exudative, chronic wounds [395] as well as for diabetic wounds. As 
such, they are a logical choice to use to deliver this sugar. The sugar was loaded on highly 
absorbent alginate dressings under sterile conditions. Our findings were that 2dDR was 
straightforward to load into alginate dressings. These were then air-dried, and when 
placed in a wet environment, they released approximately 90% of their sugar load within 
3 days. A well-established diabetic rat model was used in which a full-thickness 20 mm 
diameter skin wound was made. While the area of these wounds reduced by 
approximately 70% by 20 days they were still not fully healed. Addition of alginate did 
significantly accelerate wound healing but macroscopic wound closure analysis clearly 
showed that 2dDR released from alginate further improved the wound healing in the area 
of implantation. By day 20, wounds treated with 5 or 10% 2dDR loaded alginate dressing 
were essentially fully healed. The histological assessment also demonstrated a better 
healing of the skin wounds and an increased angiogenic activity in the implantation are 
when treated with 2dDR loaded alginate as evidenced by the presence of a new 
epithelium and blood vessels, respectively. 
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Although I did not primarily aim to establish a complete mechanism of action for the 
angiogenic activity of 2dDR, I investigated whether this activity is VEGF-dependent or 
not. For this, HAECs were incubated in low serum EC GM supplemented with 100 µM of 
2dDR, 1 mM of 2dDR, and 80 ng/mL VEGF. Non-supplemented low serum EC GM was 
used as a control. The analysis of the collected media at day 1, 3 and 5 demonstrated that 
the VEGF production by HAECs in response to direct treatment of 2dDR was statistically 
significant even at day 1. The amount of VEGF went up by approximately 48-fold and 70-
fold, respectively by 100 µM and 1 mM 2dDR treatment. At the end of day 5, VEGF 
production of HAECs was increased by 74-fold and 80-fold, respectively by the addition 
of 100 µM and 1 mM 2dDR. This data was in support with the current literature, which 
hypothesises that an increase in the level of VEGF expression of endothelial cells in the 
presence of 2dDR [82,84].  
In the future, experiments need to be carried out to explore the complete mechanism of 
action of this small deoxy sugar molecule to understand what is happening in the 
molecular level.  
To test the angiogenic activity of alternative drugs, biomechanical stimulus and cells, 
angiogenesis models are important tools [22], and the current angiogenesis assays can 
be divided into three categories: in vitro assays which focus on evaluating proliferation, 
migration, and tube formation capabilities of ECs [512], ex-vivo assays and in vivo assays 
[23]. Although in vivo, assays are the most representative and reliable models for the 
evaluation of angiogenesis, they are also expensive, technically difficult, time-consuming 
and ethically questionable. On the other hand, in vitro angiogenesis assays are 
inexpensive, quick, technically simple, and reproducible, but they are usually based on 
evaluating only one aspect of angiogenesis, and as such do not represent the complexity 
of angiogenesis which occurs in vivo. 
When all the drawbacks of these methods are considered, there is a need for a 3D dynamic 
system which enables the study of angiogenesis in vitro in a more physiological complex 
3D environment which includes the introduction of flow which is a major stimulus for 
neovascularisation in vivo. 
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In Chapter III, IV and V, I demonstrated the development of three different platforms 
which enable researchers to study several aspects of sprouting angiogenesis under either 
static or dynamic conditions. 
First, I developed a synthetic vascular network made of PHBV combining electrospinning 
and 3D printing in Chapter III. 3D printing technique allows the control of the production 
of a large number of scaffolds with exactly the same geometries in a short time while 
electrospinning enables the production of TE scaffolds with a wide range of properties in 
terms of material composition, fibre diameter, thickness, porosity, and degradation rates 
[438–441]. The PHBV polymer was chosen for synthetic vascular scaffolds not only 
because of the previous experiences of our research group [143,417,423], but also 
because electrospinning of PHBV nanofibers can be used to create a barrier for cells 
which is easier to do with this material. Furthermore, the comparison of the biological 
performance of the two widely-used polymers, PHBV and PCL, showed us that PHBV was 
better for supporting the attachment and proliferation of ECs. For the production of the 
synthetic vascular channels, alginate, which is a natural, and biocompatible 
polysaccharide was largely preferred for biomaterial applications [442,443] and was 
used as a sacrificial substrate to create a temporary support material as synthetic 
channels. Our initial experiments aimed to mechanically characterise the scaffolds. The 
results of the mechanical testing showed us the scaffolds had similar properties with 
those used in vascular tissue engineering.  
Following the production and mechanical characterisation of the scaffolds, synthetic 
channels were repopulated with HDFs to gain experience and to confirm the bio-
suitability of the scaffolds for cells to adhere and form a uniform layer. HDMECs were 
then seeded to channels either in isolation or in the presence of HDFs on the outer surface 
to support. Results showed that the physical appearance of HDFs improved the survival 
and homogeneous distribution of ECs within the channels. However, I found that PHBV 
SVN could be cellularised with evenly distributed ECs either in isolation or in the 
presence of HDFs depending on the intended purpose of use. Once a uniform endothelium 
monolayer was obtained, the developed SVN was tested for its potential use in studying 
angiogenesis with two sets of experiments. In the first experiment, the outgrowth of 
HDMECs to VEGF and 2dDR loaded Matrigel was investigated. The results of the Matrigel 
experiments showed that HDMECs were outgrowing and forming interconnected tube-
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like structures within the Matrigel close to edges of the pierced synthetic PHBV channels. 
The tube-like formed structures were obvious and well-organised in 80 ng/mL loaded 
VEGF loaded Matrigel groups when compared with 100 µM 2dDR loaded and control 
groups. The formation of the tube-like structures was pretty similar to those which can 
be observed in Matrigel tube formation assays [350]. Our observations were in support 
of the literature where VEGF has been reported to regulate outgrowth of ECs [462–464]. 
I have also demonstrated that 2dDR improved the tube formation of ECs at 100 µM 
concentration (the data presented in Chapter 2). Although the results showed some 
promising steps for this model to be used as an alternative in vitro system to study the 
aspects of neovascularisation, the reproducibility and the reliability of the model were 
found to be fairly low. The outgrowth of ECs was witnessed in only 20% of the 
experiments for VEGF loaded Matrigel and 13.3% of the 2dDR loaded and control groups, 
respectively. Formation of complete tube-like structures by ECs was seen in only a 
minority of the VEGF-loaded Matrigel groups.  
This lack of reproducibility demonstrates that the proposed PHBV SVN model as an in 
vitro platform to study angiogenesis is not fully reliable to investigate angiogenesis by its 
own. The causes behind this variation in these results were not studied further due to the 
complex structure of the developed model. I hypothesised that the most probable reasons 
could be: (a) Matrigel is rich in ECM proteins, but the exact concentrations of the 
ingredients are not clearly defined, and it shows high batch‐to‐batch variations, (b) the 
thickness of Matrigel was not possible to control very well due to the complex geometry 
of the PHBV SVN scaffolds even though the same volume was used for each experiment. 
The gel thickness might cause a variation in EC survival and migration, (c) Microvascular 
ECs are very sensitive to culture conditions and show batch to batch variations which 
might be a cause for these variations, (d) the holes were pierced on SVN channels 
manually, and they were randomly oriented, and their positions and diameters might 
have an impact on the variations in the outgrowth of ECs. 
Following the Matrigel experiments, a more physiologically relevant tissue model, TE 
skin model, was next explored for assessing the vascularisation potential. The TE skin 
model was successfully developed by co-culturing human dermal keratinocytes and HDFs 
on DED for 14 days (2 days as submerged in media and 12 days at the air-liquid interface) 
using a well-established protocol [420]. The air-liquid interface has previously been 
283 
 
confirmed to provide a strong stimulus for the gradual differentiation of keratinocytes 
[411]. The histological evaluation of the reconstructed TE skin models showed that the 
TE skin model achieved a normal-looking gross skin morphology in 14 days. A multi-
layered epithelium was formed and found to be well attached to the dermis. Once a skin 
model was successfully developed, the performance of the PHBV SVN to be used for 
vascularisation of a reconstructed TE skin model (with or without VEGF added to growth 
medium) were then investigated in comparison with the vascularisation studies of TE 
skin models on CAM. Phalloidin-FITC and DAPI staining showed that there was a 
monolayer which had formed within the channels and some cells were localised on the 
outer surface of the scaffolds.  
In order to identify the type of cells present in the system, immunostained (Anti-human 
CD31+) sections showed that HDMECs were evenly distributed within the channels and 
formed a monolayer, and the HDFs were localised evenly on the outer surface of the PHBV 
SVN either in VEGF-added or non-supplemented control groups. High magnification 
images of the immunostained sections revealed that the outgrowing cells from the PHBV 
channels towards the reconstructed skin models were CD31 positive HDMECs. The 
outgrowth of HDMECs was mostly observed from the connection edges of two separate 
electrospun sheets, and the inclusion of VEGF to the growth media significantly increased 
the outgrowth distance of HDMECs approximately 4.4-fold (when compared to controls) 
towards the reconstructed TE skin model.  
Unfortunately, no cells were able to reach to the DED layer, and they were not found to 
be invading into the dermal layer of the developed skin models in any of the groups. The 
most probable explanations for this are those (i) the outgrowth direction of HDMECs was 
against the gravity, (ii) the rate of outgrowth of HDMECs from PHBV channels was very 
low. Furthermore, (iii) the orientations, positions and diameters of the manually pierced 
random holes might also negatively affected the outgrowth of HDMECs. 
These results were consistent with the CAM assay studies. Even though CAM is a highly 
vascularised and dynamic environment, the results showed that there were no blood 
vessels growing into the dermal layer of the reconstructed skin substitutes. However, the 
presence of dermal cells significantly improved the vascularisation in the area of 
implantation. In addition, the administration of 80 ng/day/embryo VEGF and 
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200 µg/day/embryo 2dDR showed increased angiogenic activity in the implantation 
area.  
In the future, studies could focus on the standardisation of the manufacturing method to 
increase the reproducibility of this in vitro platform by optimising the thickness of 
Matrigel, orientation and the diameters of the holes. Use of ECs in co culture with different 
cell types and investigating their interaction might also bring a new perspective to the 
use of developed platform. Further experiments with other pro-angiogenic factors and 
flow conditions could be performed to study their relation to angiogenesis using the 
developed model to increase the reliability of the model. Furthermore, inclusion of flow 
might increase the reliability of the results that can be obtained from the TE skin model 
experiments. The positive influence of shear stress on EC outgrowth was demonstrated 
in Chapter V. Finally, the majority of results obtained from these experiments were 
qualitative results. Future studies could focus on obtaining more quantitative results such 
as cell viability, expression of angiogenic markers and factors. 
Then, I developed a natural synthetic vascular network by decellularising baby spinach 
leaves and explored their potential for studying and inducing angiogenesis in Chapter IV. 
An immersion decellularisation protocol was adapted and modified from previously 
published protocols [166,167]. After initiation of decellularisation, leaves began to lose 
their green colour over time and became translucent by the end of day 7. The surface 
became more wavy due to burst plant cells and bigger stomatal pores, and the success of 
the decellularisation protocol followed was verified by quantification of the DNA content 
which showed that 98% of the DNA content of spinach leaves was successfully removed.  
The biocompatibility of decellularised spinach leaves was investigated in vitro and using 
an ex-ovo CAM assay. The results demonstrated an increase in the metabolic activities of 
HDFs growing on decellularised spinach leaves from day 1 to 11, and the results of the 
CAM assay confirmed that decellularised spinach leaves showed no toxicity to chick 
embryos. Furthermore, gelatin coating significantly enhanced the attachment and 
proliferation of HDFs to decellularised spinach leaf at all time points. Cellulose is the 
major component of the plant cell wall [491], and in vitro and in vivo biocompatibility of 
the plant-derived cellulose has been previously studied by several groups recently. 
Modulevsky et al. reported the in vitro biocompatibility of decellularised McIntosh Red 
apple slices by assessing the proliferation of mammalian cells on them [316] Recently, 
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Gershlak et al. assessed the feasibility of decellularised spinach and parsley to be used as 
TE scaffolds. They demonstrated that hPS-CMs were viable and contracting five days after 
initial seeding [166]. Our experiments showed results which were in agreement with the 
literature. Cellulose is a readily available, inexpensive, and a biocompatible biomaterial 
that may prove a good candidate to be used in tissue engineering applications.  
Decellularised baby spinach leaves have been developed for two purposes: (a) to promote 
angiogenesis (when repopulated with pro-angiogenic cells) and (b) to be used as an in 
vitro platform for the study of angiogenesis.  
In-vitro prevascularisation of TE constructs, which can be derived from synthetic or 
natural sources prior to implantation is a promising approach to overcome the slow 
vascularisation problem. The idea of this prevascularisation technique is to shorten the 
time required for neovascularisation in the post-implantation period by establishing a 
connection between existing vessels and the cultured ECs [485,486]. The effectiveness of 
the prevascularisation technique has previously been studied by many groups. Tremblay 
et al. reconstructed an endothelialised skin model repopulated with HUVECs and 
reported the inosculation of HUVECs with the host mice vasculature during the first 4 
days [485]. Similarly, Nor et al. implanted biodegradable poly-L-lactic acid scaffolds 
prevascularised with HDMECs subcutaneously into immunodeficient mice and 
demonstrated the differentiation of HDMECs into functional human microvessels which 
anastomosed with the host vasculature in less than 7 days [501]. Schechner et al. 
reported the formation of primitive capillary-like structures by HUVECs cultured within 
a 3D gel and showed successful inosculation of HUVECs with the host vasculature when 
implanted into mice [118]. Unger et al. investigated the functionality of in vitro pre-
formed microvasculature in vivo and reported that co-culture of HDMECs with 
osteoblasts stimulated the ingrowth of host’s blood vessels into TE construct, and 
chimeric vessels were also observed at the end of 14-day period [493]. 
Accordingly, in this study, I repopulated the acellular spinach leaves with HDMECs (in the 
presence of helper HDFs which have been found to help to increase the survival of ECs in 
the channels). The angiogenesis was evaluated using ex-ovo CAM assay. The results 
showed that endothelialised spinach leaves increased the angiogenic activity when 
compared to HDFs only and leaf only controls in the area of implantation. This data 
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provided evidence on prevascularisation stimulating new blood vessel growth at the site 
of implantation.  
Finally, I tested the potential of decellularised spinach leaves to be used as an in vitro 
platform to study angiogenesis. For this aim, I investigated the outgrowth of HDMECs 
from the channels towards a chemical attractant. Briefly, I explored the outgrowth of 
HDMECs from the channels of decellularised spinach leaves to Matrigel either plain or 
loaded with VEGF. Unfortunately, our results demonstrated that the outgrowth of the 
HDMECs from the channels was extremely rare (outgrowing HDMECs were witnessed 
only in 5% of the experiments). However, the outgrowth distance of the HDMECs through 
VEGF loaded Matrigel was higher, and a more organised structure was observed when 
compared with non-loaded Matrigel groups.  
In future, further investigation of the inosculation of HDMECs with host vasculature 
needs to be investigated. Furthermore, even if the leaves were gelatin coated and the 
HDFs were used as helper cells, HDMECs were not found to penetrate into the smaller 
branches of the acellular spinach leaves. In considering the potential use of the 
decellularised spinach leaves as prevascularised constructs, this lack of homogeneity in 
the distribution of HDMECs might prove a problem for establishing a connection with the 
endothelial cells of the host tissue. Further developments on endothelial cell distribution 
in the scaffolds may lead to a better angiogenic response from host tissue.  
In the field of decellularisation of the native tissues and organs, the complete 
recellularisation of the acellular 3D scaffolds in vitro is a long-standing problem, and 
further investigations are needed to improve the cell distribution in the scaffolds [502]. 
Although the CAM assay is a useful platform to study biocompatibility and angiogenicity 
of materials in vivo, one of its drawbacks is that the chick does not have a fully developed 
immune system during the period of use for the CAM assay [69,89]. Thus, comparison of 
plant-derived and animal-derived decellularised constructs using an animal model with 
a competent immune system will be interesting in the future to compare the relative 
merits of both. When it comes to using the developed scaffolds as an in vitro platform to 
study angiogenesis, further developments on this assay would be required to increase its 
reproducibility. It possibly merits more development as it combines both migration and 
cell differentiation in a 3D environment.  
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In Chapter V, we developed a 3D dynamic system through the combination of 
electrospinning and emulsion templating to be used for testing of angiogenic drugs and 
flow in a more physiologically relevant environment to stimulate angiogenesis. 
Experiments in this study were designed with two key objectives; (i) to develop a 3D 
dynamic system to be used for testing of angiogenic drugs, (ii) to evaluate the efficiency 
of 2dDR to encourage proliferation and infiltration of HAEC using in vitro 3D dynamic 
system. We investigated the suitability of our model to be used as a 3D in vitro 
angiogenesis model. The 3D dynamic system was designed as a tubular form as seen in 
tissue engineering vascular graft (TEVG) design to enable the application of lateral flow 
[533–535]. It was designed to be two-layers; the inner tube of PHBV electrospun 
nanofibres to serve as a suitable environment, mimicking the basement membrane, for 
ECs to adhere, proliferate and form a monolayer to represent an endothelium, and the 
emulsion templated PCL PolyHIPE outer tube was expected to be highly porous to enable 
proliferation and migration of ECs from the formed endothelial monolayer to the outer 
tube. Nanofibres have been shown to provide better surface properties for ECs to adhere 
and proliferate on them over microfibres [456–458]. The manufacturing route of PCL 
based PolyHIPEs was recently reported by our group, and biocompatibility and structural 
suitability of the PCL PolyHIPE for cell infiltration were also shown [419,424]. 
The results of the 3D flow experiments showed that static culture and lower shear 
stresses (1 dyn/cm2 and 2 dyn/cm2) enabled the formation of a continuous endothelial 
monolayer, but the application of higher stress (10 dyn/cm2) resulted in a discrete layer 
of HAECs (no monolayer formation was observed in any of the experiments when high 
shear stress was applied). This is possibly due to the cells being washed out at the high 
rate of flow [540]. Low shear stress promoted the outgrowth of HAECs for over 7 days. 
2 dyn/cm2 shear stress significantly increased the outgrowth distance of HAECs and 
normalised cell density when compared with 1 dyn/cm2 and 10 dyn/cm2, whereas no 
outgrowth was observed under static culture conditions. Our findings of the effect of flow 
experiments on ECs are consistent with the literature [541,542]. Under static conditions, 
administration of 2dDR and VEGF stimulated EC outgrowth and cell density when 
compared with the static control group (no agents administered). However, the most 
dramatic increase in outgrowth distance and cell density was observed when the pro-
angiogenic agents (2dDR and VEGF) were administered under 2 dyn/cm2 shear 
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conditions. Similar to our results, Song et al. have previously reported that VEGF and fluid 
forces cooperate to improve endothelial invasion [547].  
This chapter makes a novel contribution by demonstrating a novel 3D model which can 
be used to study angiogenesis in vitro in a 3D dynamic environment. Our model enables 
users to monitor cell proliferation and migration simultaneously under more 
physiologically relevant conditions. 
In the future, studies trying to include a quantitative assessment of angiogenesis markers 
could be trialled in an attempt to give a better insight into the response of ECs to an 
external stimulus and to flow. This will clearly increase the reliability of the developed 
model and increase the accuracy of the results obtained. In addition, further studies 
exploring co-culture of ECs with another cell line could bring a whole new perspective to 
the use of this model. For example, the inclusion of bone cells in the PolyHIPE layer in co-
culture with ECs (in the electrospun layer) could enable users to study aspects of 
vascularisation in bone tissue engineering. Finally, the assessment of different cell 
combinations, pro-angiogenic factors, and flow regimes could be studied in relation to 
angiogenesis in future studies. 
Overall, I aimed to circumvent the drawbacks of the current angiogenesis systems by 
developing three angiogenesis models in the scope of this thesis. All of them offer some 
novel and promising alternatives to the established in vitro angiogenesis models and have 
pros and cons. The comparison of the pros and cons of the developed in vitro angiogenesis 
models are summarised in Table 22. 
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Table 22. A comparison of the pros and cons of the in vitro angiogenesis models developed. The levels 
of each parameter have been indicated as “+++” = high, “++” = medium, and “+” = low 
Parameters  
Angiogenesis Model 
PHBV Synthetic 
Vascular Network 
Decellularised Baby 
Spinach Leaves 
Bilayer 3D dynamic 
tubular model 
Ease of Fabrication ++ +++ + 
Duration of Fabrication ~ 2 days ~ 9 days ~ 5 days 
Cost ++ + ++ 
Reproducibility +++ +++ +++ 
Ease of Cellularisation + ++ +++ 
Multiple channel 
structure 
Yes No No 
Batch to Batch 
Variation 
No Yes No 
Suitable for the 
Introduction of Flow 
Yes No Yes 
Suitable for the 
Investigation of  
Migration,  
Tube Formation 
Migration 
Proliferation, 
Migration 
Suitable for the 
Histological Analysis  
Yes No Yes 
Ease of Visualisation ++ +++ ++ 
 
Alongside working with the development of several angiogenesis models, I also 
investigated the practicability of the prevascularisation approach to promote 
angiogenesis in an ex-ovo CAM assay by pre-seeding simple electrospun PHBV scaffolds 
with a combination of endothelial cells and fibroblasts (Chapter VI). The investigation of 
the effect of gelatin coating and the presence of HDFs, as helper cells, showed that gelatin 
coating and co-culture of HDFs both showed a positive impact on HDMECs viability and 
growth.  
Communication of ECs with surrounding stromal cells such as SMCs, fibroblasts or 
pericytes has also been proven to have significant importance for the angiogenic process 
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[551,552]. Our group has previously reported the positive effect of HDFs on improving 
the survival and growth of HDMECs [323]. Recently, I revealed that non-cross-linked 
gelatin coating is a simple and effective method to improve the attachment and growth of 
HDMECs to biomaterials that have relatively weak biological properties [480]. In line 
with our results, Ma et al. reported that surface modification of electrospun PCL scaffolds 
with gelatin coating enhances the EC spreading and proliferation [553]. The positive 
impact of either non-cross-linked or cross-linked gelatin coating on attachment and 
proliferation of human Schwann cells has been shown by Vleggeert-Lankamp et al. [499]. 
Following the determination of the optimal culture conditions for HDMECs, three 
different cell culture systems were investigated in the ex-ovo CAM assay in terms of 
improving the angiogenic activity, as a prevascularisation approach. The results of the 
CAM assay revealed that both HDFs and HDMECs either in isolation or when co-cultured 
together significantly increased the angiogenic activity in the area of implantation. 
HDMECs were found to be more effective for stimulating angiogenesis. However, the most 
significant angiogenic response was observed when HDFs were also present in indirect 
contact with HDMECs. 
In the future, studies could focus on investigating the anastomosis of HDMECs with the 
host vasculature to confirm the effectivity of the prevascularisation technique. In 
addition, the use of stem cells in this prevascularisation system could be interesting to 
provide more reliable information as the ultimate goal of this technique is the translation 
of it to the clinic. This is more applicable when patient’s own cells are harvested and 
expanded on TE constructs to create a prevascularised construct to shorten the time 
required for neovascularisation post-implantation.  
Alongside the work I have done in an attempt to contribute to the world of angiogenesis, 
we also aimed to develop systems to be used in tissue engineering and regenerative 
medicine. For this, we developed a bilayer PCL barrier membrane (BM) in Chapter VII to 
be used in guided bone/tissue regeneration (GBR/GTR) applications by combining 
electrospinning and emulsion templating. Periodontal regenerative procedures require 
the use of GTR/GBR in various conditions such as socket preservation, grafting, maxillary 
sinus elevation and the treatment of the chronic periodontitis [562]. The main principle 
of the GTR/GBR procedure is to place a BM between epithelial tissue and bone or bone 
graft to prevent migration of the fast-proliferating epithelial cells into the defect site to 
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be able to preserve a space for infiltration of bone cells into periodontal defect site 
[563,564].  
A BM is expected to be in contact with both hard and soft tissues, and it has different 
functions on each side. While being cell occlusive on the side in contact with soft tissue, it 
should encourage bone regeneration on the other side. Accordingly, our BM has been 
designed to have two layers: (a) PCL electrospun layer to limit epithelial invasion, (b) PCL 
PolyHIPE layer to support bone growth. Initially, several solvent compositions were tried 
to find the best blend for manufacturing PCL electrospun nanofibres. The 
chloroform:DMF (70:30) composition was found to be the best and selected for the 
manufacturing of nanofibrous barrier layer due to multiple factors including the 
improved electrospinnability, the decreased fibre diameter, and the smaller pore size. 
First, the PolyHIPE layer was fabricated via emulsion templating, and PCL was then 
electrospun on top of the PolyHIPE layer using the selected solvent blend. The resulting 
BM showed no delamination, and its structure was qualitatively resilient to torsion and 
stretching, and it was straightforward to handle. Following the fabrication of the BM, both 
layers were tested for their intended purpose of use. The nanofibrous electrospun PCL 
has been shown to have barrier properties by limiting the ingrowth of HDFs up to 4 weeks 
in vitro while the metabolic activity of the cells increased. Then the highly porous and 
interconnected structure of PCL PolyHIPE layer was proven to provide a favourable 
environment for murine osteocyte-like cells to attach, migrate, and proliferate. PolyHIPE 
layer also stimulated the deposition of collagen and minerals on this layer, and the ex-ovo 
CAM assay was used to reveal that the pore structure and size of PolyHIPE was suitable 
for allowing the ingrowth of blood vessels from the chick membrane. 
In future, studies could focus on the culture of both cell types together to see the effect of 
cell-cell interaction on the behaviour of both cells. The in vitro results were very 
encouraging for further assessments of the BM. Thus the assessment of the in vivo 
performance of the BM could be really interesting and might potentially reveal the 
potential of the developed BM to be used in the clinic.  
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CHAPTER IX 
Overall Conclusion 
The overall aim of this project is to enhance our knowledge in the world of angiogenesis 
and regenerative medicine by designing systems that have the capability of being used to 
induce and study angiogenesis particularly for regenerative medicine applications.  
Initially, the dose-dependent angiogenic activity of 2dDR was revealed using well-
established in vitro and in vivo systems. Results showed us 2dDR was a promising pro-
angiogenic agent to stimulate angiogenesis and wound healing as an alternative to the 
use of exogenous VEGF. The loading of 2dDR into polymer-based and hydrogel-based 
tissue-engineered constructs has been found to be a very effective way of delivering it to 
the implantation area and stimulating angiogenesis post-implantation. To conclude, 
2dDR was a great alternative for the upregulation of VEGF rather than the exogenous use 
of it. 2dDR was found not only to be highly angiogenic but also a potential agent to 
accelerate wound healing in non-healing diabetic wounds. This work involved a 
collaboration with Associate Professor Muhammad Yar in Pakistan 
Secondly, I developed several systems that enable the study of angiogenesis under 
physiologically more relevant conditions. 
In the first system, I demonstrated the development of synthetic vascular networks made 
of PHBV nanofibres to be used as an in vitro platform to study angiogenesis and to 
investigate the vascularisation of complex tissue models. The nanofibrous PHBV channels 
were found to provide a suitable environment for HDMECs to form a monolayer either in 
the presence or absence of HDFs. The indirect co-culture with HDFs was shown to be a 
desirable approach depending on the intended use of the PHBV SVN. This in vitro 
platform enabled the study of more than one aspect of angiogenesis (migration and tube 
formation) when combined with Matrigel. In addition, PHBV SVN provided a convenient 
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platform to study vascularisation of a reconstructed human skin model as a 
physiologically more relevant and complex structure. 
The second model was a natural vascular network fabricated via decellularisation of a 
baby spinach leaves to retain the natural vasculature of it. The results demonstrated that 
98% of the native DNA of the baby spinach leaves was removed successfully by serial 
detergent washes without any damage to the structural integrity of the leave. The 
intrinsic 3D vascular architecture was maintained after decellularisation, and these 
channels were then successfully recellularised with HDMECs and the potential use of the 
developed system to stimulate neovascularisation and to study angiogenesis was 
revealed. 
In the third model, we developed a 3D dynamic system that can be used to study the 
angiogenic activity of agents under flow conditions. This project was conducted in 
collaboration with my colleague, Betül Aldemir, and carried out at the Institute for 
Medical Engineering and Science, Massachusetts Institute of Technology. This research 
focused on the development of the bilayer tubular scaffolds composed of an emulsion 
templated PCL PolyHIPE outer tube and an electrospun PHBV inner tube. The dynamic 
system was then successfully cellularised with HAECs, and the potential use of the system 
in the study of angiogenesis was demonstrated by evaluating the proliferation and 
migration of HAECs in response to flow and the pro-angiogenic agents, 2dDR and VEGF. 
Thirdly, I showed the effectiveness of a prevascularisation technique to induce 
angiogenesis by pre-seeding simple electrospun scaffolds with combinations of HDMECs 
and HDFs. I used an ex-ovo CAM assay to reveal that the presence of HDMECs showed a 
stronger angiogenic response than the introduction of HDFs alone, but the use of HDMECs 
and HDFs together gave the most significant angiogenic activity. 
Finally, as a side project, I developed a bilayer barrier (BM) membrane to be used in 
GTR/GBR applications. The experiments in this project were carried out in collaboration 
with my colleague, Betül Aldemir. In this study, a bilayer BM made of PCL was successfully 
fabricated by combining electrospinning and emulsion templating. The electrospun 
nanofibrous PCL layer has been confirmed for its barrier features for the prevention of 
soft tissue invasion whereas the interconnected PCL PolyHIPE layer has shown potential 
for use as a bone promoting layer providing the key requirements of cell compatibility, 
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supporting cellular infiltration, and promoting collagen and mineral deposition. The 
biocompatibility of the membrane and the suitability of the pore size of the developed BM 
were further examined with an ex-ovo CAM assay. The results showed that the pore size, 
interconnectivity and the pore structure of the PCL PolyHIPE layer were suitable for 
blood vessel ingrowth.  
Overall, the developed approaches offer novel ways to increase our knowledge on how 
external factors affect the angiogenic process. The pros and cons of all these systems with 
future perspectives are discussed in Chapter VIII. All models have shown promising 
results to overcome the drawbacks of the current systems and to be very useful in 
studying neovascularisation. 
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